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ABSTRACT 
Investigations were conducted to determine the scientific basis for the traditional use 
of several plant species for dementia and other memory disorders, selected from 
Ayurvedic, Chinese and European herbal medicine, the plant parts investigated being 
used traditionally for central nervous system (CNS) disorders. Bioassays selected 
were associated with the pathological mechanisms that have consistently been 
associated with Alzheimer's disease (AD) and cognitive dysfunction. 
A series of plant extracts and essential oils were assessed for in vitro 
anticholinesterase (antiChE) activity. Bioassay guided fractionation (including 
droplet counter-current chromatography (DCCC), flash column chromatography 
(FCC) and preparative thin layer chromatography (TLQ of one of the most active 
antiChE extracts from Convallaria majalis, and the analysis of plant extracts and 
fractions using TLC and high performance liquid chromatography-mass spectroscopy 
(LC-MS), was conducted to identify the types of compound responsible for activity. 
Plant extracts, essential oils and essential oil components (identified using gas 
chromatography-mass spectroscopy (GC-MS)) were investigated for oestrogenic (and 
anti-oestrogenic) activity using a recombinant yeast screen; active extracts and 
essential oil constituents were also investigated in the human Ishikawa. cell line, in 
receptor binding studies using the isolated a- and P-oestrogen receptors, and in vivo. 
Structure-activity relationships of essential oil constituents that demonstrated 
oestrogenic and anti-oestrogenie activity were also investigated using molecular 
graphics (with the computer program HyperCheMTM), to identify potential 
interactions with the oestrogen receptor, and were compared to known ligands for the 
oestrogen receptor. 
A radioimmunoassay was conducted to assess inhibitory activity of plant extracts, 
essential oils and pure compounds against enzymes of the arachidonate cascade, to 
identify potential anti-inflammatory activity. Plant extracts and essential oils were 
also analysed in bioassays for inhibition of lipid peroxidation of bovine brain 
liposomes to determine anti-oxidant activity, for binding to GABAA and GABA13 
receptors, and for their effects on differentiation of neural stem cells isolated from rat 
brain and spinal cord. 
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t time 
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TBS+ Tris-buffered saline containing 0.0 1% Triton X- 100 
TCM traditional Chinese medicine 
TIC total ion current 
TJM traditional Japanese medicine 
TLC thin layer chromatography 
TNF tumour necrosis factor 
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UV ultraviolet 
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1.1 Alzheimer's Disease 
The word "dementia" comes from the Latin word demens, meaning to be out of one's 
mind. There are numerous causes of dementia, including Lewy body disease (Lewy 
bodies are composed of proteinaceous material, which cause neuronal damage), 
Pick's disease, cerebrovascular disease and Alzheimer's disease (AD), the last which 
is reported to be the most common form of dementia (Evans el al., 1989; Nordberg, 
1996). Alzheimer's disease is estimated to account for 50% - 60% of dementia cases 
in persons over 65 years of age (Francis et al., 1999). Dementia may also be a feature 
of other conditions, including Parkinson's disease, Huntington's disease and 
Creutzfeld-Jacob disease (CJD). The varieties of conditions that may feature 
dementia make their diagnosis and subsequent treatment difficult. 
AD is a progressive, neuro degenerative disease that primarily affects the elderly 
population, and is a major public health concern. It is estimated that approximately 
800,000 people in Britain and almost 4 million Americans have AD, and it is 
predicted that this figure may reach 9 million by 2004 (Gopinath, 1998; Max, 1993; 
Yankner and Mesulam, 1991); AD has been estimated to affect 10% of the population 
in the US over the age of 65 years (Evans et al., 1989). It has been proposed that 
delaying the onset of AD may reduce the number of cases by up to 50% (Gopinath, 
1998; Marx, 1996). Therefore, knowledge of the mechanisms that may initiate or 
accelerate AD may lead to the development of effective treatments. The costs of AD 
in the UK are reported to be over 11,600 million each year, and close to US $100 
billion each year in the US (Ernst and Hay, 1994; Gopinath, 1998), therefore effective 
treatments may not only alleviate AD symptoms and suffering, but may also reduce 
the economic burden to society. 
There has been extensive research into the causes and pathogenesis of AD since it was 
first described by Alois Alzheimer in 1907. However, understanding of this complex 
disorder is still very limited, and a more complete understanding of AD is necessary 
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for drug discovery to proceed successfully, to identify a cure for this debilitating 
disease. 
1.1.1 Pathology and Symptoms of Alzheimer's Disease 
1.1.1.1 Symptoms Associated with Alzheimer's Disease 
The main symptoms associated with AD involve cognitive dysfunction, primarily 
memory loss (Desgranges el al., 1998; F6rstl et al., 1995; Grafffian et al., 1990; 
Grosse et al., 1991). Language deficits, depression, behavioural problems including 
agitation, mood disturbances and psychosis are also features associated with the later 
stages of AD (Kumar el al., 1998b; McGuffey, 1997; Wragg and Jeste, 1989). The 
neurobiological basis underlying memory impairment in AD is not fully understood. 
Although increasing age is a risk factor for AD development, AD may also occur at 
an earlier age, usually between ages 35 to 60 years (early onset AD). It is reported 
that there may be neuropathological and neurochernical differences between early and 
late onset AD cases (Rosser et al., 1984; Zubenko et al., 1989). Late onset AD is 
characterised by more profound impairment on semantic memory processing, which 
has been correlated with activity in the temporoparietal and frontal association 
cortices of the left hemisphere of the brain (Desgranges el al., 1998; Grosse et al., 
1991). 
1.1.1.2 NeurofibrillaLy Tangles and Amyloid Plaque 
The pathological features of AD that occur, which are identified in the post-mortem 
brain, are neurofibrillary tangles, located in neuronal cytoplasm and composed of 
paired helical filaments containing abnormally hyperphosphorylated tau protein, and 
diffuse and neuritic plaques composed of degenerating neurites and proteins, which 
include synucleins (involved in synaptic membrane formation), apolipoprotein E 
(ApoE) and, primarily P-amyloid (Clayton and George, 1998; Crystal, 1993; Glenner 
and Wong, 1984; Goedert, 1999; Ihara et al., 1986; Johnson and Jenkins, 1996; Lu el 
al., 1999; Masters el al., 1985; Ruben el al., 1997; Wisniewski and Frangione, 1992). 
Because of abnormal hyperphosphorylation, tau from paired helical filaments cannot 
bind to microtubules or promote microassembly (Alonso el al., 1994; Lu and Wood, 
49 
1993), which may lead to impaired neurotransmission. It has been reported that tau is 
phosphorylated by a complex formed between a protein (p25) and an enzyme (cyclin- 
dependent kinase 5 (Cdk5)); in AD higher levels of Cdk5 result in binding to p25, 
rather than only binding to p35, the precursor of p25, which promotes the subsequent 
hyperphosphorylation (Evans, 2001). The protease calpain converts p35 to p25 (Lee 
et al., 2000; Nath et al., 2000; Taniguchi et al., 2001), so may promote neurofibrillary 
tangle formation. Inhibitors of calpain may prove useful in preventing neurofibrillary 
tangle formation. 
Hyperphosphorylation of tau however, is not essential to the development of 
neurofibrillary pathology and oxidative stress may also be a contributing factor 
(Johnson and Jenkins, 1996). Neurofibrillary tangles interfere with intracellular 
transport, cell structure and contribute to neuronal cell death (Blass, 1993; Yankner 
and Mesulam, 1991). Neurofibrillary tangles and senile plaques were first described 
by Alois Alzheimer in 1907, following postmortem analysis of a patient with 
dementia (Blass, 1993; Johnson and Jenkins, 1996; Yankner and Mesulam, 1991). A 
correlation between the number of neurofibrillary tangles and cognitive impairment in 
Alzheimer's disease has been identified (Arriagada et al., 1992; Roth et al., 1967). 
The formation of senile plaques may occur as a result of abnormal metabolism of 
amyloid precursor protein (APP). APP may occur as a transmembrane protein, or in a 
secreted form, which has been located in plasma and cerebrospinal fluid (Ghiso et al., 
1989; Podlisny et al., 1990). The physiological role of APP is unclear, but has been 
reported to be required for the maintenance of neuronal and synaptic structure and 
function and cell adhesion (Huber et al., 1997; Qui et al., 1995; Saitoh and Mook- 
Jung, 1996). The secreted form of APP has been proposed to be involved in 
regulation of blood coagulation, wound-healing, neurite extension, cell adhesiveness 
and cell growth and differentiation (Araki el al., 1991; Cole el al., 1990; Cunningham 
el al., 1991; Jin et al., 1994; Milward et al., 1992; Saitoh et al., 1989; Schubert et al., 
1989; Smith el al., 1990). The functions associated with APP may be linked with AD 
development. For example, secreted APP may participate in neuronal outgrowth, 
which may accelerate AD pathogenesis (Ihara, 1988), but further research is 
necessary to establish links between APP function and AD. APP is cleaved by 
proteases (e. g. P- andy-secretases) to yield the abnormal insoluble form of P-amyloid 
(Chen, 1997); inhibition of these enzymes may be exploited for AD therapy. 
f wa. ) 
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It is unknown if the plaques are responsible for AD onset (i. e. they trigger neuronal 
degeneration), or if they are a feature of disease progression (i. e. they occur as a result 
of neuronal degeneration induced by other factors). P-Amyloid has been shown to 
induce neuronal toxicity in vilro, which may be explained by promoting neuronal 
oxidative stress, and by increasing susceptibility of neurons to excitotoxins (Behl el 
al., 1992; Behl el al., 1995; Behl el al., 1997; Koh el al., 1990; Mattson el al., 1992; 
Yankner et al., 1990). The exact mechanisms by which P-amyloid is neurotoxic 
remain to be established, but interactions with cell membranes and interference with 
Ca 2+ transport and elevation of Ca2+ intracellular levels have been implicated in its 
neurotoxicity (Mattson et al., 1992; Wu et al., 1997). Fibrillar P-amyloid 
administration to aged rhesus monkey cerebral cortex resulted in tau phosphorylation, 
microglial proliferation and neuronal loss, but administration did not induce toxic 
effects in the young adult rhesus monkey, indicating that aging may render the brain 
vulnerable to P-amyloid toxicity (Geula et al., 1998). This may reflect tile loss of 
protective factors, or increased levels of neurotoxic co-factors, or perhaps impaired 
degradation of P-amyloid, with increasing age. Therefore, P-amyloid may be a 
significant factor in promoting neuronal degeneration and is a possible cause of AD 
onset in the elderly population. 
It has been proposed that P-amyloid may occur as a result of neuronal degeneration as 
part of the disease process (Cummings el al., 1996) so may play a significant role in 
disease progression, but not in disease onset. It may be that P-amyloid promotes 
neuronal degeneration in the early stages of AD pathogenesis, but is also generated as 
a result of disease progression, leading to further neuronal degeneration. It is also 
possible that an imbalance between the neurotrophic and neurotoxic functions of APP 
occur in AD pathology. It is apparent that the association of APP and P-amyloid with 
AD pathology is complex and further research is necessary to improve understanding 
of AD pathogenesis. 
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1.1.1.3 Alterations in Neurotransmitter System 
Alterations in neurotransmitter systems, including acetylcholine (ACh) (1), dopamine, 
y-aminobutyric acid (GABA) (16), glutarnate, 5-hydroxytryptarnine (5-HT) and 
noradrenaline (NA) have been associated with AD pathology (Advokat and Pellegrin, 
1992; Fowler ef al., 1992; Giacobini, 1990; Nordberg, 1992; Palmer el al., 1987a; 
Palmer ef al., 1987b; Perry et al., 1978; Perry, 1986; Plotkin and Jarvik, 1986; Read, 




N-CH 3 H3C I 
CH3 
Acetylcholine (1) 
A consistent neuropathological occurrence associated with memory loss, is a 
cholinergic deficit, which has been correlated'with the severity of AD (Bierer et al., 
1995; Collerton, 1986; Giacobini, 1990; Perry et al., 1978; Perry, 1986; Plotkin and 
Jarvik, 1986; Read, 1987). This is more pronounced in the hippocampus and cerebral 
cortex, which are involved in cognitive function. Postmortem analysis of the brains 
of AD patients shows that the neurons of the basal nucleus of Meynert in the basal 
forebrain, a major source of cholinergic innervation of the cerebral cortex (responsible 
for higher learning function), undergo selective degeneration and atrophy (>75%) 
(Whitehouse el al., 1982). The neurons of the nucleus basalis of Meynert are also 
reported to project to the amygdala, brainstem, hippocampus, entorhinal cortex and 
neocortex (Johnston et al., 1979; Whitehouse et al., 1982). The amygdala and basal 
forebrain form part of the limbic system, which mediates emotional behaviour. Tile 
degeneration of the neurons of the nucleus basalis of Meynert may therefore influence 
a number of processes involving cognition and behaviour. 
Impairment of cholinergic neurotransmission has also been reported during normal 
aging, not associated with AD (de Lacalle et al., 1991) but degeneration of 
cholinergic neurons is more pronounced in AD, identified by a reduction in 
cholinergic markers such as choline acetyltransferase (ChAT) activity, ACh (1), 
acety1cholinesterase (AChE) and muscarinic and nicotinic receptors (Bierer et al., 
1995; Bowen et al., 1976; Court et al., 2001; Davies, 1979; Davies and Maloney, 
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1976; London el al., 1989; Martin-Ruiz el al., 2000; Nordberg, 1993; Perry el al., 
1977a; Perry et al., 1977b; Perry el al., 1990; Rosser et al., 1984; Shimohama et al., 
1986; Whitehouse and Kalaria, 1995). Cognitive impairment in patients with mild 
AD was comparable to anti-cholinergic treatment (using scopolamine) of control 
individuals (Christensen el al., 1992), which correlates with the cholinergic deficit in 
AD. 
The basis for this cholinergic abnormality is unknown. P-Amyloid infusion into rat 
brain has been shown to decrease ChAT activity in the frontal cortex and 
hippocampus, and also decreased ACh (1) and-dopamine release from cholinergic and 
dopaminergic neurons respectively (Itoh el al., 1996a; Nabeshima and Nitta, 1994; 
Nitta el al., 1994). P-Amyloid plaque deposition may therefore contribute to the 
neurotransmitter abnormalities observed in AD. However, this does not explain the 
relatively selective loss of cholinergic neurons. 
Cholinergic neurons use choline for two purposes: in the form of ACh (1) for 
neurotransmission and in the form of phosphatidylcholine, for cell membrane 
maintenance. It has been proposed that, in AD, choline metabolism is disturbed and 
under these conditions, cholinergic neurons may use membrane-bound choline for 
neurotransmission (Wurtman, 1992). This may result in impaired cell membrane 
structure and neuronal degeneration, and may also expose the transmembrane domain 
of APP to enzymes that metabolise APP to give P-amyloid, which may be deposited 
to form the senile plaques. Other theories that have been proposed to explain 
cholinergic impairment in AD include decreased energy metabolism, which may 
consequently affect APP metabolism, arising from oxidative damage to mitocliondrial 
DNA (Gabuzda et al., 1994; Mecocci el al., 1994). However, impaired energy 
metabolism may also affect other neurons, and would perhaps not be selective for 
cholinergic neurons. Further knowledge regarding the relatively selective loss of 
cholinergic neurons in AD is necessary to validate the theories proposed, and identify 
potential causes of AD. 
Decreased cholinergic activity in AD has also been associated with enhancement of 
APP processing, so perhaps increases senile'plaque formation (Haas et al., 1995). 
Some studies have shown that cholinergic abnormalities, including decreased 
cholinergic neurons in the basal nucleus of Meynert and decreased ChAT activity, 
were not observed in the brains of AD patients (Palmer et al., 1986; Pearson el al., 
1983). As the diagnosis of AD is often difficult, due to symptomatic and pathological 
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similarities to other forms of dementia, it may be possible that the cases that showed 
no cholinergic impairment may not have been caused by AD. It may also be possible 
that AD may exist as several subtypes, which may vary in their pathology and 
severity of cholinergic abnormalities. This would make diagnosis and treatment more 
difficult. 
1.1.2 Proposed Causes of Alzheimer's Disease 
1.1.2.1 Genetics 
Although increasing age appears to be the main risk factor for AD, identification of 
the cause or causes in the majority of cases of AD has yet to be established. Several 
factors have been proposed to cause AD, including genetics. 
In a small proportion of AD cases, a gene on chromosome 21 has been identified, 
which initiates abnormal metabolism of P-amyloid to promote the formation of the 
insoluble form located in senile plaques; this rare cause of AD has been associated 
with early onset AD (Goate et al., 199 1; Heston et al., 198 1), but does not explain the 
majority of other cases. Patients with late onset AD have not shown linkage to 
chromosome 21 markers (St George Hyslop el al., 1990). Chromosome 21 is 
responsible for Down's syndrome, and may explain why the brains of Down's 
syndrome patients show similar pathology to AD, and why relatives of patients with 
Down's syndrome also have an increased risk of developing AD (Griffin etal., 1989; 
Masters et al., 1985; Rumble el al., 1989).. However, chromosome 21 does not 
explain all cases of early onset AD, and is perhaps an infrequent cause of early onset 
AD in the general population (van Duijn el al., 1991). 
Genes located on chromosomes I and 14, which code for the proteins presenilin 2 and 
1, have been associated with senile plaque formation, and have also been found to 
explain a small number of familial AD cases (Gopinath, 1998; Mullan and Crawford, 
1993; Selkoe, 1996). 
A gene located on chromosome 19, which codes for ApoE (responsible for transport 
of lipids) has been shown to influence AD risk. The rare isoform ApoE 2 allele (7%) 
is associated with a reduced risk of AD development, the more common isoform 
ApoE 3 allele (78%) has not been associated with an effect on AD risk, but the ApoE 
4 allele (15%) has been associated with an increased risk of AD development (Lendon 
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el al., 1997; Roses, 1996; Yankner and Mesulam, 1991). ApoE 4 has been reported to 
promote amyloidogenesis (Castafio et al., 1995; Kindy el al., 1995). It is reported that 
ApoE may be involved in transporting P-amyloid from the brain, but the ApoE 4 
allele may result in less efficient removal of P-amyloid, thus contributing to senile 
plaque formation (Evans, 2001). This may explain the role of ApoE 4 in AD 
pathology, although other mechanisms may also occur. For example, the reduction in 
ChAT activity in the cortex of AD patients has been found to be proportional to the 
ApoE 4 allele, indicating ApoE 4 may be associated with cholinergic degeneration 
(Soininen et al., 1995). 
It has been estimated that genetic links may account for approximately 50% of AD 
cases (Plassman and Breitner, 1996). In the other AD cases, environmental factors 
may be more significant contributing factors, perhaps by interaction with 
undetermined genetic factors. 
More recently, genes on chromosome 10 have also been associated with senile plaque 
formation, and increase the risk of developing late onset AD (Butcher, 2000; Majores 
el al., 2000). In view of this discovery, it is apparent that genetic influences may be 
more significant in AD risk than has been suggested previously, and that the genetic 
association with senile plaque formation indicates that senile plaques are a significant 
factor in the early pathogenesis of AD. 
1.1.2.2 Alterations in the Blood-Brain Barrier 
The blood-brain barrier (BBB) is composed of specialised cerebral endotheliurn 
(capillary and arteriolar endothelium), which restricts the passage of molecules from 
blood to the brain (Bradbury, 1984; Conford, 1985). It has been proposed that injury, 
or abnormalities in the BBB may be involved in AD pathogenesis. Evidence suggests 
that in AD, the BBB becomes leaky due to'gaps in tight junctions, and there are 
significant changes in glucose transport, events that may contribute to cerebral 
hypoperfusion and neuronal death (de-Figueiredo et al., 1997). Serum proteins (e. g. 
amyloid P component) are reported to be detected in senile plaques (Perlmutter, 
1994), which indicates BBB impairment may allow toxins to reach the brain. It has 
been proposed that it is 0-amyloid that promotes the initial degeneration of the 
vasculature of the BBB (Kalaria, 1997; Perlmutter, 1994; Vinters; and Pardridge, 
1986; Wisniewski et al., 1997). Therefore BBB dysfunction may not be a cause of 
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AD, but may participate in the pathological processes associated with AD 
progression. 
1.1.2.3 Environmental Factors 
Environmental factors that have been proposed to cause AD include infections (e. g. 
herpes simplex virus) and exposure to toxic agents (e. g. excessive alcohol and 
aluminium) (Gopinath, 1998; Haase el al., 1986; Royston et al., 1992; Savory el al., 
1996). High levels of calcium, silicon, iron and aluminium have been located in 
brains of AD patients, and have therefore been linked with AD development, perhaps 
due to increased oxidative stress. It is unknown if the presence of metal ions in 
plaques of AD patients contribute to their development or if they accumulate after 
plaques have formed. 
Dietary aluminium intake has been proposed to be associated with an increased risk of 
AD (Rogers and Simon, 1999). Aluminium increases BBB permeability (Banks and 
Kastin, 1983), which could result in neurotoxins reaching the brain and causing 
neurodegeneration. It has been reported that aluminium can induce the formation of 
neurofibrillary tangles, similar to those identified in AD, in villo (Barker and 
Branford, 1991). A rare form of dementia has also been identified in dialysis patients, 
which has been associated with excess aluminium in the dialysing fluid, and which 
shows similar pathology to AD (Barker and Branford, 1991; Candy et al., 1992; 
Flaten el al., 1996; Scholtz el al., 1987). These occurrences suggest aluminium may 
contribute to AD development, but this theory has been questioned. For example, in 
cases of aluminium toxicity, AD pathology has not been established and, in workers 
in an aluminium reduction plant, no significant increase in AD risk was found (Barker 
and Branford, 199 1; Moulin el al., 2000). 
Head injury is reported to trigger the formation of P-amyloid plaques, for example, 
dementia pugilistica has been linked to the repeated head trauma incurred by boxers 
(Roberts et al., 1991; Royston el al., 1992). The occurrence of P-amyloid plaque 
formation in dementia induced by both genetics and head injury, reinforces tile 
significance of plaque formation in dementia pathogenesis. 
Diet has also been linked to AD. Some studies have shown a correlation between low 
serum concentrations of folate and vitamin B12, and high levels of homocysteine, 
which has been associated with an increased risk of AD (Clarke et al., 1998; Lehmann 
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el al., 1999; Miller, 1999). Raised homocysteine levels are also associated with 
cardiovascular disease, which may also be a contributing factor in AD pathogenesis. 
Homocysteine has been found to potentiate Pýamyloid-mediated toxicity in neuronal 
cultures (White el al., 2001), suggesting that the hyperhomocysteinaemia associated 
with AD may contribute to the cytotoxic effects of P-amyloid. It is unknown if 
supplementing the diet with folate and vitamin B12 would protect against AD, and 
further investigation is necessary to establish this. 
Copper deficiency has also been proposed to be a contributing factor to AD risk, and 
has been implicated in neuronal degeneration (Hartmann and Evenson, 1992). 
Further investigations are necessary to establish any dietary links with AD, but 
considering the multipathogenic nature of the disease, and the variety of proposed 
causes, diet is unlikely to be the only contributing factor in AD pathogenesis. 
1.1.2.4 Other Proposed Contributing Factors 
Alterations in cerebral microvasculature, cerebrovascular disease and hypertension 
have also been implicated as causes of dementia (Abe et al., 1991; Bu6e el al., 1994; 
Skoog, 1997). These occurrences may cause vascular insufficiency (e. g. as a result of 
cerebral infarcts) or BBB dysfunction, thus allowing toxins to permeate through to the 
brain. A specific role for these conditions in AD pathogenesis remains to be 
established. 
It has been proposed that the neurotransmitter glutamic, acid may cause 
neurodegeneration. Increased levels of glutamic acid may stimulate highly sensitive 
N-methyl-D-aspartate (NMDA) and amino-3-hydroxy-5-methylisoxasole-4-propionic 
acid (AMPA) receptors, resulting in glutamatergic neuronal death (Ossowska, 1993). 
It has not been established if glutamic acid plays a significant role in the initiation of 
AD, but it is likely to participate in the pathological processes in AD. For example, 
peptides identified in P-amyloid protein enhanced the neurotoxicity of glutamic acid 
through NMDA and kainite receptors (Mattson el al., 1992). 
Other factors that have been linked with AD development include oxidative stress to 
neurons, inflammatory processes within the CNS and alterations in hormone levels 
with the aging process. These factors are further discussed in relation to potential AD 
treatment (refer to 1.2.2,1.2.3 and 1.2.4). 
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1.2 Therapeutic Stratellies for Management of Alzheinier's Disease 
It is apparent that AD involves multiple pathogenic events, including neurotransmitter 
disturbances, senile plaque and neurofibrillary tangle formation, and oxidative and 
inflammatory processes. Management of AD should address the known underlying 
pathologies in order to improve symptoms, and perhaps to prevent and delay disease 
progression. 
1.2.1 Enhancement of Cliolinergic Function 
The presynaptic synthesis of ACh (1) from choline and acetyl coenzyme A in neurons 
is catalysed by the enzyme ChAT (Marshall and Parsons, 1987). Once syntliesised, 
ACh (1) is stored in synaptic vesicles and is released upon neuronal stimulation into 
the synaptic cleft (Marshall and Parsons, 1987). ACh (1) may then stimulate post- 
synaptic receptors (or pre-synaptic receptors to regulate ACh (1) release) before being 
hydrolysed to yield choline and acetate, under the action of AChE. Improving 
cholinergic function by targeting the -processes involved in cholinergic 
neurotransmission is a rational approach to palliative treatment of AD. 
However, cholinergic therapies have been relatively unsuccessful and when effective, 
only give moderate symptomatic improvement. Consequently, cholinergic enhancers 
may require use with other agents proposed to be relevant in AD therapy, to maximise 
cognitive benefits. 
1.1 Precursors of Acetylcholin 
Adequate availability of choline has been proposed to permit adequate ACII (1) 
synthesis for neurotransmission. Precursors of ACh (1) (e. g. choline and lecithin) 
have been investigated for their effects on synthesis and release of ACh (1), with a 
view to increasing ACh (1) release and cholinergic, activity. Few studies have 
reported any significant beneficial effects on cognitive fiinction, and only modest if 
any, beneficial effects were observed (Kumar el al., 1998b). 
Therapy failure may be due to impaired uptake mechanisms of choline causing the 
reduction in ACh (1) synthesis, and not due to insufficient choline supply. This is 
apparent as it has been reported that more choline occurs in the cerebrospinal fluid 
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(CSF) of AD patients than in patients without AD, and that choline levels increased 
with disease progression (Giacobini, 1993; Kumar el al., 1998b). Therapy with ACh 
(1) precursors was also limited by side-effects, including gastro-intestinal 
disturbances such as nausea, vomiting and diarrhoea. 
ACh (1) precursors have been combined with AChE inhibitors, with the aim of 
enhancing cholinergic effects. Combinations of the AChE inhibitors tacrine (7) and 
physostigmine (5) with lecithin did not promote additional cognition enhancing 
effects in AD patients (Chattellier and Lacomblez, 1990; Peters and Levin, 1979; 
Wettstein, 1983). Therefore, precursors of ACh (t) do not appear to be important for 
AD treatment. 
1.2.1.2 Stimulation of Cholinergic Receptor 
Cholinergic agonists are reported to facilitate learning and memory but cholinergic 
antagonists impair learning and memory (Blokland, 1996; Karczmar, 1995), thus 
cholinergic agonists may be appropriate in cognitive disorders such as AD. 
Nicotinic Receptor Ligands 
Behavioural studies have shown that nicotinic receptors, which are ligand-gated ion 
channels, participate in functions such as attention, memory and cognition 
(Miliailescu and Drucker-Collin, 2000). Nicotinic receptors have been shown to be 
reduced in cortical brain areas in AD (London et al., 1989; Martin-Ruiz el al., 2000; 
Nordberg, 1993; Perry et al., 1990; Shimohama et al., 1986); nicotine (2) is reported 
to upregulate nicotinic receptors and to increase ACh (1) release (Balfour and 
Fagerstr6m, 1996; Flores et al., 1992; Whitehouse and Kalaria, 1995). Thus nicotinic 
receptor agonists may enhance cholinergic neurotransmission in AD. Nicotine (2) 
treatment in various iii vivo studies, including administration to rats with cholinergic 
brain lesions and in aged monkeys, has been shown to improve cognitive function 
(Buccafusco and Jackson, 1991; Decker el al., 1992; Rezvani and Levin, 2001). 
It is also reported that smoking may have protective effects against AD development 
and that administration of nicotine (2) to AD patients improved cognitive function 
(Graves and Mortimer, 1994; Newhouse and Kelton, 2000; Sahakian el al., 1989; van 
Duijn and Hofman, 1991). However, some cohort studies have shown that smoking 
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shows either no association with AD risk, or moderately increases AD risk (Kukull, 
2001; Merchant et aL, 1999; Tyas el al., 2000). Perhaps a possible increased AD risk 
may be related to the consequences of smoking (e. g. free radical production and 
cerebrovascular disease). As several studies have also shown that nicotine (2) alone 
(in the absence of other chemicals associated with smoking) may enhance cognitive 
function, use of nicotine (2) or related compounds may be an approach in AD therapy. 
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Nicotine (2) 
The cognition enhancing effects of nicotine (2) reported in animals and humans, may 
be due to nicotinic receptor stimulation. But nicotine (2) may also protect against AD 
by other mechanisms. Nicotine (2) has been shown to inhibit P-amyloid formation ill 
vill-o (Salomon el al., 1996; Zamani and Allen, 2001), which may also explain tile 
apparent protective effects of smoking against AD. However, one study that involved 
analysis of AD brains showed that smoking did not appear to protect against senile 
plaque formation (Ulrich et al., 1997). Nicotine (2) has been reported to inhibit the 
neurotoxic effects of excitatory amino acids (e. g. glutamate) and to enhance the 
effects of nerve growth factor (NGF) (Akaike et al., 1994; Whitehouse and Kalaria, 
1995), which may explain the possible protective effects of smoking against AD and 
favourable effects on cognition. 
Numerous nicotinic receptor subtypes have been identified (Williams el al., 1994). 
For example, the a7 and a402 receptor subtypes have been found in brain regions 
important for cognition, including the cerebral cortex and hippocampus, and the 
compound GTS-21 is a relatively selective agonist for the a7 receptor (and also 
interacts with the a4P2 receptor) (Kem, 2000; Rezvani and Levin, 2001). GTS-21 is 
reported to enhance cognition ill vivo, and was neuroprotective to neuronal cells 
exposed to P-amyloid ill vilro (Kem, 2000). Thus, GTS-21 may be useful in AD 
therapy. 
If nicotinic agonists continue to be thoroughly assessed, and consistently enhance 
cholinergic function or perhaps influence other mechanisms in AD patients, there is 
the opportunity for selective drug development to minimise adverse-effects associated 
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with nicotine (2) (e. g. cardiovascular effects (Benowitz, 1992)) and maximise 
efficacy. ABT-418, a nicotinic receptor agonist, has been shown to interact more 
selectively with the CWP2 receptor subtype and was as effective as nicotine (2) in 
memory tasks in vivo, but with fewer adverse effects than nicotine (2) and, was 
neuroprotective hi vitro (Arneric et al., 1995). Therefore, selective nicotinic receptor 
agonists may have potential in future AD therapy. 
Muscarinic Receptor Ligands 
Although muscarinic receptors, which are coupled to G-proteins, are not reported to 
be significantly reduced in AD (with the exception of the M2 receptor subtype) 
(Nordberg, 1992; Price el al., 1985), treatment with muscarinic agonists has not 
shown significant benefit in cognitive function. 
Treatment with xanomeline, a muscarinic receptor agonist, showed some 
improvement in behavioural symptoms and cognition in AD patients in a double- 
blind, placebo-controlled trial, but 52% of patients discontinued treatment due to 
adverse effects, including gastro-intestinal side-effects (Bodick et al., 1997). Tile 
muscarinic agonist RS-86 (3) also showed no significant benefits in cognitive 
function, which would suggest it is not appropriate in AD therapy (Bruno et aL, 1986; 














Arecoline (4), which has relative selectivity for M, receptors, only moderately 
improved cognitive function and recognition in AD patients (Raffaele et al., 1996; 
Tariot ef al., 1988). Arecoline (4) is reported to poorly penetrate the BBB 
(Krogsgaard-Larsen ef al., 1989), which may explain the lack of significant benefits 
observed in vivo. The unpleasant side-effects reported to be associated with 
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muscarinic agonists (e. g. arecoline (4), pilocarpine, RS 86 (3)) may prevent their 
clinical use. 
Muscarinic antagonists (e. g. tile M2 antagonists DX-116, AF-DX384 and AQ-RA 
741) acting at presynaptic autoreceptors, at which ACh (1) regulates its own release, 
elevated ACh (1) levels in vitro and in vivo (Consolo el al., 1987; Hoss et al., 1990; 
Stillman et al., 1993; Stillman et al., 1996; Torocsik and Vizi, 1991; Wilson et al., 
1993). However, as it is the M2 receptors which are reported be reduced in AD 
brains, M2 receptor levels may not be sufficiently high to enable significant 
enhancement of cholinergic activity with these compounds. 
It is reported that no muscarinc agonists with a high selectivity for a particular 
receptor subtype (Mi - M5) exist (Caulfield and Birdsall, 1998). Knowledge of the 
most relevant receptor subtype in AD treatment, and the development of highly 
selective muscarinic agonists (or presynaptic receptor antagonists) may be appropriate 
for AD management. 
1.2.1.3 Inhibition of Acetyleholinesterase 
The cholinesterases hydrolyse choline esters, with AChE being more specific for ACh 
(1) hydrolysis. The functions of butylcholinesterase (BuChE) are uncertain, including 
any possible involvement it may have in AD pathogenesis (Taylor, 1991). AChE, but 
not BuChE, has been shown to promote amyloid formation (Inestrosa el al., 1996a; 
Inestrosa el al., 1996b). AChE is bound to tile pre- and post-synaptic membrane, 
where it hydrolyses ACh (1). Therefore the availability of ACh (1) released into the 
synaptic cleft may be prolonged, by inhibiting its hydrolysis by AChE through the use 
of AChE inhibitors. 
Six isoenzymes of AChE, which is a large glycoprotein, have been identified: 
globular monomers (GI), dimers (G2) and tetramers (G4), and tailed asymmetric 
tetramers (A4), double tetramers (A8) and triple tetramers (A12) (Brimijoin, 1983). 
The majority of AChE in nervous tissue is globular, with 80% - 90% in mammalian 
brain being in the G4 form, and most of the remainder occurring as the G, form; tailed 
forms of AChE are reported to compose <1% of brain AChE (Brimijoin, 1983). In 
AD, a reduction in the tetrameric form (G4) of AChE in the cortex and hippocampus 
is accompanied by a 300- 400-fold increase in asymmetric AChE, particularly A12, 
and G, levels also increase (Arendt el al., 1992; Fishman, et al., 1986; Ogane el al., 
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1992; Younkin et al., 1986). The significance of the changes in the forms of AChE in 
AD is unknown. 
Physostiamine and Rivastigmin 
Physostigmine (5) has been shown to inhibit both G, and G4 AChE forms (Ogane et 
al., 1992), the major AChE isoenzymes present in mammalian CNS. This effect 
indicates that physostigmine (5) inhibits CNS AChE but, as G4 AChE levels are 
reported to be decreased in AD brains (Ogane et al., 1992; Younkin el al., 1986), 
there may be clinical implications regarding efficacy. An inhibitor that is more 
selective for the G, AChE form, may be more relevant in AD. Physostigmine (5) 
inhibited AChE and BuChE with similar potency (Otoguro el al., 1997). Therefore, 
adverse effects associated with BuChE inhibition may also occur with physostigmine 
Physostigmine (5), a short-acting reversible AChE inhibitor, was reported to show 
cognitive benefits in both non-AD and AD patients (Davis and Molis, 1982; McCaleb, 
1990; Shu, 1998; Sitaram et al., 1978), but clinical use may be limited by its short 
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Rivastigmine (6), an analogue of the alkaloid physostigmine (5), was licensed for use 
in the UK in 2000 for the symptomatic treatment of mild to moderately severe AD. 
Rivastigmine (6) improves cognition in AD patients, an effect that has been correlated 
with the level of AChE inhibition (Agid el al., 1998; Cutler el al., 1999; Grossberg 
and Desai, 2001; Kumar el al., 1999; Spencer and Noble, 1998). Rivastigmine (6) 
preferentially inhibits the G, form of AChE (Polinsky, 1998), which may occur at 
elevated levels in AD. Greater selectivity for the G, form of AChE may enhance 
efficacy and minimise adverse effects. Inhibition of other forms of AChE in the 
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peripheral nervous system (e. g. in muscles and cardiovascular system) may increase 
the incidence of adverse effects, such as cramps and bradycardia. Rivastigmine (6) is 
reported to inhibit AChE in the cortex and hippocampus (Polinsky, 1998), brain areas 
involved in cognition. Rivastigmine (6) is therefore a more appropriate candidate for 
use in AD patients than physostigmine (5). 
Tacrine 
The first AChE inhibitor to be licensed for management of AD was tacrine (7), a 
centrally active reversible inhibitor, which requires dosing three times daily due to the 
relatively short half-life. Tacrine (7) is longer acting than physostigmine (5), 
therefore has some dosing advantages; tacrine (7) readily crosses the BBB and 
moderate improvement in symptoms was observed following its use in AD patients 
(Farlow el al., 1993; Knapp el- al., 1994; Olin and Sclincier, 1995; Summers el al., 
1986). Tacrine (7) may also enhance cholinergic neurotransmission by stimulating 






Routine use of tacrine (7) is restricted by liepatotoxic side-effects (Hammel el al., 
1990; Watkins el al., 1994). Both tacrine (7) and physostigmine (5) have been shown 
to antagonise scopolamine-induced impairment of cognitive function in rats (Yoshida 
and Suzuki, 1993), which is further evidence for their favourable effects on 
cholinergic function M vivo. Tacrine (7) and physostigmine (5) both have low 
bioavailability (17% - 37% and 3% - 8% respectively), compared to newer ACIIE 
inhibitors such as donepezil (8), rivastigmine'(6) and galantamine (9) (40% - 100% 
bioavailability) (Nordberg and Svensson, 1998). 
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Donepezil 
Donepezil (8), an inhibitor relatively selective for CNS AChE, was licensed for use in 
the UK in 1997 for the symptomatic treatment of mild to moderately severe AD. 
Severe liepatotoxicity is not associated with donepezil (8), and dosing is required once 
daily due to the drug's longer half-life (70hr - 80hr), which are advantages over 
tacrine (7). Donepezil (8) has also shown significant improvements in the cognitive 








Galantamine (9) is reported to be more selective for AChE than BuChE, and provides 
complete oral bioavailability (Bickel et al., 1991; Fulton and Benfield, 1996; Harvey, 
1995). Galantamine (9) is licensed in Europe for AD treatment and was well tolerated 
and significantly improved cognitive function when administered to AD patients, in a 





Galantamine (9) is also reported to stimulate nicotinic receptors (Woodruff-Pak el al., 
2001), which may also enhance cholinergic function and memory. This additional 
activity, suggests galantamine (9) may have therapeutic advantages over other AChE 
inhibitors. 
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Other AChE Inhibitors for Potential AD Therap 
Several other AChE inhibitors have been investigated for their potential in AD 
therapy. E2020 inhibited brain AChE in rats following subcutaneous administration, 
and consequently increased ACh (1) levels in the cortex, but increases in levels of 
dopamine and noradrenaline were also observed (Giacobini el al., 1996). These 
results indicate that dopaminergic and noradrenergic neurons may have been 
influenced by the E2020 stimulated cholinergic system, such interactions have 
previously been reported (Decker and McGaugh, 1991; Moroni el al., 1983; Vizi, 
1980), or that perhaps E2020 may independently interact with these neuronal systems 
to influence neurotransmitter levels. 
The alkaloid huperzine A (10), isolated from the moss Hipei-zia sel-I-ala, which has 
been used in China for centuries to treat fever and inflammation, is also a reversible 
inhibitor of AChE (Ashani et al., 1992; Lagani6re el al., 199 1; McKinney et al., 199 1; 
Wang el al., 1986b). Huperzine A (10) is used in China for the symptomatic 
treatment of dementia, and is being investigated for international use (Houghton, 





Huperzine A (10) 
In a multi-centre, double-blind trial, huperzine A (10) significantly improved memory 
and behaviour in AD patients, and was reported to be more selective for AChE than 
BuChE and less toxic than donepezil (8) and tacrine (7) (Small et al., 1997; Shu, 
1998). 
The AChE inhibitors in clinical use are natural alkaloids or structurally related to 
natural alkaloids, and contain nitrogen within a ring system. Arisugacins A (11) and 
B (12) are non-alkaloidal selective inhibitors of AChE (and were not selective for 
BuChE) from Penicillhan spp. and have been shown to be 200-fold more potent than 
tacrine (7) at inhibiting AChE activity in vitl-o (Omura el al., 1995; Otoguro el al., 
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1997). The arisugacins may have potential in AD therapy, but further studies in vivo 
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Phenserine (13), a derivative of physostigmine (5), is a selective inhibitor of AChE 
(>50-fold inhibitory activity for AChE than BuChE), with 100% bioavailability 
(Greig el al., 2000). Phenserine (13) is also reported to reduce APP levels by 
interfering in transcription processes, and subsequent senile plaque formation (Evans, 
2001). 
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Plienserine (13) 
Administration of phenserine (13) to rats with learning impairment (induced by a 
NMDA receptor antagonist) resulted in improved cognitive function (Patel el al., 
1998). This indicates that phenserine (13) may additionally influence glutaminergic 
function, and is a potential candidate for AD therapy. 
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Assessment of the Use of AChE Inhibitors in Alzheimer's Disease 
The efficacy of AChE inhibitors is limited by several factors. Functional cholinergic 
neurons are necessary for the effectiveness of drugs that aim to improve cholinergic 
neurotransmission, which may limit efficacy, particularly in the later stages of AD 
when neuronal degeneration is significant. Tile low levels of AChE reported to occur 
in AD (Arendt, et al., 1992; Atack et al., 1983; Hammond and Brimijoin, 1988) may 
also limit successful treatment. 
Tile use of AChE inhibitors for AD treatment has been proposed to actually induce 
harm rather than favourable effects; AChE levels in AD are imbalanced, which may 
reflect an underlying pathology of AD in addition to the adverse effects reported 
(Shen, 1996). Inhibition of AChE activity may further disrupt AChE activity, causing 
further imbalance and perhaps promote disease progression. The adverse effects 
induced by AChE inhibitors may cause harm. For example, anti chol i nesterase 
(antiChE) organophosphates are reported to induce myopathy, myocardial pathology 
and polyneuropathy (Millard and Broomfield, 1995), but these effects may not be 
associated with the AChE inhibitors designed for AD therapy. However, other 
potentially serious adverse effects have been associated with AChE inhibitors (e. g. 
donepezil (8)), including bradycardia (perhaps mediated by peripheral M2 receptors 
(Lazartigues et al., 1998)) and seizures; in addition hal luci nations, aggressive 
behaviour and agitation have been reported to occur (CSM and MCA report, 1999). 
In conclusion, AChE inhibitors appear to offer some short-term benefits in cognition 
in some, but not all, AD patients, and clinical use may be limited by adverse effects 
(e. g. nausea, vomiting and diarrhoea). Thus, antiChE therapy in AD should continue 
to be evaluated to justify routine use, but AChE inhibitor use in AD may be more 
appropriate with the development of more selective AChE inhibitors. 
1.2.2 Oestrogen Replacement Therapy 
The oestrogen (or estrogen) receptor (ER) is a member of the steroid receptor 
superfamily of transcription factors, which also includes receptors for vitamin D, 
thyroid hormone and retinoic acid. The ER has been found to occur as two subtypes: 
ERa and ERP. The ER is responsible for regulation of gene expression, for genes 
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involved in tissue growth and differentiation. ER(x and ERO have different 
transcriptional activation properties. 
ERa is predominantly expressed in breast, uterus, pituitary and ovary but ERP is 
predominantly expressed in prostate, bone, vascular tissue and uterus in rats 
(Dechering et al., 2000; Kuiper el al., 1997; Mason, 2001). ERa and predominantly 
ERP have been detected in the hippocampus, an area important for cognition in the 
monkey, and oestrogen treatment was suggested to modulate behaviours and 
functions mediated by the amygdala (Osterlund el al., 1998; Register el al., 1998). 
More recently, ERa has also been detected in rat cerebral cortex and human 
amygdala, hypothalamus, cerebral cortex and hippocampus (Butler el al., 1999; 
Osterlund et al., 2000), which suggests that ERa modulation may not only be related 
to endocrine function, but also to cognitive function. 
AD is reported to affect 1.2 - 3.5 times more women than men, an effect that has not 
been associated with greater longevity in women (Birge, 1997; McGuffey, 1997). 
Although oestrogen levels are lower in men than women, levels are reported to be 
maintained at a constant level throughout life in men due to intracerebral metabolism 
of testosterone to oestrogen, until testosterone levels decline. Epiderniologic studies 
show that AD incidence increases in women after the age of 65 years, but gender 
differences are not associated with early onset AD, in which oestrogen levels are 
generally at constant levels in both men and women (Birge, 1996; Paganina-Hill and 
Henderson, 1996; Payami el al., 1996). 
Several studies indicate that oestrogen (or estrogen) replacement therapy (ERT) may 
have favourable effects in the prevention and treatment of AD. ERT in women is 
associated with a reduced risk of developing AD and, oestrogen treatment in women 
with AD is reported to enhance cognitive function and also enhance the response to 
tacrine (7) (Birge, 1997; Fillit el al., 1986; Honjo el al., 1989; Olikura el al., 1994; 
Schneider el al., 1996). ERT is also reported to enhance cognitive function in women 
without AD. For example, high serum oestrogen concentrations in women have been 
associated with less impairment of cognitive function than low oestrogen levels, and 
ERT improved memory skills in post-menopausal women (Kampen and Sherwin, 
1994; Yaffe el al., 2000). ERT also improved cognitive function in ovariectomised 
rats (Birge, 1997). However, some studies did not show cognitive improvement in 
AD patients (Mu1nard et al., 2000). 
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The mechanisms by which oestrogens may protect against AD are unclear, but may be 
mediated by ERs in the basal forebrain and hippocampus, effects on neurotransmitter 
systems, modulation of neurotrophic growth factor levels, maintenance of synaptic 
density, enhancement of cerebral blood flow, anti-oxidant effects or other unknown 
mechanisms. 
1.2.2.1 Anti-Oxidant Activity of Oestrogens 
170-Oestradiol (E2) (14) protected hippocampal neuronal cells from oxidative stress- 
induced cytotoxicity following exposure to 0-amyloid, H202 or glutamate ill vitro; 
other hormones including progesterone, aldosterone and corticosterone, were not 
neuroprotective (Behl el al., 1995). Other studies have also shown that oestrogens 
(e. g. estriol and E2 (14)) are anti-oxidant and that other steroids (e. g. progesterone 
and testosterone) were not anti-oxidant (Mooradian, 1993). E2 (14) and 2-hydroxy- 
E2 have also been shown to be good inhibitors of lipid peroxidation (Ruiz-Larrea et 
al., 1994; Wiseman et al., 1990). These results suggest that oestrogens may protect 
against the oxidative processes, including peroxidative damage to cell membranes, 




Several synthetic oestrogens (e. g. di ethyl sti lboestrol (15)) and some anti-oestrogens 
(e. g. ICI 164,384 and tamoxifen) are also reported to be anti-oxidant and were 
inhibitors of lipid peroxidation in vitro (Wiseman et al., 1990; Wiseman and 
Halliwell, 1993; Wiseman, 1994). 
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1.2.2.2 Effect of Oestroizens on Neurotransmitter Systems 
Steroids have been shown to affect various neurotransmitter systems in the CNS, 
which may also contribute to the proposed beneficial effects of oestrogens in AD. 
Steroids are reported to act non-transcriptionally in neurons and may influence 
neurotransmission and synaptic function (McEwan, 1991; Moss et al., 1997), which 
suggests they may have functions other than cell growth and differentiation. 
E2 (14) treatment in ovariectomised rodents increased dopamine turnover and striatal 
dopamine release hi vivo (Becker, 1990; Di Paolo et al., 1985). It is not yet 
understood how E2 (14) may influence dopamine release, but it may involve binding 
to an external ER binding site in the striaturn (Xiao and Becker, 1998). E2 (14) also 
increased striatal dopamine receptors in rat brain hi vivo (Hruska, 1986). The 
potential for oestrogenic compounds to enhance dopamine release and upregulate 
dopamine receptors may be relevant in AD and also Parkinson's disease. 
Other neurotransmitter systems which have been influenced by E2 (14) include 
GABAergic, glutamatergic, noradrenergic and serotonergic systems; both increases 
and decreases in receptor densities have been observed (Biegon et al., 1983; Frangois- 
Bellan et al., 1989; Herbison et al., 2000; McEwen et al., 1995; Moss ef al., 1997; 
Woodley el aL, 2000). Further studies are required to confirm these effects and 
identify any relevance to AD. E2 (14) also decreased monoamine oxidase (MAO)-A 
activity in rat brain (Luine and McEwen, 1977). This suggests that E2 (14) may 
suppress MAO-A activity, thus reducing degradation of 5-HT, which may be relevant 
in AD and depression. 
Perhaps more relevant to AD, cholinergic neurons in the basal forebrain are reported 
to have ERs that are co-localised with NGF receptors (Sohrabji el al., 1994; Toran- 
Allerand et al., 1992). This indicates that oestrogens may influence cholinergic 
function and perhaps regulate NGF. E2 (14) has been found to increase ChAT 
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activity in various brain regions, including the basal forebrain and hippocampus in 
rats (Kaufman et al., 1988; Luine, 1985), so may enhance cholinergic function. The 
basal forebrain of male rats did not show increased ChAT activity in response to E2 
(14) treatment, which may reflect the differences in basal forebrains between male 
and female rats (females have smaller and more densely packed cholinergic neurons 
that males) (McEwen el al., 1995), or perhaps differences in ER distribution. 
1.2.2.3 Oestroizens and P-Amyloid 
In vitro, E2 (14) promotes the metabolism of APP to P-amyloid peptides that are less 
likely to form senile plaque deposits (Jaffe et al., 1994). E2 (14) has also been 
proposed to modulate inflammatory responses involved in senile plaque formation 
(Birge, 1997). P-Amyloid induced cytotoxicity hi vitro was prevented by E2 (14), via 
interaction with ER(x (Kim et al., 2001). ERa ligands may therefore be appropriate 
for reducing P-amyloid-induced cytotoxicity in AD, but it cannot be excluded that 
other favourable effects associated with ERT may be mediated by ERP, or perhaps 
receptor independent mechanisms. E2 (14) also enhanced the uptake of P-amyloid by 
microglia in vitro, which may result in enhanced clearance of P-amyloid in AD, thus 
reducing senile plaque formation (Li et al., 2000). 
The environmental oestrogen, bisphenol A, also protects neurons from P-amyloid- and 
glutamate-induced cytotoxicity in vitro (Gursoy et aL, 2001). Therefore synthetic 
oestrogens may also have potential in cognitive disorders. 
Further research regarding the use of ERT in AD patients is necessary to establish the 
potential benefits. However, there is significant evidence to suggest that ERT may 
have a preventative effect against AD development, and may be useful in slowing 
disease progression. Consideration must also be given to the potential adverse effects 
of ERT (e. g. carcinogenesis). Phyto-o estrogens (e. g. soy isoflavones) are also 
reported to offer protection against AD development (Pharm. J., 2001) and may act 
similarly to ERT or via different mechanisms. Phyto-oestrogens have not been 
associated with the carcinogenic effects of ERT, and may be a more appropriate 
alternative in the prevention of AD. 
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1.2.3 Anti-Inflammatory Drugs 
The inflammatory processes that occur in AD are complex, and the pathology remains 
poorly understood. Pro-inflammatory cytokines (e. g. tumour necrosis factor (TNF) 
and interleukins (EL-I and EL-6)), complement proteins (e. g. Clq) and acute phase 
proteins (e. g. a-l-antitrypsin) have been identified in senile plaques (Dickson and 
Rogers, 1992; McGeer and McGeer, 1995; Schenk el al., 1995). AD pathogenesis is 
reported to include activation of the classical complement system, expression of 
complement and cytokine receptors by microglia, and upregulation of toxic cytokines 
(Eikelenboorn et al., 1989; McGeer and McGe er, 1997; McGeer and McGeer, 1999a; 
McGeer and McGeer, 1999b; Rogers et al., 1996; Vandenabeele and Fiers, 1991). 
The co-localisation of inflammatory mediators with AD lesions (e. g. senile plaques) 
indicates that inflammatory processes may mediate neuronal damage, or may be a 
consequence of lesion formation, or both. 
1.2.3.1 Acute Phase Reactants 
The occurrence of acute phase reactants in AD brain suggests that local inflammatory 
processes may be involved in AD pathogenesis. The acute phase reactants associated 
with inflammation in AD include a- I -anti chymotrypsin (ACT), a-2-macroglobulin, a- 
I-antitrypsin, serum amyloid P (SAP) and C-reactive protein (Rogers ef al., 1996); 
ACT and a-2-macroglobulin have been identified in senile plaques (Rozemuller et al., 
1990). ACT and SAP have been reported to alter the rate of aggregation of P-amyloid 
into the neurotoxic form, and ACT promoted O-amyloid deposition in vivo (Nilsson el 
al., 2001; Rogers et al., 1996). SAP is a significant component of senile plaques and 
has been associated with neurofibrillary tangles (Akiyama et al., 1991; Pepys et al., 
1982). 
The association of these mediators with senile plaque formation, and perhaps 
neurofibrillary tangle formation, suggests that they are contributors to disease 
progression, 
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1.2.3.2 Complement Proteins 
The complement system is designed to promote phagocytosis and destroy foreign 
matter. The classical complement system is reported to be activated in AD brains 
(McGeer and McGeer, 1999b). Complement proteins associated with senile plaques 
and neurofibrillary tangles in AD include CI - C9 (McGeer and McGeer, 1999b; 
Rogers et al., 1996). 
O-Amyloid may initiate the complement pathway, which may explain the 
inflammatory processes that occur in AD brain. P-Arnyloid may bind to Clq, which 
may then activate the complement system (Webster et al., 1997a). The activation of 
the complement pathway by P-amyloid was potentiated in vitro by ApoE 4, but not 
ApoE 2 or ApoE 3 (McGeer et al., 1997). Individuals with the ApoE 4 allele, a risk 
factor for AD, may therefore experience significant inflammatory events in the brain, 
which may contribute to further neuronal degeneration. Clq itself also accelerates the 
aggregation of P-amyloid (Webster et al., 1994). Therefore, inhibition of Clq binding 
to P-amyloid may be a target for reducing the inflammatory processes in AD, to 
minimise neuronal damage. 
C1 activation cleaves C2 and C4 to generate a series of other complement proteins, 
and eventually C5b may combine with C6, C7, C8 and C9 to form C5b-9, the 
membrane attack complex (MAC), which inserts into membranes and causes lysis and 
death (McGeer and McGeer, 1999b). MAC has been reported to occur in degenerated 
neurons containing neurofibrillary tangles in the AD brain (Schenk et al., 1995; 
Webster el al., 1997b). 
Synthesis of complement proteins occurs in the pyramidal neurons in cortical brain 
regions (Shen et al., 1997). Rat pyramidal neurons express mRNA for cyclo- 
oxygenase-2 (COX-2), involved in eicosanoid generation (Tocco et al., 1997), which 
may also explain the involvement of COX in inflammatory processes in AD. 
Therefore, regulation of complement protein activity could be one approach to 




Inflammatory cytokines amplify and sustain inflammation and immune responses, and 
may be produced in the CNS by cells, including astrocytes, microglia and neurons 
(McGeer and McGeer, 1997). Activated T-cells may also produce cytokines and 
cross the BBB, and have been located in lesioned areas of AD brain (McGeer and 
McGeer, 1995). The cytokines identified as markers of inflammation in AD include 
IL-1, IL-6 and TNF. 
The cytokine IL-I is present in non-diseased brain where it is involved in the acute 
phase response and immune function. The APP gene is reported to be induced by IL- 
I in vitro, and IL-I immunoreactivity is increased in AD (Griffin el al., 1989; 
Royston et al., 1992), indicating that IL-I over-expression in AD may increase APP 
synthesis and subsequent plaque deposition. IL-I and TNF have been reported to 
regulate NGF synthesis, and increased NGF-mRNA in vitro (Lindholm et al., 1987). 
The sprouting of neuronal axons and dendrites, associated with Alzheimer's 
pathology, may be explained by the neurotrophic effects of IL-I (or TNF) stimulated 
NGF. It has also been proposed that IL-I and TNF may induce IL-6, which in turn 
may induce al-antichymotrypsin, which is also a component of senile plaques 
(Vandenabeele and Fiers, 1991). IL-I induced COX-2 expression and prostaglandin 
(PG) E2 secretion in human neuroblastoma cells in vitro (Hoozemans et al., 2001a). 
This suggests that IL-I may also upregulate COX-2 expression in AD, and generate 
damaging inflammatory mediators. 
IL-1 receptor antagonists may therefore be of therapeutic value in AD, and may also 
inhibit neuronal damage induced by cerebral ischaemia; in rats IL-1 expression was 
induced by brain ischaemia (Minami el al., 1992). It has also been reported that 
intracerebroventricular administration of an IL-I receptor antagonist to rats 
significantly reduced APP density (Royston et al., 1992). 
1.2.3.4 Immunosilobulin 
Intercellular adhesion molecule-I (ICAM-1) accumulates in microvascular 
endothelial cells and in senile plaques, which indicates that the infiltration of 
lymphocytes into the brain may occur in AD (Akiyama ef al., 1993; Verbeek el al., 
1994). However, ICAM-1 is also produced in astrocytes (Akiyama et al., 1993; 
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Rosenman el al., 1995), suggesting that the inflammatory processes in AD may also 
originate in the CNS. 
1.2.3.5 Microglia and Astrocyie 
Postmortem analysis of the brains of AD patients show evidence of inflammatory 
processes, including the presence of reactive microglia, which are cells involved in 
inflammatory responses in the CNS, compared to control tissue; microglia in AD are 
co-localised with senile plaques (Dickson and Rogers, 1992; DiPatre and Gelman, 
1997; Lue et al., 1996). 
Microglia express numerous receptors, including complement receptors, 
immunoglobulin receptors, ICAM-1 receptors and antigens, and may be activated by 
various mediators, including complement proteins, cytokines and also 0-amyloid 
(McGeer and McGeer, 1995; McGeer and McGeer, 1999b). Activated microglia may 
produce nitric oxide (NO), superoxides, glutamate, prostaglandins and possibly other 
inflammatory mediators and neurotoxins (McGeer and McGeer, 1999b), which may 
also contribute to neuronal death. In transgenic mice, both microglia and astrocytes 
increased in the presence of 0-amyloid, and were closely associated with P-amyloid 
deposits (Matsuoka el al., 200 1). 
Astrocytes, which are involved in the maintenance of synaptic fiInction, are believed 
to be a source of arachidonic acid (AA) derivatives and other inflammatory mediators 
in the brain. Astrocyte proliferation may be stimulated by the elevated IL-1 levels in 
AD, resulting in secretion of various growth factors, interleukins, prostaglandins, 
leukotrienes, thromboxanes, ACT and complement factors (McGeer and McGeer, 
1995; Walker el al., 1998). 
Prostaglandins (synthesised via COX) may potentiate glutamate toxicity by inhibiting 
re-uptake of glutamate by astrocytes (Breitner et al., 1996b). Inhibitors of enzymes in 
the AA cascade (e. g. COX) may therefore be of therapeutic value in AD. Senile 
plaque formation in AD brain is reported to disturb the functions of astrocytes 
(Kerokoski et al., 2001). This may result in impaired synaptic function and perhaps 
altered secretion of toxic mediators from astrocytes. Astrocytes have also been 
located in mature plaques (Frederickson, 1992), which is perhaps associated with their 
production of ApoE (Mrak el al., 1995). 
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1.2.3.6 Oriains of Inflarnmatorv Processes 
There is considerable evidence that inflammatory mechanisms occur in AD, but the 
reasons why these inflammatory processes occur are unclear. Immunological 
processes may explain the inflammatory mechanisms; perhaps impaired BBB 
integrity may allow immunological reactants to reach the brain. BBB permeability is 
reported to be impaired in neuroinflammatory diseases including AD, and it has been 
hypothesised that this may permit inflammatory mediators and other neurotoxins to 
enter the brain and perhaps initiate AD pathogenesis (De Vries et al., 1997). It is 
possible however, that BBB impairment occurs during AD progression, as a result of 
inflammatory mechanisms. 
Brain injury, arising from ischaernia, head injury or senile plaque formation may also 
contribute to inflammatory processes. For example, IL-1 expression is induced 
following brain injury or cerebral ischaernia (Minami et al., 1992). An immune 
response to toxins, including senile plaque components and neurofibrillary tangles, 
may stimulate the inflammatory processes in the AD brain. Further neuronal death 
and senile plaque formation may then exacerbate inflammation resulting in 
continuous disease progression. 
P-Amyloid stimulates cytokine production, which in turn stimulates APP production 
(Araujo and Cotman, 1992; Forloni et al., 1992; Gitter el al., 1993), which may 
promote further P-amyloid plaque formation, in a cyclic mechanism. P-Amyloid has 
also been reported to induce microglial phagocytosis, expression of inducible NO 
synthase and NO production, and neuronal loss in rat CNS hi vivo (Weldon et al., 
1998). 
It has also been proposed that viral infections may initiate an inflammatory response 
in the CNS, leading to senile plaque formation (Dickson and Rogers, 1992; 
Vandenabeele and Fiers, 1991), but this remains to be established in relation to AD. 
1.2.3.7 NSAIDs 
It is evident that inflammation is not the only pathogenic mechanism that occurs in 
AD. However, it is apparent that inflammatory processes may contribute to 
neurodegeneration and perhaps accelerate disease progression, therefore the use of 
anti- i nfl ammatory agents may be important as part of AD therapy. 
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There are several studies that show that non-steroidal anti-inflammatory drugs 
(NSAIDs) may reduce the risk of developing AD, and that patients with rheumatoid 
arthritis, who often use NSAIDs, have a lower incidence of AD (Breitner, 1996a; 
Breitner et al., 1995; Jenkinson et al., 1989; McGeer et al., 1990; McGeer et al., 
1996). The relative risk of AD decreases with increased duration of NSAID use 
(Stewart et al., 1997). 
It could be proposed that individuals with a genetic predisposition to rheumatoid 
arthritis may also have a genetically associated lower risk of developing AD. This 
could explain the apparent inverse relationship between AD and rheumatoid arthritis. 
However, use of dapsone, which is an anti-leprosy drug with anti-inflammatory 
activity, has also been associated with a lower incidence of AD (McGeer et al., 1992). 
This suggests that anti-inflammatory therapy may be successful in delaying AD 
progression. This is also suggested by the results of a study in which treatment with 
indomethacin in a six month, double-blind, placebo-controlled trial, showed cognitive 
improvement in AD patients (Rogers et al., 1993). 
The pharmacological action of NSAIDs in the brain that may protect against AD 
remains unclear. COX inhibitors suppress prostaglandin synthesis (prostaglandins 
inhibit astrocyte reuptake of the neurotoxin glutamate), which may suppress the 
potentiation of glutaminergic transmission and so protect against excitotoxic cell 
death (Breitner, 1996b); over-stimulation of neuronal glutamate receptors, arising 
from excessive glutamate release, is neurotoxic (Rothman and Olney, 1986). It has 
also been shown that NSAIDs are neuroprotective in vitro (Klegeris et aL, 1999), 
which may explain their beneficial effects against AD. NSAIDs are also reported to 
prevent APP over-expression and over-production of amyloidogenic peptides (Lee 
and Wurtman, 2000), which indicates they may inhibit senile plaque formation. 
Although the potential protective effects of NSAIDs against AD progression are well 
documented (Breitner, 1996a; Breitner, 1996b; Breitner et al., 1995; Klegeris el al, 
1999 McGeer et al., 1996; Rogers et al., 1993), NSAID use, particularly in long-term 
therapy, is restricted by adverse effects (e. g. gastro-intestinal bleeding and ulceration) 
and potential interactions with other drugs. Consequently, there is a need for effective 
anti-inflammatory agents, which have advantages over the NSAIDs in terms of the 
adverse effect profile and efficacy. 
NSAIDs are inhibitors of COX-1 and COX-2, but COX-2 inhibition may be more 
relevant to AD treatment. COX-2 may contribute to neuronal vulnerability, and is 
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reported to be expressed in the neocortex, which is involved in cognitive function 
(Felician et al., 1997; O'Banion, 1999). COX-2 was upregulated in astrocytes 
associated with P-amyloid deposits in transgenic mice, and also stimulated P-amyloid 
production hi vitro (Kadoyama et al., 2001; Matsuoka et al., 2001). Thus, COX-2 
may participate in senile plaque formation AD. COX-2 levels were substantially 
upregulated in lesioned areas of AD brain, but COX-I levels were only slightly 
upregulated (Yasojima et al., 1999b). Therefore COX-2 inhibitors may be more 
appropriate for use in AD, particularly as the adverse effects of NSAIDs have been 
associated with COX-I inhibition. But, COX-1-positive microglia associated with 
senile plaques have been identified in AD brains (Hoozemans et al., 2001a). This 
suggests that COX-I inhibition may also be relevant in AD therapy. Further 
investigations regarding the potential cognitive benefits of COX-I and COX-2 
inhibitors in AD are therefore warranted. 
Prednisone treatment in patients with AD did not provide cognitive benefits, but 
showed behavioural decline compared to the placebo (Aisen, 2000). This outcome 
does not necessarily mean that anti-inflammatory therapy is not useful in AD, as 
NSAIDs may have favourable effects that are not mediated by steroids. As steroids 
may cause psychogenic effects, their use in AD to alleviate inflammation may not be 
appropriate. 
Numerous plants and plant constituents have demonstrated anti-inflammatory 
properties (Bing6l and $ener, 1995; Deepak and Handa, 2000; Handa et al., 1992; 
Hoult and PayA, 1996; Laughton el al., 1991; Skaltsa et al., 2000; Welton et al., 
1986), thus there is potential for novel anti-inflammatory agents to be identified, 
which may be useful in AD therapy, with fewer adverse effects than drugs currently 
available. For example, ferulic acid, which is an anti-oxidant and anti-inflammatory 
compound derived from plants, ameliorated the 0-amyloid-induced reduction in ACh 
(1) levels in the cortex and P-amyloid-induced IL-I immunoreactivity in the 
hippocampus in mice, and also improved cognitive function (Yan et al., 2001). 
1.2.4 Anti-Oxidant TheraPy 
Free radicals may damage biological materials including carbohydrates, DNA, lipids 
and proteins. The peroxidation of phospholipid cell membranes is a free radical- 
mediated process. A primary free radical interacts with a polyunsaturated fatty acid 
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(PUFA), which then rearranges to form a conjugated diene, which may react with02 
to yield a peroxyl radical. The peroxyl radical can abstract H from another lipid 
molecule in a propagative process, which initiates a complex series of reactions that 
yield various degradation products (Halliwell and Gutteridge, 1995; Slater, 1984). 
The degradation products (e. g. hydroxyalkenals) from lipid peroxidation may cause 
various biological effects, including enzyme inhibition and modulation of DNA 
synthesis (Slater, 1984). Lipid peroxide arising from lipid peroxidation in cells is 
cytotoxic, causing disruption of cell membranes (Ando el al., 1990); this mechanism 
has been found to be one of the major biochemical markers of aging. 
Free radical reactions are reported to initiate cell injury, and have been implicated in 
the pathology of many diseases including aging processes, atherosclerosis, ischaemic 
heart disease and neuro degenerative diseases (Maxwell, 1995; Slater, 1984; Spiteller, 
1993). It has been proposed that oxidative processes may be involved in AD 
pathogenesis. Therefore, the use of anti-oxidants may slow AD progression and 
minimise neuronal degeneration. 
1.2.4.1 Oxidative Stress in Alzheimer's Disease 
Oxidative damage to proteins and DNA has been found in the brains of AD patients 
(Lyras et al., 1997). Lipid peroxidation in the brain may be associated with normal 
aging. In rats, aged brains showed higher levels of lipid peroxides, perhaps due to 
altered protection systems against oxidative damage (Ando et al., 1990). However, 
lipid peroxidation is reported to be more extensive in AD brains than normal aged 
brains. Lipid peroxidation of membranes has been identified in various brain regions, 
including the hippocamPus and amygdala, of AD patients and, ApoE peroxidation has 
been correlated to AD (BaUzs and Leon, 1994; Christen, 2000; Lovell et al., 1995), 
which may reflect the extent of oxidative damage at various stages of AD 
pathogenesis. Elevated levels of glutathione peroxidase, superoxide dismutase 
(SOD), glutathione reductase and catalase have also been reported to occur in AD 
brains, perhaps as a compensatory response to free-radical activity (Lovell et al., 
1995). 
Most lipid peroxidation M vivo is metal-ion dependent (Halliwell el al., 1989). 
Elevated levels of iron in AD brains have been associated with senile plaques, and 
this has also been implicated in oxidative processes (Christen, 2000; Connor el al., 
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1992; Smith el al., 1997). Cerebral ischaernia, which has been implicated in dementia 
pathology, has also been reported to initiate oxygen radical mechanisms (Traystman 
et al., 199 1). 
1.2.4.2 P-Amyloid 
Although oxidative processes in AD are well characterised, the source of oxidative 
stress in AD pathogenesis is unclear. One contributing factor may be P-amyloid. 
Cortical neurons from Down's syndrome brain, which also show elevated levels of 0- 
amyloid, showed an increase in intracellular levels of reactive oxygen species 
compared to controls ill vitro, and spontaneous apoptosis was reduced by free radical 
scavengers (Buscuglio and Yankner, 1995; Oyama el al., 1994). P-Amyloid inhibited 
the electrical stimulation of NA release and increased intracellular Ca2+ levels in rat 
brain cortical slices and synaptosomes, respectively; both effects were prevented by 
N-tert-butyl-a-phenylnitrone (PBN), a free radical scavenger (Li and Smith, 1996). 
The preventative effect of the free radical scavenger, indicates that free radical 
generation may be involved in the neurotoxic effects of P-amyloid. 
It has been shown that P-amyloid causes oxidative stress to neurons ill vitro and that 
free radical attack of cell membranes initiates lipid peroxidation (Behl el al., 1994; 
Hensley et al., 1994; Mark et al, 1995; Marx, 1996). Generation of free radicals, via 
an unknown mechanism, also promoted the toxicity of P-amyloid in rat hippocampal 
cells ill vitro (Manelli and Puttfarcken, 1995). P-Amyloid has also been reported to 
cause an accumulation of H202 and lipid peroxides in cells, which may be inhibited 
by catalase (Behl et al., 1994). These results indicate that P-amyloid may promote 
oxidative damage to neurons in AD, perhaps due to H202 via hydroxyl radicals (OH), 
although other mechanisms of oxidative damage may also occur. 
1.2.4.3 Neurofibrillary Tangles 
The formation of neurofibrillary tangles has been proposed to occur as a result of 
oxidative mechanisms, but may also contribute to oxidative stress. An increase in 
oxidative stress in neurons has been proposed to decrease tau binding to microtubules 
causing microtubule instability; such events may cause inappropriate tau 
accumulation and subsequent hyperphosphorylation and facilitation of filament 
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formation (Guttman et al., 1995; Schweers el al., 1995; Wille el al., 1992). However, 
treatment of cortical neurons with H202 did not cause hyperphosphorylation of tau in 
vitro (Davis et al., 1997), indicating that oxidative stress may not cause 
neurofibrillary tangles. The formation of paired helical filaments containing 
abnormally hyperphosphorylated tau has been associated with oxidative stress 
(Johnson and Jenkins, 1996), which may contribute to further oxidative damage to 
neurons. It remains unclear whether neurofibrillary tangle formation involves 
oxidative processes in vivo. 
1.2.4.4 Anti-Oxidants 
Oxidative processes appear to be a contributing factor to neuronal degeneration in AD 
pathogenesis, but their role in the cause of AD remains unclear. The use of anti- 
oxidants as part of AD therapy may slow deterioration caused by oxidative reactions. 
Various anti-oxidants have been investigated for their potential in AD therapy. The 
anti-oxidants vitamin E and propyl gallate (PpG) (135) have been shown to protect 
neurons from P-amyloid toxicity in vilro (Behl et al., 1992). An anti-oxidant 
derivative synthesised from prostaglandin B2 and ascorbic acid, inhibited free radical 
formation and lipid peroxidation in rat brain, following ischaernic injury (Sakamoto el 
al., 1991) and chronic anti-oxidant treatment improved cognitive function in aged rats 
(Socci et al., 1995). 
It is important that anti-oxidants used as part of AD therapy, are able to cross the BBB 
and reach their site of action. The pyrrolopyrimidine anti-oxidants (e. g. U-101033E) 
are reported to cross the BBB and enter the brain and are neuroprotective (Schmid- 
Elsaesser el al., 1997), so may have potential in AD. 
Injury of plant cells, as well as mammalian cells, is associated with the activation of 
lipoxygenases, which catalyse the formation of hydroperoxides of PUFAs; a 
hydroperoxide radical may react with fatty acids to produce dioxoenes, which are 
regarded as plant defence compounds (Spiteller, 1993). The occurrence of oxidative 
mechanisms in plants may explain why an abundance of anti-oxidant compounds 
have been identified in plant tissue, Their anti-oxidant'effects in plants may therefore 
have relevance in mammals, particularly in disorders involving oxidative stress such 
as AD. 
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A wide range of plants and their constituents have been shown to be potent anti- 
oxidants by various mechanisms, including free radical scavenging activity and 
inhibition of lipid peroxidation. 
Some plants with anti-oxidant activity include Aesechis hippocastanum, Allium 
intlans, Artendsia spp., Guiei-a senegalensis, Hanlanielis virginiana, Romnarinus 
officinalis, Salvia officinalis, Tararacum officinale and Thymus vulgat-is (Aruoma el 
al., 1996; Bouchet el al., 1998; Cuvelier et al., 1996; Deans et al., 1993; Hagymdsi et 
al., 2000; Kimura el al., 1985b; Masaki el al., 1995; ýtajner et al., 1999; Youdirn and 
Deans, 1999). Phytochemicals with anti-oxidant effects include cinnamic acids, 
coumarins, diterpenes, flavonoids, lignans, monoterpenes, phenylpropanoids, tannins 
and triterpenes (Aesbach el al., 1994; Bouchet el al., 1998; Craig, 1999; Foti el al., 
1996; Kelm et al., 2000; Kimura el al., 1985b; Laughton et al., 1989; Lu and Liu, 
1991; Okuda et al., 1983; Ruberto and Baratta, 2000; Sassa et al., 1990; Schwarz and 
Ternes, 1992; Seidel el al., 2000; Youdirn and Deans, 2000; Zhu el al., 1999). 
Some plants and plant compounds have shown' favourable effects in the CNS, so may 
be appropriate for use in AD. Curcumin from Curcuma longa reduced lipid 
peroxidation in rat brain following oral administration to rats with ethanol-induced 
brain injury (Rajakrishnan el al., 1999), and Bacopa monniera, which is reported to 
have cognition enhancing effects, induced a dose related increase in SOD, catalase 
and glutathione peroxidase activities in the rat frontal cortex, striatum and 
hippocampus (Bhattacharya el al., 2000c). Thynnis vulgal-is essential oil maintained 
higher PUFA levels in various tissues, including the brain in rats, indicating protective 
anti-oxidant effects (Youdirn and Deans, 1999). Therefore the use of plants and their 
constituents in the diet and as supplements may be relevant in slowing AD 
progression. 
1.2.5 Modulation of GABAergic Function 
GABAergic neurons have been identified in the mammalian nervous system, 
including the autonomic nervous system and the CNS, and GABA (16) is an 
important inhibitory neurotransmitter within the CNS (Bowery el aL, 1981; Bowery et 
aL, 1987; Ong and Kerr, 1983; Parkman el aL, 1993; Sivilotti and Nistri, 1991; 
Wilkin, 1981). GABA (16) activates membrane-bound receptors GABAA, GABA13 
and GABAc, although other receptor subtypes may also exist. 
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1.2.5.1 GABAc Receptors 
OH 
H2 N-(CH 2)37-ý 
0 
y-aminobutyric acid (16) 
GABAc receptors have low affinity for GABAA and GABAB receptor modulators, 
including bicuculline (17) and baclofen (20)'respectively (Woodward et al, 1992; 
Woodward et aL, 1993). The role of GABAc receptors is uncertain but their 
localisation in retinal neurons suggests that they may be involved in light responses 
(Feigenspan and Bormann, 1994). 
1.2,5.2 GABAA Receptors and Cognitive Function 
GABAA receptors are involved in the action of anxiolytics (e. g. benzodiazepines) and 
hypnotics (e. g. barbiturates). The activation of GABAA receptors by GABA (16), 
which increases neuronal Cl- conduction, is enhanced by these compounds. Several 
drugs used for management of epilepsy also influence GABAA receptors; these 
include benzodiazepines, valproate and vigabatrin, which enhance GABA-mediated 
neuronal inhibition. GABAA receptor ligands have been implicated in cognition. 
GABAA agonists disrupt memory in animals and humans and benzodiazepine agonists 
and inverse agonists impair and enhance cognition respectively, whilst GABAA 
antagonists enhance memory (Brioni el aL, 1989; Brioni el aL, 1990; Izquierdo and 
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84 
Administration of the GABAA agonist muscimol (18) decreased memory. acquisition 
of passive avoidance learning in mice , and also inhibited the cognitive enhancement 
induced by the AChE inhibitor physostigmine (5) (Zarrindast et aL, 1998). 
The benzodiazepine antagonist ZK 93426 increased cortical ACh (1) release in both 
young and aged rats, and the GABAA antagonist bicuculline (17) increased striatal 
ACh (1) output in rats but, the GABAA agonist muscimol (18) decreased striatal and 
hippocampal ACh (1) release (DeBoer and Westerink, 1994; Gorman et aL, 1994; 
Moore et aL, 1992). This suggests that memory enhancing effects of GABAA 
receptor modulators may be due to stimulation of cholinergic neurotransmission. The 
AChE inhibitor bis(7)-tacrine (19) is also a potent GABAA receptor antagonist (Li et 
aL, 1999), which may result in superior cognitive enhancement when compared to 
GABAA antagonists or AChE inhibitors alone'. However therapeutic use of GABAA 
antagonists may induce seizures, therefore the identification of antagonists with 
partial agonist activity, which also stimulate ACh (1) release, may be more 
appropriate. 
N-(CH N 2)7ý---N N HH 
Bis(7)-tacriiie (19) 
The anaesthetics propofol and thiopental have been found to be neuroprotective 
against anoxia and physical trauma to dendrites, an effect mediated by potentiation of 
GABAA receptor function, and the GABAA agonist muscimol (18) was similarly 
neuroprotective (Hollrigel el al., 1996). Regulation of GABA (16) within the CNS 
may also be neuroprotective by maintaining a balance with glutamate activity. These 
effects may be clinically relevant in neurodegenerative disorders but, as GABAA 
agonists have been reported to impair cognitive function (Brioni el al., 1990), their 
use in AD management may be unwise and use may be more appropriate in disorders 
such as head injury. 
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1.2.5.3 GABAB Receptors and Cognitive Function 
GABAB receptor ligands are used therapeutically for various disorders. For example, 
the GABAB agonist baclofen (20) is used to manage spasticity and trigerninal 
neuralgia, but adverse effects include drowsiness, dizziness, seizures, hallucinations 
and mental confusion (British National Formulary, 2001). GABAB receptors, which 
have been identified in the mammalian CNS, have also been shown to influence steep 
regulation, interactions with alcohol and have been implicated in cognition (Allan and 
Harris, 1989; Crunelli et aL, 1992; Getova el aL, 1997; Hill and Bowery, 1981; 
Mondadori et aL, 1992). 
GABAB agonists (e. g. baclofen (20)) are associated with cognitive impairment 
(Carletti el aL, 1993; Castellano et aL, 1989; McNamara and Skelton, 1996; Tang and 
Hasselmo, 1996), and reduced GABA (16) levels and abnormalities in GABAB 
receptor systems have been identified in AD (Chu et aL, 1987; Klunk et aL, 1994; 
Klunk et aL, 1995; Ossowska, 1993). It is therefore feasible that modulation of 
GABAB receptors may be of clinical relevance in CNS disorders involving cognitive 




GABAB presynaptic and postsynaptic receptors differ in their physiological role, and 
in their affinity for ligands. Antagonism of presynaptic GABAB receptors is proposed 
to counteract the autoinhibition of GABA (16) release, making the occurrence of 
long-term potentiation (LTP) more difficult, whereas antagonism of postsynaptic 
GABAB receptors is reported to facilitate the occurrence of LTP, and postsynaptic 
receptors are completely blocked by lOOgM CGP 35348, whereas presynaptic 
receptors require ImM for complete antagonism (Davies et aL, 1991; Olpe ef aL, 
1993). Administration of CGP 35348 to rats enhanced memory moderately at low 
doses (12.5mg/kg - 25mg/kg), substantially at an intermediate dose (50mg/kg), but at 
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higher doses (100mg/kg - 300mg/kg) effects on memory declined (Stdubli el aL, 
1999). This may be explained by memory enhancement (and LTP occurrence) at 
concentrations at which postsynaptic blockade dominates, but as the concentration of 
CGP 35348 was increased, antagonism of presynaptic receptors occurred and memory 
was not facilitated. It is therefore the antagonism of the postsynaptic receptors that 
may be clinically relevant in cognitive dysfunction. 
GABAB receptor antagonists have been investigated for their potential as anti-amnesic 
agents. The GABAB antagonist CGP 36742 (21), a compound able to cross the BBB, 
reverses age-related deficits in old rats in an active avoidance test, and enhances 
spatial learning performance and antagonises amnesia induced by the GABAB agonist 
baclofen (20) in mice (Carletti el aL, 1993; Froestl et aL, 1995). The memory 
enhancing effects of CGP 36742 (21) were detectable only 20hr after a single 
treatment and although cognition declined with time, effects were still evident after 
four months, suggesting that CGP 36742 (21) may influence long-term memory 
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Treatment with CGP 36742 (21) also improved learning and memory impairment in 
mice caused by colchicine, a compound that induces neurofibrillary degeneration, 
hippocampal lesions and reduces ChAT activity (Bensimon and Chermat, 1991; 
Nakagawa el aL, 1987; Yu el aL, 1997). The more potent GABAB antagonists, CGP 
71982, CGP 62349 and CGP 55845A, improved learning and memory retention in 
active avoidance tests in rats (Getova and Bowery, 1998). These results provide 
further evidence for the potential of GABAB antagonists in the management of 
memory disorders but the mechanism of action of cognition enhancement remains to 
be established. 
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The influence of GABA receptor modulation on the cholinergic system has been 
implicated to explain the effects of GABA agonists and antagonists on cognitive 
function (Decker and McGaugh, 1991). The GABAB receptor antagonist pliaclofen 
(22) modulates ACh (1) release in rat brain slices, the muscarinic receptor agonist 
oxotremorine attenuates the cognitive impairment induced by baclofen (20) in passive 
avoidance tests in rodents, oral administration of CGP 36742 (21) attenuates the 
baclofen- and scopolamine-induced learning deficit in rats and, baclofen (20) 
decreases the learning improvement induced by physostigmine (5) in mice (Arenas el 
aL, 1990; Castellano and McGaugh, 1991; Nakagawa and Takashima, 1997; 
Zarrindast et al., 1998). CGP 35348 dose-dependently potentiates the excitatory 
responses of cortical neurons elicited by ACh (1) (Andre et aL, 1992). The 
mechanisms for these effects remain to be elucidated but these results indicate that 
GABAB receptors may influence cholinergic neurons. 
It has also been reported that spontaneous inhibitory postsynaptic currents in the basal 
forebrain (a major source of cholinergic input to the cerebral cortex) are regulated by 
GABAB receptors, and the amygdala and hippocampus, brain areas involved in 
memory formation, contain cholinergic neurons under the inhibitory control of the 
GABAergic system (Akaike el at, 1992; Izquierdo and Medina, 1991). The results 
from these studies suggest that the cognitive enhancement by GABAB receptor 
antagonists may involve cholinergic function, although other mechanisms of action 
may also occur. 
Modulation of glutamate release has also been proposed to explain the effects of 
GABAB antagonists on cognitive function; an increase in glutamate release may occur 
following a decrease in GABA-mediated inhibition (Bemasconi el at, 1992; 
Bernasconi et at, 1993). Muscimol (18) and baclofen (20) (GABAA and GABAB 
agonists respectively) decrease striatal ACh (1) output in rats, the GABAA antagonist 
bicuculline (17) increases striatal ACh (1) release, but the GABAB antagonist 2- 
hydroxy-saclofen (23) does not influence striatal ACh (1) output (DeBoer and 
Westerink, 1994). It was therefore proposed that although modulation of GABAA 
receptors on cholinergic neurons may regulate ACh (1) release, the GABAB mediated 
effects may be due to presynaptic inhibition of the glutamatergic input of striatal 
cholinergic neurons. But, it cannot be excluded that GABAB antagonists other than 2- 
hydroxy-saclofen (23) may enhance ACh (1) release. 
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GABAB antagonists are also reported to up-regulate GABA receptors (Pratt and 
Bowery, 1993), which may also explain the improvements observed in cognitive 
function. For AD management the use of multiple drug therapy to target 
neurotransmitter systems involving GABAergic and cholinergic function, may 
provide clinical advantages over current approaches to enhance cholinergic function 
alone with AChE inhibitors. 
Depression may also be a feature of AD (Berg, and Morris, 1990) but antidepressant 
use may be limited due to adverse effects (e. g. tricyclic antidepressants are 
anticholinergic and may impair cognition). GABAB receptor activation is reported to 
suppress catecholamine and 5-HT release from brain slices and it was proposed that 
GABAB antagonists may alleviate depression by inhibiting the suppression of NA 
release, induced by GABA (16) acting on presynaptic GABAB receptors on 
noradrenergic terminals (Bowery el al, 1980; Pratt and Bowery, 1993). However, 
there have been conflicting reports regarding the effect of antidepressants on GABA 
binding to GABAB receptors (Arranz el al, 1992; Lloyd and Pilc, 1984; Pratt and 
Bowery, 1993). In view of these findings, the potential for GABAB antagonists to 
treat depression cannot be ignored, but does require further investigation. 
1.2.6 Other Therapeutic Strategies 
1.2.6.1 Modulation of Other Neurotransmitter Systems 
As several neurotransmitter systems are affected in AD pathogenesis, drugs that 
enhance neurotransmission, other than cholinergic neurotransmission, have been 
investigated as potential therapy. Potentiation of noradrenergic function has been 
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explored, but the a-adrenoceptor agonist clonidine did not show any cognitive 
benefits (Mohr et al., 1989). The MAO-B inhibitor selegeline reduces dopamine 
metabolism, so may enhance doparninergic activity in the brain. Selegeline showed 
some beneficial effects on behaviour and cognition in AD patients (Schneider el al., 
1991; Tariot et al., 1987) but the MAO-B inhibitor milacemide was ineffective in AD 
patients (Dysken et al., 1992). Enhancement of 5-HT levels using trazodone has been 
shown to improve the behavioural problems associated with AD (e. g. irritability, 
restlessness and anxiety) (Lake and Grossberg, 1987; Lebert et al., 1994; Simpson 
and Foster, 1986). It is apparent that attempts to modulate other neurotransmitter 
systems to date have been relatively unsuccessful, which emphasises the need to 
identify alternatives to treat symptoms of AD. 
Glutamate may induce neuronal degeneration, by over-stimulation of NMDA 
receptors. The development of NMDA receptor antagonists may offer some 
protection against neuronal degeneration in AD. Memantine (24), an NMDA receptor 
antagonist, is reported to be under investigation in phase III clinical trials in the USA 
and is already approved for use in dementia in Germany (Evans, 2001; Marx, 2000). 
NH2 
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1.2.6.2 Cerebral Vasodilators 
Brain capillaries are also affected in AD. P-Amyloid surrounds the brain vasculature, 
which may result in thickened capillaries with impaired elasticity resulting in 
impaired cerebral blood flow and eventually degeneration (Vinters el al., 1994). 
Cerebral vasodilators, including co-dergocrine, isoxsuprine, cyclandelate and ergoloid 
mesylates, have been investigated (alone or in combination with lecithin) to enhance 
cerebral blood flow, but have also shown little promise as potential AD therapy 
(Jenike el al., 1986; Weyer et al., 2000). 
Extracts from Ginkgo biloba leaf have improved symptoms in AD patients (Kanowski 
el al., 1997; Le Bars et al., 1997; Le Bars et al., 2000; Rigney et al., 1999), which was 
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perhaps due to vasodilatory flavonoids but other mechanisms of action may also be 
responsible for the favourable effects observed (refer to 1.3, Table 1.1). 
1.2.6.3 Modulation of Senile Plaque Formation 
Manipulation of senile plaque formation, a critical event in AD pathogenesis, is 
another approach to AD management. For example, the inhibition of secretases 
thought to be responsible for APP metabolism, in an attempt to reduce P-amyloid 
plaque formation, has been reported (Evans, 2001; Kisilevsky, 1998). The 
compounds brefeldin A and monensin are reported to inhibit the conversion of the 
immature form of P-secretase (beta-site APP cleaving enzyme (BACE)) from the 
mature form of BACE, which is under the action of a furin-like proprotcin convertase 
(Bennett et al., 2000). Compounds that bind to presenilin, which form a complex 
with y-secretase, are also under investigation for their inhibition of senile plaque 
formation (Evans, 2001). 
Other targets may include reducing P-amyloid deposition, perhaps by enhancing its 
clearance. The anti-psychotics haloperidol and droperidol dosc-dependently inhibited 
P-amyloid formation in human neurons iii vitro, which may have occurred via 
inhibition of proteolysis (Higaki el al., 1997). These findings indicate that some anti- 
psychotics may have therapeutic potential in AD. 
Some proteins are able to bind to P-amyloid, including AChE, which has been shown 
to accelerate the formation of P-amyloid deposits, and AChE has been found to be 
localised in senile plaques and also in neurofibrillary tangles (Coleman et al., 1992; 
Inestrosa el al., 1996a, Inestrosa et al., 1996b; Morfin et al., 1993). These findings 
indicate that AChE may participate in senile plaque formation, and that its inhibition 
may inhibit senile plaque formation. AChE inhibitors (e. g. tacrine (7)) have been 
shown to reduce APP secretion iii vitro (Lahiri el al., 1994; Lahari el al., 2000), 
suggesting that AChE inhibitors may inhibit senile plaque formation in AD. 
Transgenic mice that had overexpressed human AChE neurons showed a progressive 
cognitive decline (Beeri et al., 1995). AChE may impair cognition, perhaps by 
hydrolysing ACh (1) and affecting neurotransmission, by modulating P-amyloid 
deposition, by modulating neurofibrillary tangle formation or, by unknown 
mechanisms. 
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The prevention of senile plaque formation using a vaccine has also been investigated. 
The vaccine composed of AN-1792, an artificial form of P-amyloid, was found to 
reduce existing senile plaques and prevent further senile plaque formation in 
transgenic mice, and did not stimulate autoirnmunity (Helmuth, 2000; Marwick, 
2000). 
1.2.6.4 Nerve Growth Factor 
NGF is important in growth and maintenance of cholinergic neurons and its 
administration to rodents, improved learning and retention (Fischer el al., 1987; 
Ricceri et al., 1996; Schneider, 1996). The mechanism to explain these observations 
has not been established, but could be due to one or more effects. NGF is reported to 
upregulate cholinergic neuron function, reverse cholinergic neuron atrophy, increase 
nicotinic receptors, improve cerebral blood flow, raise ChAT levels in forebrain 
cholinergic neurons in vitro and in vivo and protect against neuronal degeneration 
(Fischer ef al., 1987; Nordberg, 1996; Sofroniew, 1996). NGF treatment may 
alleviate symptoms of AD, but may not halt disease progression and potential adverse 
effects in vivo require thorough investigation (e. g. sustained hyperalgesia has been 
reported to occur (Olsen, 1997; Sofroniew, 1996)). Other problems that may be 
associated with NGF treatment could be a lack of specificity (for neurons within the 
CNS) and delivery to the brain would be restricted by the BBB. Direct injection into 
the brain may be complicated by the potential for infections and perhaps interference 
in brain activity resulting in convulsions. 
Leteprinim potassium (NeoTrofin), which can cross the BBB, is reported to stimulate 
the synthesis of various growth factors in neuronal cells, and may also enhance V- 
secretase activity, which reduces the abnormal metabolism of APP and subsequent 
senile plaque formation (Evans, 2001). 
1.2.6.5 Symptomatic Treatment 
Various treatments are also used to relieve symptoms of AD other than memory. The 
use of anti-psychotics (e. g. thioridazine and haloperidol) for control of agitated 
behaviour and psychosis is reported to be marginally effective (Schneider et al., 1990; 
Teri el al., 2000), but their use is limited by extrapyramidal side-effects and anti- 
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cholinergic effects including dry mouth, constipation, blurred vision and perhaps 
further impairment of cholinergic function. More effective treatments with fewer 
adverse effects would be preferred to anti-psychotics. 
The use of anxiolytics (e. g. benzodiazepines such as diazepam) is an approach to 
manage behavioural symptoms and insomnia, but adverse effects on cognition may 
worsen confusion and cognitive function (British National Formulary, 2001). The use 
of these drugs should therefore be limited. Other drugs which are reported to be of 
some use in behavioural disturbances, but not in memory improvement, in AD 
patients include the 5-HTIA partial agonist buspirone, anticonvulsants (e. g. 
carbamazipine) and P-blockers (e. g. propranolol) (Blokland, 1996; Kumar el aL, 
1998b), however side-effects including dizziness and confusion and nausea may make 
their routine use inappropriate. 
Depression, also a feature of AD, warrants the use of anti-depressants (e. g. tricyclics 
such as imipramine), which should also be used with caution due to the potential 
cardiovascular and anti-cholinergic effects. Selective serotonin reuptake inhibitors 
(SSRIs) (e. g. citaloprarn and sertraline) are reported to be effective in controlling 
agitated behaviour and depression in AD patients (Kumar et aL, 1998b; Nyth and 
Gottfries, 1996), and may therefore be useful in symptomatic treatment. 
1.3 Use of Plants for ManaLrement of CoEmitive Disorders 
There are numerous drugs available in Western medicine which have been directly 
isolated from plants, or are derived from templates of compounds from plant sources. 
For example, the cardenolide digoxin, originally from Digitalis spp., is used for heart 
failure and ephedrine, originally from Ephedra spp., is used as a decongestant. 
Phytochemicals that have acted as templates for the development of drugs used 
clinically, include opioid analgesics (chemically related to opioid compounds from 
Papavet- soniniferum L. ) and the anti-coagulant warfarin (chemically related to the 
coumarins). 
The use of plant extracts for medicinal purposes may offer some benefits over the use 
of single drugs. For example, the many constituents present in a plant extract may act 
synergistically to enhance a particular pharmacological activity, may provide more 
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than one relevant pharmacological activity for a particular disease, or may contain 
constituents which counteract the toxic effects of other constituents. 
Compounds may not only act synergistically -with other compounds from the same 
plant, but may also enhance the activity of compounds from other plant species. This 
approach has been used in various practices of traditional medicine, including 
Ayurveda and traditional Japanese and Chinese medicine (TCM) where a mixture of 
plants is commonly prescribed. 
Numerous alkaloids from plant sources have been investigated for their potential in 
AD therapy, and are now in clinical use (e. g. galantamine (9) from Galantillis nilalis 
L. is used in the UK and huperzine A (10) from Hiperzia set-i-ata Thunb. is used in 
China, for AD). The chemical structure of physostigmine (5) from PIlysosligina 
venenositni Balf, provided a template for the development of rivastigmine (6), which 
is also licensed in the UK for AD. Various other plant species have shown favourable 
effects in AD, or pharmacological activities indicating the potential for use in AD 
therapy, some of which are summarised in Table 1.1. 
The pharmacological activities of plants and their constituents often reflect tile use of 
the plant in traditional herbal medicine. For example, the traditional Japanese 
prescription Choto-san, which is composed of eleven crude drugs (e. g. Ginseng radix, 
Glycyt-i-Ifizae and Zingiberis rhizoma), was used traditionally to treat cerebrovascular 
related disorders; recent studies showed anti-amnesic effects in mice and a clinical 
trial showed favourable effects in patients with vascular dementia (Terasawa el al., 
1998; Yuzurihara et al., 1999). 
This ethriopharmacological approach has provided leads to identifying potential new 
drugs, including those for memory disorders (some of which are summarised in Table 
1.1) and may aid the discovery of a more varied and efficacious selection of drugs for 
AD treatment. In the present study, various plants used in traditional Ayurvedic, 
Chinese and European medicines for their memo ry-enhancing and anti-dementia 
effects, were investigated to identify any pharmacological basis for their reputed 
activities. The plants selected for investigation are described (refer to 1.4). 
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Table 1.1. Some plants and isolated compounds with relevant activities in relation to 
treatment of cognitive disorders, including Alzheimer's disease. 
Plant Compounds Traditional Uses, Plia rmaco logical and 
Isolated Clinical Effects 
Angelica Compounds The crude alcoholic extract of Angelica 
archangelica L. responsible for archangelica displaced nicotine (2) 
displacement of binding to nicotine receptors in a 
nicotine (2) concentration dependent manner (Perry et 
receptor binding al., 1996). 
are unknown. 
Artendsia Compounds The crude alcoholic extract of Artethisia 
absinthium L. responsible for absinthium displaced nicotine (2) binding 
displacement of to nicotine receptors in a concentration 
nicotine (2) dependent manner (Perry ef al., 1996). 
receptor binding 
are unknown. 
Bacopa monniera Compounds Bacopa monniera has been used in 
responsible for Ayurvedic medicine to improve memory 
activity require and intellect. 
further study, but Bacopa monniera extract is reported to 
activity may be facilitate learning acquisition and showed 
due to bacosides A anti-oxidant effects in rat frontal cortex, 
and B (saponins). striatum and hippocampus; bacosides A 
and B are reported to inhibit the amnesic 
effects of scoPolamine in rodents 
(13hattacharya el al., 2000c). 
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Table I. I. (Continued) Some plants and isolated compounds with relevant activities 
in relation to treatment of cognitive disorders, including Alzheimer's disease. 
Plant Compounds Traditional Uses, Pharmacological and 
Isolated Clinical Effects 
Biota orientalis L. Compounds Biota orientalis is used in TCM for 
responsible for insomnia and amnesia. 
activity require Biola orientalis extract ameliorated the 
further study. memory acquisition disorder induced by 
amygdala lesions in mice (Nishiyama et 
al., 1992). 
Coplis chinensis Berberine and Coptis chinensis and berberine and 
Franch. palmatine palmatine are AChE inhibitors (Huang, 
(alkaloids). 1993), suggesting potential in AD therapy. 
Crocus sativus L. Crocin (diterpene). Crocus sativits was used in folk medicine 
as an antispasmodic, sedative, carminative 
and nerve sedative. 
Crocus sativus extract and crocin 
improved ethanol-induced impairment of 
learning behaviour in mice (Abe and 
Saito, 2000). 
Ewodiarittaecarpa Dehydroevodiamine Evodia nitaecarpa is used in TCM for 
Benth. (alkaloid). cardiovascular and analgesic effects. 
Evodia rulaecarpa and 
dehydroevodiamine inhibited AChE in 
vitro in a dose-dependent manner, and 
reversed scopolamine-induced memory 
impairment in rats (Park et al., 1996). 
Dehydroevodiamine is also reported to 
increase cerebral blood flow (Haji et al., 
1994). 
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Table I. I. (Continued) Some plants and isolated compounds with relevant activities 
in relation to treatment of cognitive disorders, including Alzheimer's disease. 
Plant Compounds 
Isolated 
Traditional Uses, Pharmaco logical and 
Clinical Effects 
Galanthus nivalis Galantamine (9) Galanthus nivalis was used traditionally in 
L. (also Narcissus (alkaloid). Bulgaria and Turkey for neurological 
spp. ) conditions (Shu, 1998). 
Galantamine (9) slowed the decline in 
cognition and functional ability in AD 
patients (Wilcock et al., 2000). 
Ginkgo biloba L. Ginkgolides (e. g. Ginkgo biloba is used in TCM for 
ginkgolide B) respiratory disorders, and its use in 
(sesquiterpenes circulatory disorders dates back to the 
and diterpenes) 1960s (Kenner and Requena, 1996). 
and flavonoids. The plant extract EGb 761 showed 
favourable effects on cerebral circulation, 
on neuronal cell metabolism, on the 
muscarinic cholinergic system, showed 
anti-oxidant activity and was 
neuroprotective against 0-amyloid-induced 
toxicity and NO-induced toxicity in vili-o 
(Barth et al., 1991; Bastianetto et al., 
2000a; Bastianetto el al., 2000b; Heiss and 
Zeiler, 1978; Kristofikovd et al., 1992; Tea 
et al., 1987; Yao et al., 2001) (continued 
on next page). 
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Table I. I. (Continued) Some plants and isolated compounds with relevant activities 
in relation to treatment of cognitive disorders, including Alzheimer's disease. 
Plant Compounds 
Isolated 
Traditional Uses, Pharmacological and 
Clinical Effects 
Ginkgo hiloha L. Ginkgolides (e. g. Ginkgolide B is a platelet-activating factor 
ginkgolide B) (PAF) antagonist (Braquet et al., 1994), 
(sesquiterpenes. indicating activity against inflammatory 
and diterpenes) processes. 
and flavonoids. Clinical efficacy (modest improvements in 
cognitive function) of Ginkgo hiloha 
extracts, including EGb 761, was observed 
following administration to AD and non- 
AD patients in various studies, including 
randomised, double-blind, placebo- 
controlled, multi-centre trials (Kanowski et 
al., 1997; Le Bars et al., 1997; Le Bars et 
al., 2000; Rigney et al., 1999). 
Huperzia serrata Huperzine A (10) Huperzia serrata is used in TCM for 
Thunb. (alkaloid). promoting circulation, for fever and as an 
anti-inflammatory and analgesic, and the 
prescription, Qian Ceng Ta, has been used 
in TCM to alleviate problems of memory 
loss (Foster, 1989; Skolnick, 1997). 
Huperzine A (10) is an AChE inhibitor in 
vitro and in vivo (Ashani el al., 1992; 
Lagani&re et al., 1991; McKinney et al., 
1991; Wang el al., 1986b) (continued on 
next page). 
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Table I. I. (Continued) Some plants and isolated compounds with relevant activities 
in relation to treatment of cognitive disorders, including Alzheimer's disease. 
Plant Compounds Traditional Uses, Pharmacological and 
Isolated Clinical Effects 
Huperzia serrata Huperzine A (10) Huperzine A (10) is reported to decrease 
Thunb. (alkaloid). neuronal cell death induced by glutamate 
toxicity (Skolnick, 1997). 
Huperzine A (10) improved memory 
retention processes in cognitively 
impaired aged and adult rats (Lu el al., 
1988). 
Huperzine A (10) improved cognitive 
performance in AD patients (Shu, 1998). 
Huperzine A (10) is used in China for the 
symptomatic treatment of AD (Houghton, 
1999; Skolnick, 1997). 
Hypericum Hypericin Hypericum perforalum and HyI)ericum 
perforatum L. and (bianthraquinone) calycinum were found to be as effective as 
Hypericum and hyperforin anti-depressant drugs (e. g. desipramine) in 
calycinuln L. (phenolic animal models (OztOrk et al., 1996). 
phloroglucinol 
derivative). 
Lippia Pulegone-1,2- Pulegone-1,2-epoxide was shown to 
stoechadifolia epoxide inhibit AChE in vitro (Grundy and Still, 
H. B. + K. (monoterpene). 1985), indicating potential as AD therapy. 
Macleaya cordata Sanguinarine Sanguinarine is an inhibitor of AChE 
Willd. (alkaloid). (Huang, 1993), therefore may have 
potential in AD therapy. 
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Table I. I. (Continued) Some plants and isolated compounds with relevant activities 
in relation to treatment of cognitive disorders, including Alzheimer's disease. 
Plant Compounds Traditional Uses, Plia rm aco logical and 
Isolated Clinical Effects 
Magnolia Honokiol and Honokiol and magnolol are reported to 
officinalis L. magnolol increase ChAT activity and inhibit AChE 
(phenolic activity ill vitro, and increased 
compounds). hippocampal ACh (1) release in vivo (Hou 
et al., 2000). 
Melissa officinalis Compounds In traditional European medicine, Melissa 
responsible for officinalis leaf was acclaimed for restoring 
displacement of memory (McVicar, 1994). 
nicotine (2) The crude alcoholic extract of Melissa 
receptor binding officinalis displaced nicotine (2) binding to 
are unknown. nicotine receptors in a concentration 
dependent manner (Perry et al., 1996) 
(also refer to 1.4.3.2). 
Physostignia Physostigmine (5) Physostignia venenosum was used 
venenosum Balf (alkaloid). traditionally in Africa as a ritual poison, 
claimed to determine the guilt or 
innocence of persons accused of a crime 
(McCaleb, 1990). 
Physostigmine (5) is reported to protect 
mice against cognitive impairment caused 
by oxygen deficit, and to improve learning 
in rats (McCaleb, 1990). 
Physostigmine (5) antagonised 
scopolamine-induced impairment of 
cognitive function in rats (Yoshida and 
Suzuki, 1993) (continued on next page). 
100 
Table I. I. (Continued) Some plants and isolated compounds with relevant activities 
in relation to treatment of cognitive disorders, including Alzheimer's disease. 
Plant Compounds Traditional Uses, Pliarmacological and 
Isolated Clinical Effects 
Physostignia Physostigmine (5) Physostigmine (5) is reported to have 
venenosum Balf (alkaloid). shown significant benefits in cognition in 
both normal and AD patients (Shu, 1998; 
Sitararn et al., 1978). 
Salvia a-Pinene (53), Salvia lavandulaefolia essential oil and the 
lai, andulaefolia 1,8-cineole (56) oil constituents a-pinene (53), 1,8-cineole 
Vahl. and camphor (57) (56) and camphor (57) inhibited AChE in 
(monoterpenes). vitro (Perry et al., 2000a). 
Salvia officinalis Camphor (57), Salvia officinalis was used traditionally to 
citral, 1,8-cineole 'strengthen' the brain and enhance 
(56), linalool (74) memory: John Gerard stated that 'Sage is 
and a-pinene (53) singularly good for the head and brain, it 
(monoterpenes). quickeneth the senses and memory 
(Greive, 1984). 
Salvia officinalis extract inhibited brain 
AChE in a concentration dependent 
manner (Perry et al., 1996). 
Camphor (57), citral, 1,8-cineole (56), 
linalool (74) and a-pinene (53) 
(constituents known to be present in Salvia 
officinalis essential oil) inhibited AChE in 
vitro (Perry et al., 2000a; Ryan and Byrne, 
1988). 
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1.4 Plants With Reputcd Anti-Dementia or Mcmorv Enhancing Effects 
Investigated in this Study 
In the present study, plants with reputed beneficial activities in relation to AD were 
selected with reference to traditional Ayurvedic, Chinese and European medicine, and 
also by consultation with traditional herbal practitioners. The plant parts used in the 
pharmacological investigations were those used traditionally, for their reputed 
memory-enhancing or anti-aging effects. The plants selected are discussed below. 
1.4.1 Traditional Ayurvedic Medicinal Plants 
1.4.1.1 Centella asiatica L. (Umbelliferae) 
Centella asiatica leaf is an ancient Ayurvedic remedy, which is used as a revitalising 
herb that strengthens nervous function and memory. It is reported to restore youth, 
memory and longevity (Kapoor, 1990). For example, an Ayurvedic formulation 
composed of four herbs, including C. asiatica, is used to retard age and prevent 
dementia, and the herb combined with milk is given to improve memory (Manyam, 
1999). The herb is also taken as a tonic for poor digestion and rheumatism; the latter 
suggesting it may have anti-inflammatory effects. C aslatica is also used in TCM for 
skin ailments and ulcers, as well as leprosy and syphilis and, is used for combating 
physical and mental exhaustion (Brinkhaus et al., 2000; Duke and Ayensu, 1995). 
An essential oil (0.1% of the plant), containing monoterpenes and sesquiterpenes, has 
been extracted from C asiatica leaf (Asakawa et al., 1982; Brinkhaus et al., 2000). 
The monoterpenes present in the essential oil include bornyl acetate (51), myrcene 
(52), a-pinene (53), P-pinene (54) andy-terpinene (55) and the sesquiterpenes include 
caryophyllene (82), elemene, trans-farnesene and germacrene D (Asakawa el al., 
1982; Brinkhaus et al., 2000). The triterpenes, which account for 1% - 8% of the 
constituents isolated, include asiatic acid (102), asiaticoside (101), brahmoside, 
brahminoside, madecassic acid (25), madecassoside (26) and thankuniside (Brinkhaus 
el al., 2000; Gfinther and Wagner, 1996; Kapoor, 1990; Maquart et al., 1999). 
Various alkaloids have also been isolated from C asiatica, including hydrocotylin 
(Duke and Ayensu, 1995). A bitter principle vallerine, is present in the roots and 
leaves, along with amino acids (e. g. alanine, scrine), flavonoids (e. g. quercetin (104), 
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kaempferol), fatty acids (e. g. linoleic acid, oleic acid, palmatic acid), phytosterols 
(e. g. campesterol, sitosterol (88), stigmasterol), resin and tannins (Brinkhaus et al., 





Although used in Ayurvedic medicine for memory disorders, relatively few studies 
have been conducted regarding the pharmacological basis of the reputed anti-amnesic 
effect. An alcoholic extract of the leaves is reported to be tranquillising in rats, an 
activity that was attributed to brahmoside (Kapoor, 1990; Sakina and Dandiya, 1990). 
In mice, an extract of C asiatica leaf was sedative, anti-depressant and showed 
cholinornimetic activity, which was blocked by atropine (Sakina and Dandiya, 1990). 
These results indicate that C asiatica may be appropriate to treat symptoms of 
depression and anxiety in AD, and may also enhance cholinergic activity and thus, 
cognitive function. The mechanism for the potential cholinergic effects of the herb, 
remains to be established. An aqueous extract of C. asiatica leaf improved learning 
and memory processes in rats, and modulated doparnine, 5-HT and NA systems in rat 
brain in vivo (Nalini et al., 1992). These results suggest that the more polar 
compounds (e. g. saponins) present in C. asiatica leaf may enhance cognitive function 
by influencing neurotransmitter systems in the CNS. Further studies are necessary to 
confirm this to identify any potential relevance in AD treatment. 
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Numerous studies have been conducted on the wound healing effects of C asiatica 
(Maquart et al., 1999; Shukla et al., 1999), which reflects its use in Ayurvedic 
medicine for wound healing following topical application. Other pharmacological 
activities of C asiatica leaf include anti-bacterial, anti-protozoal and anti-viral 
activities and anti-convulsant, diuretic, hypoglycaernic and immunomodulatory 
effects (Brinkhaus et al., 2000; Kapoor, 1990). 
1.4.1.2 Withania somnifera L. (Solanaceae) 
Withania somnifera root (ashwagandha) is one of the most highly regarded herbs in 
Ayurvedic medicine and its use dates back almost 4000 years. It is classed among the 
rejuvenative tonics ("Rasayanas") and the Ayurvedic scholar Charaka (1013C) wrote 
about W. somnifera, "One obtains longevity, regains youth, gets a sharp memory and 
intellect and freedom from diseases, gets a lustrous complexion, and strength of a 
horse" (Upton, 2000). The herb is also traditionally used to treat inflammatory 
conditions, including bronchitis and arthritis. 
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Figure 1.1. Withania somnifera plant. Figure 1.2. Withania somnifera root. 
The primary constituents of the root include numerous alkaloids, which comprise 
0.13% - 4.3% of the herb, including anaferine (60), anahygrine, ashwagandhine, 
aswhagandhinine, cuscohygrine (61), dl-isopelletierine isopelletierine, pseudotropine, 




withaninine and withasomine (Harborne and Baxter, 1993; Mills and Bone, 2000; 
Schwarting et al., 1963; Upton, 2000). Nicotine (2) is reported to be present in W. 
soinnifera root (Kapoor, 1990), but some investigations have not detected its presence 
(Das et al., 1963; Schwarting et al., 1963). This may be explained by variation in the 
source of the herb, as chemical composition may be influenced by several factors, 
including environmental conditions for cultivation and storage conditions, or by 
different extraction procedures used to isolate chemical constituents. 
Several steroidal derivatives have also been isolated from W. somnifera root. These 
include the withanolide aglycones (e. g. 5-dehydroxywithanolide R, withanolides A- 
Y, withasomniferols A-C, withaferin A (109), withasomidienone, withasomniferin 
A) and the glycosylated sitoindosides (e. g. sitoindosides VII - X) (Ghosal et al., 1989; 
Mishra et al., 2000; Rhaman et al., 1991; Rhaman et al., 1993). 
Other constituents reported to be present include amino acids (e. g. aspartic acid, 
cysteine, glycine), choline, essential and fixed oils, glycosides, phenylpropanoids (e. g. 
cholorogenic acid (107)), phytosterols (e. g. sitosterol (88)) and saccharose 
(Bhattacharya et al., 1987; Ghosal et al., 1988; Kapoor, 1990; Upton, 2000). 
There have been numerous studies regarding the cognitive enhancing activities of W. 
somnifera. For example, sitoindosides IX (65) and X (66) augmented learning 
acquisition and memory in both young and old rats (Ghosal et al., 1989). The 
mechanisms for this effect are unclear, but may involve modulation of cholinergic 
neurotransmission, as an extract containing the sitoindosides VII -X and withaferin A 
(109) was administered to mice and effects on the neurotransmitter systems in the 
brain were observed. The results showed that the extract enhanced AChE activity in 
the lateral septum and globus pallidus and decreased AChE activity in the vertical 
diagonal band, enhanced M, receptor binding in the lateral and medial septum and in 
the frontal cortices, and increased M2 receptor binding sites in cortical regions but did 
not affect GABAA, benzodiazepine receptor binding, nor NMDA or AMPA glutamate 
receptor subtypes (Schliebs et al., 1997). The extract containing the sitoindosides VII 
-X and withaferin A (109) also reversed the ibotenic acid-induced cognitive deficit 
and reversed the reduction in cholinergic markers (e. g. ACh (1), ChAT) in rats 
(Bhattacharya et al., 1995). The reputed cognition enhancing effects of W. somnifera 
root may therefore be explained by a preferential action on cholinergic 
neurotransmission in the cortical and basal forebrain, brain areas involved in cognitive 
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function. These observations indicate that the sitoindosides VII -X and withaferin A 
(109) may have potential in AD therapy. 
The methanol extract of W. somnifiera root dose-dependently promoted dendrite 
formation in human neuroblastoma cells in vitro (Tohda et aL, 2000). If this effect 
occurred in the CNS, treatment of AD patients with the root extract may promote 
synaptic fonnation, which involves neurite outgrowth; thus cholinergic function may 
be enhanced. 
The glycowithanolides showed anxiolytic and anti-depressant activities in rats 
(Bhattacharya et aL, 2000d), which may be applicable in the symptomatic treatment 
of AD. An alkaloid extract also had tranquillising effects in vivo, and potentiated 
barbiturate-, ethanol- and urethane-induced hypnosis in mice (Malhotra et aL, 1965). 
W. somnifera root and some constituents are also reported to have anti-oxidant and 
anti-inflammatory activities, which may also be relevant in AD therapy. The crude 
extract is reported to inhibit lipid peroxidation in vitro and in vivo (Dhuley et aL, 
1998; Panda et aL, 1997; Panda and Kar., 1998). The root extract and the 
glycowithanolides (consisting of equimolar concentrations of sitoindosides VII -X 
and withaferin A (109)) are hepatoprotective in rats and mice, an effect attributed to 
the anti-oxidant activity against hepatic lipid peroxidation (Bhattacharya et aL, 2000a; 
Chaurasia et aL, 2000). 
The compounds responsible for anti-oxidant activity include the withanolides 
(Bhattacharya et aL, 2001; Mills and Bone, 2000; Mishra et aL, 2000; Scartezzini and 
Speroni, 2000; Upton, 2000), but other compounds in the root may also be anti- 
oxidant. The glycowithanolides decreased lipid peroxidation in various tissues 
including the brain in rodents, and both the glycowithanolides and the sitoindosides 
(VII - X) enhanced catalase and glutathione peroxidase activities in rat frontal cortex 
and striatum (13hattacharya. et aL, 1997; Bhattacharya et aL, 2001; Chaurasia et aL, 
2000). 
A root extract was effective against arthritis in rats (Begum and Sadique, 1988) and 
reduced serum protein levels (e. g. a2-macroglobulin, an indicator of arthritis and 
inflammatory conditions) (Anbalagan and Sadique, 1981a; Anbalagan and Sadique, 
1981b; Anbalagan and Sadique, 1985), and in a double-blind, placebo-controlled, 
cross-over study, treatment in patients with osteoarthritis resulted in an improvement 
in symptoms (Kulkani et aL, 1991). W. somnifiera administration to mice treated with 
a carcinogen reduced IL-1 and TNF-(x levels (Dhuley, 1997), which may also be 
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relevant in AD, considering the possible involvement of these inflammatory 
mediators in senile plaque formation and neurodegeneration. W. somnifiera leaves are 
also reported to have anti-inflammatory activity (Sudhir et al., 1986). The numerous 
pharmacological activities of W. somnifera root indicate that this herb may have 
multiple beneficial effects in AD patients; this also emphasises the advantages the 
complex mixture of an extract may have over a pure compound. 
JV somnifiera root has shown adaptogenic effects (i. e. enhances the resistance of an 
organism to various stress-inducing effects) in vivo. For example, the root extract and 
sitoindosides IX (65) and X (66) produced anti-stress activity in mice, assessed by 
various parameters (e. g. increased physical endurance in swimming) (Archana and 
Namasivayam, 1999; Dhuley, 2000; Ghosal et al., 1989; Rege et al., 1999; Singh et 
al., 2000). The herbal formulation Siotone, composed of five herbs including W. 
soninifiera, showed adaptogenic activities against a variety of behavioural, 
biochemical and physiological stress-inducing effects in rats (13hattacharya et al., 
2000b). 
Other reported activities of IV somnifiera include anti-microbial, anti-tumour, 
hypocholesterolaernic, hypotensive, diuretic, hypoglycaemic, immunomodulatory and 
thyroid-stimulating effects (Andallu and Radhika, 2000; Asthana and Raina, 1988; 
Budhiraja and Sudhir, 1987; Ghosal et al., 1989; Mishra et al., 2000; Panda and Kar, 
1999). 
1.4.1.3 Ziziphuv jyjuba Mill. (Rhamnaceae) 
Ziziphusjujuba is used for numerous conditions in Ayurvedic medicine. The bark is 
used for fever, gout, rheumatism and to heal ulcers and wounds, the leaves are used as 
a laxative, the fruit is used for bronchitis, fever and hepatic disorders and the seeds are 
used for skin disorders and coughs and also as a tonic for the heart and brain (Kapoor, 
1990; Kirtikar and Basu, 1935). Z jujuba is also used in TCM: the fruit is used as a 
sedative and for arthritis, the plant is used to treat nephritis and nervous disease and 
the seeds are used to treat insomnia, palpitations, anxiety, vertigo and amnesia (Chang 






Figure 1.3. Ziziphusjujuba fruit used in the present study. 
The seeds contain 0.1% saponins (e. g. jujubosides A and B, which yield the aglycone 
jujubogenin (27) upon hydrolysis), flavone-C-glycosides (e. g. swertisin (150) and 
spinosin (149)), triterpenes (e. g. betulic acid and betulin), and a large amount of fixed 





There is a lack of studies aimed at investigating the pharmacological basis for the 
reputed anti-amnesic effect of Z jujuba seeds. The CNS activities that have been 
reported to occur in vivo include anxiolytic, anti-convulsant, sedative and hypnotic 




attributed to the flavones, particularly swertisin (150) (Tang and Eisenbrand, 1992), 
but other unidentified compounds may also have sedative effects. 
Other activities reported to occur with Z jujuba seeds include analgesic, hypothermic 
and hypotensive effects and seeds were effective as a treatment for bums (Chang and 
But, 1987). 
1.4.2 Traditional Chinese Medicinal Plants 
1.4.2.1 Alisma orientalis (Sam. ) Juzepcz. (Alismaceae) 
Alisma orientalis root is used in TCM as a diuretic in the treatment of oedema, and is 
used in hyperlipidaernia, hypertension, vertigo and acute urinary infection (Chang and 
But, 1987; Huang, 1993; Pharmacopoeia of the People's Republic of China, 1992; 
Tang and Eisenbrand, 1992). Constituents isolated from the root include triterpenes 
(e. g. alisols A (28), B (30) and C (32), alisol A monoacetate (29), B monoacetate (31) 
and C monoacetate (33), epi-alisol A, alismaketones B 23-acetate and C 23-acetate) 
and sesquiterpenes (e. g. alismol (34), alismoxide (35) and orientalols A (136), B (137) 
and C (138)) (Huang, 1993; Matsuda et al., 1999; Murata et al., 1970; Murata and 
Miyamoto, 1970; Oshima et al., 1983; Yoshikawa et al., 1992). 
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Figure 1.4. Alisma orientalis root used in the present study. 
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The root is also reported to contain alkaloids, amino acids (e. g. valine), choline, 
lecithin, essential oil, stigmasterol and sugars (e. g. fructose, glucose, sucrose) and 
large quantities of starch (Chang and But, 1987; Huang, 1993; Shimizu et al., 1994; 
Tomoda et al., 1994). It is improbable that the presence of choline and lecithin in the 
root can explain reputed beneficial effects on memory as these compounds have not 
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Toki-shakuyaku-san (TSS) is a prescription used in traditional Japanese medicine 
(TJM), which consists of six herbs, including A. orientalis root. TSS is reported to 
improve learning and memory deficits in vivo, to stimulate ChAT activity in the 
cortex, and to stimulate nicotinic receptor synthesis in brain (Itoh et al., 1996b). 
Experiments have shown that it ameliorated the scopolamine-induced deficit in ACh 
(1) levels in mouse brain, but did not influence ACh (1) levels in untreated mice (Itoh 
et al., 1996b). These findings suggest that TSS may promote favourable cognitive 
effects in AD, as cholinergic function is impaired. The effects observed with TSS 
may be due to one or more of the herb components and further investigations are 
required to establish the influence of A. orientalis root alone on memory disorders and 
cholinergic function. 
Triterpenes (e. g. alismaketones B 23-acetate and C 23-acetate) from A. orientalis root, 
inhibited NO production in macrophages (Matsuda et al., 1999) and it is noteworthy 
that inhibition of NO production by microglia in the CNS may provide 
neuroprotection in AD. 
A. orientalis root and constituents are also reported inhibit platelet aggregation, to 
have immunological, hypoglycaemic and hypotensive activities, and to treat 
hypercholesterolaernia (Shimizu et al., 1994; Tomoda et al., 1994; Tang and 
Eisenbrand, 1992). Activity against hypercholesterolaemia may lower the risk of 
cardiovascular disease, and perhaps protect against ischaernia-induced dementia. 
1.4.2.2 AlZocvnum lancifolium L. (ApocyLiaceae) 
Apocynum lancifolium leaf and root are used in TCM for hypotensive, cardiotonic and 
diuretic effects. The root and leaf are recommended for hypertension, heart disease, 
neurosis, oedema and nephritis, and are also used for chronic bronchitis and influenza 
(Chang and But, 1987; Huang, 1993). In the northern provinces of China, the tea is 
used to ease dizziness (Jianming, 1988). 
The root contains cardiac glycosides (e. g. cyrnarin (48), strophanthidin (47), K- 
strophanthin-P (49)) and hydroxyacetophenone; the stem and leaves also contain 
cardiac glycosides, flavones (e. g. quercetin (104)), flavonol-0-glycosides (e. g. 
hyperin), phenylpropanoid substituted flavan-3-ols (e. g. apocynins A- D), lauric acid, 
phenolic compounds, steroid saponins, cournarins (e. g. scopoletin) and triterpenes 
III 
(e. g. a-amyrin and lupeol) (Chang and But, 1987; Duke and Ayensu, 1995; Fan et al., 
1999; Huang, 1993; Jianrning, 1988; Miaohua and Fengshan, 1991). 
The majority of research on A. lancifolium has focused on the cardioactive properties 
of the herb and its cardiac glycosides. The leaves are reported to slow heart rate and 
cardiac contractility, but high doses (Ig/kg administered to cats and dogs) have been 
associated with arrhythmias, and administration of a 6% solution of the cardiac 
glycosides caused ventricular tachycardia and death (Chang and But, 1987). 
Administration of the root decoction to cats and administration of the cardiac 
glycosides to dogs, increased coronary blood flow and myocardial 02 consumption 
(Chang and But, 1987). The latter vasodilatory effects indicate that cerebral blood 
flow may also be enhanced, although cardiotoxicity may restrict clinical use. A tea 
prepared from the leaves was administered to 196 and 427 patients with hypertension 
and a reduction in blood pressure was observed in 82% and 89% of patients 
respectively (Chang and But, 1987; Ranming, 1988). 
There is a comparative lack of studies regarding the potential memory-enhancing and 
anti-aging effects of A. lancifolium. The leaf extract increased SOD activity and 
prevented damage to DNA (Hao et al., 1988; Ma and Chen, 1989), which suggests the 
leaf may have anti-oxidant activity. 
The leaf is also reported to be effective in the treatment of chronic bronchitis and viral 
infections, hyperlipidaernia and is also sedative (Chang and But, 1987; Chen and Liu, 
1991; Jianming, 1988; Ma and Chen, 1989; Miaohua and Fengshan, 1991). 
1.4.2.3 Codonopsis pilulosa (Franch) Nannf (Campanulaceae) 
In TCM, Codonopsis pilulosa root is used for various disorders, including amnesia, 
anorexia, asthma, cancer and insomnia, and is believed to promote blood circulation 
and enhance vitality (Duke and Ayensu, 1995). 
The water-soluble components present in the root include amino acids (e. g. aspartic 
acid, proline and valine) and sugars (e. g. fructose and inulin) (Jiang et al., 1986; Liu 
and Wang, 1983; Sha et al., 1988). Other compounds identified in the root include 
saponins, alkaloids (e. g. perlolyrine (36), sterols (e. g. a-spinosterol), triterpenes and 
also mucilage, resin and an essential oil containing methyl palmitatc, octadecane, 
nonadecane and heptadecane (Chang and But, 1987; Liao and Lu, 1987; Liu et al., 
1988; Tang and Eisenbrand). 
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Figure 1.5. Codonopsis pilulosa plant. 
Pharmacological studies on C pilulosa root to date have not included investigations 
regarding the reputed anti-amnesic effects. The root is reported to enhance 
reticuloendothelial phagocytosis and increase erythrocyte levels in vivo, to induce 
hyperglycaernia (due to the sugar content of the root) and hypotension in vivo and in 
clinical studies, the root is reported to treat neurosis (in combination with vitamin B), 
4L 
nephritis and gastric ulcers, and was also an anti-emetic (Chang and But, 1987). 
CH 2 OH 
Perlolyrine (36) 
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1.4.2.4 Polygala tenuifolia Willd. (Polygalaceae) 
Polygala tenuifolia root is used in TCM as a cardiotonic and cerebrotonic, as an 
expectorant, sedative and tranquilliser, and for amnesia, forgetfulness, neuritis, 
nightmares and insomnia (Chang and But, 1987; Duke and Ayensu, 1995). 
According to the Chinese Materia Medica, the root is supposed to have special effect 
upon the will and mental powers, giving strength of character, improving 
understanding, strengthening the memory, and increasing physical powers (Chang and 
But, 1987; Duke and Ayensu, 1995). 
I 
Figure 1.6. Polygala tenuifolia root used in the present study. 
Constituents isolated from the root of this herb include the alkaloid tenuidine, the 
phenylpropanoid 3,4,5-trimethoxy-cinnamic acid (37), triterpene saponins (including 
prosapogenin, onjisaponins A-G and tenuifolin (67)), phenolic glycosides 
(tenuifolisides A- F), oligosaccharides (tenuifolioses A- P), xanthone derivatives 
(e. g. 1,2,3,7-tetramethoxyxanthone (38)), fixed oil and resin (Chang and But, 1986; 
Fujita et al., 1992; Huang, 1993; Ikeya et al., 1991a; Ikeya et aL, 1991b; Ikeya et al., 
1994; Miyase et al., 1991; Miyase et al., 1992; Sakuma and Shoji, 1981a; Sakuma 
and Shoji, 1981 b; Tang and Eisenbrand, 1992; Trease and Evans, 1996). 
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There have been numerous studies regarding the reputed memory enhancing potential 
of P. lenuffiblia root. For example, the traditional Chinese prescription DX-9386, 
composed of four herbs, including P. tenuifolia root, has shown favourable effects in 
relation to AD symptoms in several animal models. DX-9386 improved motor 
activity, reduced lipid peroxidation, ameliorated memory impairment and prolonged 
the lifespan of senescence accelerated mice and, ameliorated the ethanol- and 
scopolamine-induced memory impairment in mice (Nishiyama et al., 1994a; 
Nishiyama et al., 1994b; Nishiyama et al., 1994c; Zhang et al., 1994b). Further 
investigations are required to clarify the contribution of each of the four herbs in DX- 
9386 to the observed pharmacological activities. 
Kami-utan-to (KUT), a prescription containing thirteen herbs including P. tenuffiblia 
root and also Z jujuba fruit and seeds, is used in TJM to treat psychoneurological. 
diseases. KUT dose-dependently upregulated ChAT activity and increased NGF 
secretion in vitro, improved passive avoidance behaviour and induced ChAT activity 
in the cerebral cortex of aged rats and in scopolamine-induced memory impaired rats 
in vivo (Yabe et al., 1997; Yamada and Yabe, 1997). The effects on ChAT activity 
and NGF secretion in vitro were not as pronounced when treated with KUT in the 
absence of P. tenuifolia root, but P. tenuifolia root extract alone did upregulate ChAT 
activity and increase NGF secretion in vitro (Yabe et al., 1997; Yamada and Yabe, 
1997). The cinnamic acid derivative sinapinic acid (39), from P. tenuifolia root 
increased ChAT activity in the frontal cortex in brain-lesioned rats (Yabe et al., 
1997). These results indicate that P. tenuifolia root, particularly the cinnamic acid 
derivatives, significantly contributes to the pharmacological activities of KUT, and 
may explain the reputed beneficial effects of KUT in TJM. KUT treatment in AD 
patients is also reported to improve memory related behaviour (Yamada and Yabe, 
1997). 
115 
A dopamine receptor ligand tetrahydrocolumbamine (40) has also been isolated from 
P. tenuifolia root (Shen et al., 1994), but its potential agonistic or antagonistic activity 
in vivo, and any relevance to CNS disorders such as AD or Parkinson's disease, 








Sinapinic acid (39) Tetrahydrocolumbamine (40) 
An aqueous extract of P. tenuifolia root inhibited IL- I mediated TNF secretion by 
astrocytes in vitro (Kim et al., 1998), which suggests the reputed favourable effects of 
the herb in CNS disorders, may also involve anti-inflammatory activity but, this 
requires confirmation in vivo. The aqueous extract also dose-dependently inhibited 
ethanol-induced IL-1 secretion in vitro (Koo et al., 2000). 
P. tenuffiblia root is also reported to stimulate uterine contraction, to prolong 
hexobarbital sleeping time in mice (due to onjisaponon F) and, have anti-convulsant, 
anti-bacterial, hypotensive and expectorant properties (Chang and But, 1987; Huang, 
1993; Tang and Eisenbrand, 1992). 
1.4.2.5 Polygonum muLi: Loruni Thunb. (Polygonaceae) 
Polygonum multiflorum root is used in TCM for various conditions including 
constipation, dizziness, tinnitus, insomnia, neurosis, neurasthenia and in combination 
with three other herbs, forrns one of China's great herbal tonics to maintain 
youthfulness and general good health; in the Chinese Materia Medica, the root is 
described as having wonderftd restorative and reviving powers (Chang and But, 1986; 
Duke and Ayensu, 1995; Huang, 1993). 
Compounds identified in P. multiflorum root include anthraquinones (e. g. emodin 
(41) and physcion (42)), stilbenes (e. g. resveratrol (43)), hydroxylated stilbene 
glycosides (e. g. 2,3,5,4-tetrahydroxystilbene 2-0-p-D-glueopyranoside (44)) and 
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lecithin (Chang and But, 1986; Grech et aL, 1994; Harbome and Baxter, 1993; 


















2,3,5,4-Tetrahydroxystilbene 2-0-ß-D-glucopyranoside (44) 
Research conducted on P. multiflorum root has not focused on potential cognitive 
enhancing effects. The traditional Korean prescription Shao-yin-ren shi-quang-da-bu- 
tang (SDT), composed of ten herbs, including P. multiflorum root, restored the decline 
in cerebral choline content following oral treatment in senescence accelerated mice 
(Ma et al., 1999). This result suggests that SDT may influence cholinergic function, 
which may be relevant in AD treatment. It is unknown which of the plants contribute 
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to this effect, or if compounds acted synergistically. One study showed that P. 
multiflorum root did not improve scopolamine-induced learning and memory deficits 
in rats (Hsieh et al., 2000), which suggests that potential cognitive enhancing effects 
of the root may not be related to cholinergic function. Other pharmacological 
activities of P. multiflorum root in relation to memory require further investigation. 
Figure 1.7. Polygonum multiflorum plant. 
Several studies have shown anti-oxidant and anti-inflammatory effects with P. 
multiflorum root and some of its isolated constituents, which may explain the anti- 
aging claim in TCM. Previous studies have shown P. multiflorum root (aqueous 
extract) to inhibit lipid peroxidation and scavenge free radicals (Hong et al., 1994; lp 
et al., 1997). This suggests that the compounds responsible for the reported anti- 
oxidant effects are more polar than those compounds present in the less active ethanol 
extracts. A traditional Chinese prescription composed of Angelica sinensis and 
Astragalus membranaceus protected against rat myocardial ischaemia-reperfusion 
injury, which involves reactive oxygen species; this effect was enhanced by additional 
treatment with P. multiflorum root, but P. multiflorum root alone did not significantly 
protect against ischaemia-reperfusion injury (Yim et al., 2000). This study suggests 
P. multiflorum root may act synergistically with other phytochemicals to enhance 
anti-oxidant activity. 
Resveratrol (43) and 2,3,5,4'-tetrahydroxystilbene 2-0-0-D-glucopyranoside (44) 
are inhibitors of lipid peroxidation in rat liver microsomes (Kimura et al., 1983). 
These are phenolic compounds, a phenolic component being a common feature of 
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many plant derived anti-oxidants. The presence of the more polar glycosides would 
be expected in the aqueous extract of this plant so these compounds may explain the 
reported anti-oxidant activity of the aqueous extracts. A standardised extract from a 
related species Polygonum cuspidatum, consisting of 20% resveratrol (43) and 10% 
emodin (41) (Protykin), and the ethyl acetate fraction of an ethanolic extract from P. 
mullij1orum is reported to have potent free-radical scavenging activity (Chen et aL, 
1999; Sato et aL, 2000). Several other compounds isolated from P. multiflorum root 
are also known anti-oxidants; these include gallic acid, (+)-catechin, (+)-epicatechin, 
3-0-galloyl-(-)-catechin and 3-0-galloyl-(-)-epicatechin (Bouchet et aL, 1998; 
Nonaka et aL, 1982). 
P. multij7orum has been shown to inhibit acute ear oedema in mice (Cu6llar et aL, 
1998), indicating anti-inflammatory activity. Another member of the Polygonaceae, 
Polygonum cuspidalum, has shown anti-inflammatory effects but the mechanism of 
action is unconfirmed. However resveratrol (43), present in the root extract of P. 
cuspidatum, suppresses NF-KB activation, which is a nuclear transcription factor that 
regulates the expression of genes involved in inflammation (Manna et aL, 2000). It is 
possible that P. multijloruni root may influence inflammatory mechanisms as 
resveratrol (43) has been identified in the root. 
The anthraquinone emodin (41) is a potent inhibitor of NF-icB activation (Kumar et 
aL, 1998a) but shows no effect on COX-2 mRNA, and does not inhibit PGE2 
synthesis (Chen et aL, 2000). Stilbenes (resveratrol (43) and its glucoside, piceid) 
isolated from Polygonum spp. are reported to interfere with 5-hydroxy-6,8,11,14- 
eicosatetraenoic acid (5-HETE), 17-hydroxyheptadecatrienoic acid (HHT) and 
thromboxane B2 (TXB2) synthesis in rat peritoneal leukocytes, attributed to the 
inhibition of COX and 5-LOX (Kimura et aL, 1985a). . 
P. multiflorum root is reported to lower cholesterol, increase coronary circulation and 
antagonise tachycardia in vivo, and to have anti-bacterial properties; the root has also 
shown favourable effects in patients with neurasthenia, insomnia, 
hypercholesterolaernia or schizophrenia (Chang and But, 1986; Huang, 1993). 
1.4.2.6 Salvia miltiorrhiza Bung. (Labiatae) 
Throughout history the Labiate Salvia miltiorrhiza has been used for the treatment of 
a variety of medical conditions. The dried root of S. miltiorrhiza is red in colour, and 
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was therefore used in folk medicine for the management of blood disorders. It is 
prescribed in TCM to stabilise the heart and calm nerves (Huang, 1993). Official 
indications for the root include treatment of menstrual disorders, menostasis, 
menorrhagia, blood circulation disorders, angina pectoris, insomnia, neurasthenia and 
alleviation of inflammation (Tang and Eisenbrand, 1992). 
lop 
Figure I. S. Salvia miltiorrhiza plant. 
Figure 1.9. Salvia miltiorrhiza root used in the present study. 
Constituents identified in S. miltiorrhiza root include vitamin E and numerous 
diterpenoids (e. g. tanshinones 1 (115) and Ila (116), cryptotanshinone (117), 
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tanshindiols (A (119) and B (120)), isotanshinones (1 (121) and 11 (122)), 
neocryptotanshinone 11 (118)) (Huang, 1993; Ikeshiro et aL, 1991; Kusami et aL, 
1985; Lin and Chang, 2000; Luo et aL, 1986; Tang and Eisenbrand, 1992). Several 
water-soluble compounds have been isolated from the aqueous extract of S. 
miltiorrhiza root, including danshensu (45) (Chen and Liu, 1980), the salvianolic 
acids A (123) (Li et al., 1984), B (124) and C (125) (Ai and Li, 1988) and rosmarinic 







S. miltiorrhiza, or Chinese sage, has been the subject of thorough investigation, and 
consequently numerous pharmacological activities that may be relevant in CNS 
disorders, including AD, have been identified. S. miltiorrhiza has been employed for 
the treatment of cerebral vascular disease, and there are several studies to investigate 
possible mechanisms for the protective effect of S. miltiorrhiza against cerebral 
ischaernia. 
S. miltiorrhiza root has been implicated in attenuating dysfunction of vasoactive 
intestinal peptide (VIP) (Kuang et al., 1989), a neuropeptide distributed within the 
gastro-intestinal tract and central nervous system (CNS). VIP may participate in the 
changes that occur in cerebral ischaernia. Distribution abnormalities of the 
neuropeptide substance P have been associated with some CNS disorders, including 
AD. Decreased levels of substance P have been suggested as a consequence of 
neuron damage following cerebral ischaernia; S. miltiorrhiza root has been implicated 
in protecting neurons from ischaemia (Kuang et al., 1991), and so may actively 
protect against cerebral ischaernia and perhaps other CNS disorders via this 
mechanism. 
Other beneficial effects of S. miltiorrhiza root against cerebral ischaernia have also 
been explored. S. miltiorrhiza root may inhibit neuronal cell death by inhibition of 
presynaptic glutamate release (Kuang and Xiang, 1994), and it has been suggested 
that inhibition of NO fonnation may also explain CNS protective effects observed 
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with S. miltiorrhiza root (Kuang et al., 1996a). It should also be considered that the 
biological function of NO has been suggested to involve the effects of excitatory 
amino acids, including their effects on brain development, learning and memory 
(Moncada et al., 1991). This physiological role may aid the explanation of the effects 
of S. miltiorrhiza root on the CNS. Further investigations indicate S. miltiorrhiza root 
may modify ischaemic cell changes by modulating somatostatin, a CNS neuropeptide 
that has implicated in learning and memory (Kuang et al., 1993). 
S. milliorrhiza root may offer an additional therapeutic approach to management of 
stroke and ischaemia. Reperfusion to aid recovery of ischaernia can cause further 
brain damage. During reperfusion, metabolism of free fatty acids from the breakdown 
of lipid membranes during ischaernia has been proposed to generate oxygen free 
radicals, leading to further brain injury (Traystman et al., 1991). S. milliorrhiza root 
has been shown to offer protection against this process by reducing lipid peroxidation 
(Kuang et al., 1996b; Liu et al., 1992; Peigen et al., 1996; Zhao, et al., 1996). 
The anti-oxidant effects of S. miltiorrhiza root have been studied and several 
compounds have been identified with significant anti-oxidant activity. Several 
quinones isolated from S. miltiorrhiza root have demonstrated an anti-oxidant effect 
in lard, with dihydrotanshinone, tanshinone 1 (115), methylene tanshinquinone and 
cryptotanshinone (117) providing significant antioxidant activity; tanshinone Ha (116) 
has shown no anti-oxidant activity (Weng and Gordon, 1992; Zhang et al., 1990). 
Other components of S. miltiorrhiza root have displayed anti-oxidant effects including 
salvianolic acid A (123) (a compound found to protect against memory impairment 
induced by cerebral ischaemia, reperfusion in mice (Guanhua and Juntian, 1997)), 
salvianolic acid B (124) and rosmariquinone (also known as miltirone; it has been 
isolated from another labiate, Rosmarinus officinalis) and several other phenolic 
compounds (Huang and Zhang, 1992; Kang et al., 1997; Liu et al., 1992; Weng et al., 
1992). The compounds that show anti-oxidant effects may be also useful in AD 
therapy. 
'Salvia composilus' is a herbal mixture of the Chinese herbs S. milliorrhiza and 
Delbergia odorifera, traditionally used for management of coronary heart disease 
(Fan et al., 1979). Investigations suggest this herbal remedy has a potential role in 
anti-oxidation of lipids (Zhang et al., 1994a), and in amelioration of cerebral oedema 
(Kuang et aL, 1995), providing firther evidence for therapeutic advantage in cerebral 
disorders. 
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'Salvia compositus' has shown effects on electrical activities of the cerebral cortex, 
showing a CNS depressant action (Fan et al., 1979). There are reports of S. 
milliorrhiza root being analgesic and sedative. A reduction in the spontaneous 
activity of mice, and increased duration of the hypnotic action induced by chloral 
hydrate and barbiturates in the presence of S. miltiorrhiza root have been observed 
(Huang, 1993; Chang and But, 1986). Further investigation has established a 
structure-activity relationship of rosmariquinone (miltirone), a quinone isolated from 
S. miltiorrhiza root, as an active central benzodiazepine receptor ligand (Chang et al., 
1991). Rosmariquinone and perhaps other quinones from S. miltiorrhiza may explain 
the tranquillising effects observed, and may aid the development of a novel class of 
anxiolytic agents. 
Tanshinones isolated from S. miltiorrhiza root have demonstrated anti-inflammatory 
activity in mice and were active against 5-LOX in porcine leukocytes, but were not as 
active as the crude extracts (Chang and But, 1986; Paulus and Bauer, 2000). The 
tanshinones are also reported to show weak oestrogenic activity (Chang and But, 
1986). These activities require further investigation for confirmation, but may be 
relevant in AD therapy. 
Other activities reported to occur with S. miltiorrhiza root include anti-bacterial 
activity, inhibition of platelet aggregation, potential as an anti-ulcer treatment, and 
efficacy in angina and hypertensive patients, and in the treatment of hepatitis, 
infectious diseases and tonsillitis (Fang et al., 1976; Huang, 1993; Murakami et al., 
1990; Onitsuka et al., 1983; Tang and Eisenbrand, 1992). 
1.4.3 Traditional European Medicinal Plants 
1.4.3.1 Convallaria maialis L. (Liliaceae) 
Convallaria majalis has been used in traditional European medicine as a diuretic and 
cardiotonic, and was also used as an embrocation for sprains and rheumatism and the 
aqueous extract was used for inflammatory eye conditions (Grieve, 1984). Herbalists 
throughout history have suggested that C majalis may be useful in cardiovascular and 
cognitive disorders. 
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'It doth strengthen the Memoric and comfortcth the Hartc' 
-Dodoens, 1560 (Grieve, 1984). 
'It without doubt strengthens the brain and renovates a weak memory' 
-Culpepper (Grieve, 1984). 
C majalis contains 0.2% - 0.3% of at least forty different types of cardiac glycoside, 
including convallamarin, convallatoxin (50), convalloside (46), sarhamnoloside and 
tholloside (Saxena and Chaturvedi, 1992; Jurenitsch et al., 1982; Kopp and Kubelka, 
1982; Schrutka-Rechtenstamm. et al., 1986). Flavonoids, steroidal saponins, tannins 
and volatile oil constituents are also reported to be present in the herb (Frohne and 
Pf'dnder, 1984; Grieve, 1984; Weiss, 1988). The phytochemical composition may 
vary, depending on the geographical source (e. g. in western and north-westem 
European plants, the primary cardenolide present is convallatoxin (50), but in central 





There has been considerable research regarding the cardioactive properties of C 
majalis and its cardenolides (David et al., 1982; Gupta and Chopra, 1987); activity 
that was indicated by the herbalists Culpepper and Dodoens. In some European 
countries the cardiac glycosides are used as an alternative to Digitalis spp. for 
cardiovascular disorders such as heart failure (Dewick, 1997) but all parts of C 
majalis are toxic, which limits clinical use. Toxicity, which may be fatal, occurs due 
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to the arrhythmogenic cardenolides (Cooper and Johnson, 1984; David et al., 1982). 
Convallatoxin (50) has low oral bioavailability (Bruneton, 1995), which may reduce 
toxic effects but could also limit efficacy. 
In contrast there is a comparative lack of pharmacological studies to investigate the 
reputed cognitive enhancing effects of C majalis. Further research is necessary to 
identify any pharmacological basis for the reputed activities of C majalis, other than 
its cardioactive effects. 
1.4.3.2 Melissa officinalis L. (Labiatae) 
Melissa officinalis leaf has been used as a medicinal plant for more than 2000 years. 
In the Middle Ages, it was used to soothe tension, dress wounds and to cure toothache 
(McVicar, 1994). In traditional European medicine M. officinalis was used as a 
calming and strengthening remedy and to treat digestive disorders, migraines, 
melancholia, neuroses and hysteria and the plant has been acclaimed for promoting 
long life and for restoring memory (Bisset, 1994; Kenner and Requena, 1996; 
McVica. r, 1994; Yamell, 1998). In Arabic medicine it was used to treat depression 
(McVicar, 1994). The Commission E Monograph in Germany approves the use of M 
officinalis for nervous insomnia and gastro-intestinal disorders. In modem alternative 
medicine, M. officinalis essential oil is used in aromatherapy to alleviate depression 
and insomnia (McVicar, 1994). 
Figure 1.10. Melissa officinalis plant. 
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Melissa officinalis: 'Good for disorders of the head and stomach' 
- John Hill, 1751 (Crellin and Philpott, 1990). 
Approximately 250 constituents are reported to have been isolated from M officinalis, 
with almost 200 of these being essential oil constituents, chiefly monoterpenes (>60% 
of the essential oil composition) and sesquiterpenes (>35% of the essential oil 
composition) (Bisset, 1994; Schultze et al., 1993). The essential oil from M 
offilcinalis is localised in glandular trichomes in the leaves, as with other Labiates. 
The primary monoterpenes identified in the essential oil include citronellal (68), 
geranial (70) and neral (71), and the main sesquiterpenes identified include 
caryophyllene (82), cubebene (80) and germacrene-D (Bisset, 1994; Guenther, 1949; 
$arer and Kbkdil, 1991; Tittel et al., 1982). Tannins (e. g. caffeic acid (106) and 
related derivatives), triterpenes, phenylpropanoids (e. g. chlorogenic acid (107) and 
rosmarinic acid (RA) (108)) and flavonoids (e. g. apigenin and luteolin (114)) have 
also been identified in M officinalis leaf (Agata et al., 1993; Bisset, 1994; Bruneton, 
1995; Heitz et al., 2000; Mulkens and Kapetanidis, 1987; Schultze et al., 1993; 
Yarnell, 1998). 
M. oJfIcinalis has been the subject of research regarding its potential as a sedative and 
anxiolytic, activities that may be appropriate to provide symptomatic relief for 
behavioural problems such as agitation in AD. M officinalis leaf was reported to 
alleviate mild anxiety and nervousness in a double-blind study, and in combination 
with Valeriana officinalis root, was reported to be as effective as triazolam, and did 
not cause drowsiness or impair concentration the next day (Yarnell, 1998). A 
hydroalcoholic (30% ethanol) extract of M officinalis leaf was sedative in mice and 
potentiated barbiturate induced sleep, but the M officinalis essential oil did not 
demonstrate these sedative effects (Soulimani et al., 1991). 
Other activities of M offi'cinalis leaf extracts that may be useftil for AD therapy 
include anti-oxidant effects (Hohmann et al., 1999; Lamaison et al., 1991; Marinova 
and Yanishlieva, 1997; Tagashira and Ohtake, 1998) and binding to muscarinic and 
nicotinic receptors in vitro (Perry et al., 1996; Wake et al., 2000), which suggests that 
favourable effects on cholinergic function may occur in AD patients. 
Other activities identified in M offi'cinalis essential oil include anti-bacterial, anti- 
fungal, anti-parasitic and anti-viral activities (e. g. activity against Herpes simplex 
labialis) and the potential for treatment of hyperthyroidism (Koytchcv et al., 1999; 
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Larrondo et al., 1995; Mikus et al., 2000; Schultze et al., 1993; Yarnell, 1998). The 
essential oil is also widely used in cosmetics and perfumery, for its citrus odour. 
1.4.3.3 Rosmarinus officinalis L. (Labiatae) 
Rosmarinus officinalis leaf was used in European folk medicine as an application for 
wounds and for eczema, and has also been used traditionally as a carminative, to 
stimulate appetite, for nervous depression and had a reputation for strengthening the 
memory and enhancing mental alertness (Bisset, 1994; Grieve, 1984; Kenner and 
Requena, 1996). The herb has also been used as an analgesic, anti-rheumatic, 
diuretic, expectorant and for treatment of respiratory disorders (Al-Sereiti et al., 
1999). 
Figure 1.11. Rosmarinus officinalis plant. 
Rosmarinus officinalis: 'It helpeth the brain, strengtheneth the memorie, and is 
very medicinable for the head' 
Roger Hacket, 1607 (Grieve, 1984). 
R. officinalis leaf constituents identified include flavonoids (e. g. luteolin (114), 
apigenin) and corresponding glycosides, phenolic compounds (e. g. caffeic acid (106) 
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and chlorogenic acid (107)), diterpenoid (e. g. carnosol (142)) and triterpenoid 
compounds (e. g. oleanic; acids, a- and 0-amyrin and rofficerone), and a volatile oil 
composed mainly of monoterpenes (Bisset, 1994; Ganeva et al., 1993; Newall et aL, 
1996; Okamura et al., 1994). The major constituents of R. offilcinalis essential oil are 
1,8-cineole (56) (15-30%), camphor (57) (15-250/o), a-pinene (53) (up to 25%) and 
other monoterpenes (e. g. borneol (58), bornyl acetate (51), limonene (73)) (Bisset, 
1994; Panizzi et al., 1993; Trease and Evans, 1996). 
R. offi'cinalis has been investigated for various biological activities, including some 
that are perhaps relevant in the treatment and prevention of AD, but studies that show 
direct effects of the herb on cognitive function are lacking. The essential oil 
stimulated respiratory and locomotor activity in mice and the oil constituent 1,8- 
cineole (56) was detected in blood, following inhalation (Kovar et al., 1987). The 
pharmacological basis and the oil constituents responsible for these observations 
remain unclear, but the results indicate that oil constituents may reach the systemic 
circulation following inhalation, and may therefore potentially cross the BBB and 
show pharmacological activity in the brain (lipid-soluble molecules with a molecular 
mass <40ODa - 60ODa may readily cross the BBB (Pardridge, 1998)). The essential 
oil is also reported to improve circulation (Al-Sereiti et al., 1999). This suggests the 
oil may also improve cerebral blood flow and perhaps cognitive function, but this 
effect requires investigation. R. offi'cinalis essential oil also weakly inhibited AChE in 
vitro (Perry et al., 1996), but this activity requires confirmation in vivo. 
R. officinalis leaf extracts and constituents (e. g. diterpenes including carnosic acid 
(143)) have demonstrated anti-oxidant activity (Al-Sereiti et al., 1999; Haraguchi et 
al., 1995; Joyeux: et al., 1995; Lamaison et al., 1991; Masaki et al., 1995). The 
pharmacological basis for the reputed memory-enhancing effects of R. ofjlcinafis may 
be due to effects on cerebral blood flow, anti-oxidant activity or other unknown 
mechanisms, but further investigations are required to establish this. 
R. officinalis essential oil is also reported to have anti-bacterial, anti-fungal, muscle 
relaxant and hyperglycaernic activities (Al-Hader et al., 1994; Aqel, 1991; Mangena 
and Muyima, 1999; Newall et al., 1996; Panizzi et al., 1993) and the plant extracts 





Plant material was extracted using solvents of varying polarity for assessment of 
activities in the bioassay investigations. Investigations were conducted to separate the 
chemical constituents of the dried leaf of Convallaria majalis to obtain fractions for 
analysis in the in vitro studies. C majalis leaf was subjected to various separation 
techniques, including droplet counter-current chromatography (DCCC), flash column 
chromatography (FCC) and preparative thin layer chromatography (TLC). The 
fractions obtained using these separation methods were tested for inhibition of 
acetyleholinesterase (AChE) activity in vitro, and were analysed using high 
performance liquid chromatography (HPLC), liquid chromatography-mass 
spectroscopy (LC-MS) and TLC, to obtain information regarding the phytochemistry 
of C. majalis leaf, and regarding the nature of the compounds responsible for 
anticholinesterase (antiChE) activity. Essential oils and oil constituents were 
analysed using gas chromatography-mass spectroscopy (GC-MS) to obtain 
information regarding their chemical composition and purity, prior to use in the 
bioassay investigations. 
2.1 Phytochemical Methods 
2.1.1 Materials 
2.1.1.1 Materials: Herbs, Essential Oils and Commercially Obtained Constituents 
Alisnia orientalis root, Codonopsispilulosa root, Polygala tenuffiblia root, Polygonum 
multiflorum root, Salvia miltiorrhiza root (2 batches obtained) and Ziziphus jujuba 
fruit with seeds were supplied by the Chi Clinic, 10 Greycoat Place, London, SWI, 
England (herbs were imported from China). Apocynum lancifolium leaves and 
Ziziphus jujuba var. spinosa seeds were obtained from Mayway (UK) Ltd., 43 
Waterside Trading Estate, Trumpers Way, Hanwell, W7 2QD, England (products 
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imported from 506 South Building, Zhong Guan Cun, Beijing, China); Centella 
asiatica leaves were obtained from Brome and Schimmer Ltd., 3 Greatbridge Road, 
Romsey, Hants, England; Convallaria majalis leaves were obtained from The Herbal 
Apothecary, High Street, Syston, Leicester, LE7 1GQ, England; Melissa officinalis 
dried leaf was obtained from G. Baldwin and Co., Walworth Road, London, SE17 
I RW, England; Rosmarinus officinalis dried herb was obtained from Cotswold Health 
Products Ltd., Units 5-6 Tabernacle Road, Wotton-Under-Edge, Gloucestershire 
GL12 7EF, England; Withania somnifera root was obtained from PAK Chemicals 
Ltd., Karachi, India. 
The essential oils were obtained as follows: Rosmarinus officinalis essential oil from 
G. Baldwin and Co., Walworth Road, London, SE17 IRW, England; Melissa 
officinalis essential oil from Fragrant Earth, Taunton, England; Melissa officinalis 
phytol extract (and crude extract), grown and extracted by Clwydian Fragrant Oils, 
Llyn-y-Pandy Lane, Pantymwyn, Clwyd, Wales. 
The constituents citronellal (85-95%), DL-citronellol (95%), convallatoxin (80%), 
cymarin, y-aminobutyric acid (GABA), geraniol (98%), oc-humulene, (+)-limonene 
(97%) and nerol (98%) were purchased from Sigma, Fancy Road, Poole, Dorset, 
England; camphor (96%), caryophyllene oxide (90%), 1,8-cineole (99%), citral 
(95%), eugenol (99%), (±)-linalool (97%), 6-methyl-5-hepten-2-one (99%), nerolidol 
(98%) and nonanal (95%) were purchased from Aldrich Chemical Company, New 
Road, Gillingham, Dorset, England; citral was also purchased from Lancaster (MTM 
Research Chemicals), Eastgate, White Lund, Morecambe, England; (+)-calarene 
(>99%), (+)-p-cedrene (97%), (-)-a-cubebene (ý: 98%), ocimene (97%) and (-)-trans- 
caryophyllene (99%) were purchased from Fluka Chemicals, The Old Brickyard, New 
Road, Gillingham, Dorset, SP8 4XT, England; hyperoside was obtained from Extra 
Synth&se, Fluorochem Ltd., Wesley Street, Old Glossop, Derbyshire, SK13 9RY, 
England. Chlorophyll (water soluble biological stain) was obtained from Hopkin and 
Williams, Essex, England. 
2.1.1.2 Chromatography Materials 
Normal phase silica gel TLC plates (60F254) and silica gel (60PF254) were obtained 
from Merck Ltd., Magna Park, Lutterworth, Leicestershire, England. Microgranular 
130 
cellulose powder (CC41) was obtained from Whatman International Ltd., Springfield 
Mill, Maidstone, England. Spray reagent chemicals were obtained as follows: 
anisaldehyde and chloramine T (n-chloro-p-toluene sulphonamidc sodium salt) were 
obtained from Sigma, Fancy Road, Poole, Dorset, England; 3,5-dinitrobenzene 
carboxylic acid, diphenyl-boric-amino-ethyl-ester complex (DPBAE) and bismuth 
subnitrate were obtained from Aldrich Chemical Company, New Road, Gillingham, 
Dorset, England; polyethylene glycol (PEG) 4000 and ninhydrin (idanetrione hydrate) 
were obtained from BDH Supplies, Poole, England; trichloroacetic acid was obtained 
from Fisher Scientific International Company, Loughborough, Leicestershire, LE1 1 
5RG, England. 
Biotage prepacked polyethylene cartridges (prepacked with KP-SilTm 32-63gm, 60A 
silica) and sample injection modules (SIMTM) were obtained from Biotage UK Ltd., 
15 Harforde Court, Foxholes Business Park, John Tate Road, Hertford, SG13 7NW, 
England. Solvents were obtained from BDH Supplies, Poole, England and Rathburn 
Chemicals Ltd., Hunter Boulevard, Magna Park, Lutterworth, Leicestershire, LE17 
4X'N, England. 
2.1.2 Authentication of Plant Material 
Apocynum lancifiblium leaf and Ziziphusjujuba var. spinosa seeds were authenticated 
by Mayway (UK) Ltd., 43 Waterside Trading Estate, Trumpers Way, Hanwell, W7 
2QD, England. Centella asiatica leaf was authenticated by Brome and Schimmer 
Ltd., 3 Greatbridge Road, Romsey, Hants, England. Convallaria majalis leaf was 
authenticated by The Herbal Apothecary, High Street, Syston, Leicester, LE7 IGQ, 
England. Rosmarinus officinalis dried herb was authenticated by Nicente Bravo, 
Spain. Melissa officinalis dried herb was authentictated by Viva Plantes, La Tourette, 
France. A lisma orientalis root, Codonopsis pilulosa root (voucher no. EB C8 0745 3 6: 
2/179), Polygala tenuifolia root, S. miltiorrhiza root (2 batches) (voucher no. EBC 
80003 TCMK 4), Ziziphusjujuba fruit with seeds (voucher no. EBC 80090 TCMK 
68) and Ziziphusjujuba var. spinosa seeds (voucher no. EBC 80646 TCMK 95) were 
authenticated (against plant material obtained from China by The Royal Botanic 
Gardens, Kew, England), and were confirmed to be the correct species, in 
collaboration with Ms Christine Leon and Professor Monique Simmonds, using 
morphological and microscopical analysis, at The Chinese Medicinal Plants 
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Authentication Centre, The Royal Botanic Gardens, Kew, Surrey, TW9 3AB, 
England. Polygonum multifloruni root was authenticated against Gentiana scabra 
root (voucher no. EBC 80728 TCMK 78) and Rosmarinus officinalis fresh herb was 
authenticated against an authentic sample of Rosmarinus q cinalis fresh herb, in Of, 
collaboration with Dr Renee Grayer at The Royal Botanic Gardens, Kew, Surrey, 
TW9 3A-B, England, as described below. 
2.1.2.1 Authentication of Polvjzonum multiflorum Root 
0.5g Polygonum multiflorum root sample was cut, ground using a pestle and mortar 
and then added to 10ml CH3COCH3 in a sealed glass bottle. After 24hr the bottle 
contents were filtered and evaporated using a rotary evaporator. The residue was 
dissolved in Iml MeOH and filtered through a 0.45pm filter (Gelman nylon acrodisc) 
prior to analysis using HPLC. HPLC parameters were as follows: column: C18 
(Supelco Discovery), 250mm x 4.6mm (particle size: 5[im); pump: Waters 600E; UV 
detector: L-4000 (Merck Hitachi); wavelength: 210nm; solvent gradient: 75% A, 25% 
B (t=Omin) then a linear gradient to 0% A, 100% B (t--20min), followed by 5min 
isocratic elution at 100% B then 75% A, 25% B (t--26min); where solvent A: 2% 
CH3COOH in distilled H20; solvent B: MeOH : H20 : CH3COOH (18: 1: 1). This 
process was repeated for analysis of Gentiana scabra root. Refer to 2.2.1.1 for results 
and discussion. 
2,1.2.2 Authentication of Rosmarinus oficinalis Fresh Leaf 
0.5g Rosmarinus officinalis leaf (sample: frozen leaf) was weighed and immersed in 
15ml (C2HS)20 in a sealed glass bottle for external extraction of compounds of low 
polarity. 0.5g R. officinalis leaf (sample: frozen leaO was weighed and immersed in 
15ml 80% MeOH, then boiled for 5min for internal extraction of the more polar 
compounds, and the bottle was sealed. Both extracts were left for 24hr, prior to 
filtration. The filtered extracts were evaporated using a rotary evaporator. The 
residue was dissolved in Iml MeOH and filtered through a 0.45pm filter (Gelman 
nylon acrodisc) prior to analysis using HPLC. HPLC parameters were as follows: 
column: C18 (Supelco Discovery), 250mm x 4.6mm. (particle size: 5[tm); pump: 
Waters 600E; UV detector: L-4000 (Merck Hitachi); wavelength: 210nm; solvent 
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gradient: 75% A, 25% B (t--Omin) then a linear gradient to 0% A, 100% B (t=20min), 
followed by 5min isocratic elution at 100% B then 75% A, 25% B (t--26min); where 
solvent A: 2% CH3COOH in distilled H20; solvent B: MeOH : H20 : CH3COOH 
(18: 1: 1). This process was repeated for analysis of the authentic R. offilcinalis plant 
material (fresh leaf). 
The essential oil composition of the sample and authentic R. officinalis leaf was 
determined by thermal desorption-GC-MS, by placing two leaves in the desorption 
tube. Thermal desorption parameters were as follows: thermal desorber: Perkin Elmer 
ATD400; desorption temperature: 100"C; desorption time: 10min; focussing trap: 
Tenax TA80-100 mesh at 4'C; trap desorption: ballistic heating to 300*C; transfer 
line temperature: 200'C; outlet split enabled. GC parameters were as follows: GC: 
Perkin Elmer Autosystem; column: 30m x 0.22mm i. d., (particle size: 5pm) PE5-MS 
(Perkin Elmer); temperature program: 40"C - 260"C (4'C. min-1); pressure: l5psi. MS 
parameters were as follows: Quadruple Perkin Elmer TurboMass; source: electron 
ionisation (70eV); temperature: 180'C; scan range: mlz 38 - 300. Refer to 2.2.1.2 for 
results and discussion. 
2.1.2.3 Authentication of Withania somnifera Powdered Root 
TLC analysis and authentication of Withania soninifera powdered root was conducted 
according to the method described by Upton, 2000. Iml NI-13 (25% in H20) was 
added to I 00mg powdered herb and the mixture was shaken. I Oml MeOH was added 
and the mixture was sonicated for 10s. The mixture was then heated to boiling in a 
water bath for 3min, and was then filtered. After evaporating to dryness using a 
rotary evaporator, the residue was reconstituted in I ml MeOH. 
10pl aliquots of this test solution were applied to a silica gel plate (60F254) and 
developed using the mobile phase: C6H5CH3 : EtOAc : CHOOH (50: 15: 5). The plate 
was examined after spraying with 10% H2SO4 reagent in MeOH under UV light (at 
254nm and at 366nm), and in daylight. Refer to 2.2.1.3 for results and discussion. 
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2.1.3 Extraction Methods of Plant Material 
Plant material was ground using a grinding mill or kitchen blender and a known 
quantity (approximately lg of plant material per 10ml of solvent) of plant material 
was extracted with solvents of different polarity as described below: 
2.1.3.1 Hot Ethanolie Extraction 
Plant material was refluxed in 96% EtOH for 20min. 
2.1.3.2 Hot Aqueous Extraction 
Plant material was refluxed in distilled H20 for 20min. 
2.1.3.3 Ethanolic Extraction at Room Temperature 
Plant material was immersed in 96% EtOH in a glass vessel, sealed to prevent solvent 
evaporation, and stored at room temperature in the dark for one week. 
2.1.3.4 Soxhlet Extraction 
Soxhlet Extraction of Ziziphusjujuba Seeds 
Sequential extraction of 4.3g of ground Z jujuba seeds was perfonned using solvents 
of increasing polarity: 200ml PS, 200ml 96% EtOH and 200ml distilled H20 for Shr 
each time. 
Soxhlet Ex1raction of Convallaria majalis Leaves 
Sequential extraction of 25g of C majalis leaves was performed using solvents of 
increasing polarity: 350ml C61114,350ml DCM and 350ml distilled H20 for 21/2hr 
each time. 
Each extract (2.1.3.1 - 2.1.3.4) was filtered and evaporated using a rotary evaporator 
(except aqueous extracts that were freeze dried). A known quantity of each residue 
was reconstituted with 96% EtOH to give extract concentrations ranging from 2mg/ml 
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to 20mg/ml, further dilution with 96% EtOH was performed to give a series of 
dilutions for use in the in vitro studies. Reconstituted extracts were stored at 40C; 
dried extracts were stored at -201C. 
2.1.4 Methods for Preparation of Spray Reagents for TLC Analysis (Prepared 
According to Stahl, 1969) 
Acidic Anisaldchyde: 0.5% anisaldehyde in MeOH : glacial CH3COOH 
concentrated H2SO4 (85: 10: 5). After spraying the plate was heated at II O'C for 5min 
-I Omin and observed in daylight. 
Chloramine T/Trichloroacetic Acid: Solution a: freshly prepared 3% chloramine T 
in distilled H20; solution b: 25% trichloroacetic acid in EtOH. 10ml solution a was 
added to 40ml solution b for use as the spray reagent. After spraying the plate was 
heated at 11 O'C for 7min and observed under UV light (3 66mn). 
Dragendorff's Reagent: 100ml stock solution (consisting of 1.7g bismuth subnitrate, 
20ml glacial CH3COOH, 100ml 50% KI solution and 80ml distilled H20) and 200ml 
glacial CH3COOH were made up to 1L with distilled H20. After spraying the plate 
was observed in daylight. 
Kedde's Reagent: Kedde's solution a: 2% dinitrobenzoic acid in MeOH; Kedde's 
solution b: 3% KOH in MeOH. After spraying with solution a, then solution b, the 
plate was observed in daylight. 
Natural Product Reagent (NPR): Solution a: 1% DPBAE in MeOH; solution b: 5% 
PEG 4000 in EtOH. After spraying with solution a, then with solution b, the plate 
was observed under UV light (366rmi). 
Ninhydrin: 0.2% ninhydrin in CH3COCH3. After spraying the plate was heated at 
II O'C for 5min -I Omin and observed in daylight. 
135 
2.1.5 Method for the Preparation of Preparative TLC Plates 
2.1.5.1 Preparation of Cellulose Plates 
Imm thick cellulose plates were prepared by vigorously shaking approximately 40g 
cellulose powder with 100ml distilled H20 for 4min - 5min. The resulting slurry was 
evenly spread across 5 glass plates and left overnight at room temperature to dry. 
2.1.5.2 Preparation of Silica Gel Plates 
Irmn thick silica gel plates were prepared as follows: 90g silica gel (Keiselgel 
60FF254) was dissolved in 200ml distilled H20 and shaken vigorously for 4min - 
5min. The resulting slurry was evenly spread across 5 glass plates and left overnight 
at room temperature to dry. Plates were placed in a TLC tank and MeOH was run to 
the top of each plate; the top 1.5cm - 2. Ocm of silica on each plate was removed to 
eliminate contaminants. Plates were dried in an oven (60'C) for 45min to evaporate 
any remaining solvent. 
2.1.6 Analysis of Convallaria majalis Leaf. - Separation Methods 
2.1.6.1 Flash Column Chromatography of C. maialis Leaf Extract (a) 
An ethanolic extraction at room temperature of 6g C majalis leaf yielded 0.609g of 
extract, which was reconstituted in 3ml MeOH, mixed with 4g silica gel (60PF254), 
ground in a mortar and allowed to dry overnight. The silica coated sample was 
applied to a Biotage SIMTM (35ml volume). As solvents of increasing polarity (C6H, 4 
(100%); DCM (100%); DCM : C143COCH3 (1: 1); CH3COCH3 : MeOH (1: 1) and 
MeOH (100%)) were added (500ml of each) under pressure (N2: 5psi), compounds 
were passed through a Biotage prepacked column (i. d.: 15cm x l2mm, 8g); flow rate: 
5ml. min-1.55 fractions were collected and monitored using TLC and similar fractions 
were pooled to give 16 fractions (Fla - Fl6a). Each fraction was evaporated using a 
rotary evaporator, then final traces of solvent removed by blowing with N2 at room 
temperature. Fractions were weighed and diluted in 96% EtOH to give a final 
136 
concentration of 10mg/ml. Fractions were stored at 41C. Refer to 2.2.2.1 and 2.2.2.3 
for results and discussion. 
2.1.6.2 Flash Column Chromatography of C maialis Leaf Extract (b) 
5g of an ethanolic extract of C majalis leaf (extracted at room temperature) was 
partitioned between 375ml DCM and 375ml H20. This process was repeated twice. 
The DCM fraction (1) was evaporated to dryness and stored at -20'C. The aqueous 
fraction was freeze dried, and further partitioned between 250ml EtOAc and 250ml 
H20 (Figure 2.1). The EtOAc fraction (2) was evaporated to dryness, and the 
aqueous fraction (3) was freeze dried; extracts were stored at -20'C. 
Fractions (1,2,3) were analysed using TLC (stationary phase: silica gel (6017254); 
mobile phase: C6H5CH3: EtOAc : MeOH (5: 6: 4); spray reagent: acidic anisaldehyde). 
Fraction I (the DCM layer) was also compared with the crude ethanolic extract of C. 
majalis leaf and with F8a (from FCC (a)) by application to silica gel (60F254) plates. 
This was conducted to determine if the compounds present in the active F8a were also 
present in the DCM layer of the ethanolic extract. Compounds not of interest (i. e. 
those absent in the active fraction) could be eliminated, permitting a higher yield of 
active compounds in the FCC separation. Plates were developed using C6145CH3 : 
EtOAc : MeOH (5: 6: 4) as the mobile phase, and examined using 2 different spray 
reagents: acidic anisaldehyde and NPR. 
As compounds in the active 178a were present in the DCM fraction, this fraction was 
selected for further separation. 3.924g of the DCM fraction was reconstituted in 
DCM and mixed with silica gel (60PF254). then ground in a mortar and allowed to dry 
overnight. The silica coated sample was applied to a Biotage SIMTM (35ml volume). 
Solvents of increasing polarity were added (500ml of each) under pressure (N2: 5psi): 
PS (100%); PS : DCM (1: 1); DCM (100%); DCM : MeOH (9: 1); DCM : MeOH 
(6: 1); DCM : MeOH (3: 1); DCM : MeOH (1: 1) and MeOH (100%); flow rate: 
5ml. min-1. As solvent passed through the SIMTM, the compounds from the sample 
were passed on to the Biotage prepacked column (i. d.: 15cm x 12mm, 8g). 70 
fractions were collected and monitored using TLC and similar fractions were pooled 
to give 17 fractions (FIb - F17b). Each fraction was evaporated using a rotary 
evaporator, then under N2 at room temperature. Fractions were weighed and diluted 
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in 96% EtOH to give a final concentration of 10mg/ml. Fractions were stored at 4'C. 












EtOAc fraction (2) 
Freeze dried 
H20 fraction (3) 
Figure 2.1. Diagram to show the partition of the ethanolic extract of C majalis leaf. 
5g ethanolic extract of C majalis leaf 
138 
2.1.6.3 Droplet Counter-Current Chromatography of C. maialis Leaf Extract 
Liquid-liquid separation of a concentrated extract of C majalis leaf (ethanolic 
extraction at room temperature) was performed with reference to the DCCC 
conditions discussed by Hostettmann et aL (1986). The BUchi-670 DCCC employed 
for separation was constructed with 290 silica glass vertical columns of 2.7mm 
diameter, each connected by capillary Teflon@ tubes in a series of 6 racks. 
Parameters were set as follows: flow rate: Iml. min-1, maximum pressure: 30 bar and 
motor pump: 12 - 16. MeOH (100%) was passed through the system to prepare for 
addition of the stationary and mobile phases. The two-phase solvent system used for 
separation was DCM : MeOH : H20 (5: 6: 4). The upper (stationary) phase was passed 
through the system. 3.219g of C majalis leaf EtOH extract was dissolved in 20ml of 
the solvent system (1: 1 of upper and lower solvent phases), and filtered prior to 
addition to the sample chamber. The lower less polar (mobile) phase was passed 
through the series of columns, displacing the extract from the sample chamber to form 
a series of descending droplets. 459 fractions (2ml - 3ml each fraction) were 
collected using a Retriever II (ISCO) fraction collector. Fractions were monitored 
using TLC and similar fractions pooled to give 17 final fractions, which were 
evaporated using a rotary evaporator, then under N2 at room temperature. Fractions 
were weighed and diluted in 96% EtOH to give a final concentration of 10mg/ml. 
Fractions were stored at 4'C. Refer to 2.2.2.4 for results and discussion. 
2.1.7 Analysis of C majalis Leaf. Thin Layer Chromatography Methods 
2.1.7.1 TLC Analysis of C maialis Leaf Extracts Obtained by Soxhlet Extraction 
5gl -I OpI applications of each of the extracts obtained by soxhlet extraction (C6HI4, 
DCM, H20; refer to 2.1.3.4), and the crude EtOH extract of C. majalis leaf, were 
developed on silica gel plates (6017254) using the following solvent systems: the lower 
less polar phase of the solvent system DCM : MeOH : H20 (5: 6: 4), and C6H5CH3 : 
EtOAe : MeOH (5: 6: 4). Plates were examined under UV light (at 254nm and at 
366nm), and in daylight after spraying with acidic anisaldehyde reagent. Refer to 
2.2.4 for results and discussion. 
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2.1.7.2 TLC Analysis of Flash Column Chromatography Fractions of C maialis Leaf 
(a) 
lOgI - 20gl applications of each sample (fractions and reference sample of the 
unfractionated extract) were applied to the silica gel plate (60F254) and plates were 
developed using different solvent systems to establish the most appropriate solvent 
system: CHC13 (1000/0); C6H5CH3 (100%); C6H5CH3: EtOAc (9: 1); C6H5CH3: EtOAe 
(3: 1); D CM (100%), then after drying, developed again with EtOAc : MeOH (19: 1) to 
approximately half the length of the solvent front; DCM (100%), then after drying, 
developed again with EtOAc : MeOH (1: 1) to approximately half the length of the 
solvent front. The latter solvent system was selected for TLC analysis of the 
fractions. Every P- 5"' fraction was applied to the plate and developed using the 
selected solvent system. Fractions of higher polarity (F39 - F55) were also analysed 
using the solvent systems: EtOAc : MeOH (1: 1) and EtOAc : MeOH : H20 
(100: 13.5: 1). All plates were examined under UV light (at 254nm and at 366nm), and 
in daylight after spraying with acidic anisaldehyde, followed by respraying with 
concentrated H2SO4 : H20 (1: 1) and reheating at II O'C for 5min (unless otherwise 
stated). 
Fractions were also analysed using the solvent systems EtOAc : glacial CH3COOH 
CHOOH : H20 (100: 11: 11: 26) and the upper phase of butan- I -ol : glacial CH3COOH 
: H20 (4: 1: 5) and analysed using NPR. 
Fractions which demonstrated antiChE activity were also analysed for presence of 
cardenolides: 10pl applications of fractions and reference samples (convallatoxin 
(50), cymarin (48) and the unfractionated extract) were applied to a silica gel plates 
(60F254) and developed using the lower less polar phase of the solvent system DCM : 
MeOH : H20 (5: 6: 4). Plates were analysed with Kedde's reagent, and also with 
chloramine T/trichloroacetic acid. Refer to 2.2.2.1 and 2.2.2.3 for results and 
discussion. 
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2.1.7.3 TLC Analysis of Flash Column Chromatography Fractions of C. maialis Leaf 
(b) 
Every 5 th fraction of the total of 70 fractions was analysed as follows: 1041 - 20[d 
applications of each sample (fractions and reference samples of the unfractionated 
extract, and F8a from FCC (a)) were applied to the silica gel plate (60F254), and 
developed using the solvent system C6H5CH3 : EtOAc : MeOH (5: 6: 4) (e. g. F23 - 
F49, Figure 2.2). 
F23 
1*1 
F25 F27 F29 F31 F33 F35 F F37 F39 F41 F43 F45 F47 F49 
Figure 2.2. TLC profiles of flash column chromatography (b) fractions (1723 - F49) 
from C. majalis leaf extract. Chromatography conditions: stationary phase: silica gel 
(60F254). mobile phase: C61-15CH3 : EtOAc : MeOH (5: 6: 4), spray reagent: acidic 
anisaldehyde. E= DCM fraction of EtOH extract of C. majalis leaf. 
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Fractions of greater polarity were also analysed using the solvent systeMS C6H5CH3 : 
EtOAc : MeOH (3: 5: 8) and EtOAc : McOH : H20 (100: 13.5: 10). 
Fractions of lower polarity were also analysed using the solvent Systems C6115CH3 : 
EtOAc (93: 7), C6HSCH3: CHC13 (1: 1). C6115CH3: CHC13 (4: 1), C6HI4 : CHC13 (4: 1) 
and C6HI4: CHC13 (3: 2). All plates were examined under UV light (at 254nm and at 
366nm), and in daylight after spraying with acidic anisaldehyde reagent. Refer to 
2.2.2.2 and 2.2.2.3 for results and discussion. 
2.1.7.4 TLC Analysis to Compare C. maialis Leaf FCC (a) and (b) Active Fractions 
For comparison of FCC fractions, a solvent system Of C6H5CH3 : EtOAc : MeOH 
(5: 6: 4) and a stationary phase of silica gel (60F254) plates were used; plates were 
examined under UV light (at 254nm and at 366nm), and in daylight after spraying 
with acidic anisaldehyde reagent. The crude EtOH C majalis leaf extract and the 
DCM layer of the crude EtOH extract (prepared as described previously: 2.1.6.2 FCC 
(b)) were used as reference solutions. 
The TLC profiles of F5b, F6b, F7b, F8b, F9b, FlOb and Fl lb (from FCC (b)) were 
compared with F8a (from FCC (a)), and the TLC profiles of FlOb and Fl lb (from 
FCC (b)) were compared with F15a and Fl6a (from FCC (a)). Refer to 2.2.2.3 for 
results and discussion. 
2.1.7.5 Comparison of Crude Ethanolic Extract of C maialis Leaf with Chlorophyll 
S[LI aliquots of the EtOH extract of C majalis leaf, and chlorophyll (dissolved in H20, 
I mg/ml) were applied to two silica gel (6017254) plates; solvent systems DCM : MeOH 
(9: 1) and DCM : MeOH (1: 1) were used, respectively. Plates were examined under 
UV light (at 254mn and at 366nm), and in daylight after spraying with acidic 
anisaldehyde reagent. Refer to 2.2.5 for results and discussion. 
2.1.7.6 Investigation to Establish an Appropriate Solvent System for Separation of C 
mqLalis Leaf Extract Using DCCC 
A crude C. majalis leaf EtOH extract was applied to both cellulose (prepared as 
described previously: 2.1.5.1) and silica gel (60F254) plates. Plates were developed 
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using the upper and lower phases of the solvent systems DCM : MeOH : H20 (5: 6: 4) 
and CHC13: MeOH : nPrOH : H20 (5: 6: 1: 4) (Hostettmann et aL, 1986). All silica gel 
plates were examined under UV light (at 254nm and at 366nm), and all plates were 
examined in daylight after spraying with acidic anisaldehyde reagent. Refer to 2.2.2.4 
for results and discussion. 
2.1.7.7 TLC Analysis of DCCC Fractions of C. myLalis Lea 
Every 6'h DCCC fraction was applied to silica gel (60F254) plates and developed using 
the lower less polar phase of the solvent system: DCM : MeOH : H20 (5: 6: 4) (e. g. 
F295 - F395, Figure 2.3). 
F295 F305 F315 F325 F335 F345 E F355 F365 F375 F385 F395 
Figure 2.3. TLC profiles of droplet eounter-eurrent chromatography fractions (F295 
- F395) from C majalis leaf extract. Chromatography conditions: stationary phase: 
silica gel (60F254). mobile phase: less polar phase of DCM : MeOH : H20 (5: 6: 4), 
spray reagent: acidic anisaldehyde. E= crude EtOH extract of C majalis leaf. 
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Fractions of greater polarity were also analysed using the upper, more polar phase of 
this solvent system, and also the solvent system EtOAc : MeOH : H20 (100: 13.5: 10). 
The unfractionated crude extract was applied to each plate for reference. Plates were 
examined under UV light (at 254nm and at 366nm), and in daylight after spraying 
with acidic anisaldehyde reagent. F4 (obtained by pooling F62 - F71 from the 
original 459 DCCC fractions) was compared with F8a (from FCC(a)), and 
preparative TLC F3 and F4, using the lower less polar phase of the solvent system: 
DCM : MeOH : H20 (5: 6: 4), and was examined under UV light (at 254run and at 
366nm), and in daylight after spraying with acidic anisaldehyde reagent. Refer to 
2.2.2.4 for results and discussion. 
2.1.7.8 Preparative TLC: C maialis Leaf Ethanol Extract 
40mg of C majalis leaf crude EtOH extract, dissolved in 2ml 96% EtOH, was applied 
to one silica gel plate (prepared as described previously: 2.1.5.2) and dried at room 
temperature. The plate was developed using the lower less polar phase of the solvent 
system DCM : MeOH : H20 (5: 6: 4), dried, and a small section of the plate sprayed 
with acidic anisaldehyde reagent. The plate was also analysed under ultraviolet light 
(at 254mn and at 366mn). The plate was divided into 7 sections (including the 
baseline) and each section (excluding the sprayed section) was scraped off and 
dissolved in 20ml - 40ml DCM : MeOH (1: 1). Each of the 7 fractions were filtered to 
remove silica, evaporated to dryness by blowing with N2 at room temperature and 
dissolved in 96% EtOH to give a 2mg/ml concentration. Fractions diluted in EtOH 
were stored at 4"C. 
Each of the 7 fractions was analysed by application to silica gel (60F254) plates, and 
developed using the solvent system C6145CH3: EtOAc : MeOH (5: 6: 4). The plate was 
examined under UV light (at 254nm and at 366nm), and in daylight after spraying 
with acidic anisaldehyde reagent. 
F3 and F4 (which inhibited AChE, refer to Chapter 3,3.2.4.5) were also compared 
with the crude EtOH extract of C. majalis leaf, and with the active F8a (from FCC 
(a)) by application to silica gel (60F254) plates. The solvent systems used for analysis 
were the lower less polar phase of the solvent system DCM : MeOH : H20 (5: 6: 4), 
and C61-15CH3 : EtOAc : MeOH (5: 6: 4). Plates were examined under UV light (at 
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and at 366mn), and in daylight after spraying with acidic anisaldehyde reagent. Plates 
were also examined for the presence of alkaloids using Dragendorff s spray reagent, 
instead of acidic anisaldehyde. Refer to 2.2.2.5 for results and discussion. 
2.1.8 Analysis of C majalis Leaf Extract and Fractions Using HPLC and LC-MS 
2.1.8.1 Analysis of C mgjalis Leaf Crude Ethanolic Extract and Preparative TLC 
Fractions 
LC-MS investigations were conducted by Dr Geoffrey Kite, The Royal Botanic 
Gardens, Kew, England and HPLC analysis of F3 (from preparative TLC separation 
of C. majalis leaf EtOH extract, refer to 2.1.7.8) was conducted by Dr Renee Grayer, 
The Royal Botanic Gardens, Kew, England. 
LC-MS analysis of the crude EtOH extract and the preparative TLC fractions (FI - 
F7) of C majalis leaf, was conducted as follows: 
15mg of dried EtOH extract was dissolved in 2ml MeOH; dried fractions (F1 - F7) 
were also dissolved in MeOH. HPLC parameters were as follows: column: C18 
(Supelco Discovery), 250mm x 4.6mm, 5pm; pump: Waters 60013; UV detector: L- 
4000 (Merck Hitachi); wavelength: 210mu; solvent gradient (for crude extract): 70% 
H20,20% MeOH, 5% C2H3N (t--Omin), 0% H209 95% MeOH, 5% C2113N (t=25min), 
solvent gradient (for fractions): 60% H20,35% MeOH, 5% C2H3N (t--Omin), 0% 
H20i 95% MeOH, 5% C2143N (t--25min), flow rate: I ml. min-1. 
MS parameters were as follows: MS: quadruple ion-trap (Finnigan MAT, model 
LCQ); source: APCI operating in positive mode; vaporisation temperature: 450*C; N2 
pressures: 80psi (sheath), 20psi (auxillary); needle voltage: 4.2kV. The MS was set to 
record a survey scan in the range nilz 100 - 2000, and then the CID spectrum of the 
most intense ion in the survey scan. Refer to 2.2.3 for results and discussion. 
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HPLC analysis of preparative TLC F3 from the EtOH extract of C. niajalis leaf, was 
conducted as follows: 
Column: Lichrosphere lOORP, 250mm x 4mm; column temperature: 30*C; pump: 
Waters LC 600; UV detector: L-4000 (Merck Hitachi); wavelength: 257nm; solvent 
gradient: 75% A, 25% B (t=Omin), 0% A, 100% B (t--20min), followed by isocratic 
clution to t=23min (where solvent A: 2% CH3COOH in distilled H20; solvent B: 
MeOH : H20 : CH3COOH (18: 1: 1)), flow rate: I ml. min". Refer to 2.2.3 for results 
and discussion. 
2.1.8.2 LC-MS Analysis of C maialis Leaf Flash Column Chromatogmphy Fractions 
(FCC (b» 
LC-MS analysis of F6b and F7b (from FCC (b)) was conducted by Dr Geoffrey Kite, 
The Royal Botanic Gardens, Kew, England. 
LC-MS analysis of F6b and F7b (from FCC (b)) of C majalis leaf extract was 
conducted as follows: 
15mg of each fraction was dissolved in 2ml McOH. HPLC parameters were as 
follows: column: C18 (Merck LiChrosphere), 250mm x 4mm (particle size: 5pm); 
pump: Waters 60013; UV detector: L-4000 (Merck Hitachi); wavelength: 335nm; 
solvent gradient: 25% - 100% MeOH in 1% CF13COOH in 20min, flow rate: 
Iml. min-1. MS parameters were as follows: MS: quadruple ion-trap (Finnigan MAT, 
model LCQ); source: APCI operating in positive mode; vaporisation temperature: 
450'C; N2 pressures: 80psi (sheath), 20psi (auxillary); needle voltage: 4.2kV. The 
MS was set to record a survey scan in the range nilz 100 - 2000, and then the CID 
spectrum of the most intense ion in the survey scan. Refer to 2.2.3 for results and 
discussion. 
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2.1.9 Analysis of Herbal Extracts for the Presence of GABA 
All aqueous and ethanolic extracts of each plant were analysed for the presence of 
GABA (16). This analysis was performed to enable exclusion of all GABA (16)- 
containing extracts from the GABA (16) receptor binding assay; presence of GABA 
(16) in an extract would interfere in this assay by giving false positive results. 
20pl applications (equivalent to 100pg of herbal extract) were applied to cellulose 
plates (prepared as described in 2.1.5.1), and also to silica gel (60F254) plates. 5PI 
GABA (16) (20nmoles in distilled water) was applied to each plate for reference. 
Plates were developed using the solvent system butan-l-ol : H20 : CH3COOH 
(60: 25: 15), and sprayed with ninhydrin reagent. Refer to 2.2.6 for results and 
discussion. 
2.1.10 Gas Chromatography-Mass Spectroscopy 
2.1.10.1 Analysis of M. officinalis Essential Oil and Commercially Obtained Oil 
Constituents 
GC-MS investigations were conducted in collaboration with Dr Geoffrey Kite, The 
Royal Botanic Gardens, Kew, England. 
GC-MS analysis was conducted using a GC (Perkin-Elmer 8500) with parameters set 
as follows: oven temperature: 60'C - 200"C (3'C. minute"), carrier gas: lie (20psi). 
Tile column used was a capillary column, length: 25m x 0.22mm W., coating: 0.25pm 
of BPX5 (SGE Ltd., I Potters Lane, Kiln Farm, Milton Keynes, MKI I 34X). The 
MS was a Finnigan Ion Trap Detector, 400 series, scanning: nilz 38 - 300. The 
injection volume for all samples was I pl, split. 
The major components in the oils were identified by comparing mass spectra with 
published data (Adams, 1995) and calculating KI values. The identifications of citral 
(geranial (70) and neral (71)), geraniol (72) and linalool (74) were confirmed by 
comparison with standards. Percentage compositions were calculated from both the 
peak areas in the total ion chromatogram (TIC) and the peak areas in the flame 
ionisation detection (FID) trace. 
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Samples analysed were as follows: 
Sample Oil/Compound Source Dilution 
Melissa officinalis Fragrant Earth 1/100 in C61-114 
Melissa officinalis phytol extract CI-vvydian Fragrant Oil 1/100 in (C21715)20 
Melissa officinalis phytol Clwydian Fragrant Oil I /100 in (C2H5)2O 
(crude extract) 
Citral (95%) Aldrich 1/1000 in C6HI4 
Citral Lancaster 1/1000 in C6HI4 
Geraniol (98%) Sigma 1/1000 in C61-114 
(±)-Linalool (97%) Aldrich 1/1000 in C61114 
Nerol (98%) Sigma 1/1000 in C61-114 
2.1.10.2 Assessment of Metabolism of Comnounds by Yeast 
GC-MS investigations were conducted with Dr Geoffrey Kite, The Royal Botanic 
Gardens, Kew, England. 
To determine if metabolism of the four compounds (citral, eugenol (84), geraniol (70) 
and nerol (75)) by the yeast cells occurred, each compound was incubated in the 
presence and absence of yeast, and the results compared using GC-MS analysis (refer 
to Chapter 4,4.1.5,4.7.2 and 4.10.2). 
Tile (C2145)20 phase from each glass vessel, containing yeast suspension and 
(C21'15)20, was removed and stored in a sealed glass vessel at 4*C. 
The vessel contents were analysed using a Perkin Elmer model 8500 GC; column: 
25m x 0.2mm i. d., coating: 0.25pm BPX5 (SGE Ltd., I Potters Lane, Kiln Farm, 
Milton Keynes, MKI I 34X); carrier gas: He (20psi); oven programme: 80'C - 200*C 
(5*C. min*'); detection: FID and ITD (Finnigan-MAT) with ITD parameters of nz/ýz 38 
- 400 scan range, AGC background mass 38,1 scan. s-1, and an injection volume of 
I Pl, split. 
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2.2 Results and Discussion 
2.2.1 Authentication of Plant Material 
2.2.1.1 Authentication of Polygonum multiSorum Root 
Morphological analysis of the P. multiflorum root sample, compared with a sample of 
authentic plant material, indicated that the sample was not P. multiflorum root 
(Figures 2.4 and 2.5). 
Figure 2.4. Polygonum mulliflorum root. 
Figure 2.5. Sample claimed to be Polygonum multijlorum root in the present study. 
L 
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To investigate this fialher, the P. multiflorum root sample was compared with 
Gentiana scabra root, a herb which was morphologically similar to the P. multiflorum 
root sample, using HPLC analysis. The chromatograms for each herb were similar, 
although not identical (refer to Table 2.1 and appendix, Figures Al and A2). The 
major component of both extracts gave a peak in the chromatogram. at the retention 
time of 6.4min, however the maximum absorbance in the UV spectrum of this peak 
was too high in the Gentiana scabra root chromatogram, due to the high 
concentration of the compound giving this peak, to accurately determine the 
maximum absorbanec (refer to appendix, Figures Al. and A2). The peaks in both 
chromatograms with retention times from 15.3min - 19.7min gave similar UV spectra, 
suggesting the compounds responsible for these peaks are chemically related (refer to 
appendix, Figures Al and A2). 
Table 2.1. Retention times (min) of peaks in the chromatograms of Gentiana scabra 
root (authentic) and Polygonum multiflorum root (sample) using HPLC analysis. 
Gentiana scabra Root 
(Authentic) 







19.41min 19.4 1 min 
In view of the morphological similarities and the similar chromatograms given by 
both extracts, it may be concluded that the P. multiflorum root sample is likely to be a 
Gentiana spp., but does not appear to be Gentiana scabra as there were some 
differences between the chromatograms (refer to appendix, Figures Al and A2). 
Further analysis of the P. multiflorum root sample is required to confirm which 
Gentiana spp. it is. Therefore, the P. multiflorum root sample will be described as 
'adulterated P. niultiflorum root'. 
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2.2.1.2 Authentication of Rosmarinus offlicinalis Fresh Leaf 
Analysis of the 80% MeOH and the (C2H5)20 extracts of Rosmarinus ofo)rIcinalis fresh 
leaf using HPLC indicated that the R. officinalis leaf sample was the correct species. 
The corresponding chromatograms for the sample and the authentic plant material 
were similar but not identical (refer to appendix, Figures A3, A4, A5, A6, A7 and 
A8). 
Differences observed between the chromatograms may have occurred due to natural 
variation in R. officinalis plants (e. g. due to cultivation conditions or time of 
harvesting). The R. qjjlcinalis leaf sample was frozen prior to HPLC and GC-MS 
analysis, which may also have influenced the chemical composition, but the authentic 
R. officinalis leaf was not frozen. The UV spectra of the peaks in the chromatograms 
yielded information regarding the chemical composition of the sample and authentic 
R. offilcinalis plants (Tables 2.2 and 2.3). The phytochemistry of the authentic plant 
material was similar to that of the R. officinalis sample (Tables 2.2 and 2.3 and 
appendix, Figures A3, A4, A5 and A6) and in view of the differences in preparation 
of the plant material prior to analysis, indicates that the sample is R. officinalis. 
Analysis of the essential oil composition of both the sample and authentic R. 
officinalis plants was conducted to provide further information regarding the 
authenticity of the R. officinalis sample. The essential oil compositions of the plants 
are different (refer to Table 2.4 and appendix, Figures A7 and A8), which may be 
explained by the cultivation conditions, by the plants being different varieties or at 
different stages of development, or the freezing process of the R. officinalis sample. 
There are some essential oil components common to both of the R. qjjlcinalis 
essential oils, although their percentage composition does differ. 
151 
Table 2.2. Retention times (min) of peaks in the chromatograms of Rosmarinus 








(Based on UV Spectra) 
3.62 - caffeic acid derivative 
4.09 - caffeic acid derivative 
9.80 - flavone glycoside 
11.69 - unidentified 
11.92 - unidentified 
12.20 - unidentified 
12.39 - unidentified 
12.70 12.73 flavone glycoside 
12.96 - unidentified 
13.26 - rosmarinic acid 
- 13.73 unidentified 
13.93 - unidentified 
14.34 14.34 flavone glycoside 
14.61 - unidentified 
15.20 15.2 flavone glycoside 
15.72 - flavone glycoside 
16.22 flavone glycoside 
16.51 - unidentified 
16.87 16.87 flavone glycoside 
- 17.17 unidentified 
24.33 24.30 phenylpropanoid 
26.80 26.80 phenylpropanoid 
27.57 27.57 phenylpropanoid 
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Table 2.3. Retention times (min) of peaks in the chromatograms of Rosmarinus 
offiCinalis leaf (sample and authentic) diethyl ether extracts using HPLC analysis. I- 
R. officinalis Leaf 
(Authentic): 
Rt (min) 




(Based on UV Spectra) 
4.64 4.65 unidentified 
- 5.62 phenolic acid 
6.45 phenolic acid 
8.57 unidentified 
10.24 unidentified 
- 12.74 flavone glycoside 
13.35 - rosmarinic acid 
13.73 13.73 unidentified 
14.35 14.34 flavone glycoside 
- 16.87 unidentified 
16.90 - flavone glycoside 
- 17.13 unidentified 
17.17 - phenylpropanoid 
- 17.49 unidentified 
17.52 - caffeic acid derivative 
18.16 - caffeic acid derivative 
- 18.31 unidentified 
- 19.01 flavone aglycone 
20.28 20.27 flavone aglycone 
- 22.95 flavone aglycone 
23.41 23.41 flavone, aglycone 
24.34 24.30 phenylpropanoid 
25.18 25.15 diterpene 
26.10 - unidentified 
- 26.80 phenylpropanoid 
27.57 27.52 phenylpropanoid 
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Table 2.4. Percentage composition of Rosniarinus officinalis leaf essential oils 
obtained from a sample and from authentic plant material, determined by desorption- 
GC-MS analysis. 
Component R, (min) R. Officinalis R. officinalis 
(Sample) (Authentic) 
tricyclene 9.4 <0.1 0.3 
a-pinene 10.0 4.2 21.3 
camphene 10.6 2.3 6.3 
thuja-2,4(10)-diene 10.8 <0.1 0.4 
P-pinene 11.8 2.4 2.2 
3-octanone, 12.4 <0.1 1.0 
myrcene 12.5 8.0 3.9 
unidentified 13.0 1.8 0.4 
a-terpinene 13.5 0.5 0.6 
o-cymene 13.9 0.5 0.4 
limonene 14.1 4.5 4.5 
1,8-cineole 14.2 18.5 9.5 
y-terpinene 15.3 1.0 0.7 
unidentified 15.8 0.6 0.3 
terpinolene 16.4 0.6 0.7 
unidentified 17.0 <0.1 0.3 
linalool 17.2 1.0 1.3 
chrysanthenone 17.9 0.3 2.0 
camphor 19.0 23.1 10.4 
unidentified 19.4 <0.1 0.7 
borneol 20.0 7.3 7.6 
unidentified 20.3 0.8 0.6 
oc-terpineol 21.0 2.6 1.1 
verbenone 21.4 11.2 11.9 
unidentified 22.5 <0.1 0.9 
unidentified 22.8 <0.1 1.3 
unidentified 23.6 <0.1 0.5 
bomyl acetate 24.1 1.9 1.2 
piperitenone 26.0 <0.1 0.4 
caryophyllene 28.8 2.2 4.8 
unidentified 29.8 <0.1 0.2 
(x-humulene 30.0 4.2 0.8 
caryophyllene oxide 34.0 0.3 0.7 
unidentified 35.7 <0.1 0.2 
unidentified 36.3 0.3 0.7 
The major constituents reported to be present in R. officinalis essential oil are 1,8- 
cineole (56) (15-30%), camphor (57) (15-25%), a-pinene (53) (up to 25%) and other 
monoterpenes including borneol (58) and limonene (73) (Bisset, 1994; Trease and 
Evans, 1996). 1,8-Cineole (56) and camphor (57) composed 18.5% and 23.1% 
respectively of the sample essential oil, but only 9.5% and 10.4% respeetively of the 
authentic essential oil; however, a-pinene (53) was at a higher concentration in the 
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authentic essential oil (21.3%) than in the sample essential oil (4.2%) (refer to Table 
2.4). Borneol (58) and limonene (73) were at similar concentrations in both essential 
oils. The similar composition of both essential oils and the presence of constituents 
reported to be present in R. officinalis essential oil, indicates that the sample of R. 
officinalis leaf is the correct species. 
2.2.1.3 Authentication of Withania somniLera Root 
The sample of Withania somnifera root was analysed using TLC, after spraying with 
10% H2SO4 reagent in MeOH and examination in UV light (366nm) and also in 
daylight (refer to 2.1.2.3 for method). The TLC profile for the sample was similar to 
the TLC profile of authentic W. somnifera root, as described by Upton, 2000. 
Notably, in the TLC profile of the sample, there was a light blue fluorescent zone (Rf: 
0.58) visible in UV light (366nm) that corresponds to P-sitosterol (88), and there was 
a pink-red zone (Rf: 0.17) visible in daylight that corresponds to withaferin A (109) 
(both compounds visible after spraying with the reagent) (Figure 2.6). 
Rf. 0.58 
Figure 2.6. TLC profile of Withania somnifera root sample. Mobile phase: 
C6H5CH3 : EtOAc : CHOOH (50: 15: 5); spray reagent: 10% H2SO4 in MeOH. Rf: 
0.17 corresponds to withaferin A; Rf: 0.58 corresponds to P-sitosterol. 
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The TLC profile, including the identification of the reference compounds P-sitosterol 
(88) and withaferin A (109), indicates that the sample of W. somnifera root used in the 
present study is the correct species. 
2.2.2 Analysis of Separation Methods of C majalis Leaf Extracts 
2.2.2.1 Analysis of Flash Column Chromatography (a) Fractions of C maialis Lea 
Ethanolic Extract 
Several solvent systems were investigated to establish the most efficient solvent 
system for analysis of the FCC fractions using TLC. The solvent systems CHC13 
(100%) and C6H5CH3 (100%) gave insufficient separation of compounds. These 
solvent systems were used to analyse fractions including Fl - F6 (of the total S5 
fractions), which consisted of compounds of low polarity (C61-114 fractions). 
Inadequate separation was observed following examination under UV light (at 254nm 
and at 366run), and in daylight after spraying with acidic anisaldehyde. The solvent 
system C6H5CH3 : EtOAc (9: 1) gave better separation of the less polar fractions (F I- 
176), however this system was unsuitable for analysis as the polarity of the compounds 
in the fractions increased. Increasing the polarity of the solvent system to achieve 
better separation was carried out by using a system Of C6H5CH3 : EtOAc (3: 1). 
Separation of FI- F15 was improved, but this system was unsuitable for separation of 
F 16 - F55. A disadvantage of the solvent systems C6H5CH3 : Et0Ae (9: 1 and 3: 1) 
was the observation of trailing of some zones on the TLC plate. The most efficient 
separation was observed with the solvent system DCM (100%), and then after drying, 
with EtOAc : MeOH (1: 1) to approximately half the length of the solvent front. This 
method of analysis was employed for FI - F40, but did not give adequate separation 
for F41 - F55. F41 - F55 were analysed using the solvent systems EtOAc : MeOH 
(1: 1) and EtOAc : MeOH : H20 (100: 13.5: 1); syst ems suitable for the separation of 
more polar compounds such as the cardiac glycosides, reported to be present in C 
niajalis leaf (Bruneton, 1995). 
The fractions and the crude EtOH extract, were also analysed using the solvent 
systems EtOAc : glacial CH3COOH : CHOOH : H20 (100: 11: 11: 26) and the upper 
phase of butan-l-ol : glacial CH3COOH : H20 (4: 1: 5), and sprayed with NPR and 
analysed in daylight for detection of flavonoid compounds. The latter solvent system 
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gave good separation of compounds. An orange zone (Rf- 0.29) in the crude EtOH 
extract indicated that it may be a flavonoid other than rutin (Rlr. 0.47) or hyperoside 
(Rf- 0.60). However, no other flavonoid compounds were detected in the fractions. 
The glycosidic forms of flavonoids may be present in the vacuoles of the epidenn and 
mesophyll of leaves, and would therefore be expected to occur in C majalis leaf. 
Flavonoid aglycones that are more lipophilic are often present in the cuticle of leaves; 
however, these may be in low concentration or absent in the dried C majalis leaf. 
From TLC examination, the fractions (from the original 55 fractions) containing 
similar constituents were pooled to give 16 fractions. Fractions (some of those that 
inhibited AChE in the in vitro assay, refer to Chapter 3,3.2.4.2) 173a - F5a, 178a - 179a 
and Fl3a - Fl6a, and also the crude EtOH extract, were analysed for the presence of 
cardenolide compounds. Analysis with Kedde's reagent did not demonstrate the 
presence of cardenolides in any of the fractions or crude extract, however the 
reference compounds (convallatoxin (50) and eymarin (48)) gave the characteristic 
purple colour zones. These fractions were also analysed with chloramine 
T/trichloroacetic acid to confirm the results; the reference compounds convallatoxin 
(50) (Rr. - 0.30) and cymarin (48) (Rf- 0.52) gave blue-green fluorescence under 366nm 
UV light. In F3a, one zone (Rf- 0.73) was fluorescent blue under 366mn UV light 
before spraying, but was fluorescent green after spraying; and in 178a, one zone (Rf- 
0.27) was fluorescent orange under 366nm UV light before spraying, and was 
fluorescent green after spraying. These results indicate that cardenolide compounds 
may be present in both Ba and 178a. 
The negative results for cardenolides in the other fractions analysed may be due to the 
absence of such compounds, or due to their presence in a concentration too low for 
detection. The cardenolides present in Ma and F8a did not appear to be either 
convallatoxin (50) or cyrnarin (48), as the Rf values show. Convallatoxin (50) has 
been reported to be the major cardiac glycoside from the flowers and leaves of C 
majalis (Harbome, 1993). It would therefore be reasonable to expect the detection of 
this compound in the crude extract or in one or more fractions of C majalis leaf This 
may be explained by differences in the chemical composition of C majalis due to 
variation in cultivation conditions (e. g. climate, season, soil, and temperature), in 
harvesting processes, in storage conditions of the harvested plants, or differences in 
phenotype. 
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2.2.2.2 Analysis of Flash Column Chromatography (b) Fractions of C mgLalis Lea 
Extract (Obtained from the Dichloromethane Lqyer of an Ethanolic Extract) 
The partition of the EtOH extract of C majalis leaf between DCM and H20 would 
have removed many of the more polar compounds present in the aqueous layer, which 
did not significantly inhibit AChE (refer to Chapter 3,3.2.4.1), leaving the less polar 
compounds in the DCM layer. It is reported that some cardenolide glycosides may be 
water soluble, and others more readily soluble in CHC13 (Lugt, 1975). It is therefore 
concluded that some glycosides and the aglycones were present in the DCM fraction 
of the EtOH extract, while other glycosides would have been extracted into the 
aqueous fraction. The DCM fraction was selected for further separation, as 
compounds corresponding to those in the active 178a (from FCC (a)) were present. 
The solvent system C6H5CH3 : EtOAc : MeOH (5: 6: 4) gave efficient separation of 
F 10 - F43. The more polar fractions (1744 - F70) were also analysed using the solvent 
systems C6H5CH3: EtOAc : MeOH (3: 5: 8) and EtOAc : MeOH : H20 (100: 13.5: 10), 
the latter giving better separation for analysis. Fl - F9 were also analysed using 
several solvent systems; C61-114 : CHC13 (4: 1) was most suitable for F1 - F6, and 
C6H5CH3: CHC13 (1: 1) was most suitable for analysis of F7 - F9. 
2.2.2.3 TLC Analysis to Compare FCC (a) and (b) Active Fractions 
Fractions from both FCC separations ((a) and (b)), which showed activity in the 
antiChE assay, were analysed to identify any common constituents. 
Six zones in F8a (from FCC (a)) were also present in F7b (from FCC (b)), one giving 
a green zone (Rjr 0.56) after spraying with acidic anisaldehyde, the others giving 
fluorescent orange zones (Rf-. 0.4, Rf, 0.54, Rf, 0.59, Rf. 0.77, Rf, 0.85) when 
examined under UV light (366nm). Four of these zones (Rf. - 0.54, Rf. 0.59, Rjr. 0.77, 
Rf. 0.85) were also present in 176b, two zones (Rf-. 0.4, Rf. 0.85) were also present in 
F8b, one zone was also present in F5b (Rr 0.85), and one zone (Rf- 0.54) present in 
F9b from FCC (b). 
These results suggest that a compound (or compounds) identified in both active 
fractions from both FCC (a) and (b) may be responsible for the antiChE activity 
observed in the in vitro assays. Alternatively, different compounds in the active 
fractions may have antiChE activity. This may explain the antiChE activity observed 
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with Fl5a and Fl6a (from FCC (a)) and FlOb and Fllb (from FCC (b)) (rcfcr to 
Chapter 3,3.2.4.2 and 3.2.4.3), as no compounds were identified to be present in both 
FCC (a) (Fl5a and Fl6a) and FCC (b) (FlOb and Fl lb) fractions. 
2.2.2.4 TLC Analysis of DCCC Fractions of C maialis Leaf Ethanolic Extmct 
DCCC was selected for separation of the constituents of C majalis leaf EtOH extract, 
as it has the advantage that no irreversible adsorption of the sample occurs during 
separation, due to the absence of a solid support (e. g. the stationary phase in FCC). 
Therefore, theoretically, there should be complete recovery of the sample. Separation 
of the constituents is achieved as the solute is partitioned between the stationary phase 
and the mobile phase (the droplets). 
A DCCC separation method using the upper and lower phases of the solvent systems 
DCM : MeOH : H20 (5: 6: 4) and CHC13: MeOH : H20 (5: 6: 4) has been used for the 
isolation of cardiac glycosides from Digitalis lanata leaf (Krilger et al., 1983); 
strophanthidin glycosides have been isolated from the arrow poison Lophopetalum 
toxicum using the solvent systems of CHC13 : MeOH : nPrOH : H20 (5: 6: 1: 4) and 
CHC13: MeOH :n PrOH : H20 (45: 70: 5: 40) in a DCCC system (Hostettmann et al., 
1986). These solvent systems were selected to assess the most appropriate system for 
separation of the compounds in the EtOH extract of C majalis leaf. Ternary solvent 
systems were selected to influence droplet size and achieve good separation of 
compounds. A binary solvent system is not suitable for this, as the large difference in 
polarity between the two solvents would not achieve suitable droplets for the 
separation of similar compounds; addition of a third solvent minimises the differences 
in polarity of the system. Solvent systems composed of chlorinated components have 
high densities and low viscosities, and are reported to be suitable for use as the mobile 
phase in DCCC separations, and in combination with H20 and MeOH give good 
formation of droplets (Hostettmann et al., 1984). Solvent systems composed of 
CHC13 (or DCM) : MeOH : H20 in varying proportions have been employed for the 
successful isolation of several types of compound, including glycosides, tannins, 
alkaloids, saponins, xanthones, lignans and diterpenoids (Hostettmann, 1980; 
Hostettmann et al., 1984). Therefore the use of solvent systems DCM : MeOH : H20 
(5: 6: 4) and CHC13 : MeOH : H20 (5: 6: 4), suggests there is potential for the isolation 
of cardiac glycosides and other compounds present in C majalis leaf. 
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The crude EtOH extract of C majalis leaf was examined by TLC using the less polar 
phase of the two solvent systems as the mobile phase, and silica gel (6017254) for the 
stationary phase. The Rf values of the zones dictate which of the two solvent phases 
are appropriate for the mobile and stationary phases in the DCCC system. The less 
polar phase of the solvent system CHC13 : MeOH : H20 (5: 6: 4) resulted in 4 zones 
with Rf values <0.5 and 6 zones with Rf values >0.5 (Table 2.6, Figure 2.8). This 
suggests that the compounds separated are relatively non-polar, therefore the less 
polar phase of the solvent system would be favoured for the mobile phase. The less 
polar phase of the solvent system CHC13: MeOH : "PrOH : H20 (5: 6: 1: 4) resulted in 
7 zones with Rf values <0.5 and 4 zones with Rf values >0.5 (Table 2.7, Figure 2.9). It 
would be more appropriate in this case to select the polar phase of the solvent system 
for the mobile phase, as the compounds separated are of higher polarity. 
Analysis of the Rf values with the less polar phases of the two solvent systems DCM 
MeOH : H20 (5: 6: 4) and CHC13 : MeOH : nPrOH : H20 (45: 70: 5: 40) showed 5 zones 
with Rf values >0.5, and 5 zones with Rf values <0.5 (Tables 2.5 and 2.8, Figures 2.7 
and 2.10). Consequently, either phase of the solvent system may be selected for the 
mobile phase. The solvent system DCM : MeOH : H20 (5: 6: 4) was selected for 
separation using DCCC, as this system gave more efficient separation of the 
compounds than with the other three solvent systems. The more lipophilic phase was 
used as the mobile phase and the polar phase used as the stationary phase (descending 
mode). 
The DCCC F4 (obtained by pooling fractions 62 - 71 from the original 459 DCCC 
fractions) was compared with the F8a (from FCC(a)), and preparative TLC F3 and 
F4. The zones which were identified in 178a (from FCC(a)), and preparative TLC F3 
and F4 (see below: *, ** and ***, Figure 2.13 and Tables 2.9 and 2.10) were not 
identified in DCCC F4. Five of the ten zones in DCCC F4 had low Rf values (Rf 
values: 0.03,0.12,0.19,0.36,0.43) but other zones present had higher Rf values (Rf 
values: 0.56,0.65,0.73,0.83,0.98). This indicates that both polar and more 
lipophilic compounds are present in this fraction. 
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Table 2.5. Rf values of zones from C majalis leaf ethanolic extract (corresponding to 
Figure 2.7), examined in daylight (detection using acidic anisaldehyde, * examination 
under 366nm UV light). 






Green (Orange*) 0.54 
Deep Pink 0.62 
Pink 0.68 
Pink 0.84 




Figure 2.7. TLC profiles of C. majalis leaf EtOH extract (A, C) and cymarin (B). 
Chromatography conditions: stationary phase: silica gel (60F254). mobile phase: less 
polar phase of DCM : MeOH : H20 (5: 6: 4), spray reagent: acidic anisaldehyde. 
I 
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Table 2.6. Rf values of zones from C majalis leaf ethanolic extract (corresponding to 
Figure 2.8), examined in daylight (detection using acidic anisaldehyde, * examination 
under 366nm UV light). 
Zone on TLC Plate Rf value 





Green (Orange*) 0.61 
Deep Pink 0.68 
Pink 0.73 
Pink 0.83 
Green (Orange*) 0.88 
RP 0.5 
Figure 2.8. TLC profiles of C. majalis leaf EtOH extract (A, C) and cymarin (B). 
Chromatography conditions: stationary phase: silica gel (60F254). mobile phase: less 
polar phase of CHC13: MeOH : H20 (5: 6: 4), spray reagent: acidic anisaldehyde. 
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Table 2.7. Rf values of zones from C majalis leaf ethanolic extract (corresponding to 
Figure 2.9), examined in daylight (detection using acidic anisaldehyde, * examination 
under 366nm UV light). 










Brown (Orange*) 0.91 




Figure 2.9. TLC profiles of C. majalis leaf EtOH extract (A, C) and cyrnarin (B). 
Chromatography conditions: stationary phase: silica gel (6017254). mobile phase: less 
polar phase of CHC13 : MeOH : "PrOH : H20 (5: 6: 1: 4), spray reagent: acidic 
anisaldehyde. 
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Table 2.8. Rf values of zones from C majalis leaf ethanolic extract (corresponding to 
Figure 2.10), examined in daylight (detection using acidic anisaldehyde, 
* examination under 366nm UV light). 









Brown (Orange*) 0.91 




Figure 2.10. TLC profiles of C. majalis leaf EtOH extract (A, C) and cymarin (B). 
Chromatography conditions: stationary phase: silica gel (60F254). mobile phase: less 
polar phase of CHC13 : MeOH : 'PrOH : H20 (45: 70: 5: 40), spray reagent: acidic 
anisaldehyde. 
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2.2.2.5 Preparative TLC: C. maialis Leaf Ethanolic Extract 
After the plate was developed using the less polar phase of the solvent system: DCM : 
MeOH : H20 (5: 6: 4), the plate was analysed under UV light (at 254run and at 366ruyl) 
and a small section of the plate was sprayed with acidic anisaldehyde reagent (Figure 
2.11); the plate was divided into 7 sections. 
7 
AiLkil- 
Figure 2.11. TLC profiles of C. majalis leaf EtOH extract, divided into 7 sections for 
preparative TLC. Chromatography conditions: stationary phase: silica gel (60F254). 
mobile phase: less polar phase of DCM : MeOH : H20 (5: 6: 4), spray reagent: acidic 
anisaldehyde. 
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Each of the 7 fractions, from each section removed from the plate, was analysed by 
application to silica gel (60F254) plates, and developed using the solvent system 
C6H5CH3 : EtOAc : MeOH (5: 6: 4). The plate was examined under UV light (at 
254nm and at 366nm) and in daylight after spraying with acidic anisaldehyde reagent 
(Figure 2.12 and Table 2.9). The results show that F2, F3 and F4 contain a similar 
zone (Rf value: 0.66). F3 and F4 showed similar antiChE activity (refer to Chapter 3, 
3.2.4.5). This suggests that the same compound(s) present in these fractions may be 
ChE inhibitors. Three zones (Rf values: 0.37,0.55,0.66) were present in F3 and F4, 
the zones with Rf values of 0.37 and 0.55 being also present in F7. F3, F4 and F7 
were the most active of all the preparative TLC fractions tested for antiChE activity 
(refer to Chapter 3,3.2.4.5). Therefore, the compounds giving zones with the Rf 
values of 0.37 and 0.55 may be the active antiChE constituents. The compound(s) in 
the zones with the Rf values of 0.37 and 0.55 may contribute to antiChE activity by 
acting synergistically with other compounds, but they may not be the most active 
compound(s) of those present in the fractions (as presence in other fractions (either F5 
or 176) did not confer high antiChE activity). 
FI F2 F3 F4 E F5 F6 F7 
Figure 2.12. TLC profiles of preparative TLC fractions from C. majalis leaf EtOH 
extract. Chromatography conditions: stationary phase: silica gel (60F254). mobile 
phase: C6H5CH3 : EtOAc : MeOH (5: 6: 4), spray reagent: acidic anisaldehyde. E 
crude ethanolic extract of C majalis leaf 
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Table 2.9. Zones in 7 Cmajalis leaf preparative TLC fractions; chromatography 
conditions: stationary phase: silica gel (60F254), mobile phase: C6H5CH3 : EtOAc 











1 2 3 4 5 6 7 
0.01 Yellow Y Blue Y N N N N N N 
0.01 Yellow Y Green N Y N N N N N 
0.01 Grey N N Y N N N N 
0.01 Grey/ N N N Y N N N 
Orange 
0.01 Brown - Grey/ N N N N Y Y Y 
Brown 
0.05 Yellow - Blue/ Y N N N N N N 
Grey 
0.08 Yellow - Y Y N N N N N 
0.20 - - Green N N Y N N N Y 
0.30 Yellow - N Y N N N N N 
0.37* - Y Orange N N Y Y N Y Y 
0.38 Yellow - Orange N Y N N N N N 
0.45 Yellow/ - N Y N N N N N 
Pink 
0.55 Green Orange N N y y y N y 
0.57 Pink - N y N N N N N 
0.66 Pink - N y y y N N N 
0.69 Brown y Orange N N N N y N N 
0.76 Pink - N N N N y y y 
0.87 Pink - N N N N N y N 
0.90 -- Orange N N N N N y y 
0.94 Green y N N N N N N y 
0.96 Pink - Orange N N N N N N y 
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An active fraction (F8a) from FCC (a) (refer to Chapter 3,3.2.4.2) was compared with 
the compounds present in F3 and F4 from preparative TLC, to identify common 
compounds that may be responsible for antiChE activity. Three zones were found to 
be present in the 3 active fractions analysed, and also in the crude EtOH extract of C. 
majalis leaf (*, ** and ***, Figure 2.13 and Tables 2.9 and 2.10). It may be 
concluded that the compounds present in these 3 zones are responsible, either alone or 
in synergy, for the antiChE activity of the 3 active fractions and the crude extract. 
However, other compounds in each fraction may enhance the antiChE activity 
observed. Preparative TLC F7 also demonstrated notable antiChE activity (refer to 
Chapter 3,3.2.4.5). This fraction contained 4 zones (Rf values: 0.20,0.55,0.94 and 
0.96) not present in the much less active F6. One or more of these compounds in 
these zones may therefore have been responsible for the antiChE activity of this 
fraction. 
Preparative TLC F3 and F4, F8a (from FCC (a)) and the crude EtOH extract of C. 
majalis leaf were also assessed for the presence of alkaloids, using Dragendorff s 
reagent for detection. No compounds were identified as alkaloids, since no orange 
zones were observed after spraying. 
F3* F4* F8a 
Figure 2.13. TLC profiles of preparative TLC fractions (F3* and F4*), and Fga 
(from FCC (a)), from C. majalis leaf EtOH extract. Chromatography conditions: 
stationary phase: silica gel (60F254). mobile phase: C6H5CH3 : EtOAc : MeOH (5: 6: 4), 
spray reagent: acidic anisaldehyde. 
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Table 2.10. Zones present in F3 and F4 from preparative TLC separation, in F8a from 
FCC (a) separation, and in the crude ethanolic extract of C. majalis leaf detection 
using acidic anisaldehyde). 
Zone Rrvalue Daylight* UV Light 254nm UV Light 366nm 
I*0.29 Y Orange 
2** 0.43 Green Orange 
3*** 0.52 Pink 
2.2.3 LC-MS and HPLC Analysis of C. majahs Leaf Crude Ethanolic Extract and 
Preparative TLC Fractions 
2.2.3.1 LC-MS Analysis of the Crude Ethanolic Extract of C maialis Lea 
Analysis of the crude ethanolic extract of C majalis leaf yielded information 
regarding the constituents present (refer to appendix, Figure A9). One peak at Rt 
5.8min gave a pseudomolecular ion ([M+H]+) at m1z 166 which gave a product ion 
spectrum after MS/MS analysis the same as phenylalanine. The peak at Rt 25.5min, 
showed a pseudomolecular ion ([M+H]+) at nz1z 1031, which corresponds to a 
glycoside since in MS/MS analysis it generated product ions showing successive 
losses of sugar moieties, leaving an aglycone product ion ([A+H]) at nilz 43 1. Loss 
of 146 (rmm) is likely to be due to loss of a rhamnosyl moiety, since in plants, 
rhamnosyl is the most common sugar of 164 (rmm) involved in glycosides (rarer 
sugars are fucose and quinovose). Similarly, the peak at Rt 26.2min gave a 
pseudomolecular ion ([M+H]+) at nilz 1033, which gave a product ion spectrum also 
showing successive losses of sugar moieties after MS/MS analysis, with the 
corresponding aglycone ion ([A+H]+) at nilz 433. The overlapping peaks at Rt 31.9 
and Rt: 31.1 gave ions ([M+H]+) at nzlz 871 and nzlz 869 respectively, which in 
MS/MS analysis, both showed losses of 3 hexosyl sugar moieties (nmn: 164) to give 
the aglycone ions ([A+H]) at nzlz 433 and nilz 431 respectively. 
The peak at Rt 36.8 gave an ion ([M+H]) at m1z 621, which in MS/MS analysis did 
not fragment, even when the collision energy was increased. The compound giving 
an ion ([M+H]+) at nilz 391 was due to a contaminant (plasticiser) in the system, and 
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was therefore also evident in the chromatograms of the 7 preparative TLC fractions 
analysed. LC-MS analysis indicates that the crude EtOH extract of C. majalis leaf 
contains phenylalanine, glycosides and other unidentified compounds. Further 
investigation is required to establish if the glycosides present in the leaf EtOH extract 
are cardiac glycosides. Those glycosides (with ions at m1z 1031,1033,871 and 869) 
identified are not the cardiac glycosides convallatoxin (50) (rmm 550.7), reported to 
occur in C majalis leaf, or cyrnarin (48) (rmm 548.7). Isolation and identification of 
the constituents present in the EtOH extract is required for their identification, but 
could not be carried out due to time limitations. 
2.2.3.2 LC-MS and HPLC Analysis of Preparative TLC Fractions of C. maialis Lea 
Phenylalanine was present in both F1 and F2 (refer to appendix, Figures AIO and 
A 11). Phenylalanine is a polar amino acid, so its presence in the more polar fractions 
would be expected. 
The chromatograrn for F2 (refer to appendix, Figure Al 1) showed two major peaks at 
Rt 21.9min and Rt 22.5min, each composed of two compounds, which gave 
psedomolecular ions ([M+H]+) at nilz 922 and nilz 924 respectively. Analysis of the 
product ion spectra showed these to be glycosides, as MS/N4S analysis showed 
successive losses of 3 hexosyl sugars (n-nm 164) to yield the aglycone ions ([A+H]+) 
at nilz 484 (for [M+H]+ at nVz 922) and at m1z 486 (for [M+H]+ at nzlz 924). The peak 
at Rt 21. Omin ([M+H]+ at m1z 871 and [A+H]+ at nzlz 433) was also detected in F2. 
The presence of glycosidic compounds in a relatively polar fraction would be 
expected, as such compounds are generally polar. 
The peaks at Rt 20. Omin and Rt 20.8min were present in the chromatograms of both 
F3 and F4 (refer to appendix, Figures A12 and A14), which gave pseudomolecular 
ions ([M+H]) at m1z 277 and nVz 279 respectively. The ion at 1Wz 277 was also 
present in the chromatogram. of F5 (refer to appendix, Figure A 15), and the ion at nilz 
279 was also evident in the chromatograms of F6 and F7 (refer to appendix, Figures 
A 16 and F 17). Both F3 and F4 inhibited AChE activity in the in vitro studies (refer to 
Chapter 3,3.2.4.5), which suggests that compounds common to both fractions (e. g. 
ions at m1z 277 and m1z 279) may be AChE inhibitors. The ions at nilz 277 and at nilz 
279 were also observed in the chromatograms of F6b and F7b (from FCC (b)) (refer 
to appendix, Figures A18 and A19). The presence of these compounds in the active 
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F6b and F7b suggests that they may also have contributed to the antiChE activity of 
these fractions in vitro (refer to Chapter 3,3.2.4.3). The peak at R, 20. Omin, which 
gave the pseudomolecular ion ([M+H]) at m1z 277, gave fragment ions at m1z 135 
and m1z 121 after MS/MS analysis, often seen in the MS/MS of flavonoids. 
Therefore, F3 was also analysed using HPLC and photodiode array detection, to 
investigate the presence of flavonoids. Two of the compounds identified had UV 
spectral maxima at 240nm (refer to appendix, Figure A13); however the UV spectra 
were not characteristic of any known flavonoids, suggesting the absence of flavonoids 
in F3. In F7, the peak at Rt 26.3 also gave the ion ([M+H]+) at m1z 621 (refer to 
appendix, Figure A 17), which in MS/MS analysis did not fragment. 
LC-MS analysis has provided information suggesting that compounds yielding ions at 
m1z 277 or m1z 279 may be responsible for antiChE activity, and that these 
compounds do not appear to be flavonoids. However, it cannot be excluded that other 
components present in the crude EtOH extract or in the fractions are responsible, 
perhaps in synergy, for antiChE activity. In conclusion, it is apparent that further 
fractionation and isolation is required to identify the compounds responsible for 
antiChE activity in vitro. 




Figure 2.14. TLC profiles of C. majalis leaf extracts (1: H20,2: EtOH, 3: DCM, 4: 
C6HI4 extracts). Chromatography conditions: stationary phase: silica gel (60F254), 
mobile phase: less polar phase of DCM : MeOH : H20 (5: 6: 4), spray reagent: acidic 
anisaldehyde. 
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TLC analysis showed the EtOH and DCM extracts to contain a similar chemical 
profile. As expected, some the more polar compounds (e. g. glycosides) present in the 
EtOH extract were absent in the DCM and C61114 extracts (Figure 2.14). Similarly, 
compounds present in the EtOH and DCM fractions were absent in the less polar 
C6HI4 extract (Figure 2.14). 
2.2.5 Comparison of the Ethanolic Extract of C majalis Leaf with Chlorophyll 
Comparison of the EtOH extract of C majalis leaf with chlorophyll, using the solvent 
system DCM : MeOH (9: 1), showed two corresponding zones; one violet zone visible 
in daylight (Rf: 0.52) after spraying with acidic anisaldehyde, and one green zone, 




Figure 2.15 Figure 2.16 
Figures 2.15. and 2.16. TLC profiles of C majalis leaf EtOH extract (E) and 
chlorophyll (C). Chromatography conditions: stationary phase: silica gel (6017254), 
mobile phase: DCM : MeOH (9: 1), spray reagent: acidic anisaldehyde. Figure 2.15. 
Chromatogram before spraying. Figure2.16. Chromatograrn after spraying. 
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Using the solvent system DCM : MeOH (1: 1) the violet zone was again evident in 
daylight after spraying with acidic anisaldehyde (Rf-. 0.54), as were other violet zones 
(Rf-. 0.65 and Rf. 0.86). In UV light (366nm) the green zone was again visible (Rf. 
0.77). In daylight before spraying, both plates did not show any corresponding zones 
for the extract and chlorophyll, however in UV light (254nm) a dark zone was visible 
at the baseline of each plate for both the extract and chlorophyll. The ethanolic 
extraction of C majalis leaf would be expected to yield many components including 
chlorophyll, other pigments and lipids, as well as the cardenolide compounds. The 
subsequent separation of compounds from this extract (using FCC, DCCC and 
preparative TLC) enables all the compounds to be assessed for antiChE activity; 
consequently any effects of compounds such as chlorophyll on AChE activity can be 
taken into consideration. 
2.2.6 Analysis of Herbal Extracts for the Presence of GABA 
Analysis for GABA (16) was initially investigated using cellulose plates for TLC 
analysis. Silica gel plates are also appropriate for analysis (Stahl, 1969) and were 
therefore used for further analysis. GABA (16) (2[ig) was applied to the TLC plate 
for reference; with the solvent system butan-l-ol : H20 : CH3COOH (60: 25: 15). The 
Rf values for GABA (16) using separate TLC plates were 0.23,0.28 (Figure 2.17), 
0.24,0.26 and 0.25; Rf values may have differed due to different clution temperatures. 
All extracts with a zone detected with ninhydrin, with a Rf value corresponding to that 
of GABA (16), were regarded as being positive for GABA (16) (for example, Figure 
2.17). 
GABA (16) was detected in all extracts, except Melissa officinalis leaf aqueous 
extract, Melissa officinalis leaf ethanolic extract, Rosmarinus officinalis dried leaf 
ethanolie extract, Rosmarinus ofjIcinalis fresh leaf ethanolic extract, Ziziphusjlýllba 
var. spinosa seed aqueous extract and Ziziphus jzýuba var. spinosa seed ethanolic 
extract. 
GABA (16) is reported to be regularly present in plants (Harbome and Baxter, 1993), 
therefore the identification of GABA (16) in 22 of the 28 plant extracts analysed is 
not unexpected. Detection with ninhydrin also showed amino acids other than GABA 
to occur in the plant extracts (Figure 2.17). The presence of amino acids in plants 
may be important for nitrogen storage. 
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Figure 2.17. TLC profiles of some plant extracts (1: Salvia miltiorrhiza root EtOH 
extract, 2: Salvia miltiorrhiza root H20 extract (batch 1), 3: Salvia miltiorrhiza root 
H20 extract (batch 2), 4: Ziziphusjujuba var. spinosa seed EtOH extract, 5: Ziziphus 
jujuba var. spinosa seed H20 extract) and reference solution: GABA (G). 
Chromatography conditions: stationary phase: silica gel (6017254). mobile phase: 
butan-l-ol : H20: CH3COOH (60: 25: 15), spray reagent: ninhydrin. 
2.2.7 Gas Chromatography-Mass Spectroscopy 
2.2.7.1 Analysis of Melissa offlicinalis Essential Oil Using GC-MS 
Melissa officinalis essential oil (Fragrant Earth Co. ) was obtained from the leaves of 
M, officinalis by the process of steam distillation. During this process, steam is 
passed through the herb, which results in the volatile essential oil from the herb 
condensing in a collection chamber. This process is a reproducible and rapid method 
for obtaining large quantities of volatile oils. A disadvantage of this process is that 
some volatile oil constituents may undergo chemical changes due to exposure to water 
and due to the high temperature during the distillation process. Compounds may 
undergo rearrangement, isomerisation or oxidation. Some compounds may hydrolyse 
(e. g. the esters), and others may decompose at the high temperatures used. 
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Consequently, the chemical composition of the oil collected may differ from that of 
the oil in the original plant. 
M. officinalis phytol extract is obtained not by steam distillation, but by a process of 
'phytonics'. This process involves washing the plant material with a low boiling 
solvent (e. g. 1,1,1,2-tetrafluoroethane, which has a boiling point of -26.2*C). The 
washings are transferred to a vessel where the solvent is allowed to evaporate at room 
temperature since its boiling point is less than O*C. The evaporated solvent is re- 
condensed, and the resulting liquid used for further extraction from the herb. This 
process is of advantage over the steam distillation method, as none of the volatile 
components are lost by decomposition or hydrolysation, and is a preferred method 
over standard solvent extraction, which often involves higher temperatures to 
evaporate the solvent. 
Both the M ofjicinalis phytol extract and the crude phytol extract (which was not 
refined by removal of non-volatile oil components) were analysed for their chemical 
composition using GC-MS (refer to Table 2.11 and appendix, Figures A20 and A21). 
GC is a suitable analytical method as the essential oils are volatile, and results can be 
obtained within a relatively short time. The chromatograms for the three essential oils 
analysed show that they consist of a complex mixture of compounds which have 
differences in polarity and volatility. Some components may have low thermal 
stability. This may be a problem, as the formation of artifacts may arise, which will 
be detected and may be regarded as an original component of the essential oil. 
The chemical profiles of M ofjlcinalis phytol and the crude phytol extracts were 
compared with the M officinalis essential oil obtained by steam distillation (refer to 
Tables 2.11 and 2.12 and appendix, Figures A20, A21 and A22). The results show 
that the chemical composition of the oils analysed differs. This may be due to the 
different methods of extraction, differences arising from the storage conditions or 
differences between the M ofjlcinalis plants due to environmental factors (e. g. 
cultivation conditions such as temperature, climate, soil, duration of daylight, or the 
time of year harvested). Differences in the chemical profile between the oils may also 
occur as a result of different subspecies being used for extraction of the oil. For 
example, the oil from the altisshna subspecies has been reported to differ from that of 
the subspecies inodora (Dawson et aL, 1988; *arer and K6kdil, 1991). Genetic 
variability may also be a contributing factor to the variation in essential oil 
composition (Adzet, et aL, 1992). 
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Table 2.11. Percentage composition of Melissa offi'cinalis phytol and crude phytol 
extracts (Clwydian Fragrant Oil) determined by GC-MS analysis. 









Melissa Phytol (Crude) 
% comp. % comp. % comp. 
TIC FID* FID 
(x-thujene 212 0.09 0.18 0.23 0.13 0.32 0.53 
1 cc-pinene 222 0.05 0.12 0.16 0.08 0.78 1.30 
2 I-octen-3-ol 292 0.18 0.29 0.38 0.12 0.59 0.98 
3 6-methyl-5-hepten- - - - - - - 
2-one 
4 limonene - - - - - - - 
cis-p-ociniene, 380 0.12 0.22 0.28 0.12 0.32 0.53 
5 trans-p-ocimene 400 1.73 1.75 2.27 1.87 1.43 2.38 
6 linalool 520 0.23 0.31 0.40 0.20 0.29 0.48 
7 cis-rose oxide 540 0.05 0.16 0.21 0.05 0.10 0.17 
8 unidentified - - 
9 unidentified - - 
10 citronellal 648 4.65 3.80 4.92 4.85 2.83 4.71 
11 unidentified 672 0.06 0.12 0.16 0.06 0.07 0.12 
12 unidentified 722 0.08 0.17 0.22 0.10 0.19 0.32 
13 dodecane - - 
14 nerol 832 5.72 1.52 1.97 7.73 
15 citronellot 840 1.19 
16 neral 879 15.24 13.5 17.48 15.50 9.66 16.07 
17 geraniol 906 13.62 6.26 8.11 12.59 2.1 3.49 
18 methyl citronellate - - 
19 geranial 963 22.69 22.15 28.69 22.59 20.79 34.59 
20 methyl geranate 1084 0.32 1.63 2.11 0.28 0.32 0.53 
eugenol 1178 0.42 0.20 0.26 0.30 0.40 0.67 
21 cc-copaene 1195 0.65 0.52 0.67 0.62 1.37 2.28 
unknown 1210 2.15 2.11 2.73 3.09 0.66 1.10 
22 P-burbonene - - 
23 P-cubebene - 
geranyl acetate 1231 2.35 1.57 2.03 2.25 1.22 2.03 
24 P-elemene - - 
25 tetradecane - - 
26 trans-caryophyllene 1311 9.20 7.21 9.34 9.25 5.46 9.08 
27 unidentified - - 
28 cc-humulene 1404 1.05 0.53 0.69 0.95 0.41 0.68 
29 y-mutirolene 1458 0.11 0.23 0.30 0.12 0.17 0.28 
30 germacrene-D 1474 9.78 7.00 9.07 9.30 5.26 8.75 
31 unidentified 1504 1.61 1.07 1.39 1.42 0.86 1.43 
32 a-muurolene 1520 0.13 0.12 0.16 0.15 0.11 0.18 
33 (E, E)-a-farnesene 1538 0.64 0.52 0.67 0.57 0.41 0.68 
34 y-cadinene 1556 0.34 0.31 0.40 0.34 0.29 0.48 
35 8-cadinene 1567 0.78 0.64 0.83 0.96 0.62 1.03 
36 germacrene-D-4-ol 1721 3.93 1.72 2.23 3.40 1.76 2.93 
37 caryophyllene oxide 1732 0.28 0.56 0.73 0.19 0.50 0.83 
38 hexadecane - - 
39 epi-a-cadinol 1884 0.10 0.17 0.22 0.12 0.18 0.30 
30 5-cadinol 1891 0.12 0.17 0.22 0.17 0.23 0.38 
41 unidentified 1918 0.34 0.38 0.49 0.53 0.41 0.68 
42 unidentified - - 
TOTAL 100 77.21 100 100 66.11 100 
based on all peaks % composition unidentified due t o inadequa te resolution of peaks 
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Table 2.12. Percentage composition of Melissa officinalis essential oil (Fragrant 
Earth) detemiined by GC-MS analysis. 








1 a-pinene 227 0.08 0.43 0.34 
2 I-octen-3-ol 297 0.34 0.29 0.23 
3 6-methyl-5-hepten-2-one 308 1.45 2.11 1.69 
4 limonene 375 0.13 0.44 0.35 
5 trans-o-ocimene 406 0.74 1.49 1.19 
6 linalool 527 0.71 1.46 1.17 
7 cis-rose oxide 547 0.22 1.05 0.84 
8 unidentified 625 0.17 1.25 1.00 
9 unidentified 651 0.30 0.48 0.38 
10 citronellal 656 1.42 2.00 1.60 
11 unidentified 681 0.13 1.05 0.84 
12 unidentified 728 0.50 1.54 1.23 
13 dodecane 746 0.17 0.36 0.29 
14 nerol 839 0.75 1.45 1.16 
15 citronellol 847 0.41 0.88 0.70 
16 neml 890 12.57 11.13 8.90 
17 geraniol 911 1.23 1.11 0.89 
18 methyl citronellate 920 0.56 0.50 0.40 
19 geranial 974 16.57 14.73 11.78 
20 methyl geranate 1094 0.41 2.06 1.65 
21 cc-copaene 1207 1.34 1.76 1.41 
22 P-burbonene 1227 0.40 2.44 1.95 
23 0-cubebene 1244 2.00 0.69 0.55 
24 P-elemene 1244 2.31 0.80 0.64 
25 tetradecane 1273 0.28 0.39 0.31 
26 trans-caryophyliene 1330 28.39 23.66 18.92 
27 unidentified 1351 0.09 0.70 0.56 
28 a-humulene 1418 2.60 1.78 1.42 
29 y-muurolene 1472 0.23 0.54 0.43 
30 germacrene-D 1490 12.66 9.76 7.80 
31 unidentified 1516 0.63 0.89 0.71 
32 a-muurolene 1533 0.60 0.71 0.57 
33 (E, E)-a-famesene 1551 0.67 0.69 0.55 
34 y-cadinene 1570 0.44 0.61 0.49 
35 8-cadinene 1582 2.64 2.13 1.70 
36 germacrene-D4-ol 1734 0.27 1.75 1.40 
37 caryophyllene oxide 1747 2.56 1.75 1.40 
38 hexadecane 1772 0.58 0.18 0.14 
39 epi-cc-cadinol 1898 0.42 0.45 0.36 
30 5-cadinol 1904 0.53 0.73 0.58 
41 unidentified 1932 1.23 1.19 0.95 
42 unidentified 2335 0.30 0.60 0.48 
TOTAL - 100 100 79.95 
* based on all peaks 
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Adulteration can be a problem with M. officinalis oil, due to the low yield of the oil 
from the plant and the subsequent production cost. M officinalis oil has been 
reported to be adulterated with lemongrass oil and citronella oil (Guenther, 1949). 
Compounds that were detected in M officinalis phytol extract, but not in the steam 
distilled M officinalis oil, were ocimene (76), eugenol (84) and gernanyl acetate 
(Tables 2.11 and 2.12). Compounds detected in the steam distilled M. officinalis oil, 
but not in M officinalis phytol extract, were 6-methyl-5-hepten-2-one (85), limonene 
(73), dodecane, methyl citronellate, 0-burbonene, 0-cubebene (80), O-elemene, 
tetradecane and hexadecane (Tables 2.11 and 2.12). 
Typically, the compounds present in the essential oils analysed are largely 
monoterpenoids (e. g. geranial (70) and neral (71)). The phenylpropanoid eugenol 
(84) was detected in the M officinalis phytol extract. Phenylpropanoids are another 
group of constituents often present in essential oils but it is the terpenoids which 
predominate in the M officinalis oils. It has been reported that M officinalis oil 
contains >60% monoterpenes and >35% sesquiterpenes (Bisset, 1994). Citral 
(geranial (70) and neral (71)) comprised 35.7% of M officinalis phytol extract, 30.5% 
of M officinalis phytol extract (crude) and 20.7% of M officinalis oil. Citral has been 
reported to account for 10% - 30% of M officinalis essential oil (Bisset, 1994). The 
higher citral content in the phytol extracts may be due to the less destructive 
extraction procedure, and/or storage conditions of the oil (although other factors may 
also be responsible, as discussed previously). Neral (71) and geranial (70) occurred in 
the ratio 3: 5 in the M. officinalis phytol extract, 1: 2 in the M officinalis phytol extract 
(crude) and 3: 4 in M officinalis oil. A ratio of 3: 4-5 (geranial (70) : neral (71)) 
(Bisset, 1994), and of 4: 5 (neral (71) : geranial (70)) ($arer and Kdkdil, 1991) has 
previously been reported to occur in M officinalis essential oil. 
The essential oils were analysed using two methods of detection: FID and MS, giving 
the TIC. MS determines peak area by counting ions. Therefore, if a compound (A) 
forms more molecular ions than another compound (B), then the peak area of A will 
be greater than that of B, even if they are present in equimolar amounts. FID gives 
results for peak area based on carbon number, and could therefore be considered a 
more reliable method for assessment of essential oil composition. The essential oils 
listed in the European Pharmacopoeia (2001) and the British Pharmacopoeia (1998) 
arc assessed using GC with FID. The United States Pharmacopoeia (2000) includes a 
monograph for eucalyptol, obtained from oil of eucalyptus, which is also analysed by 
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using GC with FID. It could be assumed that these methods of analysis would have 
been tested for reliability and reproducibility prior to inclusion in the Pharmacopoeias. 
Therefore, it may be conclded that FID is the more reliable method of assessment. 
2.2.7.2 Analysis of Commercially Obtained Oil Constituents Using GC-MS 
Commercially obtained essential oil constituents were analysed to determine their 
purity, and to confirm their identification in the M officinalis oils analysed. Citral is a 
mixture of two isomeric aldehydes; geranial (70) (the trans-isomer) and neral (71) 
(the cis-isomer). Therefore it is expected that both isomers would be detected in the 
GC-MS analysis of commercial citral. One source of citral (Aldrich) was 98.7% pure, 
containing a greater proportion of geranial (70) than neral (71) (refer to Table 2.13 
and appendix, Figure A23). 
Table 2.13. Percentage composition of citral (Aldrich) determined by GC-MS 
analysis. 
Compound Retention time (s) % Comp. TIC 
alkane 316 0.08 
alkane (C12) 748 0.25 
neral 887 38.88 
geranial 970 59.78 
unidentified 978 0.39 
unidentified 1198 0.05 
unidentified 1249 0.13 
alkane (C14) 1272 0.08 
alkane (C14) 1274 0.13 
alkane (C 16) 1778 0.13 
alkane (C 16) 1782 0.09 
TOTAL - 100 
Geranial (70) was also the major isomer in another source of citral (Lancaster), which 
was 99.2% pure (refer to Table 2.14 and appendix, Figure A24). Other components 
were detected in these commercially obtained oils, including alkanes and unidentified 
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compounds. These may be degradation products of citral that may have occurred 
during storage, as exposure to light, 02 and H20 may have altered the chemical 
composition of the oils. Extraction and isolation procedures, the original source of 
citral, storage conditions and age of each oil may all have influenced the ratio of the 
isomers and this may explain the differences observed between sources of citral. 
Table 2.14. Percentage composition of citral (Lancaster) determined by GC-MS 
analysis. 
Compound Retention time (s) % Comp. TIC 
alkane (C12) 739 0.15 
neral 891 38.92 
unidentified 937 0.11 
gemnial 974 60.25 
unidentified 983 0.09 
unidentified 1165 0.22 
alkane (C 14) 1276 0.09 
alkane (C 16) 1777 0.17 
TOTAL 100 
Linalool (74) was found to be 95.7% pure (refer to Table 2.15 and appendix, Figure 
A27) but also contained the oxidised derivatives of linalool (74) (cis- and Irans- 
linalool oxide), dihydro-linalool, 1,8-cineole (56), an alkane and an unidentified 
component, also detected using GC-MS. 
The commercially obtained eugenol (84) was found to be 99.7% pure (refer to 
appendix, Figure A25) and the commercially obtained geraniol (72) was found to be 
98.2% pure (refer to Table 2.16 and appendix, Figure A26). The commercially 
obtained nerol (75) was found to be 95% pure, the other oil constituents being 
identified as geranial (70) (1.8%), geraniol (72) (1.4%) and neral (71) (1.8%) (refer to 
appendix, Figure A28). 
180 
Table 2.15. Percentage composition of linalool (Aldrich) determined by GC-MS 
analysis. 
Compound Retention time (s) % Comp. TIC 
1,8-cincole 388 0.10 
cis-linalool oxide 465 0.88 
trans-linalool oxide 501 0.89 
linalool 536 95.66 
dihydro-linalool 613 1.72 
unidentified 765 0.63 
alkane 1251 0.13 
TOTAL - 100 
Table 2.16. Percentage composition of geraniol (Sigma) deten-nined by GC-MS 
analysis. 
Compound Retention time (s) % Comp. TIC 
nerol 1082 1.0 





TOTAL - 100 
It may therefore be concluded that the ý95% composition of each of the commercially 
obtained constituents, indicates that their activities in the bioassays are due to the 
major component of each oil, and the identification of the minor components of each 
oil enables any contribution to pharmacological activity of such components to be 
accounted for. Each of the major constituents citral, geraniol (72) and nerol (75) 
contain their chemically related monoterpenes (e. g. commercially obtained geraniol 
(72) also contains geranial (70), nerol (75) and neral (71) (Table 2.16)), therefore 
comparison of each monoterpene in the bioassays allows the significance of each of 
the other monoterpenes in observed pharmacological activities to be considered. 
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2.2.7.3 Assessment of Metabolism of Compounds by Yeast 
The results from this investigation show that the peak areas of the compound under 
analysis decreased as the time at which the sample was collected from the assay was 
increased (refer to Chapter 4, Tables 4.3 - 4.5 and 4.8). This suggests that the 
concentration in the assay decreased with time (refer to Chapter 4,4.7.2 and 4.10.2 
for results and discussion). 
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CHAPTER 3 
Assessment of Antichol in este rase Activity of Plant Extracts 
and Essential Oils 
Cholinesterases are enzyme that hydrolyses esters of choline. Various methods have 
been described for the assessment of acety1cholinesterase (AChE) activity, including 
electrometric, titrimetric, and gasometric; methods (Wilson and Henderson, 1992). 
Other techniques include measurement of the pH change which occurs upon ACh (1) 
hydrolysis (Hestrin, 1949), determination of CH]-ACh hydrolysis (Johnson and 
Russell, 1975), and measurement of the yellow 5-thio-2-nitrobenzoic acid anion 
which is formed by the reaction between the thiol group, released following 
hydrolysis of the substrate acetylthiocholine (ATCh), with 5,5-dithiobis (2- 
nitrobenzoic acid) (DTNB) (Ellman et aL, 1961). The latter photometric method is a 
sensitive and reproducible technique for assessment of AChE activity. Since 
erythrocyte AChE is reported to have similar properties to brain AChE (Sorensen et 
aL, 1982), the effect of the various plant extracts and essential oils on inhibition of 
human erythrocyte AChE activity was investigated to determine potential AChE 
inhibitors relevant to AD management. Extracts and essential oils were diluted in 
either H20, or in EtOH (<I%) at a concentration that did not interfere with AChE 
activity. Inhibition of erythrocyte AChE activity occurs with increasing EtOH 
concentration but effects on AChE activity are negligible at concentrations <2% 
(Haboubi and Thumham, 1986; Ryan and Byrne, 1988). 
3.1 AChE Inhibition Assav Method 
3.1.1 Materials 
ATCh iodide, DTNB, human erythrocyte AChE and physostigmine (escrine 
hemisulfate salt) were obtained from Sigma, Fancy Road, Poole, Dorset, England. 
Na2HPO4 and NaH2PO4 were obtained from Fluka Chemicals, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT, England. NaHC03 was obtained from 
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BDH Supplies, Poole, England. Plant material, essential oils, pure compounds 
(convallatoxin, cymarin and hyperoside) and chlorophyll were obtained as described 
previously (Chapter 2,2.1.1.1); Melissa officinalis essential oil (organic) was obtained 
from Fragrant Earth, Taunton, England. 
3.1.2 Preparation of AChE Assay Solutions 
3.1.2.1 PreparatiOn of Buffer Solutions 
Sodium phosphate buffer solutions were prepared as follows: 
PH Na2HP04 (0.2M) H20 NaH2PO4 (0.2M) 
7 47ml 50MI 1-3ml until pH 7 
8 47ml 50ml 1-3ml until pH 8 
Buffer solutions were stored at 4*C, and the pH of each solution confirmed prior to 
each assay using a 3305 Jenway pH meter. 
3.1.2.2 Preparation of Assay Solutions 
AChE was dissolved in phosphate buffer (pH 8) at a concentration of 0.26 units/ml (I 
unit AChE hydrolyses 1.0 [tmole. min-1 of ATCh at 37*C); ATCh was dissolved in 
distilled H20 (0.6mM final assay concentration); DTNB was dissolved in phosphate 
buffer (pH 7) with 40mg NaHC03 per 5ml (0.5mM DTNB final assay concentration); 
physostigmine hemisulfate salt was dissolved in distilled H20 (O. ImM final assay 
concentration). All assay solutions were freshly prepared for each assay, and were 
kept on ice (4*Q away from light. 
Plant extracts, essential oils and compounds were diluted in EtOH prior to testing in 
the assay, and were stored at 4*C. 
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3.1.3 Investigation to Determine the Effect of Erythrocyte AChE Concentration 
on Breakdown of ATCh 
A concentration range (0.76 units. L-1 - 9.81 units. L-1) of human erythrocyte AChE 
(Ipl equivalent to IWO units ACK) was incubated at 4*C in 2ml sodium 
phosphate buffer (pH 8) with 20[tl of DTNB solution (triplicate readings repeated 
three times; n=3). After vortex mixing, the reaction was initiated by addition of 20PI 
of the solution containing the substrate ATCh, and vortex mixed again. After 20min 
at 37'C the reaction was terminated by addition of 20pl physostigmine hemisulfate 
salt solution to each tube at 4*C then the solutions were vortex mixed. The optical 
density was measured spectrophotometrically at 412nm, using a Shimadzu UV-VIS 
Scanning Spectrophotometcr (CPS-260). 
3.1.4 Investigation to Assess Effect of Plant Extracts, Essential Oils and Known 
Plant Constituents on Erythrocyte AChE Activity 
Enzyme activity was measured in sodium phosphate buffer (pH 8). 40ý11 of enzyme 
solution (0.26 units/ml) was pre-incubated in 2ml phosphate buffer (pH 8) and 20pl of 
the test substance diluted in EtOH (or H20), at 4'C for 30min. Duplicate tubes were 
also treated this way in the presence of 20pl physostigmine hemisulfatc salt solution 
to allow interference of the test substance in the assay to be assessed, and to control 
for any hydrolysis of ATCh not due to AChE activity. Controls (in the presence and 
absence of the AChE inhibitor physostigmine (5)) were pre-incubated with 20[11 
EtOH (or H20) instead of the test substance. To further control for the auto 
hydrolysis of ATCh in the assay, tubes were set up (2ml buffer, 20[11 EtOH or 20PI 
H20) in the absence of AChE. All solutions were vortex mixed prior to pre- 
incubation at 4'C for 30min. 
Following pre-incubation, 20[d aliquots of DTNB solution were added to each tube. 
After vortex mixing, 20[d aliquots of ATCh solution were added to each tube and 
solutions were vortex mixed prior to incubation at 37'C for 20min. Addition of 20PI 
physostigmine hemisulfate salt solution at 4'C terminated the reaction and solutions 
were vortex mixed. The optical density was measured at 412nm, using a Shimadzu 
UVNIS Scanning Spectrophotometer (CPS-260). 
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3.1.5 Data Analysis 
The enzyme activity was calculated as the difference between the absorbance of the 
initially uninhibited tubes, minus initially inhibited tubes, as follows: 
Percentage AChE inhibition is calculated by: 
AA 
- 
AB XIOO AA =Ac- Bc AB= Ap - Bp 
AA 
B, C Bp &C A-P 
ATCh ATCh ATCh ATCh 
DTNB DTNB DTNB DTNB 
EtOH / H20 Extract EtOH / H20 Extract 
AChE AChE AChE AChE 
Physostigmine Physostigmine 
Significant activity against AChE, was regarded as >20% inhibition of the enzyme. 
Data are presented as the mean (n=3-6 ± SD). Concentration dependent data were 
analysed using one-way ANOVA to determine the significance of the difference. 
Significance was regarded asp<0.05. 
3.2 Results and Discussion 
3.2.1 Effect of Erythrocyte AChE Concentration on Breakdown of ATCh 
Several successive experiments were perfonned to establish the effect of [AChE] on 
ATCh hydrolysis, and to detennine a suitable concentration of AChE for screening 
plant extracts. Initial experiments showed that increase of AChE concentration 
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increases ATCh hydrolysis (p<0.05) (Figure 3.1). A concentration of 19.1 Pg/ml (4.97 






Figure 3.1. Effect of human erythrocyte AChE concentration on the hydrolysis of 
ATCh (triplicate readings; n=3). 
3.2.2 Effect of Plant Extracts and Essential Oils on Erythrocyte AChE Activity 
As indicated in Table 3.1, AChE inhibition was apparent with the ethanolic extracts of 
Apocynum lancifiblium leaf, Centella asialica leaf, Convallaria majalis leaf, 
Rosmarinus officinalis dried leaf, Salvia miltiorrhiza root and Withania soninifera 
root; the aqueous extracts of Apocynuni lancifiblium leaf, Centella asiatica leaf, 
Melissa offi'cinalis leaf, Rosmarinus ojji'cinalis dried leaf and Withania sonwifera 
root; the petroleum spirit (PS) extract of Centella asiatica leaf, and the essential oils 
. 
ficinalis and Rosmarinus officinalis. Extracts from Apocyninn from Melissa of 
lancifiblium, Centella asialica, Convallaria majalis, Salvia miltiorrhiza and Withania 
somnifera have not previously been reported to inhibit AChE activity. 
AChE Concentration (units. 0) 
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Table1l. Inhibition of human erythrocyte AChE by plant extracts and essential oils. 
Plant Extract or Essential Oil Tested 
Extraction Solvent) 
** Adulterated Herb 






Alisma orientalis root (hot EtOH*) 19.0 0 
Alisma orientalis root (cold EtOH*) 50.0 0 
AlisMa orientalis root (hot H20*) 9.52 0 
Apoeynnin lancifolium dried leaf (cold 
EtOH*) 
52.0 25.3 ± 1.4 
ApOcynitm lancifolium dried leaf (hot H20*) 47.6 40.1 ± 4.3 
Centella asiatica dried leaf (hot EtOH*) 50.0 39.9 ± 11.5 
Centella asiatica dried leaf (hot PS*) 30.0 42.6 ± 7.1 
Centella asiatica dried leaf (hot H20*) 47.6 21.1 ± 3.8 
Codonopsis pilulosa root (hot EtOH*) 50.0 0 
Codonopsispilulosa root (cold EtOH*) 310.0 0 
Codonopsispilulosa root (hot H20*) 97.0 0 
Convallaria majalis dried leaf (cold EtOH*) 95.2 90.9 ± 4.6 
Conval ria majalis dried leaf (hot H20*) 95.2 0 
Melissa officinalis dried leaf (hot H20*) 47.6 81.8 ± 5.7 
Melissa officinafts oil (diluted in EtOH) 240.0 92.7 ± 4.2 
Polygala I nuffiblia root (cold EtOH*) 330.0 0 
Polygala tenififolia root (hot H20*) 9.52 0 
Pol num mulliflorum root (hot EtOH*) Y90 19.0 0 
Pol onum mulliflorum root (cold EtOH*) Y9 280.0 0 
Pol num mulliflorum root (hot H20*) Y90 97.0 0 
Rosmarinus qjflcinalis fresh leaf (cold EtOH*) 89.0 8.5 ± 4.4 
'Rosmarinus officinalis dried leaf (hot EtOH*) 47.6 32.3 ± 2.5 
Rosmarinus officinalis dried leaf (hot H20*) 47.6 27.2 ± 4.1 
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Table 3.1 (continued). Inhibition of human erythrocyte AChE by plant extracts and 
essential oils. 







Rosmarinus ofji"cinafis oil (diluted in EtOH) 240.0 85.4 ± 3.8 
Salvia milliorrhiza root (hot EtOH*) 19.0 26.6 ± 3.9 
Salvid miltiorrhiza root (hot EtOH*) 38.0 42.8 ± 1.7 
Salvid miltiorrhiza root (cold EtOH*) 190.0 61.8 ± 1.25 
Salt, ia miltiorrhiza root (cold EtOH*) 370.0 83.0 ± 1.25 
SaNd miltiorrhiza root (cold EtOH*) Unknown*** 51.8 ± 15.1 
Salvia miltiorrhiza root (hot H20*) 9.2 12.4 ± 3.5 
Withania somnifera root (cold EtOH*) 70.0 38.3 ± 3.5 
Withania somnifera root (cold EtOH*) 150.0 58.2 ± 1.25 
Withania somnifera root (cold EtOH*) Unknown*** 24.3 ± 6.9 
Withania somnifera root (hot H20*) 47.6 55.9 ± 5.4 
Ziziphztsjzýuba seed (hot PS*) 20.0 0 
Dziphusjujuba seed (hot EtOH*) 50.0 0 
Dziphusjujuba seed (hot H20*) 30.0 0 
Dziphusjujuba fruit (cold EtOH*) 50.0 0 
Dziphusjujuba var. spinosa seed (hot EtOH*) 97.0 0 
Ziziphzisjujuba var. spinosa seed (hot H20*) 97.0 0 
Tacrine (positive control) 9.5x10-sM 100 
Inhibition is the percentage decrease in activity in the presence of the extract/essential 
oil compared with the activity in the absence of the extract/essential oil. Results are 
calculated as the mean ± SID of 3-6 different experiments (duplicate readings for 
each experiment). AChE inhibition > 20% was regarded as active. *** Activity of 
filtered extract tested prior to evaporating to dryness and reconstituting at a known 
concentration, to confirm activity before concentrating extract with intention to 
fractionate. 
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3.2.2.1 A, 2ocvnum lanciLolium 
Apocynum lancifolium leaf and root contain several cardioactive compounds, 
including the glycosides eymarin (48) and K-strophanthin-P (49), and the aglycone 
strophanthidin (47) (Huang, 1993; Jianming, 1988). Adverse effects of this herb 
include nausea, vomiting and diarrhoea (Chang and But, 1987; Huang, 1993). These 
effects may occur with a variety of drugs, including the cardiac glycoside digoxin. 
However, these gastro-intestinal disturbances are a frequent adverse effect of the 
AChE inhibitors donepezil (8), galantamine (9) and rivastigmine (6) so it cannot be 
excluded that alkaloid AChE inhibitors are present in A. lancifolium leaf, and 
contribute to the adverse effects. Consequently, isolation and identification of active 









Convallaria majalis leaf also contains cardenolide constituents, including the 
glycosides convallatoxin (50), convallamarin, convallarin, convallaric acid, cyrnarin 
(48), sarhamnoloside and tholloside (Sclirutka-Reclitenstamm el aL, 1986; Weiss, 
1988). Activity against AChE in both these cardenolidc containing herbs raises the 
H OH 
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possibility that cardenolide compounds may inhibit AChE, if so cardenolides would 
be a new class of AChE inhibiting compounds, which are quite different in structure 
from the previously identified AChE inhibitors, alkaloids and monoterpenes. 
C) 
OH ci -00 















3.2.2.2 Convallaria maialis 
Convallaria majalis also contains traces of volatile oil (Grieve, 1984), which may 
indicate the presence of monoterpenes. Assessment of the effect of this volatile oil on 
AChE activity would be required to determine if it is responsible for the activity 
observed with the EtOH extract of the herb, or if a synergistic action with other 
H OH 
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compounds might occur. It is worth noting that the aqueous extract of C majalis 
(absent of the apolar volatile oil) did not inhibit AChE (Table 3.1). Alkaloids have 
not been identified in A. lancifolhim or C majalis, however the possibility of their 
presence cannot be excluded although it is unlikely. Alkaloids were not detected in 
the active preparative TLC fractions 3 and 4, F8a (from FCC (a)) and the crude EtOH 
extract of C. majalis herb (refer to Chapter 2,2.2.2.5). This suggests compounds 
other than alkaloids in C majalis were antiChE. 
3.2.2.3 Centella asiatica 
The PS extract of Centella asialica leaf was more active against AChE activity than 
both the aqueous and EtOH extracts; AChE inhibition was greater in the presence of 
the PS extract, even though the assay concentration of this extract was lower (Table 
3.1). This indicates the constituents responsible for AChE inhibition are relatively 
non-polar. Monoterpenes, sesquiterpenes and triterpenes are reported to be present in 
C asiatica leaf (Asakawa et aL, 1982; GOnther and Wagner, 1996). The 
monoterpenes present in the essential oil from C. asialica include bornyl acetate (51), 
myrcene (52), a-pinene (53), 0-pinene (54) and y-terpinene (55) (Asakawa el aL, 
1982). These apolar compounds would be expected to be extracted into the more 
active PS extract, suggesting these monoterpenes may contribute to antiChE activity. 
Bornyl acetate (51) is reported to reversibly inhibit electric eel AChE (Ryan and 
Byrne, 1988);, y-terpinene (55) is an inhibitor of bovine and human erythrocyte AChE 
(Miyazawa el aL, 1997; Perry et aL, 2000a). a-Pinene (53) is also an inhibitor of 
erythrocyte AChE, and was a more potent inhibitor than y-terpinene (55); but these 
monoterpene AChE inhibitors were weak compared to the antiChE alkaloid, 
physostigmine (5) (Perry et aL, 2000a). The monoterpenes bornyl acetate (51), 
myrcene (52), a-pinene (53), 0-pinene (54) and y-terpinene (55) are reported to 
comprise less than 2% of the essential oil from C. asialica (Asak-awa et aL, 1982). 
With regard to the relative antiChE potency of these monoterpenes, it is improbable 




















, y-Terpinene (55) 
Other monoterpenes present in the oil may have contributed to activity, as may other 
unidentified compounds in C asialica leaf. Alkaloids have been isolated from C 
asialica, including the alkaloid hydrocotylin (Duke and Ayensu, 1985). However, the 
potential antiChE activity of these alkaloids has not been investigated. The alkaloids, 
the monoterpenes and perhaps other constituents present in C asiatica leaf extracts 
may have inhibited AChE, perhaps synergistically. 
3.2.2.4 Melissa officinalis and Rosmarinus o6ricinalis 
Melissa offi'cinalis herb contains rosmarinic acid (RA) (108), glycosidically bound 
chlorogenic (107) and caffeic acids (106), triterpenes and flavonoids (e. g. the 
glycosides of apigenin and luteolin (114)) (Bisset, 1994; Bruneton, 1995; Mulkens 
and Kapetanidis, 1987). It is probable that the activity of the aqueous extract is due to 
the more polar constituents, perhaps glycoside compounds; the occurrence of 
significant amounts of the hydrophobic monoterpenes from the essential oil is 
unlikely in this extract so would not explain antiChE activity. 
The hot aqueous and EtOH extracts of Rosmarinus officinalis herb caused greater 
inhibition of AChE, than a higher assay concentration of the cold EtOl-l extract (Table 
1). This suggests that the heating process yielded different compounds from the 
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extract, or perhaps thermolabile compounds were converted to antiChE compounds 
upon heating. As the EtOH extract of the fresh herb was less active than the dried 
herb, it may be possible that the storage conditions of the dried herb (e. g. humidity, 
light, temperature) influenced the chemical composition. Alkaloids arc not known to 
be present in either M. officinalis or R. offi'cinalis. Further research is necessary to 
isolate and identify active constituents, perhaps alkaloids or novel antiChE 
compounds. 
The essential oils from M officinalis (obtained from G. Baldwin and Co., London and 
Id Aromatica, Leeds) and R. officinalis (obtained from G. Baldwin and Co., London) 
have previously been reported to inhibit erythrocyte AChE (Perry et al., 1996). 
Different potencies of an essential oil from the same plant may occur due to several 
contributing factors; essential oil composition may vary depending on the stage of 
development and the origin of the leaves, and other factors such as environmental 
conditions, and time of year harvested. The major constituents of R. officinalis 
essential oil are 1,8-cineole (56) (15-30%), camphor (57) (15-25%), a-pinene (53) 
(up to 25%) and other monoterpenes (e. g. borneol (58), bomyl acetate (5), limonene 
(73)) (Bisset, 1994; Trease and Evans, 1996). 
Earlier studies showed that neither 1,8-cineole (56), nor camphor (57), nor borneol 
(58) (104M) inhibited human erythrocyte AChE (Perry et aL, 1996), although 1,8- 
cineole (56) was shown to inhibit electric eel AChE, the assay concentration being 
much greater 0.78M (Ryan and Byrne, 1988). More recently, 1,8-cincole (56) and 
camphor (57) have shown activity against human erythrocyte ACK (IC5o: 0.63mM 
and >lOmM respectively) (Perry el aL, 2000a). The differences observed with the 
same compound against enzyme inhibition, may be explained by differences in the 
AChE subtype, the assay method, or the volatility of the monoterpenes at different 
assay temperatures (higher temperatures may cause loss of the volatile compounds 
from the assay solution). Limonene (73) is also reported to be a weak inhibitor of 
electric eel AChE (Grundy and Still, 1985). 
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The M. ofjlcinafis essential oil used in these investigations includes the constituents 
citral (geranial (70) and neral (71)) (11.8% and 8.9% respectively), geraniol (72) 
(0.9%), limonene (73) (0.4%), linalool (74) (1.2%) and a-pinene (53) (0.3%), with the 
major component being the sesquiterpene trans-caryophyllene (82) (18.9%) (refer to 
Chapter 2,2.2.7.1). Citral is also reported to inhibit electric eel AChE (Ryan and 
Byrne, 1988), and geraniol (72) and linalool (74) are weak inhibitors of human 
erythrocyte AChE (Perry et A, 2000a). It can be concluded that 23.5% of the M 
ofjlcinalis oil used in the present study is composed of known AChE inhibitors. The 
effect of the other components of these essential oils on AChE activity requires 
further investigation. A disesquiterpene, gossypol (59) is a reversible inhibitor of 
electric eel AChE (Ryan and Byrne, 1988). This suggests that related sesquiterpene 
compounds may also be inhibitors of AChE, however the effect of other sesquiterpene 













It may be concluded that the monoterpenes are responsible, at least in part, for the 
antiChE activity of the essential oils, and may also explain the activity of the EtOl-l 
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extracts of Centella asiatica, Convallaria majalis and R. qjjlcinalis. However, the 
structural diversity of the active monoterpencs complicates the prediction of potential 
structure-activity relationships. One feature associated with enzyme inhibition is a 
hydrophobic ligand; the hydrophobic active site of AChE is reported to be susceptible 
to hydrophobic interactions (Hansch and Deutsch, 1966). Monoterpenes consist of a 
hydrocarbon skeleton, which may explain their antiChE activity. However, no 
relationship between monoterpene lipophilicity or between molecular volume was 
identified in the study by Perry el aL (2000a). Monoterpenes may be cyclic (e. g. 1,8- 
cincole (56), and a-pinene (53)) or acyclic (e. g. geranial (70) and neral (71)); a feature 
that may also influence antiChE activity, but no structure-activity relationship has 
been established. Further investigations using the same assay method, the same 
subtype of AChE from the same source, and testing various monoterpenes at the same 
concentration may determine if a cyclic component, or particular functional group 
favours AChE inhibition. 
The nature of enzyme inhibition may also affect the potency of a ligand. For 
example, an inhibitor may bind competitively (competing with the substrate for the 
active site) or non-competitively (affecting the AChE-ATCh complex, preventing 
product fon-nation); a competitive inhibitor may interact with one or more subsites 
(the anionic, hydrophobic and esteratic sites) in the active site, or may influence a 
completely different site on the enzyme and so alter the molecular configuration, 
rendering the enzyme inactive. 
3.2.2.5 Salvia milliorrhiza 
SdIvia miltiorrhiza root (EtOH extract) was significantly active against AChE activity 
at the concentrations tested, however the aqueous extract was not (Table 3.1). This 
gives some indication of the type of compounds that are antiChE. The less polar 
diterpene compounds (e. g. tanshinone 1 (115), dihydrotanshinone, tanshinone Ila 
(116) and cryptotanshinone (117)), which have previously been isolated from the 
lipophilic extracts of S. miltiorrhiza root (Paulus and Bauer, 2000), are likely to be 
present in the EtOH extract, rather than the less active aqueous extract. It is therefore 
possible that the lipophilic components, perhaps the diterpenes, of S. milliorrhiza root 
are more potent inhibitors of AChE than the more polar components. To confirm this 
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observation, the EtOH and aqueous extracts were also assessed over the concentration 
range 5.8pg/ml - 70.9pg/ml. (refer to 3.2.3). 
3.2.2.6 Wilhania soninifera 
A lower concentration (47.6 pg/ml) of the aqueous extract of Withania sonlififera root 
was more active against AChE activity (55.9% inhibition) than a higher concentration 
(70. Opg/nil) of the EtOH extract (38.3% inhibition) (Table 3.1). This indicates that 
AChE inhibitors are present in both extracts, but those in the aqueous extract may be 
more potent, or act synergistically to enhance inhibitory activity. 
Numerous alkaloids have been identified in W. somnifera root; these include anaferine 
(60), anahygrine, ashwagandhine, aswhagandhinine, cuscohygrine (61), 
isopelletierine, pseudotropine, pseudowithanine, somniferiene, somniferinine, tropine 
(62), visamine, withanine, withaninine and withasomine (Harborne and Baxter, 1993; 
Mills and Bone, 2000; Schwarting el al., 1963; Upton, 2000). Nicotine (2) is reported 
to be present in JV soninifera root (Kapoor, 1990) but some investigations have not 
detected its presence (Das et al., 1963; Schwarting el al., 1963). This may be 
explained by variation in the source of the herb, as chemical composition may be 
influenced by several factors, including environmental conditions for cultivation and 
storage conditions, or by different extraction procedures used to isolate chemical 
constituents. 
It remains to be determined whether any of the alkaloids (perhaps those yet to be 
identified) present in the root influence AChE activity. An alkaloid containing extract 
from W. somnifera has shown tranquillising effects on the CNS in vivo (Malhotra el 
al., 1965), however effects of Withania alkaloids on cognitive function remain to be 
investigated. The various alkaloids obtained from plant sources (e. g. galantamine (9), 
huperzine A (10), physostigmine (5)) which are known AChE inhibitors, leads to the 
suggestion that the alkaloidal content of TV somnifera root is responsible for the 
antiChE effects observed, however the possibility of non-alkaloidal compounds from 
the root inhibiting AChE cannot be excluded. Withania alkaloids differ in their 
chemical structures, and include piperidine alkaloids (e. g. anaferine (60), anahygrinc, 
cuscohygrine (61)) and tropane alkaloids (e. g. tropine (62)). Some tropane alkaloids 
(e. g. hyoscine (63) and hyoscyamine (64)) are reported to be anticholinergic 
(Harbome and Baxter, 1993), and consequently induce amnesia. Potential 
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anticholinergic effects of the alkaloids from W. soninifera remain to be investigated, 
however the reputed benefits on memory in traditional medicine, suggest that any 
possible amnesic effects are counteracted by cognitive enhancement. 
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It cannot be predicted if the particular alkaloids from TV soninifera are antiChE, as 
structure activity relationships to determine affinity for the AChE enzyme have not 
been established; those alkaloids which are known AChE inhibitors vary in their 
chemical structure, for example galantamine (9) is a phenylalanine-derived alkaloid, 
berberine, palmatine and sanguinarine are isoquinoline alkaloids, physostigmine (5) is 
an indole alkaloid and solanine is a steroidal alkaloid. 
It is reported that an extraction with 45% alcohol yields the highest percentage of 
alkaloids from W. somnifera root (Kapoor, 1990). Comparison of the antiChE 
activity of such an extract, with the antiChE activity of the aqueous and EtOH extracts 
may yield further information regarding the potential antiChE activity of the JV 
somnifera alkaloids; isolation and screening of each alkaloid for antiChE activity may 
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Several steroidal derivatives have also been isolated from JV soninifiera root, 
including the withanolide aglycones (e. g. withanolides A-Y, withaferin A (109)) and 
the glycosylated sitoindosides (Ghosal et aL, 1989; Mishm el aL, 2000; Rhaman el 
aL, 1991; Rhaman et aL, 1993). It is these compounds that are believed to be 
responsible for the optimum improvement in cognitive function in several in vivo 
studies. Sitoindoside IX (65) and X (66) augmented learning acquisition and memory 
retention in young rats; however these observations were more significant in old rats 
(Ghosal et aL, 1989), suggesting therapeutic relevance in the aged brains of many AD 
patients. Withaferin A (109) was not shown to initiate this cognitive enhancement 
(Ghosal et aL, 1989), suggesting inactivity against cognitive dysfunction, or that 
synergism (perhaps with the sitoindosides) is a requirement for activity. The 
mechanism of action to explain these observations was undetermined, however the 
greater effects in the aged rat brain indicate that activity is greatest under suboptimum 
cholinergic function. It is possible that in the aged or diseased (AD) brain, 
degeneration of cholinergic neurons may be compensated for by an increased 
sensitivity of cholinergic receptors, thus promoting cholinergic function. 
Further studies have shown that W. somnifera root extracts, consisting of equimolar 
amounts of sitoindosides VII -X and withaferin A (109), significantly reversed an 
ibotcnic acid (IA) induced cognitive deficit and the reduction in cholinergic markers 
(ACh (1), ChAT, musearinic receptors) in vivo (13hattacharya and Kumar, 1995). 
These findings may explain the earlier observations on cognitive function. More 
recently the effects of an extract containing equimolar amounts of sitoindosides VII - 
X and withaferin A (109), on cholinergic markers, have been investigated (Schlicbs et 
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aL, 1997). It was found that AChE activity was enhanced in the lateral septum and 
globus pallidus, but activity was decreased in the diagonal band in rat brain, following 
systemic administration; in addition, M, musearinic receptor binding was enhanced in 
the lateral and medial septum, and in the frontal cortices, and M2 receptor binding in 
various cortical regions including the frontal and parietal cortices (Schliebs et aL, 
1997). These results suggest compounds in the extract Preferentially affect 
cholinergic function in the basal and cortical forebrain, which are areas in the brain 
important for cognitive function. It is Proposed that the changes in AChE activity 
observed in the study by Schliebs et aL (1997) may be due to loss of cholinergic 
neurons, suppression of AChE expression in neuronal cell bodies, or direct inhibition 
of the AChE enzyme. The in vitro effects against AChE activity, observed in the 
present study, confirm that W. somnifera root is an inhibitor of AChE, but this does 
not exclude the occurrence of additional mechanisms of action it? vivo. 
JV somnifera is also reported to contain choline (Kapoor, 1990), a precursor of ACh 
(1). The presence of choline in systemically administered extracts may have 
contributed to the cognition enhancing effects observed in the in vivo studies, perhaps 
by acting synergistically with other compounds. The JV somnifera root extract both 
enhanced and decreased AChE activity in different brain regions (Schlicbs et aL, 
1997), this may be due to compounds being either enzyme inducers or inhibitors, 
depending on the subtypes of AChE present in a particular brain region. As the 
extract, which influenced AChE activity in vivo, consisted of the sitoindosides VII -X 
and withaferin A (109), it is apparent that these compounds and perhaps related 
compounds may be responsible for the antiChE effects observed in vitro in the present 
study. 
3.2.3 Effect of Salvid milliorrhiza Root Extracts on Erythrocyte AChE Activity 
The EtOH extract of Salvia iniltiorrhiza root was confirmed to inhibit erythrocyte 
AChE more effectively than the aqueous extract, when tested over the concentration 
range 5.8[Lg/ml - 70.9pg/ml (Figure 3.2). The IC50 value for the EtOI-I extract was 
37.2pg/ml; the aqueous extract inhibited AChE by 45% at the maximum assay 








Figure 3.2. Inhibition of erythrocyte AChE activity by aqueous and ethanolic 
extracts of Salvia miltiorrhiza root (duplicate readings; n=3; p<0.05). 
Other Salvia spp. have been reported to inhibit AChE, including the essential oil from 
the leaves of S. officinalis, and the and the leaves and essential oil from S. 
lavandidifolia (Perry el aL, 1996; Perry el aL, 2000a). In these studies, the antiChE 
activity of the S. lavandulaefolia leaf extract was attributed to the essential oil 
content. The root of S. iniftiorrhiza is quite different in chemical composition to the 
leaf essential oil of other Salvia spp.; S. miltiorrhiza root contains diterpene pigments 
with a phenanthrenequinone structure (e. g. tanshinones and isotanshinones) as the 
major components, whereas monoterpenes are the major constituents of S. officinalis 
and S. lavandulaefolia essential oils. 
The antiChE activity of both the aqueous and EtOH extracts of S. milliorrhiza root 
indicate that different compounds are responsible for the inhibitory activity, and that 
they are novel antiChE compounds from the genus Salvia. The EtOll extract would 
be expected to contain the less polar constituents, such as the diterpene tanshinone 
compounds, and the aqueous extract would be expected to contain water soluble 
compounds as the major components, such as the plienylpropanoids (e. g. danshensu 
(45)) and salvianolic acids A (123), B (124) and C (125) (reported to be isolated from 
an aqueous extract of S. milliorrhiza root (Chen and Liu, 1980; Tang and Eissenbrand, 
Saltia mildorthiza Conccntration(pg/nil) 
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1992)). It is feasible that these compounds or other unidentified compounds are novel 
inhibitors of AChE. 
3.2.4 Effect of Convallaria majalis Leaf Extracts, Fractions and Known 
Constituents on Erythrocyte AChE Activity 
3.2.4.1 Effect of C mQjalis Leaf Extracts (Hexane, Dichloromethane, Ethanol and 
Water Extracts) on EDlhrocvtc AChE Activit 
Of the C majalis extracts tested (95.24ptg/ml), only the DCM and EtOH extracts were 
significantly active against AChE activity, giving 82.0% and 90.9% inhibition 





Figure 3.3. Inhibition of erythrocyte AChE activity by extracts from C. majalis leaf 
(duplicate readings; n=3 ± SD). 
These results indicate that compounds in C majalis leaf that are highly polar, and also 
those that are less polar are not significantly active against AChE activity. However, 
it cannot be excluded that a minor component of these extracts is a potent AChE 
inhibitor, and may have been present at a concentration too low to influence ACIiE. 
TLC analysis showed that the EtOH and DCM extracts have a similar chemical 
profile (refcr to Chapter 2,2.2.4), which may explain their high activity, compared to 




the less active aqueous and hexane extracts. C majalis leaf is reported to contain 
cardiac glycosides, flavonoid glycosides and the less polar aglycones of these 
compounds (Trease and Evans, 1996). The presence of some glycosides of these 
compounds would be expected in the more polar extracts (aqueous and EtOH 
extracts), and the corresponding aglycones in the less polar extracts (C61-114, DCM and 
perhaps EtOH). It may be these compounds or perhaps other unidentified compounds 
are active against AChE. LC-MS analysis of the crude EtOH extract showed some 
compounds to be present which appeared to be glycosides (refer to Chapter 2,2.2.3). 
These may have been cardiac or flavonoid glycosides, but were not found to be either 
convallatoxin (50) or cymarin (48), suggesting these compounds were absent in the 
EtOH extract. These glycosides may have been antiChE, but to establish this, their 
isolation is necessary. 
3.2.4.2 Effect of Flash Column Chromatogmphy Fractions from C. maialis Lea 
Ethanol Extract (a) and Pure Compounds on EWhrocvte AChE Activity 
Of the sixteen fractions (refer to Chapter 2,2.1.6.1 for fractionation method) analysed 
for activity against AChE, only four fractions were significantly active, i. e. F4a, F8a, 
F9a and F16a inhibited AChE activity by 33.5%, 34.2%, 24.7% and 34.5% 
respectively (Figure 3.4). All other fractions inhibited AChE activity by <20%. 
Flavonoid compounds were not detected in the fractions, but one zone likely to be due 
to a flavonoid was detected following TLC analysis of the crude EtOH extract (refer 
to Chapter 2,2.2.2.1). It may be concluded that the apparent absence of flavonoids in 
the active fractions suggests these compounds are not AChE inhibitors. Flavonoids 
are not known to be antiChE compounds. The pure compound hyperoside, which is a 
flavonol 0-glycoside, (flavonoid glycosides are reported to be present in C majalis 
(Trease and Evans, 1996)) did not inhibit AChE (Figure 3.4), providing further 
evidence for the inactivity of flavonoids against AChE. To confirm these results other 
classes of flavonoid compound could be tested for inhibition of AChE. 
Unidentified cardenolide compounds were detected in F3a and F8a (refer to Chapter 
2,2.2.1.1). Cardenolides are not typically associated with inhibition of AChE. 173a. 
only inhibited AChE by 16.4%, being less active than 178a. It may possible that 
cardenolide compounds present in these fractions are AChE inhibitors, either alone or 
in synergy with other compounds. The cardenolide in F3a may be less active than the 
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cardenolide detected in F8a, or may be more potent than the F8a cardenolide, but 




(Except A. 9.52ILLg/mi) 
Figure 3.4. Inhibition of erythrocyte AChE by flash column chromatography 
fractions (FCC (a)) of C. majalis leaf (ethanol extract) and pure compounds (duplicate 
readings; n=3 ± SD). A= hyperoside, B= convallatoxin, C= cymarin. 
To provide further information regarding the potential antiChE activity of 
cardenolides, two pure cardenolide compounds were assessed, convallatoxin (50) 
(reported to be the major cardenolide compound present in C majalis (Harborne, 
1993)) and cymarin (48). Of the pure compounds tested, only cymarin (48) inhibited 
AChE activity, but inhibition was not significant (18.9%) (Figure 3.4). This suggests 
that some cardenolide compounds may be weak inhibitors of AChE, and may explain 
the antiChE activity of the herb and subsequent fractions, perhaps by synergism with 
other compounds. The antiChE activity of cymarin (48) suggests some cardenolides 
are novel inhibitors of AChE; however further investigations are required to 
determine the antiChE potential of other cardenolides, and any structure-activity 
relationships. The cardenolides do not contain the nitrogen in a ring system, which is 
a feature of the antiChE alkaloids, nor are they small hydrocarbons as are the antiChE 
monotetpenes. 
- Fl F2 F3 F4 F5 F6 F7 F8 F9 FIO Fil F12 F13 F14 F15 F16 ABC 
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It is worth noting that a cholinergic link has been identified in the genesis of cardiac 
arrhythmias (David el aL, 1982), which may aid the understanding of the potential 
antiChE activity of cardenolides. It has been shown that arrhy-thmogenic agents (e. g. 
K-strophantin) induce ACh (1) release, with the exception of ACh (1) in the presence 
of physostigmine (5) (David et aL, 1982). Previous work by Schliebs et aL (1997), 
showed that Withania somnifera extracts may enhance or reduce AChE activity in 
different brain regions. This occurrence may be due to compounds acting as enzyme 
inducers or inhibitors, depending on the subtype of AChE. Similarly, a cardenolide 
may act as an enzyme inducer to initiate arrhythmias, but may act as enzyme inhibitor 
if the enzyme subtype were different, such as the AChE subtypes in the CNS. This 
theory would support the finding that some cardenolides may inhibit AChE since 
cardiogenic agents may influence ACh (1) release (David el aL, 1982), and if this 
effect were to occur in the CNS, then cholinergic function may be enhanced. This 
effect may also explain the reputed beneficial effects of C majalis leaf on memory. 
3.2.4.3 Effect of Flash Column Chromatography Fractions from C. maialis Lea 
(Dichloromethane Lgyer of an Ethanol Extract) (b) on EWhroc3le AChE Activity 
Nine of the seventeen fractions (refer to Chapter 2,2.1.6.2 for fractionation method) 
tested were significantly active against AChE activity; Flb, F3b, F5b, F6b, F7b, FlOb, 
Fllb, Fl4b and Fl5b inhibited AChE activity by 23.2%, 40.6%, 33.6%, 23.0%, 
24.2%, 36.4%, 70.4%, 21.1% and 22.6% respectively. All other fractions inhibited 
AChE activity by <20% (Figure 3.5). 
Flb was a non-polar (PS) fraction, indicting that active compounds were non-polar, 
and different to those active compounds present in the more polar Fl5b (DCM : 
MeOH (1: 1) fraction). It is therefore apparent that antiChE activity of C majalis leaf 
is due to more than one type of compound. 171 lb showed greatest inhibition of AChE 
(70.4%) of all the FCC (b) fractions tested. This fraction was obtained from the 
solvent gradient DCM : MeOH (6: 1 to 3: 1). The presence of some of these 
compounds in FlOb, may explain the antiChE activity of this fraction, although other 
perhaps less potent compounds may have contributed to activity. Compounds present 
in FI Ob and FIIb (from FCC (b)), were not apparent in F 15 a, or the more active FI 6a 
(from FCC (a)) (refer to Chapter 2,2.2.2.3) suggesting different compounds in C 
majalis leaf are antiChE. Several compounds in the active 178a (from FCC (a)) were 
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also present in F6b and F7b (from FCC (b)) (refer to Chapter 2,2.2.2.3), perhaps 







Figure 3.5. Inhibition of erythrocyte AChE by flash column chromatography 
fractions (FCC (b)) of C majalis leaf (dichloromethane layer of an ethanol extract) 
(duplicate readings; n=3 ± SD). 
3.2.4.4 Effect of Droplet Counter-Current Chromatogmphy Fmctions from C. maLalis 
Leaf Ethanol Extract on E! yjhroc3qe AChE Activi! y 
Six of the seventeen fractions (refer to Chapter 2,2.1.6.3 for fractionation method) 
tested were significantly active against AChE activity. These fractions were F2, F4, 
F8, F9, F 13 and F 17, which inhibited AChE activity by 23.0%, 89.6%, 59.1%, 64.6%, 
31.2% and 31.6% respectively (Figure 3.6). All other fractions inhibited AChE 
activity by <20%. 
Almost 90% inhibition of AChE occurred in the presence of F4 (a fraction obtained 
by pooling fractions 62 - 71 from the original 459 DCCC fractions), which was 
composed of both polar and more lipophilic compounds (refer to Chapter 2,2.2.2.4). 
The three TLC zones identified in the active F8a (from FCC (a)), and the preparative 
TLC F3 and F4 (refer to Chapter 2,2.2.2.5) were not identified in DCCC F4 (refer to 
Fl F2 F3 F4 F5 F6 F7 F8 F9 FIO Fll F12 F13 F14 FIS F16 F17 
Concentration 95.24pg/ml 
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Chapter 2,2.2.2.4), which suggests that there are compounds present in C majalis 







Figure 3.6. Inhibition of erythrocyte AChE by droplet counter-current 
chromatography fractions of C. majalis leaf (ethanol extract) (duplicate readings; n=3 
± SD) 
3.2.4.5 Effect of Preparative Thin Lgyer Chromatogmphy Fmctions from C maialis 
Leaf Ethanol Extract on EWhroc3qe AChE Activi 
Four fractions from the preparative TLC separation of C. majalis EtOH extract (refer 
to Chapter 2,2.1.7.8 for fractionation method) were significantly active against AChE 
activity; F2, F3, F4 and F7 inhibited ACK activity by 35.4%, 46.4%, 48.5% and 
46.9% respectively (Figure 3.7). All other fractions inhibited AChE activity by 
<20%. 
Following TLC analysis, three zones were found to be present in F3 and F4, and in 
F8a (from FCC (a)) and also in the crude EtOH extract of C. majalis leaf (refer to 
Chapter 2,2.2.2.5). These compounds may therefore explain the antiChE activity of 
all three fractions, and the crude extract. Alkaloids were not detected in these three 
zones and F8a (from FCC (a)) was negative for the presence of flavonoids (refer to 
Chapter 2,2.2.2.1,2.2.2.5). HPLC analysis of F3 also showed the absence of 
Fl F2 F3 F4 F5 F6 F7 F8 F9 FIO Fll F12 F13 F14 F15 F16 F17 
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flavonoid compounds (refer to Chapter 2,2.2.3.2). This suggests that these types of 
compound are not responsible for antiChE activity of these fractions; although may 
have been present at concentrations too low for detection; this would indicate 
compounds were very potent antiChEs. In addition, it cannot be excluded that such 











Figure 3.7. Inhibition of erythrocyte AChE by preparative thin layer chromatography 
fractions of C majalis leaf (ethanol extract) (duplicate readings; n=3 ± SD). 
Phenylalanine was present in FI and F2 (determined by LC-MS analysis, refer to 
Chapter 2,2.2.3.2), confirming any possible effect on AChE activity to be minimal. 
Unidentified glycoside compounds were present in F2 (refer to Chapter 2,2.2.3.2), 
which also raises the possibility that these compounds were weak inhibitors of AChE. 
Compounds (yielding ions at nilz 277 and m1z 279) detected in both F3 and F4 
confirm the results of the TLC analysis of these fractions, and may explain the similar 
antiChE activity of these fractions. The chemical nature of these compounds is yet to 
be identified, however F3 was negative for the presence of flavonoids (shown by 
HPLC analysis) (refer to Chapter 2,2.2.3.2). The compounds (yielding ions at inlz 
277 and nilz 279) were also detected in F6b and F7b (from FCC (b)) (refer to Chapter 
2,2.2.3.2), suggesting these compounds may also have contributed to antiChE activity 
vi PU F3 F4 1; 5 t; b F/ 
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of these fractions. F7 contained a compound (yielding an ion at m1z 621), which was 
absent in F6 (refer to Chapter 2,2.2.3.2); this compound may explain the antiChE 
activity of F7, but the structure of this compound remains to be elucidated. 
3.2.4.6 Effect of Chloror)hvll on Ervthrocvte AChE Activitv 
The commercially obtained sample of chlorophyll used in this investigation was 
composed of several compounds (refer to Chapter 2,2.2.5). These may include 
chlorophylls a and b, and perhaps chlorophyll derivatives and degradation products. 
Chlorophyll derivatives identified to date include pheophytins a and b, pheophorbide 
a and chlorophyllides a and b (Canjura and Schwartz, 1991; Harris et aL, 1995; van 
Breeman et aL, 1991). Chlorophylls a and b are two of the most abundant 
nitrogenous compounds in plants (Harborne and Baxter, 1993) and are composed of 
four nitrogen containing pyrrole rings chelated to a magnesium atom. It may be 
possible that degradation products of chlorophyll, containing nitrogen, may interact 
with the anionic active site of the AChE enzyme. However, the commercially 
obtained chlorophyll did not inhibit AChE activity when tested at 47.62pg/ml and at 
95.24pg/ml. This suggests that chlorophyll may not be antiChE, and does not explain 
the activity of C. majalis leaf or fractions. 
LC-MS analysis of the preparative TLC fractions confirmed that chlorophylls a and b 
(mw: 893.51 and 907.50 respectively) were absent in the active fractions (refer to 
Chapter 2,2.2.3.2). However, it cannot be excluded that nitrogen-containing 
degradation products of chlorophyll present in the C majalis extract, but absent in the 
reference chlorophyll solution, interfered with AChE activity, or were antiChE 
synergistically with other compounds. 
3.3 Conclusion 
Several herbs investigated for antiChE activity were inactive at the concentrations 
tested, including Alisma orientalis root, Codonopsis pilidosa root, Gentiana spp. 
(adulterated Polygonum mulliflorum root), Polygala lenuffiblia root, Ziziphusjujuba 
fruit and seed and Ziziphusjujuba var. spinosa seed (Table 3.1). The dried herbs of 
Dziphusjujuba, Polygala tenuffiblia and Polygonum mulliflorum have previously been 
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investigated for their effects on AChE activity, with only Polygala tenuifolia showing 
significant AChE inhibition (40%) (Park et aL, 1996). However, the roots of 
Polygala tenuifolia and the seeds of Z. jzýuba have not previously been investigated. 
The effect of Polygonum mulliflorum root on AChE activity remains to be 
investigated, as the sample used for assessment of antiChE activity was adulterated, 
and found to be Gentiana spp. root (refer to Chapter 2,2.2.1.1). 
Results for extracts showing no AChE inhibition are not necessarily conclusive. Such 
extracts may have no effect on AChE inhibition; they may have antiChE activity but 
not at the physiological stage at which they were screened, they may contain 
compounds (thiol in particular) that interfere with the spectrophotometric test by 
reacting with DTNB, or they may contain cholinesterase constituents and 
consequently interfere with the assay. Cholinesterase activity has been established in 
a number of plants, particularly the Solanaceae, although their function is unknown 
(Gupta and Gupta, 1997; Schwartz et aL, 1964). The leaves, branch and stem of 
Withania somnifera, a member of the Solanaceae, have previously shown 
cholinesterase activity, but this activity was not detected in the roots (Gupta and 
Gupta, 1997). ACh (1) is reported to occur in some plant tissues, including Phaseolus 
aureus (the mung bean) (Fluck and Jaffe, 1974). The presence of ACh (1) in the 
extracts screened for antiChE activity may also interfere with the results. ACh (1) 
may compete with ATCh for the active site of AChE; consequently a reduction in 
released thiol would occur, lowering the concentration available for the reaction with 
DTNB. 
From these investigations, it is apparent that several herbs contain ACK inhibiting 
compounds, which may explain their traditional use for memory and 
neurodegenerative disorders. Of the active herbs, some may yield known antiChE 
compounds, such as the monoterpenes (e. g. from Centella asiatica leao, some may 
yield alkaloids previously unknown to inhibit AChE (e. g. from Withania soninifiera 
root) and some may yield novel AChE inhibitors (e. g. from Convallaria majalis leaf). 
Studies on the reputed CNS effects of Convallaria majalis leaf to date are limited; 
therefore the potential for novel antiChE compounds, perhaps cardenolides, to be 
isolated from this herb would contribute to the understanding of structure-activity 
relationships for the AChE enzyme. 
Although new compounds may inhibit AChE in vitro, a wide range of factors needs to 
be considered to assess therapeutic potential. One feature would be the 
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pharmaokinetic profile of a potential drug in vivo. Although a plant may have been 
used in traditional medicine for CNS disorders, investigations are required to establish 
if isolated compounds are able to cross the BBB and reach the CNS. It is reported 
that in vivo oral administration of Salvia lavandulaefolia essential oil to mts, inhibits 
AChE activity in striaturn and hippocampus (Perry el aL, 2000b). This suggests that 
essential oil constituents have therapeutic potential in AD management, or may act as 
templates for the development of new drugs which are active in the CNS. 
An appropriate adverse effect profile is also an important feature of a potential drug. 
The cardioactive effects of the cardenolides are well documented (David el A, 1982; 
Grieve, 1984; Gupta and Chopra, 1987; Samuelsson, 1992). It is essential that a 
therapeutic dose selected to manage AD symptoms does not induce adverse effects 
such as cardiotoxicity. However, the potential antiChE activity of cardenolides, or 
other possible AChE inhibitors, may yield new therapeutic agents by acting as 




Assessment of Oestrogenic Activity of Plant Extracts, Essential 
Oils and Essential Oil Constituents 
There are a variety of in vitro test systems available for the characterisation of the 
oestrogenic activity of various test substances, including the phyto-oestrogens. 
Assessment of oestrogenic activity may be achieved by conducting receptor binding 
assays, cell-proliferation assays, reporter gene assays and by in vivo investigations. It 
is important that a substance is assessed in various assay systems to evaluate the 
oestrogenic potency, so that as much information as possible regarding the 
oestrogenic potential of that substance can be obtained. In view of the current 
availability of very sensitive screens for oestrogenic activity (Diel et aL, 1999) the 
initial aim of this study was to investigate the oestrogenic activity of the plant 
extracts, essential oils and essential oil constituents using a recombinant yeast screen 
and the Ishikawa cell line. In the light of positive results obtained for some test 
substances, the study was extended to include both oestrogen (or estrogen) receptor 
(ER) binding and in vivo studies. 
Initial screening of all plant extracts and essential oils was undertaken using an 
oestrogen-inducible yeast (Saccharomyces cerevisiae) screen expressing the human 
oestrogen receptor (hER) and containing expression plasmids carrying oestrogen- 
responsive sequences controlling the reporter gene lac-Z (encoding the enzyme P- 
galactosidase). The hER present in the yeast cell line is indistinguishable from hER 
expressed in human MCF-7 cells and affinity of 17p-oestmdiol (132) (14) for hER in 
the yeast cells is similar to that observed in the human MCF-7 cells (Metzger et aL, 
1988). Upon binding of an active ligand to the hER, P-galactosidase is synthesised 
and metabolises the chromogenic substrate chlorophenol red-p-D-galactopyranoside 
(CPRG) to give chlorophenol red (CPR) (Figure 4.1). The amount of CPR formed is 
measured spectrophotometrically at 540nm to give a measure of the level of receptor 
binding. 
Those test substances that were active in the yeast screen were also assessed for 
oestrogenic activity using the Ishikawa cell line, established by Nishida et aL (1985), 
which is derived from human endometrial carcinoma cells. This cell line is 
212 
unresponsive to oestrogens with respect to proliferation, but is sensitive to the specific 
stimulatory effect of oestrogens including phyto-oestrogens, on alkaline phosphatase 
activity; no other steroids including androgens, progestins, mineralocorticoids or 
glucocorticoids produce this effect (Littlefield et aL, 1990; Markiewicz et aL, 1993). 
Binding of an active ligand to the hER results in an increase in alkaline phosphatase 
activity. This activity is measured by addition of p-nitrophenol phosphate (P-NPP), a 
substrate for this enzyme. p-NPP is hydrolysed by alkaline phosphatase to p- 
nitrophenol (p-NP), a coloured product for which the optical density can be measured 
to give a measure of the receptor binding. 
E3tfOgen 














Figure 4.1. Schematic of the oestrogen-inducible expression system in yeast 
(Routledge and Sumpter, 1996). 1: The hER gene is integrated into the main genome 
and expressed in a forrn able to bind with the oestrogen (estrogen) response element 
(ERE). 2: Binding with ERE occurs within a hybrid promoter on the expression 
plasmid. 3: The hER is activated by binding of a ligand. 4: Expression of the reporter 
gene Lac-Z produces O-galactosidase. 5: P-galactosidase is secreted into the assay 
medium. 6: P-galactosidase metabolises CPRG (yellow) to give CPR (red). 
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Radioligand based Ishikawa cell receptor binding assays were performed to further 
investigate the receptor binding properties of the oil constituents. Binding assays 
were also conducted to determine the affinity of citral, eugenol (84), geraniol (72) and 
nerol (75) for isolated a-oestrogen receptor (ERa) and P-oestrogen receptor (ERP). 
The isolated ERa and ERP employed to assess ER binding were produced using 
recombinant baculovirus-infected insect cells (Brown and Sharp, 1990; Obourn et al., 
1993). Binding affinity of each of the compounds for the hER was determined by 
quantitation of 3 H- I 7p-oestradiol-receptor complexes. 
Estimates of oestrogenic potency may differ, depending on the nature of the in vivo 
bioassay used (Milligan et al., 1998). The oil constituents citral and geraniol (72) 
were therefore assessed for potential oestrogenic activity in vivo using two different 
assays. The first assay was based on the rapid vascular response of the uterine 
vasculature to oestrogenic stimulation (Arvidson, 1977; Milligan et al., 1998), and the 
second was based on an uterotrophic assay (Odurn et al., 1997; Shelby et al., 1996), 
which involves measurement of uterine weight following exposure to the test 
substances in the absence of endogenous oestrogen. In all investigations to assess 
oestrogenic activity, test substances were compared with the potency of the standard 
E2 (14), since this is the most commonly accepted positive control in both in vitro and 
in vivo assays (Blair et al., 2000; Korem-nan, 1969; Miksicek, 1994). 
The potential interactions (H-bond, electrostatic interactions and van der Waals 
forces) of the compounds citral (citral a (geranial) (70) and b (neral) (71)), eugenol 
(84), geraniol (72), and nerol (75) with the surrounding residues of the ligand binding 
domain (LBD) of the ERa were also investigated, to aid the interpretation of the 
results from the in vitro studies. This was achieved by using molecular graphics with 
the computer program HyperCheMTM. 
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4.1 Methods for Assessment of Oestroacnic Activity Using Reporter Gene 
Assays 
4.1.1 Materials 
Plant material, essential oils and essential oil constituents were obtained as described 
in Chapter 2,2.1.1.1. Microtitre plates were obtained from Linbro, ICN 
Biochemicals, Thame, Oxon, England and sterile flasks were obtained from 
Nunclong, Nunc Brand Products, Denmark. Unless otherwise stated, all other 
chemicals were purchased from Sigma, Fancy Road, Poole, Dorset, England. 
4.1.2 Preparation of Assay Solutions for the Recombinant Yeast Screen 
4.1.2.1 Prevamtion of Minimal Medium 
Minimal medium was composed of 13.61g KH2PO4q 1.98g (NH4)2SO4,4.2g KOH 
pellets, 0.2g MgSO4, Iml FC2(SO4)3 solution (40mg/50ml H20), 50mg L-leucine, 
50mg L-histidine, 50mg adenine, 20mg L-argenine-HCI, 20mg L-methionine, 30mg 
L-tyrosine, 30mg L-isoleucine, 30mg L-lysine-HCI, 25mg L-phenylaianine, 100mg L- 
glutamic acid, 150mg L-valine and 375mg L-serine, added to IL double-distilled 
H20- Ingredients were dissolved on a heated stirrer then sterilised in an autoclave at 
12 1 'C for I Omin and then stored at VC. 
4.1.2.2 Preparation of Glucose Solution 
A 20% w/v solution of D-(+)-glucose was prepared by adding 20g D-(+)-glucose to 
80ml double-distilled H20. The solution was sterilised in an autoclave at 1210C for 
I Omin and then stored at 4'C. 
4.1.2.3 Preparation of L-Aspartic Acid Solution 
A solution of 4mg/mI L-aspartic acid in double-distilled H20 Was sterilised in an 
autoclave at 121'C for 10min and then stored at 4'C. 
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4.1.2.4 Preparation of Vitamin Solution 
8mg thiamine, 8mg pyridoxine, 8mg pantothenic acid, 40mg inositol and 20ml biotin 
solution (2mg/100ml H20) were added to 180ml double-distilled H20. The solution 
was sterilised by filtering through a 2. Opm pore size filter into a sterile glass vessel 
and then stored at 4'C. 
4.1.2.5 Preparation of L-Threonine Solution 
A solution of 24mg/ml L-threonine in double-distilled H20 was sterilised in an 
autoclave at 12 1 'C for I Omin and then stored at 4'C. 
4.1.2.6 Preparation of Copper (11) Sulphate Solution 
A 20mM copper (II) sulphate solution was prepared by adding 160mg CUS04 to 50ml 
double-distilled H20. The solution was sterilised. by filtering through a 2.0jim pore 
size filter into a sterile glass vessel and then stored at 4'C. 
4.1.2.7 Prel2amtion of Chlorophenol Red-o-D-GalactopManoside Solution 
A solution of 10mg/ml CPRG (Bochringer Mannheim, East Sussex, England) in 
double-distilled H20 was sterilised by filtering through a 2.0[tm pore size filter into a 
sterile glass vessel, then stored at 4'C. 
4.1.2.8 Preparation of Culture Medium 
Culture medium was prepared by adding 5ml glucose solution, 1.25ml L-aspartic acid 
solution, 0.5ml vitamin solution, 0.4ml L-threonine solution and 125pl copper (11) 
sulphate solution to 45ml minimal medium. 
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4.1.3 Method to Assess Oestrogenic Activity of Plant Extracts, Essential Oils and 
Oil Constituents Using a Recombinant Yeast Screen 
The assays were carried out in 96-well plates as described by Routledge and Sumpter 
(1996) and were performed in a class 11 laminar air flow cabinet. 120[d concentrated 
yeast stock (a gift from Professor J. Sumpter, Brunel University, England) was added 
to 50ml freshly prepared culture medium with 0.5ml CPRG solution. 20[d aliquots of 
E2 (14) standard solutions diluted in EtOll (0.06nM -I [tM final assay concentration) 
and 20pl aliquots of plant extracts diluted in EtOH were added to wells and the EtOH 
evaporated (solutions of EtOH up to 40% do not denature 0-galactosidase (Shiffin and 
Hunn, 1969)). 20pl aliquots of EtOH were added to wells as a control. 20OVI of the 
yeast suspension in culture medium was added to each well. For volatile essential oils 
and oil constituents diluted in EtOH, 5[d aliquots were added to the sample wells and 
5[il aliquots of EtOH were added to all other wells (including those containing the E2 
(14) standard solutions) after the addition of 200pl yeast suspension to wells. Each 
volatile essential oil and each oil constituent were tested on separate plates to avoid 
cross contamination and false positive results. Plates were sealed and shaken for 
2min on a titre plate shaker and incubated at 321C. After 3 days (and shaking of 
plates for 2min each day), oestrogenic activity was determined from the metabolism 
of CPRG by monitoring the absorbance at 540nin using a MR 5000/7000 microtitre 
plate reader plus Reader Manager Software (Dynatech Laboratories Ltd., West 
Sussex, England). 
4.1.4 Method to Assess Oestrogenic Activity of Essential Oils and Oil 
Constituents Using a Recombinant Yeast Screen, in Scaled Vessels 
Freshly prepared culture medium containing concentrated yeast stock and CPRG was 
prepared as described above (4.1.2.8 and 4.1.3)), and 400pI aliquots were added to 
sterile glass vessels (Iml volume). Dilutions of E2 (14) and test substances 
(previously diluted in EtOH) were prepared by adding 10pi of the stock solution (of 
both E2 (14) and test substances) to 90gl of minimal medium. The assay 
concentration range for E2 (14) was 3. Ox I 0-7PM - 5. OxI 0-3 pM and for test substances, 
0.3tiM - 699.4ýM After shaking, 10ýtl aliquots of diluted E2 (14) and test substances 
were administered to the 400pI yeast suspension and the vessel contents were sealed 
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with the sterile vessel lid. Experiments were also conducted with the vessel lid not 
tightly closed, allowing gaseous exchange with the atmosphere. After shaking the 
vessel contents, samples were incubated at 32'C. After 3 days (and shaking of vessel 
contents each day), oestrogenic activity was determined by pipetting 200[tl aliquots 
into the wells of a 96-well plate, and monitoring the absorbance at 540nm using a MR 
5000/7000 microtitre plate reader plus Reader Manager Software (Dynatech 
Laboratories Ltd., West Sussex, England). 
4.1.5 Method to Assess Metabolism of Compounds by Yeast Using GC-MS 
To determine the extent of metabolism of 4 essential oil constituents (citral, eugenol 
(84), geraniol (72) and nerol (75)) by the yeast cells, each compound was incubated in 
the presence and absence of the oestrogen-responsive yeast, and the results compared 
using GC-MS analysis. Compounds diluted in EtOH (50pl) were added to 2ml 
culture medium containing yeast suspension and CPRG (as described above, 4.1.2.8 
and 4.1.3) in 6-well plates to give the following assay concentrations: citral 445PM, 
eugenol (84) 495pM, geraniol (72) and nerol (75) 439pM. Duplicate plates 
containing test compounds but with culture medium only (no yeast suspension) were 
also prepared as controls. Each oil constituent was tested on separate plates to avoid 
cross contamination and false positive results. I ml aliquots were removed from wells 
at the following time intervals: 0,1,3,24,48,72hr and added to I MI (C2HS)20 (BDH 
Supplies, Poole, England) in a sealed glass vessel. Following vigorous shaking the 
contents were allowed to equilibrate. After I hr, the (C2H5)20 phase from each vessel 
was removed and stored in a sealed glass vessel at 40C. The extracts were analysed 
using GC-MS (refer to Chapter 2,2.1.10.2). 
4.1.6 Method to Assess Anti-Ocstrogenic Activity of Eugenol Using a 
Recombinant Yeast Screen 
Eugenol (84) dilutions (in EtOH) were prepared and supplied to Dr Victoria Pocock, 
Endocrinology and Reproduction Research Group, King's College London, London, 
SEI IUL, who conducted the yeast assay to investigate potential antagonistic activity 
of eugenol (84). 
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Freshly prepared culture medium containing concentrated yeast stock and CPRG was 
prepared as described above (4.1.2.8 and 4.1.3). 20ttl aliquots of E2 (14) solution 
diluted in EtOH (0.78riM final assay concentration) were added to wells (in 96-well 
plates) and the EtOH evaporated. 20ttl aliquots of hydroxytamoxifen (10-8M - 10'5M 
final assay concentration) were administered to wells as a positive control. 200PI of 
the yeast suspension in culture medium was added to each well, then 5ýd aliquots of 
eugenol (84) (76.1pM - 609.0[tM final assay concentration) diluted in EtOH were 
added to the sample wells and 5ýtl aliquots of EtOH were added to all other wells 
(including those wells containing the positive control). Plates were sealed and shaken 
for 2min on a titre plate shaker and incubated at 32'C. After 3 days (and shaking of 
plates for 2min each day), oestrogenic activity was determined from the metabolism 
of CPRG by monitoring the absorbance at 540nm using a MR 5000/7000 microtitre 
plate reader plus Reader Manager Software (Dynatech Laboratories Ltd., West 
Sussex, England). Absorbance readings were also obtained each day for 4 days 
thereafter, to determine the effect of potential eugenol (84) antagonism over time. 
To determine if any apparent antagonistic effect of eugcnol (84) was due to cytotoxic 
effects (as a decrease in absorbance could also be explained by cell death), yeast cells 
were counted in the presence of eugenol (84) at 76.1pM - 609.0jiM, compared to the 
cell count in the presence of E2 (14) only (eugenol (84) absent). Cell counts were 
conducted by diluting I Opl assay suspension from each well with 200PI PBS, after the 
3 day incubation period. Data are presented as the mean of 10 cell counts at each 
concentration. 
4.1.7 Method for Assessment of Oestrogenic Activity in the Ishikawa Cell Assay 
4.1.7.1 Maintenanee and Passaaina of Ishikawa Cells 
Dr Jogen Kalita (Endocrinology and Reproduction Research Group, King's College 
London, London, SEI 1UL) is gratefully acknowledged for assistance with the 
maintenance and passaging of cells. Ishikawa Var-I cells (a gift from Dr E. Gurpide, 
Mount Sinai School of Medicine, New York, USA) were maintained in culture 
medium (1: 1 mixture of phenol red-free F12 HAM and DMEM), containing 1% 
amphotericin B solution, 1% sodium pyruvate (100mM) solution, 1% L-glutamine- 
penicillin-streptomycin solution (composed of 200mM L-glutamine, 10, OOOU 
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penicillin and I Omg/0.9% NaCI streptomycin solution) and 5% foetal bovine serum 
(FBS). Cells were plated at 1.5xl 06 cells/75CM2 surface area in ventilated sterile 
flasks and incubated at 37'C in a humidified atmosphere of 95% air and 5% C02- 
Cells were passaged every 3-4 days by aspirating the culture media then adding 
10ml HBSS (Ca2+ and Mg2+ free) to the flask. After shaking, Iml trypsin/EDTA 
(0.25%) was added to digest protein surrounding the cells. Following incubation at 
37'C for 3min - 5min, the flask contents containing the floating cells were centrifuged 
at 5OOg for 5min. The supernatant was aspirated and the cell pellet resuspended in 
10ml culture media, and aliquots were transferred to sterile ventilated culture flasks 
(1.5xl 06 cclls/75CM2 surface area) with fresh culture media, and incubated at 370C. 
4.1.7.2 Assgy Method 
20pl aliquots of E2 (14) standards (0.02nM - 196. InM), EtOH and test compounds 
were added to 96-well plates in the manner employed in the yeast screen assay (refer 
to 4.1.3), and allowed to evaporate to dryness. 24hr prior to each assay, the culture 
medium was replaced with assay medium (1: 1 mixture of F12 HAM and DMEM), 
absent from endogenous steroids, and containing 1% amphotericin B solution, 1% 
sodium pyruvate (IOOmM) solution, 1% L-glutamine-penicillin-streptomycin solution 
(composed of 200mM L-glutamine, 10, OOOU penicillin and 10mg streptomycin in 
0.9% NaCl solution), 5% charcoal-stripped FBS and 0.6% D-(+)-glucose (45%) 
solution. Cells were then harvested with lml trypsin/EDTA (0.25%) and centrifuged 
(as described above, 4.1.7.1), then resuspended in assay medium. The cell suspension 
was diluted with assay medium to yield a cell density of 2.5 x 104 cells/100pl. 
I 00pl aliquots of cell suspension were then administered to each well. For volatile 
essential oils and oil constituents diluted in EtOH, 21il aliquots were added to the 
sample wells and 2pl aliquots of EtOH were added to all other wells (including those 
wells containing the E2 (14) standard solutions) after the addition of the cells. Each 
volatile essential oil and each oil constituent were tested on separate plates to avoid 
cross contamination and false positive results. The cells were incubated at a 
humidified atmosphere of 5% C02 and 95% air at 37'C for 72hr. 
Following incubation, plates were inverted to remove growth medium, rinsed by 
immersion in phosphate buffered saline (PBS) and blotted dry. Plates were placed in 
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a freezer (-20'C) for 20min to rupture cell membranes then thawed at room 
temperature. 50[tl of 5mM p-NPP was added to each well and the plates incubated at 
3 7'C for I hr. Oestrogenic activity was determined from the hydrolysis of p-NPP to 
p-NP by monitoring the absorbance at 405nm using a MR 5000/7000 microtitre plate 
reader plus Reader Manager Software (Dynatech Laboratories Ltd., West Sussex, 
England). 
4.1.8 Data Analysis of Results Obtained Using the Recombinant Yeast Screen 
and the Ishikawa Cell Line 
Data are presented as the mean (n--3-6 ± SD). Concentration dependent data were 
analysed using one-way ANOVA to determine the significance of the difference. 
Significance was regarded as p<0.05. 
4.2 Methods for Oestrogen Receptor Binding Assavs 
4.2.1 Materials for Receptor Binding Assays 
Essential oil constituents were obtained as described in Chapter 2,2.1.1.1. Microtitre 
plates were obtained from Linbro, ICN Biochemicals, Thame, Oxon, England, [2,4, 
6,7_3 H]-17p-oestradiol (84. OCi. mmol-1) was obtained from Amersharn Life Science, 
Amersham, England and Optiphase Safe scintillation fluid was obtained from Wallac 
Scintillation Products and manufactured by Fisons Chemicals, Loughborough, 
Leicester, England. Unless otherwise stated, all other chemicals were purchased from 
Sigma, Fancy Road, Poole, Dorset, England. 
4.2.2 Method for Ishikawa Cell Oestrogen Receptor Binding Assay 
Ishikawa. Var-I cells were maintained and passaged as described previously (4.1.7.1). 
Cells were seeded in 6-well plates at a density of 100,000 cells per well in culture 
medium and incubated at 37*C for 72hr, until cells were confluent. The culture 
medium was aspirated off and replaced with 2ml assay medium per well, to permit 
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uniform distribution of compounds in each well. 20pl aliquots of the test compounds 
(0.6mM - 5.9mM) and E2 (14) (1. OXIO-6MM _ I. OXIO-3MM) , diluted in EtOH, and 
20ptl EtOH alone as a control, were administered to wells. Each oil constituent was 
tested on a separate plate to avoid cross contamination and false positive results. 
20[d aliquots of [2,4,6,7_3 H]-170-oestradiol (15nM) diluted in assay medium were 
added to all wells, and plates were sealed and shaken for 2min on a titre plate shaker 
and incubated at 371C for lhr; plates were shaken at 20min intervals. The medium 
was aspirated off, and the plates were washed with 3 successive administrations of 
2ml PBS to remove unbound ligand. 1.5ml EtOH was added to each well and plates 
were incubated at 25'C for 20min, to extract the ER-complexes. Iml aliquots from 
each well were administered to scintillation vials with 4ml scintillation fluid. 20PI 
aliquots of [2,4,6,7_3 H]-170-oestradiol diluted in assay medium were also vortex 
mixed with 1.5ml EtOH, and Iml removed and added to 4ml scintillation fluid to 
obtain the total count. Vials were stoppered and vortex mixed prior to quantitation of 
the radioactivity, by recording CPM (10min for each measurement) using a 
scintillation counter (LS 60001C, Beckman, UK). 
4.2.3 Method for a- and P-Ocstrogen Receptor Binding Assays 
The potential oestrogen receptor binding activity of citral, geraniol (75), nerol (75) 
and eugenol (84) was studied using recombinant hERa and hERP obtained from 
PanVera Corporation, Madison, USA, as described by Milligan et aL (2000). Test 
compounds or E2 (14) standard solutions were prepared in EtOH. Assay solutions 
were prepared as described in Table 4.1 and stored at 4'C. 20PI aliquots of the E2 
(14) standards (0.18nM - 595.2nM final assay concentration) were administered to 
1.5ml eppendorf tubes, and the EtOH was allowed to evaporate. Assay eppendorf 
tubes were placed on ice at 4'C for 30min prior to the addition of hot mix, ER 
solution and test compounds (20 I. OgM - 115930.1 pM), as described in Table 4.2. 
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Table 4.1. Solutions for ERa and ERP binding assays. 
Solution Composition and Preparation 
Binding buffer I OmM Trizma preset crystals (pH 7.5), 10% glycerol, 2mM DDT 
and I mg/ml BSA in distilled H20 
ER solution ERa or ERP diluted in binding buffer (1: 100) 
ERa wash buffer 40mM Trizma preset crystals (pH 7.5), 1 OOmM KCI, I mM EDTA 
and I mM EGTA in distilled H20 
ERP wash buffer 40mM Trizma preset crystals (pH 7.5) in distilled H20 
Hydroxylapatite lOg HAP (Aldrich Chemical Company, New Road, Dorset, UK) 
(HAP) slurry added to 100ml Tris-EDTA, stirred and allowed to settle for 
10min before the supernatant was aspirated off. This was 
repeated at least 6 times before allowing to equilibriate overnight 
at 4'C 
Hot mix l5nM [2,4,6 , 7_3 H]-170-oestradiol 
diluted in binding buffer. 
Tris-EDTA 50mM Trizma preset crystals (pH 7.5) and ImM EDTA in! L 
distilled H20 
















E2 100 10 0 20* 2** 
Test compound 100 10 0 2** 0 
Contro IC 1) 100 0 10 - 2** 
Control 2 (C2) 100 0 10 2** 0 
* 20gl E2 solution added and EtOH evaporated before addition of other assay 
solutions. 
** 2pl added after addition of all other assay solutions (i. e. added after hot mix, ER 
solution and binding buffer). 
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ER solutions were freshly prepared prior to each assay, and ERa and ERP binding 
was assessed in different assays. Controls for each assay were conducted to 
determine the effect of the assay solutions (Cl) and the effect of the test substances at 
all concentrations (C2), in the absence of the ER (Table 4.2). After vortex mixing, the 
assay tubes were incubated at 4"C overnight. 
Following incubation, the free and bound ligand was separated. 100pl HAP slurry 
was added to all tubes, which were vortex mixed three times over a 15min incubation 
period, while on ice. Subsequently, Iml wash buffer (ERa or ERO wash buffer, 
depending on the ER used) was added to each tube; tubes were vortex mixed, 
centrifuged (2000g) for 15min and the supernatant discarded. After two further 
washes, the HAP pellet was extracted with two washes of 200pl EtOH, which were 
added to 4ml scintillation fluid in scintillation vials. The vials were stoppered and 
vortex mixed, and the radioactivity determined by recording CPM (10min for each 
measurement) using a O-scintillation counter (LS 60001C, Beckman, UK). 
4.2.4 Data Analysis of Results Obtained from the Receptor Binding Assays 
Non-specific binding (Bnsb) was regarded as the binding of [3 H]-170-oestradiol in the 
presence of the maximum concentration of unlabelled E2 (14) (1 OAM for the Ishikawa 
cell receptor binding assays; 595.2nM for the ERa and ERP assays). This value was 
subtracted from the total amount of radioactivity bound in the presence of the test 
compound (Btotal) to determine the amount of test compound bound. This was 
expressed as a percentage of the maximum radioactivity bound in the absence of the 
test compound (B .... . ), and the percentage inhibition of [3 H]- I 70-oestradiol bound was 
calculated: 






Data are presented as the mean (n--3-6 ± SD) and were analysed using one-way 
ANOVA to detennine the significance of the difference. Significance was regarded 
as p<0.05. 
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4.3 Methods for in vivo Assessment of Oestrogenic Activitv 
4.3.1 Materials for in vivo Assays 
Essential oil constituents were obtained as described in Chapter 2,2.1.1.1. Unless 
otherwise stated, all other chemicals were purchased from Sigma, Fancy Road, Poole, 
Dorset, England. 
4.3.2 In vivo Assay Methods 
In vivo investigations were conducted by Dr Stuart Milligan, Endocrinology and 
Reproduction Research Group, King's College London, London, SE II UL. 
Female Swiss albino mice (A. Tuck & Son Ltd., Battlesbridge, Essex, England) 
approximately 3 months of age and weighing 25g - 35g were maintained under constant 
conditions of lighting (lights on from 06: 00hr to 18: 00hr) and temperature (21 ± PQ 
and fed on a pelleted dict (Economy Rodent Maintenance, Essex, UK) ad libitum. All 
experiments were performed on ovariectornised animals. Ovariectornies were 
performed under tribromoethanol anaesthesia at least two weeks before the start of 
each experiment. All test compounds were administered transdermally, by applying 
50pl - 1001il alcoholic solutions to the shaved backs of mice. 
4.3.2.1 Acute Ass 
In the acute assay of vascular responses, lOOpI of alcoholic solutions of citral (1.9M), 
geraniol (72) (1.9M) and E2 (14) (0.3mM) or EtOH alone were administered 
transdermally. A quantitative index of the permeability of the uterine vasculature 4hr 
after subcutaneous (s. c. ) injection of the test compound was obtained from the leakage 
of radiolabelled albumin from the circulation 3.5hr after the application of the test 
substance. 50[d of 0.5gCi [1251]-labelled human serum albumin was injected into the 
jugular vein of mice anaesthetised with tribromoethanol; 30min later a blood sample 
was drawn from the suborbital canthal sinus with a heparinised capillary pipette and 
the animals killed by cervical dislocation. The blood sample was centrifuged to 
provide a 100ýtl plasma sample. The uteri and sample of thigh muscle were removed, 
briefly washed in saline and weighed. The radioactivity in the uterus, plasma sample 
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and muscle was determined. Previous studies on the uterus have indicated that the 
blood volume of the uterus is very much smaller than the albumin space (after a 
circulation time of 30min) and that the extravascular albumin space is the major 
determinant of the total tissue albumin space (Arvidson, 1977; Milligan and Mirembe, 
1985). The tissue specific extravascular albumin volume (EAV) was expressed as 
100 x ratio of the [1251] cpm/mg of tissue to [1251] cpm/til plasma and used as an index 
of tissue vascular permeability. 
4.3.2.2 Uterotrophic Ass 
50gl of alcoholic solutions of citral (1.9M), geraniol (72) (1.9M) and E2 (14) 
(0.3mM) or EtOH alone were administered transdermally twice daily for 3 days. 12hr 
after the last administration the animals were killed, the uterine horns removed, 
blotted and weighed. 
4.3.3 Analysis of Data Obtained from in vivo Investigations 
Data are presented as the mean (n=5 ± SEM) and were analysed using one-way 
ANOVA to determine the significance of the difference between the response 
following application of EtOH (control) and the response following the application of 
the test compound. Significance was regarded asp<0.05. 
4.4 Method for Structure-Activity Assessment Using Molecular Graphics: 
Potential Interactions of Citral, Eugenol, Geraniol and Nerol with the oc- 
Oestrogcn Reccpto 
Assessment of the structure-activity relationship between ERct and receptor ligands 
(geranial (citral a) (70), neral (citral b) (71), eugenol (84), geraniol (72) and nerol 
(75)) was conducted using the computer program HyperCheMTNI (Autodesk Inc., 
Sausalito, California, USA). 
Torsion angles (TOR) on the molecule under investigation were selected (Figure 4.2) 
prior to a conformational search performed for identification of low energy 
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conformations. This method involves random variation of dihedral angles to generate 
new structures and subsequent energy minimising of each structure. Low energy 
conformations are used for further investigation, while high energy or duplicate 
structures are discarded. Random variation of acyclic bond dihedral angles uses 
rotation and for dihedral angles in a ring, angles are rotated by a motion of torsional 















Figure 4.2. Torsion angles (TOR) on the molecules geranial (citral a), neral (citral b), 
geraniol, nerol and eugenol, selected prior to a conformational search to identify low 
energy confonnations. 1: TOR 1,2: TOR 2,3: TOR 3,4: TOR 4. 
The search results generated gave the energy and torsion angles for each conformation 
of the molecule. Following inspection of the data, similar conformations of the 
molecule were grouped together (refer to 4.11, Tables 4.9 - 4.13). The conformation 
Neral (citral b) 
of lowest energy representative of each group was selected for further investigation. 
The conformers selected were compared with the structure of the known ER ligands 
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E2 (14) or raloxifene (RAL) (95), and one conformation of each molecule was 
selected. The selected conformation of each molecule was assessed for the ability to 
interact with the LBD of the ERa. This was achieved by manually introducing the 
molecule into the LBD of the ERa in such a way that it occupied a position similar to 
the bound ligands E2 (14) or RAL (95). For proposed ER agonist molecules (citral a 
(70), citral b (71), geraniol (72) and nerol (75)) the ERa structure in the presence of 
E2 (14) was selected for structure-activity investigations, and for the proposed ER 
antagonist molecule (eugenol (84)) the ERa structure in the presence of RAL (95) was 
selected. 
Once the molecule being assessed was positioned in the LBD, then it's position and 
conformation were further adjusted, by refinement of the potential energy of the 
system. This was achieved by conducting a molecular mechanics optimisation using 
an MM+ force field and a conjugate gradient least squares refinement (Polak Ribiere) 
with termination criteria of 4000 maximum cycles or a potential energy gradient of 
0.01kcal/[A mol]. This process lowers the energy of the molecular system by 
adjusting its geometry, and therefore accounts for the position of the 
agonist/antagonist molecule within the LBD. The final torsion angles of each 
molecule positioned within the LBD were determined (Table 4.14). 
An assessment was then made of the potential interactions (H-bond, electrostatic 
interactions and van der Waals forces) between the ligand and surrounding residues of 
LBD. 
Once completed, the model complex was assessed using the computer program 
WebLab ViewerLite (MSI Inc., USA). The atomic van der Waals surfaces of the 
molecular system were displayed to check for steric complementarity. These 
investigations were also employed to demonstrate the interaction of E2 (14) and RAL 
(95) with ERa. 
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4.5 Results and Discussion: Assessment of Oestrollenic Activitv of Plant Extracts 
4.5.1 Assessment of Oestrogenic Activity of Plant Extracts, Using a Recombinant 
Yeast Screen 
Aqueous and ethanolic extracts of each of the selected plants (Alisina orientalis root, 
Apocynum lancifolium leaf, Centella asiatica leaf, Codonopsis pilillosa root, 
Convallaria majalis leaf, Gentiana spp. root (adulterated Polygonum multiflorum 
root), Melissa officinalis leaf, Polygala tenuifolia root, Rosmarinus officinalis leaf 
(fresh and dried leaf), Salvia niiltiorrhiza root, Withania soinnifera root, Dziphils 
jujuba seed and fruit, and Ziziphus jujuba var. spinosa seed) were assessed for 
oestrogenic activity over the concentration range 0.4g. L-1 - 3.5g. L-1, using the 
recombinant yeast screen. 
Of the ethanolic and aqueous extracts of the plants screened, only the ethanolic extract 
of Polygala tenuffiblia root demonstrated significant dose-dependent oestrogenic 
activity (p<0.05), EC5o: 1.3g. L-1 (Figure 4.3). All other extracts gave negative results. 
This suggests that oestrogenic compounds were absent in all other extracts, or may be 
present but were metabolised to inactive compounds, or may require metabolism by 
mammalian cells to give oestrogenic compounds. It is reported that some compounds 
that were oestrogenic in vivo (using a uterotrophic assay) were not oestrogenic in the 
yeast assay (Odum et al., 1997), which perhaps reflects metabolic deficiencies in the 
yeast cells. It is also possible that the apparently inactive extracts may bind to the ER 
antagonistically. Further investigations are necessary, perhaps including antagonism 
of E2 (14) in the yeast assay or receptor binding studies, to identify potential 
antagonistic activity of the plant extracts. 
Polygala lenuffolia root EtOH extract was considerably less potent than the positive 
control, E2 (14). The oestrogenic activity of the root extract may be due to 
constituents acting synergistically, but it cannot be excluded that a minor component 
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Figure 4.3. Oestrogenic activity of Polygala tenuffiblia root ethanolic extract 
(p<0.05) and 17p-oestradiol (p<0.001), assessed by stimulation of P-galactosidase 
activity in genetically modified yeast cells (n=3-6 ± SD). 
Polygala tenuffiblia root has not previously been investigated for potential oestrogenic 
activity. As the aqueous extract of Polygala tenuffiblia root did not demonstrate 
oestrogenic activity, it is apparent that the compounds responsible for oestrogenic 
activity were not highly polar. Polygala tenuffiblia root is reported to contain 
oligosaccharides (e. g. tenuifolioses A- P), triterpene saponins (e. g. tenuifolin (67) and 
onjisaponins A- G) and xanthones (e. g. onjixanthones I and 11) (Chang and But, 
1986; Fujita et al., 1992; Ikeya et al., 1991 a; Ikeya et al., 1994; Miyase et al., 1992; 
Sakuma and Shoji, 198 1 a; Sakuma and Shoji, 198 1 b; Tang and Eisenbrand, 1992). 
The root is not known to contain constituents typically associated with oestrogenic 
activity, for example some isoflavones, cournestans and lignans, but that is not to say 
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Xanthones are chemically related to flavonoids. It may therefore be possible that 
unidentified xanthones or related flavonoid compounds in the root extract contributed 
to the observed oestrogenic effects. The presence of steroidal saponins may also 
explain oestrogenic activity. Fractionation and isolation of compounds present in the 
EtOH extract is necessary to identify if typical or atypical phyto-oestrogens were 
responsible for the apparent oestrogenic activity but was not carried out in view of the 
weak activity, and because of priority given to other aspects of work reported in this 
thesis. 
4.5.2 Assessment of Oestrogenic Activity of the Ethanolie Extract of Polygala 
lenitifolia Root, Using the Ishikawa. Cell Line 
To investigate the oestrogenic activity of Polygala tenuifolia root in mammalian cells, 
the EtOH extract was also investigated using the Ishikawa cell line. The extract 
showed significant dose-dependent oestrogenic activity (p<0.05) over the 
concentration range 27.3mgL" - 681.7mgL-1, EC50: 98.5mg. L-1 (Figure 4.4). As in 
the yeast screen, the crude EtOH extract was not as potent as E2 (14). 
Phyto-oestrogens have consistently been reported to be less potent than the 
endogenous oestrogen E2 (14) (Coldham, et al., 1997; Collins el al., 1997; 
Markiewicz et al., 1993; Milligan et al., 1998; Milligan et aL, 1999; Murkies el al., 
1998), but that is not to say that phyto-oestrogens more potent than E2 (14) are absent 
from natural sources. To identify the potency, and perhaps synergy, of the potential 
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oestrogenic compounds in P. tenuffolia root, their isolation and evaluation in various 
assay systems to assess oestrogenic activity is required. 
The Ishikawa cell line is reported to contain predominantly ERP and the yeast cell line 
is reported to contain predominantly ERa (Dechering et al., 2000). The oestrogenic 
potency of P. tenuffiblia root appeared to be greater in the Ishikawa cells (EC50: 
98.5mg. L-1) than in the yeast cells (EC50: 1.3g. L-1, refer to 4.5.1), which leads to the 
suggestion that the root extract may have greater affinity for ERP than ERa. Phyto- 
oestrogens are reported to have greater affinity for ERP, which predominate in the 
prostate, bone and vascular tissue, whereas ERa predominates in the breast, uterus 
and ovary (Dechering et al., 2000; Kuiper et al., 1997; Mason, 2001). This suggests 
P. tenuffiblia root extract may promote beneficial effects (e. g. in bone) but may not 
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Figure 4.4. Oestrogenic activity of Polygala tenuifolia root ethanolic extract 
(p<0.05) and 17p-oestradiol (p<0.001), assessed by stimulation of alkaline 
phosphatase activity in Ishikawa cells (n=3-6 ± SD). 
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The localisation of ERO in the neocortex, hippocampus and nucei of the basal 
forebrain (areas which were negative for ERa expression) indicates that ERO may be 
responsible for mediating the beneficial effect of oestrogens on learning and memory 
(Fillit, 1994; Shughrue et al., 1997; Wickelgren, 1997). Therefore, P. tenilifolia root 
extract may contain compounds that are selective for ERP, with potential for 
beneficial effects on cognition and may also be important in the prevention of AD. 
P. tenuifolia root EtOH extract was reported to strengthen the contractions and 
increase uterine muscle tone in pregnant and non-pregnant animals (Chang and But, 
1986). ERP has been located in the paraventricular and supraoptic nuclei, where ERP 
has been suggested to regulate the expression of oxytocin, a hon-none that stimulates 
uterine contraction (Alves et al., 1998; Hrabovszky et al., 1998). It may be feasible 
that the uterine contraction stimulated by P. tenuffiblia root EtOH extract, reported by 
Chang and But (1986), may be explained by the root extract interacting with ERP in 
the paraventricular and supraoptic nuclei, thus initiating oxytocin induced uterine 
contraction. Further investigations would be required to establish this. 
4.6 Results and Discussion: Assessment of Oestrogenic ActivitV of Essential Oils 
4.6.1 Assessment of Oestrogenic Activity of Melissa officinalis and Rosmarinus 
officinalis Essential Oils, Using a Recombinant Yeast Screen 
Melissa officinalis essential oil demonstrated significant oestrogenic activity over the 
concentration range O. Img. L-1 - 124.4mg. L-1 (p<0.01), EC50: 49.4mg. L-1, but was 
cytotoxic at concentrations 622.0 mg. L-1 - 1243.9mg. L-1 (Figure 4.5). Rosmarinus 
0 inalis essential oil did not demonstrate oestrogenic activity over this 0, C 
concentration range, nor was it cytotoxic (p>0.05) (Figure 4.5). 
M. officinalis essential oil has not previously been reported to have potential 
oestrogenic effects. The major components of M. officinalis essential oil are 
monoterpenes (e. g. geranial (70)), but other components include sesquiterpenes (e. g. 
nerolidol (83)) and phenylpropanoids (e. g. eugenol (84)) (refer to Chapter 2,2.2.7.1). 
The major components of the M officinalis essential oil tested were citral (geranial 
(70) and neral (71)) and trans-caryophyllene (82), which comprised 39.6% of the total 
oil composition (refer to Chapter 2,2.2.7.1). R. officinalis essential oil is reported to 
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contain 1,8-cineole (56) (15-30%), camphor (57) (15-25%), a-pinene (53) (up to 
25%) and other monoterpenes (e. g. borneol (58), bomyl acetate (51)) as the major 
constituents (Bisset, 1994; Trease and Evans, 1996). 1,8-Cineole (56), camphor (57) 
bomeol (58) and bornyl acetate (51) were not detected in the M officinalis essential 
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Figure 4.5. Oestrogenic activity of Melissa officinalis (p<0.01) and Rosmarinus 
officinalis (p>0.05) essential oils and 170-oestradiol (p<0.001), assessed by 
stimulation of 0-galactosidase activity in genetically modified yeast cells (n=3-6 
SD). 
The difference in composition between M. officinalis essential oil (which contains 
geranial (70), neral (71) and trans-caryophyllene (82) as the major components (refer 
to Chapter 2,2.2.7.1)) and R. officinalis essential oil (which does not contain geranial 
(70), neral (71) and trans-caryophyllene (82) as major components (Bisset, 1994; 
Trease and Evans, 1996)), may explain the difference in the observed oestrogenic 
potencies of these oils. Further investigations were conducted to identify which 
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essential oil constituents may have been responsible for the oestrogenic activity of M 
offiCinalis essential oil (refer to 4.7). 
4.6.2 Assessment of Oestrogenic Activity of Melissa offlicinalis Phytol Extract and 
Phytol (Crude Extract), Using a Recombinant Yeast Screen 
M. officinalis phytol extract (p<0.01) and phytol crude extract (P<0.01) also 
demonstrated significant oestrogenic activity in the yeast screen, over the 
concentration range 0.59mg. L-1 - 243.9mg. L-' (Figure 4.6). 
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Figure 4.6. Oestrogenic activity of Melissa officinalis phytol extract (p<0.01), 
Melissa officinalis phytol crude extract (p<0.01) and 170-oestradiol (p<0.001), 
assessed by stimulation of P-galactosidase activity in genetically modified yeast cells 
(n=3-6 ± SD). 
M. officinalis phytol crude extract (EC50: 85.8mg. L-1) was more potent than M. 
officinalis phytol extract (EC50: 138.5mg. L-1). Neither the phytol extract nor the 
phytol crude extract were as potent as E2 (14), and both were less active than the M 
officinalis essential oil (EC50: 49.4mg. L- 1) (refer to 4.6.1). 
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The differences observed in oestrogenic potency between the M officinalis essential 
oil, the phytol extract and the phytol crude extract may be explained by the 
differences in composition, as a result of the different extraction processes for each 
(refer to Chapter 2,2.2.7.1). The phytols may also contain non-volatile compounds 
which may have been inactive or only weakly oestrogenic, which perhaps explains 
their weaker activity compared to the M officinalis essential oil. 
To explain the apparent activity of M officinalis essential oil in the yeast screen, M 
officinalis essential oil and some of the constituents identified in this oil (refer to 
Chapter 2,2.2.7.1) were further investigated in other assays to gain further 
information regarding potential oestrogenic activity (refer to 4.6.3,4.7,4.8 and 4.9). 
4.6.3 Assessment of Oestrogenic Activity of Melissa officinalis Essential Oil, 
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Figure 4.7. Oestrogenic activity of Melissa officinalis essential oil (p>0.05) and 17p- 
oestradiol (p<0.001), assessed by stimulation of alkaline phosphatase activity in 
Ishikawa cells (n=3-6 ± SD). 
-I 7P-Oestradiol 
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M. officinalis essential oil did not show significant oestrogenic activity in the 
mammalian Ishikawa. cell line over the concentration range O. Img. L"l - 993.3mg. L-1 
(p>0.05) and was cytotoxic at concentrations ý: 496.7mg. L-1 (Figure 4.7). 
Although these results indicate that M. officinalis essential oil is not oestrogenic in the 
mammalian Ishikawa cells, other occurrences may explain the apparent inactivity. 
The essential oil constituents may interact with additional proteins, including enzymes 
in mammalian cells (which may be absent in the yeast cells), which may lower the 
concentration of an oestrogenic compound in the assay. The mammalian cells may 
have a different metabolic activity from the yeast cells, so may have metabolised 
compounds rendering them inactive, or an oestrogenic response may have occurred at 
the cytotoxic concentration, indicating inactivity. 
4.7 Results and Discussion: Assessment of Oestrogenic Activity of Essential Oil 
Constituents 
4.7.1 Assessment of Oestrogenic Activity of Some Monoterpenes Identified in 
Melissa offildnalis Essential Oil, Using a Recombinant Yeast Screen 
Some of the monoterpene constituents identified in M. qjFicinalis essential oil ($arer 
and K6kdil, 199 1; Tittel et aL, 1982, and refer to Chapter 2,2.2.7.1) were investigated 
for oestrogenic activity using the recombinant yeast screen, to identify which 
compounds may have been responsible for the observed oestrogenic activity of M 
olfficinalis essential oil and phytol extracts. 
This study suggests that some monoterpenes show evidence of weak oestrogenic 
activity. Of the monoterpenes tested, citral (p<0.001), citronellol (69) (p<0.001), 
geraniol (72) (p<0.001) and nerol (75) (p<0.001) showed significant oestrogenic 
activity in the yeast screen (Figures 4.8 and 4.9). These monoterpenes were identified 
in M officinalis essential oil (refer to Chapter 2,2.2.7.1) but are not reported to be 
major components in R. officinalis essential oil. Some of the major monoterpenes 
reported to occur in R. o ihalis essential oil, 1,8-cineole (56) (p>0.05) and camphor Iff, C 
(57) (p>0.05) (Bisset, 1994; Trease and Evans, 1996), were not significantly 
oestrogenic (Figures 4.8 and 4.9). These results offer some explanation why the M. 
L 
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officinalis essential oil demonstrated oestrogenic activity in the yeast screen and the 
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Figure 4.8. Oestrogenic activity of monoterpenes, camphor (p>0.05), 1,8-cineole 
(p>0.05), citral (p<0.001), citronellal (p>0.05) and citronellol (p<0.001), and 17p- 
oestradiol (p<0.001), assessed by stimulation of P-galactosidase activity in genetically 
modified yeast cells (n--3-6 ± SD). 
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Figure 4.9. Oestrogenic activity of monoterpenes, geraniol (p<0.001), (+)-limonene 
(p>0.05), (±)-linalool (p>0.05), nerol (p<0.001) and ocimene (p>0.05), and 17p- 
oestradiol (p<0.001), assessed by stimulation of 0-galactosidase activity in genetically 






















Three monoterpenes, which demonstrated significant oestrogenic activity in 
preliminary studies (Figures 4.8 and 4.9), citral, geraniol (72) and nerol (75), were 
also assessed for oestrogenic activity using the recombinant yeast screen over the 
concentration range 1.652gM - 3.429xl 03PM. Citral (p<0.001), geraniol (72) 
(p<0.001) and nerol (75) (p<0.001) showed significant oestrogenic activity, although 
citral and geraniol (72) displayed cytotoxicity at concentration 3.4xI 03 [LM (Figure 
4.10). The oestrogenic potencies (EC50 values) of E2 (14), citral, geraniol (72) and 
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Figure 4.10. Oestrogenic activity of monoterpenes, citral (p<0.001), geraniol 
(p<0.001) and nerol (p<0.001), and 170-oestradiol (p<0.001), assessed by stimulation 
of P-galactosidase activity in genetically modified yeast cells (n=3-6 ± SD). 
The volatility of the these monoterpenes also resulted in oestrogenic responses being 
detected in the assay wells surrounding the test wells (which contained seeded assay 
medium alone), presumably reflecting the re-solution of the volatile compounds. This 
response decreased with increasing distance from the wells containing the 
monoterpene. For example, geraniol (72) treated wells (wells 6A, 6F, 8A, 8H, 1013, 
IOF, 12C and 12H) in a 96-well plate resulted in transfer of geraniol to the 
surrounding wells (Figure 4.11). A similar occurrence has been described for some 
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alkylphenols and some polychlorinated biphenyl (PCB) compounds, an effect which 
is described as "creeping" (Beresford et al., 2000). 
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Figure 4.11. A 96-well plate containing a culture of genetically modified yeast cells 
treated with 170-oestradiol (wells IE- 4D) and geraniol (wells 6A, 6F, 8A, 8H, I OB, 
I OF, 12C and 12H). 
The volatility of the monoterpenes citral, geraniol (72) and nerol (75) resulted in the 
loss of the compounds from the test wells and makes any interpretation of dose- 
response relationships very difficult. Therefore the final assay concentration may 
have been lower than the initial assay concentration, consequently the EC50 values 
may not reflect the oestrogenic potency of each compound, which may be more potent 
than indicated. This is additionally complicated by the metabolism of the compounds 
to other products (refer to 4.7.2 and Tables 4.3 - 4.5), perhaps with less oestrogenic 
activity. This may also have decreased the assay concentration of each monoterpene. 
Other considerations when interpreting the results are the presence of impurities in the 
assay. Impurities have been shown to give false positive results indicating 
oestrogenic activity (Harris et al., 1997). The percentage purities of the compounds 
citral, eugenol (84) geraniol (70) and nerol (75) were found to be >98%, >99%, >98% 
and 95% respectively, using GC-MS analysis (refer to Chapter 2,2.2.7.2). Minor 
impurities were identified in some of these essential oil constituents including 
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alkanes, and in the nerol (75) sample analysed, geranial (70), geraniol (72) and neral 
(71) were also detected, and in the geraniol (72) sample analysed, geranial (70), neral 
(71) and nerol (75) were also detected (refer to Chapter 2,2.2.7.2). Therefore the 
contribution of these impurities in the assay must also be considered, but their low 
concentrations indicate they are unlikely to have contributed significantly to the 
effects observed in the bioassays. 
The precise structural requirements for oestrogenic activity are complex and are not 
yet fully understood. However it is generally accepted that a cyclic component (often 
phenolic) may be a structural requirement, as is a substituent (C3 hydroxyl for E2 
(14)) acting primarily as a hydrogen bond donor in the LBD of hER (Blair et aL, 
2000; Dodge, 1998). Therefore, the acyclic monoterpenes (citral a (geranial) (70), 
citral b (neral) (71), citronellol (69), geraniol (72) and nerol (75)) are novel as 
potential hER ligands. Citral, citronellol (69), geraniol (72) and nerol (75) have 
aldehyde or hydroxyl substituents that may interact with the hER (refer to 4.11 for 
further analysis). The monoterpenes that were not significantly oestrogenic may have 
lacked the structural features required for hER binding. For example, limonene (73) 
and ocimene (76) are hydrocarbons, which lack substituents perhaps required to act as 
a hydrogen bond donor in the LBD of hER. 
It must also be considered that, although some monoterpenes did not demonstrate 
significant oestrogenic activity in the yeast screen, it cannot be concluded that such 
compounds had no affinity for the hER. A hER antagonist may have bound to the 
hER in the yeast screen, but would not have initiated the oestrogenic response 
resulting in an increase in P-galactosidase activity. Further investigations are required 
including ER binding studies, to identify which of the monoterpenes are ligands for 
the hER and are perhaps hER antagonists. 
4.7.1.1 Assessment of Oestropenic Activi1y of Geraniol in a Sealed Environment, 
Using a Recombinant Yeast Screen 
Geraniol (72) (2.7ýLM - 690.3ýtM) was assessed for oestrogenic activity using the 
recombinant yeast screen, in sealed glass vessels (with lids tightly closed) and 
compared with E2 (14) (1.2xl 0-7ýtM - 5. OxIO-3ýM). However, yeast cell death 
occurred at all concentrations in the absence and in the presence of both compounds. 
242 
This indicates that cell death was independent of the presence of other compounds 






Figure 4.12. Oestrogenic activity of geraniol (p<0.001) and 17p-oestradiol 
(p<0.001), assessed by stimulation of P-galactosidase activity in genetically modified 
yeast cells, in a restricted envirom-nent (n=3-6 ± SD). 
To investigate this, the assay was repeated in the sealed glass vessels but with the lids 
not closed tightly, allowing gaseous exchange with the atmosphere. Yeast cell death 
did not occur, and an oestrogenic response was observed with E2 (14) (p<0.001) and 
with geraniol (72) (p<0.001) (Figure 4.12). These results indicate that the optimum 
gaseous supply to the yeast cells also permits loss of volatile compounds (e. g. 
geraniol (72)) from the culture medium, which makes interpretation of dose- 
dependent relationships difficult. 
4.7.2 Assessment of the Metabolism of Citral, Geraniol and Nerol, in a 
Recombinant Yeast Screen 
The products of metabolism following treatment of the yeast culture with the essential 
oil constituents was determined over 72hr to investigate the role of metabolism in 
biological activity; analysis was by GC-MS (for method, refer to Chapter 2,2.1.10.2). 
10-7 10-6 10-1 10.4 10-1 10-2 10-1 100 10,102 10, 
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Citral (geranial (70) and neral (71)) concentration decreased with time in the presence 
of yeast, and was not detected after 48hr (Table 4.3). 
Table 4.3. Assessment of metabolism of citral (geranial and neral) by yeast. 
Compounds detected in the presence and absence (x) of yeast. Peak area determined 
by ITD. 
Peak Area for Compound Detected 
Time Citronelloi Geranial Geraniol Neral Nerol Phenylethyl 
(h) Aleohol 
0 0 1.55 0 1.70 0 0 
(0) (2.35) (0) (2.35) (0 (0) 
1 0 1.25 0.02 1.65 0 0 
1 (0) (2.10) (0) (2.1) (0) 1 (0) 
3 0.04 0.65 0.08 0.80 0.04 1 0.03 
(0) (2.05) (0) (2.05) (0) (0) 
24 0.35 0.04 1.45 0.25 0.30 0.10 
(0) (1.10) (0) (1.10) (0) (0) 
48 0.30 0 0.75 0 0.30 0.95 
(0) (0.30) (0) (0.30) (0) (0) 
72 0.55 0 0.2 0 0.55 4.85 
(0) (0.07) (0) (0.07) (0) (0) 
Citral (geranial (70) and neral (71)) concentration also decreased over time in the 
absence of yeast, however both geranial (70) and neral (71) were detected at 48hr and 
78hr (Table 4.3). 
As citral concentration decreased with time in the absence of yeast, it suggests that the 
volatility of citral contributed to its decrease in concentration with increasing time. 
As citral was not detected after 48hr in the presence of yeast, it indicates that the yeast 
metabolised citral. The compounds citronellol (69), geraniol (72), nerol (75) and 
phenylethyl alcohol were detected in the presence of yeast, but not in the absence of 
yeast (Table 4.3), indicating these compounds are the products of metabolism. These 
results are consistent with research conducted by Chattejee et al. (1999), who 
determined that citral is converted to geraniol (72) by yeast (Saccharomyces 
cerevisae). Saccharomyces cerevisae has also been used for the reduction of 
monoterpene aldehydes, such as the biotransformation of citronellal (68) to citronellol 
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(69), and for the reduction of other carbonyl compounds (Nielsen and Madsen, 1994; 
Poppe et al., 1991; Young and Ward, 1991). 
Citronellol (69), nerol (75) and phenylethyl alcohol concentrations increased with 
time, which may be explained by the metabolism of citral with time. Geraniol (72) 
concentration increased up to 24hr, then decreased after 48hr (Table 4.3). This may 
be explained by the loss of geraniol (72) per well, due to its volatility or due to 
conversion to other metabolic products, such as citronellol (69). Citronellol (69) was 
detected as a metabolic product of geraniol (72) (Table 4.4). The conversion of citral 
to citronellol (69), geraniol (72) and nerol (75) may have contributed to the 
oestrogenic effects of citral. observed in the yeast assay, as these compounds also 
demonstrated oestrogenic activity (Figures 4.8. and 4.9). 
The potential oestrogenic activity of phenylethyl alcohol in the yeast assay requires 
further investigation. However, as the only metabolic product detected in the yeast 
culture treated with eugenol (84) was phenylethyl alcohol (Table 4.8) and eugenol 
(84) (including its metabolic products) did not demonstrate oestrogenic activity in the 
yeast assay (Figure 4.14), it is unlikely that phenylethyl alcohol contributed to the 
oestrogenic effects observed with citral, geraniol (72) or nerol (75) (see below). 
Table 4.4. Assessment of metabolism of geraniol by yeast. Compounds detected in 
the presence and absence (x) of yeast. Peak area determined by ITD. 
Peak Area for Compound Detected 
Time (h) Citronellol Geraniol Phenylethyl Alcohol 
0 0 27.20 0 
(0) (24.65) (0) 
1 0 21.30 0 
(0) (23.60) (0) 
3 0 15.40 0 
(0) (17.30) (0) 
24 0.20 10.60 0.20 
(0) (12.85) (0) 
48 0.35 6.90 0.35 
1 (0) 
72 0.60 1.90 0.60 1 
(0) (1.95) (0) 
-1 
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Table 4.5. Assessment of metabolism of nerol by yeast. Compounds detected in the 
presence and absence (x) of yeast. Peak area determined by ITD. 
Peak Area for Compound Detected 
Time (h) Citronellol Nerol Phenylethyl Alcohol 
0 0 28.15 0 
(0) (52.70) (0) 
1 0 22.20 0 
(0) (46.10) (0) 
3 0 19.80 0 
(0) (37.25) (0) 
24 0 14.00 0.15 
(0) (16.45) (0) 
48 0 6.90 0.30 
1 (0) (7.95) (0) 
72 1 0.10 1.10 1.10 
(0) (4.05) (0) 
Geraniol (72) and nerol (75) concentrations also decreased over time in the presence 
and absence of yeast and geraniol (72) and nerol (75) concentrations were lower in the 
absence of yeast (Tables 4.4 and 4.5). 
These results indicate that geraniol (72) and nerol (75) concentration decreased per 
well due to their volatility in the absence and presence of yeast, but concentrations 
were lower in the presence of yeast due to metabolism. Citronellol (69) and 
phenylethyl alcohol were detected in the wells containing the yeast culture, but not in 
the wells absent from yeast, and their concentrations increased over time (Tables 4.4 
and 4.5). This indicates that geraniol (72) and nerol (75) were metabolised by yeast to 
give citronellol (69) and phenyethyl alcohol; citronellol (69) concentration was lower 
after treatment of the yeast with nerol (75), than with geraniol (72). Citronellol (69), 
which also demonstrated oestrogenic activity in the yeast assay (Figure 4.8), may 




4.7.3 Assessment of Oestrogenic Activity of Some Sesquiterpenes Identified in 
Melissa officinalis Essential Oil, Using a Recombinant Yeast Screen 
Of the sesquiterpenes assessed for oestrogenic activity using the recombinant yeast 
screen, nerolidol (83) (p<0.001) and trans-earyophyllene (82) (p<0.05) demonstrated 
significant oestrogenic activity (Figure 4.13). Treatment with caryophyllene oxide 
(78) caused a decrease in the absorbance reading with increasing concentration, 
indicating significant cytotoxic effects (p<0.05) (Figure 4.13). 
The inactivity of some of the hydrocarbon sesquiterpenes, such as (+)-calarene (77), 
(+)-o-cedrene (79), (-)-cubebene (80) and a-humulene (81) may be explained by their 
structural features, perhaps the lack of substituents required to act as a hydrogen bond 
donor in the LBD of hER. Trans-caryophyllene (82) does not contain any such 
substituent, but did demonstrate apparent oestrogenic effects in the yeast screen. 
Trans-caryophyllene (82) may have interacted with allosteric sites of the hER, other 
than the LBD. The sesquiterpene nerolidol (83), which demonstrated significant 
ocstrogenic activity in the yeast screen (Figure 4.13), contains a hydroxyl substituent, 
which may have interacted favourably with the LBD of the hER to initiate an 
oestrogenic response. Again, it cannot be disregarded that the apparently inactive 
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Figure 4.13. Oestrogenic activity of sesquiterpenes, (+)-calarene (p>0.05), 
caryophyllene oxide (p<0.05), (+)-p-cedrene (p>0.05), (-)-cubebene (p>0.05), a- 
humulene (p>0.05), nerolidol (p<0.001) and trans-caryophyliene (p<0.05), and 17p- 
oestradiol (p<0.001), assessed by stimulation of P-galactosidase activity in genetically 
modified yeast cells (n=3-6 ± SD). 
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4.7.4 Assessment of Oestrogenic Activity of Some Oil Constituents Identified in 
Melissa officinalis Essential Oil, Using a Recombinant Yeast Screen 
The aldehyde nonanal (86) (p<0.01) demonstrated significant oestrogenic activity in 
the yeast screen (Figure 4.14). This observation may be due to interaction of the 
aldehyde substituent with the LBD of the hER, although nonanal (86) may have 
influenced allosteric sites of the hER. The ketone 6-methyl-5-hepten-2-one (85) 
(p>0.05) and the phenylpropanoid eugenol (84) (p>0.05) did not demonstrate 
significant oestrogenic activity in the yeast screen (Figure 4.14). Eugenol (84) has 
recently been investigated for oestrogenic activity using the yeast bioassay, and was 
again found to be inactive (Miller el al., 2001). 
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Figure 4.14. Oestrogenic activity of the M officinalis oil constituents, eugenol 
(p>0.05), 6-methyl-5-hepten-2-one (p>0.05) and nonanal (p<0.01), and 170-oestradiol 
(p<0.001), assessed by stimulation of P-galactosidase activity in genetically modified 
yeast cells (n=3-6 ± SD)- 
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4.7.5 Assessment of Oestrogenic Activity of Citral and Geraniol, Using the 
Ishikawa Cell Line 
The monoterpenes citral and geraniol (72) were two of the most active compounds in 
the yeast screen (refer to 4.7.1). Consequently, they were selected for further 
investigation of their oestrogenic potential in the mammalian Ishikawa cell line. Over 
the concentration range 0.2ýLM - 259.3ýLM, neither citral (p<0.05) nor geraniol (72) 
(p<0.05) showed significant oestrogenic activity in the Ishikawa cell line (Figure 
4.15). Both compounds were cytotoxic at concentration > 256. OpM (Figure 4.15). 
These results indicate that citral and geraniol (72) are not oestrogenic in the 
mammalian Ishikawa cells; inactivity in the Ishikawa cell line also occurred with the 
M officinalis essential oil (refer to 4.6.3). It may also be possible that the 
monoterpenes citral and geraniol (72) were antagonistic in the Ishikawa cell line, so 
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Figurc 4.15. Oestrogenic activity of citral (p<0.05) and geraniol (p<0.05), and 170- 
oestradiol (p<0.001), assessed by stimulation of alkaline phosphatase activity in 
Ishikawa cells (n=3-6 ± SD). 
The mammalian cells may have different transcriptional mechanisms, or different 
metabolic activity to the yeast cells, so may have metabolised compounds rendering 
I-. 
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them inactive. It is also possible that an oestrogenic response occurred at the cytotoxic 
concentration, so was undetected. The higher incubation temperature (370C, as 
opposed to 32'C in the yeast screen) may have increased loss of volatile compounds, 
reducing the assay concentration required to initiate an oestrogenic response. Further 
investigations were considered necessary to establish any oestrogenic potential of 
these compounds, therefore experiments were extended to determine their affinity for 
the hER in receptor binding studies and their potential oestrogenic activity in vivo 
(refer to 4.8 and 4.9). 
Inconsistent results between different in vitro assays have been identified previously, 
and may be attributed to different metabolic capabilities of the assay systems (Petit et 
al., 1997; Shelby et al., 1996). ERO expression is reported to be relatively high in 
Ishikawa cells but ERa is reported to be predominant in the recombinant yeast cells 
(Dechering et al., 2000). The monoterpenes citral and geraniol (72), and indeed the 
other essential oil constituents present in M. ofjlcinalis essential oil, may have greater 
affinity for ERa than ERP, which may explain the apparent oestrogenic response 
observed in the yeast screen, which was not apparent in the Ishikawa, cells. Receptor 
binding studies for ERa and ERP were conducted to investigate this possibility (refer 
to 4.8). 
4.8 Rcsults and Discussion: Oestrogen Receptor Binding Investigations of 
Essential Oil Constituents 
4.8.1 Assessment of Oestrogen Receptor Binding of Essential Oil Constituents, 
Using Ishikawa Cells 
4.8.1.1 Assessment of Oestrop-en Recentor Bindinp- of Geraniol, Usinp, Ishikawa Cells 
Geraniol (72) (p<0.01) significantly displaced [3 H]-170-oestmdiol from Ishikawa, cell 
ERs over the concentration range 0.06mM - 6. OmM (Figure 4.16). 
Agonistic and antagonistic activities cannot be distinguished, however this result is 
further evidence to suggest that geraniol (72) has an affinity for the ER. This result 
could also be explained by geraniol (72) altering the conformation of the ER but not 
binding to the LBD, which may also inhibit [3 H]-170-oestradiol binding. Therefore 
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the effect of other essential oil constituents, which did not demonstrate oestrogenic 
activity in the yeast screen, was investigated for their affinity for Ishikawa cell ERs 





Figure 4.16. Competitive displacement of [3 H]-17p-oestradiol from Ishikawa cell 
oestrogen receptors by geraniol (p<0.01) and 17p-oestradiol (p<0.001) (n=3-6 ± SD). 
4.8.1.2 Assessment of Oestrogen Receptor Binding of 1,8-Cineole, Eugenol, Geraniol 
and 6-Methyl-5-hepten-2-one, Using Ishikawa Cells 
The essential oil constituents, which did not demonstrate oestrogenic activity in the 
yeast screen (refer to 4.7), were selected because of their similar chemical properties 
to geraniol (72) (d: 0.889; mw: 154.25) to if investigate the effect of essential oil 
constituents on displacement of [3H]_170-oestradiol binding to ERs was selective. 
The compounds selected were 1,8-cineole (56) (d: 0.921; nnm: 154.25), eugenol (84) 
(d: 1.066; rtnm: 164.25) and 6-methyl-5-hepten-2-one (85) (d: 0.855; rmm: 126-2). 
By comparing the essential oil constituents for their displacement of [3 HJ-170- 
oestradiol from ERs, it appears that geraniol (72) may be selective for [3 H]-170- 
oestradiol displacement. This may be due to interaction with the LBD of the ER. The 
results show that 1,8-cineole (56) (p>0.05) and 6-methyl-5-hepten-2-one (85) 
(p>0.05) did not significantly displace [3 HI-170-oestradiol from ERs and only 
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displaced [3 H]-17p-oestradiol binding by 5.2% and 1.0% respectively at 6. OmM 
(Figure 4.17). These results are consistent with the results from the yeast screen, 
which indicated that 1,8-cineole (56) and 6-methyl-5-hepten-2-one (85) did not 
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Figure 4.17. Competitive displacement of [3 HI-170-oestradiol from Ishikawa cell 
oestrogen receptors by the essential oil constituents 1,8-cineole (P>0.05), eugenol 
(p<0.01), geraniol (p<0.01) and 6-methyl-5-hepten-2-one (p>0.05), and 170- 
oestradiol (p<0.001) (n=3-6 ± SD). 
Geraniol (72) (p<0.01) significantly displaced [3 HI-170-oestradiol binding to ERs by 
47.6% at 6. OmM (Figure 4.17). This result is also consistent with the results from the 
yeast screen, which indicated geraniol (72) may bind to the ER to initiate an 
oestrogenic reponse (refer to 4.7). 
Eugenol (84) (p<0.01) significantly displaced [3H]_ I 70-oestradiol binding to ERs by 
85.5% at 6. OmM (Figure 4.17), but did not demonstrate significant oestrogenic 
activity in the yeast screen (refer to 4.7.4). This could be explained by eugenol (84) 
acting as an anti-oestrogen. The potential ER antagonist properties of eugenol (84) 
were further investigated by evaluating its effect on the oestrogenic response initiated 
by E2 (14), using the yeast screen (refer to 4.10). 
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4.8.2 Assessment of a- and P-Oestrogen Receptor Binding of Citral, Eugenol, 
Geraniol, and Nerol 
Citral, eugenol (84), geraniol (72) and nerol (75) were analysed for their ability to 
displace [3 H]- I 70-oestradiol binding to isolated ERa and ERP over the concentration 
range 20 I. OýLM - 115930.1 gM. However, at the three highest concentrations for each 
test compound (25729.3[LM - 115930.1ýLM) exceptionally high CPM values were 
generated but, at the concentrations 201.0liM - 14491.3gM, dose dependent 
displacement of [3 HI-17p-oestradiol binding to ERa and ERP was observed (Figures 
4.18 - 4.21). To investigate this occurrence, the assays were repeated, but were 
extended to evaluate the effect of the test compound on [3 HI-17p-oestradiol in the 









Z CIO C9 C8 C7 C6 C5 C4 C3 C'12 Cl 
Citral Concentration (pM) 
Citral: 
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Figure 4.18. Competitive displacement of [3 HI-170-oestradiol from a-oestrogen 
receptors by citral (p<0.001) and 170-oestradiol (p<0.001) and the effect of citral in 
the assay, in the absence of a-oestrogen receptors (n=3-6 ± SD). 
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The results show that for all four test compounds, the exceptionally high CPM values 
were generated both in the presence and absence of ERa (Figures 4.18 - 4.21). At 
concentrations 201.0ýM - 14491.3gM dose dependent displacement of [3 HJ-170- 
oestradiol binding was observed in the presence of ERa, but in the absence of any 
receptor, high CPM values were not observed (Figures 4.18 - 4.21). This indicates 
that the test compounds did not interfere in the assays at low concentrations, but at 
higher concentrations (>25729.3[LM) did interfere in the assays. This could be due to 
the high concentrations of test compounds being at sufficient levels to precipitate 
[3 HJ-170-oestradiol. 
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Figure 4.19. Competitive displacement o[3 HJ-170-oestradiol from a-oestrogen 
receptors by eugenol (p<0.001) and 170-oestradiol (p<0.001) and the effect of 
eugenol in the assay, in the absence of a-oestrogen receptors (n=3-6 ± SD). 
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Figure 4.20. Competitive displacement of [3 HJ-17P-oestradiol from a-oestrogen 
receptors by geraniol (p<0.001) and 170-oestradiol (p<0.001) and the effect of 
geraniol in the assay, in the absence of ct-oestrogen receptors (n=3-6 ± SD). 
The concentrations of citral, eugenol (84), geraniol (72) and nerol (75) required to 
displace [3 H]-170-oestradiol binding were 104 _ 106_fold greater than the E2 (14) 
concentrations required. This indicates that the test compounds have only weak 
affinity for ERa and ERO, relative to E2 (14). 
Citral, eugenol (84), geraniol (72) and nerol (75) showed greater affinity for ERa than 
ERP (Figures 4.22 and 4.23; Table 4.6). This may be explained by the structures and 
LBDs of ERa and ERP being different (Dechering el al., 2000; Kuiper el al., 1997; 
Mosselman et al., 1996; Paech el al., 1997). As the test compounds showed different 
allinities for ERa and ERP, they may act specifically to displace [3 Hj- I 7P-oestradiol 
binding, perhaps by having greater affinity for the LBD of ERa than ERP. 
256 
450- 
= hER(x absent 
400- 









.0fI 0- =1 =]OVA 
3 
Mý so r, -D -50- Z NIO N9 N8 N7 N6 N5 N4 N3 N2 NI 
Nerol Concentration (pM) 
Nerol: 
N 1: 10 2 917.3 pM N2: 51458.7gM N3: 25729.3pM 
N4: 12864.7pM N5: 6432.3pM N6: 3216.2pM 
N7: 1608. IpM N8: 804.011M N9: 402. OpM 
N 10: 20 I. OgM Z: OgM (alcohol only) 
Figure 4.21. Competitive displacement of [3 H]-17p-oestradiol from a-ocstrogen 
receptors by nerol (p<0.001) and 17P-oestradiol (p<0.001) and the effect of nerol in 
the assay, in the absence of a-oestrogen receptors (n=3-6 ± SD). 
Table 4.6. Affinity (EC50 values) of citral, eugenol, geraniol, nerol and 170-oestradiol 
(E2) for isolated ERa and ERP. 
Compound ERct: EC. se ERP: EC.,; o 
Citral 1754.4liM 5610.5pM 
Eugenol 1966.2ýLM 5603.5pM 
Geraniol 5576.6pM >12864.7pM 
Nerol 6127.8pM >12864.7tLM 
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Figure 4.22. Competitive displacement of [3 H]-170-oestradiol from a-oestrogen 
receptors by citral (p<0.001), eugenol (p<0.001), geraniol (p<0.001) and nerol 




Figure 4.23. Competitive displacement of [3 H]-17p-oestradiol from P-oestrogen 
receptors by citral (p<0.001), eugenol (p<0.001), geraniol (p<0.001) and nerol 
(p<0.001), and ]7p-oestradiol (p<0.001) (n=3-6 ± SD). 
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The test compounds showing greater selectivity for ERa than ERP, may explain why 
the monoterpenes citral and geraniol (72) showed oestrogenic activity in the yeast 
assay which contains predominantly ERa (refer to 4.7.1), but did not show 
oestrogenic activity in the Ishikawa cell assay, which contains predominantly ERP 
(refer to 4.7.5). 
Eugenol (84) displaced [3 H]-17p-oestradiol binding to both ERa than ERP, again 
suggesting that eugenol (84) may have the potential to be a competitive antagonist. 
The monoterpenes showed greater affinity for ERa than ERP (Figures 4.22 and 4.23; 
Table 4.6), unlike other phyto-oestrogens (e. g. genistein (89)), which arc reported to 
have greater affinity for ERP (Mason, 2001). ERP is reported to predominate in the 
prostate, bone and vascular tissue but, ERa is reported to predominate in the breast, 
uterus and ovary (Dechering et al., 2000; Kuiper et al., 1997; Mason, 2001). This 
suggests that ERa selective compounds, perhaps the monoterpenes, may promote 
adverse effects in breast tissue, uterine tissue and ovaries, such as carcinogenesis. 
ERP is reported to mediate the beneficial effects of oestrogens on learning and 
memory (Fillit, 1994; Shughrue et al., 1997; Wickelgren, 1997). However, both ERa 
and ERP have been detected in the hippocampus, an area important for cognition 
(Osterlund et al., 1998; Register et al., 1998). More recently, ERa has also been 
detected in rat and human cerebral cortex (Butler el al., 1999; Osterlund et al., 2000). 
Therefore ERa may also be relevant in mediating the beneficial effects of oestrogens 
on cognition, but ftirther investigations are necessary regarding the relationship 
between ERa and ERP within the CNS and cognition. The potential adverse effects 
of ERa agonists also requires further assessment before any recommendations 
regarding their use for management of AD. 
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4.9 Results and Discussion: Assessment of Oestrogenic Activity of Citral and 
Geraniol in vivo 
4.9.1 Assessment of Oestrogenic Activity of Citral and Geraniol, Using a 
Uterotrophic Assay 
The uterotrophic assay requires the potential oestrogen to stimulate uterine growth 
(Martin el al., 1976; Odum el al., 1997; Shelby et al., 1996). Administration of E2 
(14) gave a 4.8-fold increase in uterine weight, compared to the control (alcohol 
only). However, after administration of the two compounds citral and geraniol (72), 
no evidence of an increase in uterine weight was observed compared to the control 
(Figure 4.24). 










170 -Oestradiol at 0-3m M 
Monoterpenes at 1.9M 
Figure 4.24. Effect of alcohol (control), citral, geraniol and 17p-ocstradiol on uterine 
weight, following transdermal administration twice daily for 3 days to ovariectomised 
mice (uterotrophic assay) (n=5 ± SEM). 
ERP expression is reported to be low in the uterus (Dechering et al., 2000), which 
indicates that ERa is responsible for mediating the uterotrophic response. The 
apparent lack of oestrogenic activity of these monoterpenes in vivo may be due to low 
affinity for ERa in uterine tissue, since although citral and geraniol (72) showed 
apparently weak oestrogenic activity in the yeast screen, in which ERa predominates 
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(refer to 4.7.1) and greater affinity for ERa than ERP in the receptor binding studies 
(refer to 4.8.2), the binding affinity of citral and geraniol (72) for ERa was much less 
potent than E2 (14) affinity (refer to 4.8.2). 
It has been reported that weak oestrogens stimulate uterine biochemical responses to a 
minimal degree (Clark and Peck, 1979). Therefore any oestrogenic effect of the 
monoterpenes may have been too small for detection, and may have required 
assessment over a longer time period. Bolus administration of the oestrogenic 
compound estriol did not initiate an increase in uterine weight in female 
ovariectornised rats (Clark et al., 1977). This was attributed to the low retention time 
of the estriol-ER complexes but, continuous administration of estriol (via implants) 
did initiate a uterine growth response (Clark et al., 1977). This result indicates that 
estriol may not be a weak oestrogen, but could be regarded as a short-terrn oestrogen. 
The negligible uterotrophic activity of estriol in vivo has also been suggested to have 
occurred due to rapid elimination from the animal (Korach et al., 1980; Kupfer, 
1987). Similarly, these occurrences may explain the lack of response with the 
monoterpenes in the uterotrophic assay. Perhaps more frequent administration of 
each compound may have permitted constant systemic concentrations, which may 
have induced an oestrogenic response. 
Citral is rapidly metabolised and excreted, with no long term storage in the rat or 
mouse; following oral administration, 14C labelled citral is rapidly absorbed and 
excreted within 72hr by the rat, and within 120hr by the mouse (Phillips et al., 1976). 
The monoterpenes may also have been rapidly metabolised to other compounds that 
are not oestrogenic in vivo. Two of the major metabolites identified in urine after 
administration of citral to the rabbit were hildebrandt acid and dihydro-hildebrandt 
acid (Ishida et al., 1989; Williams, 1959). Hildebrandt acid has also been identified 
as a metabolite of geraniol (72) in the rat suggesting that similar metabolic pathways 
occur to those in the rabbit (Chadha and Madyastha, 1984). It would be useful to 
evaluate the oestrogenic activity of these metabolites in other oestrogenic assays. 
Citral has previously been reported to induce local hyperkeratosis following repeated 
application to the same area of skin (Abramovici et al., 1987), which raises the 
possibility that this response may have interfered with transdermal absorption in the 
assays in the present study. The relative oestrogenic potency of the monoterpenes and 
E2 (14) may reflect the rate of transdermal absorbtion of each compound. Impairment 
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of transdermal absorption by hyperkeratosis may have reduced the systemic 
concentrations of the monoterpenes required to promote uterine growth. 
4.9.2 Assessment of Ocstrogcnic Activity of Citral and Geraniol, Using an Acute 
Assay 
A quantitative index of the permeability of the uterine vasculature was obtained from 
the leakage of radiolabelled albumin after the application of E2 (14) or the test 
substance. Following transdermal administration of E2 (14), changes in uterine 
vascular permeability enabled significant promotion of radiolabelled albumin leak-age, 
compared to the vascular changes in the control tissue (muscle) (Table 4.7). 
However, no such vascular changes were observed with the control (alcohol only), or 
with citral or geraniol (72) (Table 4.7). 
Table 4.7. Uterine weight and vascular penneability 4hr following transdermal 
application of 1001A alcohol, or 170-oestradiol, citral or geraniol (diluted in alcohol). 












Control (alcohol) 5 13.5+0.28 5.96+0.54 1.24+0.04 
170-Ocstradiol 5 19.0 + 0.15** 20.3 + 1.12** 0.94+0.03 
tral 5 12.5+0.88 12.5+4.31 0.95+0.04 
Geraniol 5 12.8+0.59 4.72+0.21 1.17+0.13 
The failure of any uterotrophic effect may have reflected the need to have continuous 
exposure to a weak oestrogen to sustain a uterine growth response (Martin ef al., 
1976), but this limitation did not apply to the more acute vascular permeability assay. 
The uterine vascular permeability assay is an acute, rapid and easily monitored 
response of the uterus to oestrogenic stimulation (Arvidson, 1977). Immediate 
vasoactive effects on the ventral prostate of adolescent rats following a single 
transdennal dose of citral (22.8mg/150g rat) to the lumbodorsal region of skin have 
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been reported to occur (Scolnik et al., 1994). The mechanism of action for this effect 
was unknown, but may have been due to the initial stages of a neoplastic effect. 
Due to the volatile nature of citral and geraniol (72), the amounts of the monoterpenes 
reaching the systemic circulation is likely to have been considerably less than was 
actually applied, which may have contributed to a sub-optimal dose of citral being 
present in the systemic circulation. This occurrence may explain the apparent lack of 
oestrogenic activity of the monoterpenes in vivo. 
It has been reported that geraniol (72) was not absorbed through the intact shaved 
abdominal skin of the mouse after 2hr (Meyer and Meyer, 1959), which could also 
explain the lack of oestrogenic effects of geraniol (72) in vivo in the present study. 
However, dermal application of 20mg or more of citral daily (or less frequently) is an 
established model for inducing prostatic hyperplasia in vivo, but these studies 
involved citral administration for periods of I-3 months (Abramovici et al., 1987; 
Geldof et al., 1992; Massas et al., 1991; Servadio et al., 1986). This suggests that 
prolonged and continuous administration of the monotcrpenes may be required to 
promote an oestrogenic response in vivo. Such doses compare to 29.6mg citml/mouse 
(acute assay) and only 14.8mg citral/mouse (uterotrophic assay) per application in the 
present study. 
The mechanisms by which citml induces prostatic hyperplasia in mts remains 
uncertain. Synergism between citml and testosterone has been proposed to explain 
hyperplastic changes in the rat ventral prostate (Engelstein el al., 1996), and an 
inflammatory response was also suggested to explain the effects of citml on rat 
prostate (Scolnik et al., 1994). It has also been suggested that the proliferative effects 
observed in the prostate following administration of citral may be due to an 
oestrogenic effect (Geldof et al., 1992). Oestrogen receptors have been identified in 
human prostate (Schulze and Claus, 1990) and E2 (14) has been linked to the 
development of prostatic hyperplasia (Habenicht and El Etreby, 1988). In addition, 
the application of citral directly to the vagina of ovariectomised mts increased the 
proliferation of the vaginal epithelium, similar to the effect of E2 (14) (Geldof et al., 
1992). It was also reported that citral inhibited E2 (14) binding to ERs using mt 
uterine cytosol, while no such inhibition was observed with testosterone for androgen 
receptors (Geldof et al., 1992). However, the evidence of oestrogenic activity from 
these studies by Geldof el al. (1992) was not conclusive. The mitotic responses in the 
vagina may have occurred due to local kemtinisation effects of citral, which may 
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reflect hypertrophy that is not associated with oestrogenic activity, and the data on 
competition with E2 (14) for oestrogen receptors was very limited (tested at only 
three concentrations). 
It is apparent that further investigations regarding the mode of action of the 
monoterpenes citral and geraniol (72) are necessary, to explain their reported effects 
on induction of prostatic hyperplasia and proliferation of vaginal epithelium, and to 
confirm absence of effects on uterine weight over an extended period of time. 
4.10 Results and Discussion: Assessment of Anti-O estrogenic Activity of Eugenol 
4.10.1 Assessment of Anti-Ocstrogenic Activity of Eugcnol, Using the 
Recombinant Yeast Screen 
Oestrogenic compounds that bind to the ER are reported to initiate ER dimerisation 
and binding to oestrogen response elements (ERE) on DNA, with subsequent 
interaction with transcription factors, which modulates gene transcription (Beckman 
et al., 1993; Dechering et al., 2000; Diel et al., 1998; Parker, 1993; Ryffel el al., 
1988). Anti-oestrogens may compete with an oestrogenic compound and bind to the 
ER, but do not activate gene transcription effectively (Jordan and Murphy, 1990; 
Thompson, ef al., 1989; Wakeling, 1992; Wolf and Fuqua, 1995). 
Eugenol (84) did not demonstrate oestrogenic activity in the yeast screen (refer to 
4.7.4, Figure 4.14) but did competitively displace [3 H]-170-oestradiol from ERa and 
ERP (refer to 4.8.2 and Figures 4.19,4.22 and 4.23). These results indicate that 
eugenol (84) may have partial agonist or antagonistic effects for the ER. To 
investigate this, an anti-oestrogen screen was conducted. This involves evaluating the 
inhibition of E2 (14) activity by a particular chemical (Routledge and Sumpter, 1997; 
Sohoni and Sumpter, 1998). The oestrogenic effect of E2 (14) (0.78nM) in the 
presence of eugenol (84) was assessed in the yeast screen. 0.78nM E2 (14) was used, 
as this concentration allows both positive and negative effects on 0-galactosidase 
activity to be assessed. 
In the yeast screen, eugenol (84) (p<0.001) produced a significant dose-dependent 
decrease in P-galactosidase activity in the presence of E2 (14), which was associated 
with a decrease in CPRG metabolism (Figure 4.25). This indicates eugenol (84) has 
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weak antagonistic activity (EC50: 23 I. OpM). The positive control, hydroxytamoxifen 
(p<0.001; EC50: 0.4gM), significantly antagonised E2 (14) stimulation of P- 
galactosidase activity, but was almost 600-fold more potent than eugenol (84) (Figure 
4.25). Hydroxytamoxifen has previously been reported to inhibit E2 (14) induced 
expression of P-galactosidase activity (Routledge and Sumpter, 1997; Sohoni and 
Sumpter, 1998). 
2.5- - E2 
- Hydroxytarnoxifen 
- Hydroxytamoxifen + 0.78nM E2 
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Figure 4.25. Anti-oestrogenic and oestrogenic activity of hydroxytainoxifen 
(p<0.001), hydroxytainoxifen in the presence of 0.78nm 170-oestradiol (p<0.001), 
eugenol in the presence of 0.78nM 170-oestradiol (p<0.001) and 17p-ocstradiol 
(p<0.001), assessed by stimulation of P-galactosidase activity in genetically modified 
yeast cells (n=3-6 ± SD). 
Hydroxytamoxifen appeared to show weak partial agonist activity in the absence of 
E2 (14) (Figure 4.25). This occurrence has previously been reported (Beresford et al., 
2000). It has been proposed that the action of tamoxifen is similar to 
hydroxytamoxifen, and shows weak agonistic activity at low concentrations, but acts 
antagonistically at higher concentrations (Hedden el al., 1995). The mechanism of 
action of tamoxifen involves binding to the LBD at low concentrations, thus allowing 
expression of ligand-independent activation function but, as tamoxifen concentration 
increases and the LBD becomes saturated, interaction with a second domain on the 
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ER occurs (which is not recognised by E2 (14)), which abolishes the agonistic activity 
(Hedden et al., 1995; Wolf et al., 1995). 
This occurrence may therefore also explain weak agonistic activity of 
hydroxytamoxifen in the yeast assay in the absence of E2 (14), when ER saturation 
had not occurred. The anti-oestrogens tamoxifen and hydroxytamoxifen have been 
shown to inhibit E2 (14) induced 0-galactosidase activity in the yeast screen, but the 
anti-oestrogen ICI 182,780 did not inhibit the E2 (14) induced response and showed 
agonistic activity in the yeast screen but ICI 182,780 did display anti-oestrogenic 
activity in other bioassays (Beresford el al., 2000; Routledge and Sumpter, 1997; 
Sohoni and Sumpter, 1998; Zacharewski, 1997). It is therefore apparent that the yeast 
screen is useful for detection of some anti-oestrogens but not others, perhaps due to 
different mechanisms of anti-oestrogenic action of the substance being investigated. 
This occurrence may be explained by the yeast not containing the appropriate proteins 
necessary for antagonistic activity (Gaido et al., 1997). 
The effect of eugenol (84) on P-galactosidase activity in the yeast cells, stimulated by 
E2 (14), was also assessed for four days after the three day incubation period of the 
assay was completed. The results show that P-galactosidase activity increases as a 
function of time (Figure 4.26). 
This is perhaps due to the eugenol (84) concentration in the assay decreasing with 
time, due to its volatility and perhaps metabolism to other compounds (see below for 
assessment of eugenol metabolism by yeast cells: 4.10.2). 
As eugenol (84) concentration decreases, so does the antagonistic effect, hence the 
increased P-galactosidase activity in the presence of 0.78nM E2 (14). P-Galactosidase 
activity also increased as a ftinction of time in the presence of E2 (84), absent from 
antagonists (Figure 4.26). This observation may be explained by the continued 
metabolism of CPRG to CPR by 0-galactosidase in the presence of E2 (14). 
To determine if the decrease in P-galactosidase activity was due to antagonism of E2 
(14) by eugenol (84), and not due to cytotoxic activity of eugenol (84), the number of 
yeast cells was counted after completion of the three day assay incubation period. 
The results showed no significant difference (p>0.05) between cell number in the 
presence and absence or eugenol (84), nor was cell number significantly affected by 
eugenol (84) concentration, over the concentration range 76.1 JtM - 609.0[IM (Figure 
4.27). This suggests eugenol (84) may have inhibited the oestrogenic activity of E2 
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Figure 4.26. Anti-oestrogenic activity of eugenol in the presence of 0.78nM 17p- 
oestradiol (p<0.001) and oestrogenic activity of 17P-oestradiol (p<0.001), assessed by 
stimulation of P-galactosidase activity in genetically modified yeast cells, as a 
function of time (n=3-6 ± SD). 
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Figure 4.27. Yeast cell number in the presence and absence of eugenol and 0.78nM 
17P-oestradiol, after three days incubation at 32'C (n=10 ± SD). 
76 1 1523 304.5 NNO 
Eugenol Concentration (pM) 
in the Presence of 0.78nM 170-Oestradiol 
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Eugenol (84) may have antagonised E2 (14) binding to the ER in the yeast screen by 
competitively binding to the LBD domain of the ER directly and preventing 
dimerisation, or by preventing the binding of the receptor dimer to ERE, or by 
mechanisms independent of ER LBD binding, perhaps by interaction with allosteric 
sites. 
Further investigations are required for more complete characterisation of the potential 
anti -oestrogenic properties of eugenol (84). The potential for eugenol (84) to interact 
with the LBD of the ERa was investigated using molecular graphics (refer to 4.11). 
4.10.2 Assessment of the Metabolism of Eugenol, in a Recombinant Yeast Screen 
To investigate if the apparent lack of oestrogenic effects of eugenol (84) in the yeast 
screen (refer to 4.7.4) were due to the metabolism of eugenol (84) to other 
compounds, or if the apparent antagonistic activity in the yeast screen (refer to 4.10.1) 
was due to a metabolite, the metabolism of eugenol (84) by the yeast cells was 
assessed. The results show that eugenol (84) concentration decreased with time in the 
presence and absence of yeast indicating loss of eugenol (84) from each well due to 
its volatility (Table 4.8). 
Table 4.8. Assessment of metabolism Of eUgenol by yeast. Compounds detected in 
the presence and absence (x) of yeast. Peak area detennined by ITD. 
Peak Area for Compound Detected 
Time Eugenol Phenylethyl Alcohol 
(h) 
0 31.65 0 
(31.95) (0) 
1 26.70 0 
1 (28.90) (0) 
3 23.20 0 
(33.95) (0) 
24 25.90 0.50 
(28.20) (0) 
48 21.10 2.00 
(27.00) (0) 
72 17.60 2.10 
1 (17.40) 1 (0) 1 
268 
Phenylethyl alcohol concentration increased with time in the presence of yeast but 
was not detected in the absence of yeast, indicating it was a metabolic product of 
eugenol (84). The loss of eugenol (84) from the assay medium, shown by the 
decrease in eugenol (84) concentration in the absence of yeast (Table 4.8) presumably 
explains the loss of the antagonistic effect of eugenol (84) with time in the yeast 
screen (refer to 4.10.1, Figure 4.26). 
The potential anti-oestrogenic; effects of phenylethyl alcohol remain to be identified, 
however, as eugenol (84) displaced binding of CH]-170-oestradiol from isolated ERa 
and ERP (refer to 4.8.2) in the absence of the metabolic processes which occurred in 
the yeast cells, it is more likely that eugenol (84) was responsible for the anti- 
oestrogenic effects observed in the yeast screen (refer to 4.10.1). 
4.11 Results and Discussion: Structure-Activity Assessment Using Molecular 
Graphics: Potential Interactions of Citral (a and b), Eugenol, Geraniol and Nerol 
with the oc-Ocstroeen Receptor 
4.11.1 Conformational Search Results 
This study proposes the agonist binding mechanism of citral a (70), citral b (71), 
geraniol (72) and nerol (75), and the antagonist binding mechanism of eugenol (84) 
for the LBD of the ERa. Torsion angles (TOR) on the molecule under investigation 
were selected (refer to method, 4.4 and Figure 4.2) prior to a conformational search 
performed for identification of low energy conformations. The search results 
generated gave the energy and torsion angles for each conformation of the molecule. 
Following inspection of the data, similar conformations of the molecule were grouped 
together (Tables 4.9 - 4.13). 
After selecting the conformation of lowest energy representative of each group 
(conformation I for each group in Tables 4.9 - 4.13) the molecule of the selected 
conformation was manually introduced into the LBD of the ERa, in such a way that it 
occupied a position similar to the bound ligands E2 (14) or RAL (95). The position 
and conformation of each molecule were ftirther adjusted, by refinement of the 
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potential energy of the system and the final torsion angles of each molecule 
positioned within the LBD were determined (Table 4.14). 
Table 4.9. Low energy conformations of the molecule citral a (geranial), generated by 
a conformational search. 
Conformation TOR 1 TOR 2 TOR 3 TOR 4 
1 ±180 ±180 0 +180 
2 +85 ±180 +1 +180 
3 -85 ±180 -2 +180 
4 ±180 ±180 -100 +180 
5 ±180 ±180 +100 ±180 
6 +85 ±180 +100 ±180 
7 -85 ±180 -100 ±180 
8 -85 ±180 +100 ±180 
9 +85 ±180 -100- ±180 
10 ±180 ±180 +0.14 +0.05 
11 +85 ±180 -0.2 -0.2 
12 -85 ±180 +0.2 +0.2 
13 ±180 ±180 +100 +0.3 
14 ±180 ±180 -100 -0.3 
15 -85 ±180 +100 +0.3 
16 +85 ±180 -100 -0.3 
17 -85 ±180 -100 -0.3 
18 +85 ±180 +100 +0.3 
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Table 4.10. Low energy conformations of the molecule citral b (neral), generated by 
a conformational search. 
Conformation TOR 1 TOR 2 TOR 3 TOR 4 
1 ±180 ±180 0 ±180 
2 +85 ±180 +1 ±180 
3 -85 ±180 -2 ±180 
4 ±180 ±180 +100 ±180 
5 ±180 ±180 -100 ±180 
6 +85 ±180 +100 ±180 
7 -85 ±180 -100 ±180 
8 -85 ±180 +100 ±180 
9 +85 ±180 -100 ±180 
10 ±180 ±180 -0.1 +1 
11 -85 ±180 -0.1 +0.1 
12 +85 ±180 -0.2 -0.1 
13 ±180 ±180 -100 -0.4 
1 ±180 ±180 +100 +0.3 
15 -85 ±180 +100 +0.3 
16 +85 ±180 -100 -0.1 
17 -85 ±180 -100 -0.4 
18 +85 ±180 +100 +0.3 
Table 4.11. Low energy conformations of the molecule eugenol, generated by a 
conformational search. 
Conformation TOR 1 TOR 2 TOR 3 
1 -92.1 96.1 -73.0 
2 ±180 ±180 ±180 
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Table 4.12. Low energy conformations of the molecule geraniol, generated by a 
conformational search. 
Conformation TOR 1 TOR 2 TOR 3 TOR 4 
1 ±180 ±180 -55 +110 
2 ±180 ±180 +55 -110 
3 ±180 ±180 -55 -110 
4 ±180 ±180 +55 +110 
5 ±180 -80 +55 -110 
6 ±180 +80 +55 -110 
7 ±180 -80 -55 +110 
8 ±180 ±180 ±180 -150 
9 ±180 +80 -55 +110 
10 ±180 +80 -55 -110 
11 ±180 +80 +55 +110 
12 ±180 -80 -55 -110 
13 ±180 ±180 ±180 +130 
14 ±180 -80 +55 +180 
15 ±180 ±180 ±180 +180 
16 ±180 -80 -55 -155 
17 ±180 -80 ±180 +120 
18 ±180 +80 ±180 -120 
19 ±180 +80 ±180 +180 
20 ±180 -80 ±180 -140 
21 ±180 0 ±180 ±180 
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Table 4.13. Low energy conformations of the molecule nerol, generated by a 
conformational search. 
Conformation TOR I TOR 2 TOR 3 TOR 4 
1 ±180 ±180 -55 +110 
2 ±180 ±180 +55 -110 
3 ±180 ±180 -55 -110 
4 ±180 ±180 +55 +110 
5 ±180 -80 +55 -110 
6 ±180 +80 +55 -110 
7 ±180 -80 -55 +110 
8 ±180 ±180 ±180 -150 
9 ±180 +80 -55 +110 
10 ±180 -80 -55 -110 
11 ±180 +80 +55 +110 
12 ±180 +80 -55 -110 
13 ±180 ±180 ±180 +130 
14 ±180 -80 +55 ±180 
15 ±180 ±180 ±180 ±180 
16 ±180 -80 -55 -150 
17 ±180 +80 ±180 -120 
18 ±180 -80 ±180 +120 
19 ±180 +80 ±180 ±180 
20 ±180 -80 ±180 -135 
21 ±180 0 ±180 ±180 
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4.11.2 Comparison of the Chemical Structures of the Monoterpenes and Eugenol 
with 17P-Oestradiol and Raloxifene 
Table 4.14. Torsion angles for each molecule complexed with ERa. 
Compound TOR I (') TOR 2 (*) TOR 3 () TOR 4 (') 
Citral a (geranial) +180.0 +179.6 +102.5 +179.9 
Citral b (neral) -85.0 +179.6 +102.5 +179.9 
Eugenol -0.1 -94.0 -114.0 - 
Geraniol -177.4 -68.0 -61.6 -137.6 
Nerol 171.3 44.2 161.3 161.1 
Each molecule (torsion angles as described in Table 4.14) was analysed to determine 
any similarities in structure with the endogenous ER agonist E2 (14) (and for eugenol 
(84), also with the ER antagonist RAL (95)). Each image of a molecule with E2 (14) 
or RAL (95) is shown from 3 different angles (the molecule being analysed is 
represented in bold type) (Figures 4.28 - 4.33). 
Figure 4.28. Comparison of the structure of citral a (geranial) with 17p-oestradiol, 
each represented by the proposed conformation in ERa. 
1 
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The selected conformations of citral a and b (geranial (70) and neral (71)) show some 
similarities to the conformation of E2 (14) (Figures 4.28 and 4.29). 
The hydroxyl substituent on the 6-membered ring of E2 (14) is similarly positioned to 
the aldehyde substituent on the citral a (70) and b (71) molecules. This indicates that 
both citral a (70) and b (71) may interact similarly to E2 (14) in the LBD of the ER. 
The planarity of both citral a (70) and b (71) molecules are also similar to E2 (14), 
although citral a (70) is less so than citral b (71) (Figures 4.28 and 4.29). There are 
clear differences between E2 (14) and the monoterpene molecules. Citral a (70), 
citral b (71), geraniol (72) and nerol (75) are smaller molecules than E2 (14) and 
would therefore occupy a smaller volume in the LBD. These monoterpenes also lack 
a second the hydroxyl substituent that is present on the pentacyclic ring of E2 (14), 
and they are also acyclic compounds. However, the configurations of the 
monoterpenes are possibly similar enough to E2 (14), to enable similar interactions in 
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The configurations of the molecules geraniol (72) and nerol (75) also enable their 
hydroxyl substituents to be similarly situated to the hydroxyl substituent on the 6- 
membered ring of E2 (14) (Figures 4.30 and 4.31). The configurations of these 
monoterpenes also appear to share similar planarity to the E2 (14) molecule. The 
monoterpenes are also considerably hydrophobic, which may enable similar 
hydrophobic interactions to E2 (14), to occur in the LBD. The potential interactions 
of the monoterpenes with the LBD of ERa were investigated further (Figures 4.35 - 
4.38). 
The configuration of the molecule eugenol (84) showed planarity similar to E2 (14) 
(Figure 4.32), and the phenolic component of eugenol (84) may be similarly 
positioned to the phenolic component of E2 (14) in the LBD of the ER, which may 
explain the relatively high affinity of eugenol (84) for ERa, compared to the 
monoterpenes (refer to 4.8.2). The phenolic moiety of eugenol (84) could also be 
positioned similarly to the phenolic component of RAL (95) (Figure 4.33), but 
eugenol (84) is a smaller molecule than RAL (95), so may occupy a smaller volume in 




Figure 4.30. Comparison of the structure of geraniol with 17p-oestradiol, each 




Figure 4.31. Comparison of the structure of nerol with 17p-oestradiol, each 
represented by the proposed conformation in ERa. 
Figure 4.32. Comparison of the structure of eugenol with 170-oestradiol, each 
represented by the proposed conformation in ERa. 
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Figure 4.33. Comparison of the structure of eugenol with raloxifene, each 
represented by the proposed conformation in ERa. 
4.11.3 Assessment of the Potential Interactions of Compounds with the ERct 
Figure 4.34. Potential interactions () of 170-oestradiol with the surrounding 
residues of the ligand binding domain of the ERa. 
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The aldehdye substituent of the citral a (70) and b (71) molecules may interact with 
the guanidiniurn substituent of arginine (ARG) 394 of the LBD, with shortest bond 
distances of 2.83A and 2.98A respectively (Figures 4.35 and 4.36). This is 
comparable to the binding of the C3 hydroxyl substituent on E2 (14) to ARG 394 
(Figure 4.34), and to the hydroxyl substituent on oestrone (87), which is a weaker 
oestrogen than E2 (14) (Blair et al., 2000) (this may be due to the binding differences 
in the LBD). 
HO HO 
17P-Oestradiol (14) Oestrone (87) 
279 
Figure 4.36. Potential interactions () of neral (citral b) with the surrounding 
residues of the ligand binding domain of the ERa. 
The C3 hydroxyl substituent of E2 (14) also interacts with the carboxylate substituent 
of glutamic acid (GLU) 353 and a water molecule, and the C 17 hydroxyl substituent 
interacts with histidine (HIS) 524 in the LBD (Brzozowski et al., 1997 and Figure 
4.34). The absence of these latter interactions for citral a (70) and b (71), and also for 
geraniol (72) and nerol (75) in the LBD, may reflect the much weaker oestrogenic 
activity and ER binding properties observed in the in vitro assays (refer to 4.7 and 
4.8). 
Using molecular graphics, it can be shown that the hydroxyl substituents of geraniol 
(72) and nerol (75) may interact with both the guanidiniurn substituent of ARG 394 
(shortest bond lengths: 2.06A and 2.11 A respectively) and the carboxylate substituent 
of GLU 353 (shortest bond lengths: 2.54A and 2.80A respectively) (Figures 4.37 and 
A- 
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Figure 4.37. Potential interactions( of geraniol with the surrounding residues 
of the ligand binding domain of the ERa. 
E2 (14) also participates in a number of hydrophobic interactions in the LBD 
(Brzozowski et al., 1997 and Figure 4.34). The positioning of the proposed agonist 
monoterpene molecules may also favourably participate in such hydrophobic 
interaction, as shown by the atomic van der Waals surfaces of the molecular systems, 
which show steric complementarity (Figures 4.35 - 4.38). 
The structural requirements of a molecule for binding to the hER are complex, 
however it is generally accepted that a cyclic component (often phenolic) is a 
structural requirement, as is a substituent (C3 hydroxyl for E2 (14)) acting primarily 
as a hydrogen bond donor in the LBD of hER (Blair et al., 2000; Brzozowski et al., 
1997; Dodge, 1998; Katzenellenbogen, 1995; Miller et al., 2001; Mueller and Kim, 
1978; Routledge and Sumpter, 1997). Therefore, the acyclic monoterpenes (citral a 
(70), citral b (71), geraniol (72) and nerol (75)) are novel as potential ERa ligands. 
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Figure 4.38. Potential interactions( of nerol with the surrounding residues of 
the ligand binding domain of the ERa. 
To date, a vast array of ligands, which have affinity for the hER, have been identified, 
and include the endogenous oestrogens (e. g. E2 (14)), which are steroidal, and non- 
steroidal compounds (e. g. alkyl phenols) (Blair et al., 2000; Dodge, 1998; Harris et 
al., 1997; Miller et al., 2001; Mueller and Kim, 1978; Routledge et al., 1998; 
Routledge and Sumpter, 1996; Routledge and Sumpter, 1997). 
E2 (14) has a hydrocarbon core structure, with a phenolic substituent at the C3 
position of the aromatic A-ring, and an alcohol substituent at the C 17 position. Other 
natural steroids may have a ketone group at the C17 position, for example, oestrone 
(87). This may reflect its considerably weaker oestrogenic activity than E2 (14). 
Both E2 (14) and oestrone (87) have been identified in plant tissue (Harborne and 
Baxter, 1993), which is surprising as phytosterols generally differ from animal sterols. 
The structure of phytosterols often consists of an additional methyl (or ethyl) 
substituent in the side chain (e. g. sitosterol (88)). E2 (14) is reported to occur in the 
seeds of the Phaseolus vulgaris, and oestrone (87), in seeds of both Phoenix 
dactylifera and Punica granatum (Harborne and Baxter, 1993). Therefore, it would 
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not be surprising to discover that other groups of compounds (synthesised by plants), 
such as the monoterpenoids and phenylpropanoids, can interact with steroidal 
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Other oestrogenic compounds, which have been identified from plant sources, include 
isoflavones (e. g. genistein (89)), cournestans (e. g. cournestrol (90)) and lignans (e. g. 
mataircsinal (91)). Cournestrol (90) and genistein (89) showed oestrogenic activity in 
the recombinant yeast screen, but required concentrations 100- to 1000-fold greater 
than E2 (14) (Collins et al., 1997). These compounds contain the phenolic hydroxyl 
substituent, considered important for binding to the hER. It has been reported that 
methylation of either hydroxyl substituent on cournestrol (90) reduces the oestrogenic 
activity (Dodge, 1998). Loss of activity may be due to the lack of a hydroxyl 
substituent to interact with ARG 394 in the LBD of the ER. Other structural 
modifications to cournestrol (90) that reduce oestrogenic activity include opening of 
the furan ring and increasing the number of hydroxyl substituents (Dodge, 1998). 
These occurrences may affect activity of cournestrol (90), by reducing the steric 






Several environmental oestrogens, including the macrolactones (e. g. zearalanol (92)) 
and the alkylphenols (e. g. nonyl phenol (93)), also contain a phenolic component in 
their structure, which has been considered a structural requirement for favourable 
binding to the hER. However, non-aromatic oestrogens have been identified, such as 
some halogenated carbocycle compounds (e. g. hexachlorocyclohexane (94)). 
However, hexachlorocyclohexane (94) has not been shown to bind to hER, although 
oestrogenic activity has been demonstrated in vitro (Dodge, 1998). 
Hexachlorocyclohexane (94) does contain a cyclic component, unlike the 
monoterpenes analysed for their oestrogenic potential in these investigations. 
OH 0 CH 3 
(CH2)8 CH 3 
I 
HO OH HO"' 




Another feature, which has been identified as important in determining the 
oestrogenic potency of phenolic additives, is molecular weight (Miller et al., 2001). 
The oestrogenic potency of phenolic additives diminished as the molecular weight 
decreased from an optimum range of 200 - 230, with a molecular weight of 140 - 250 
being proposed to favour oestrogenic activity (Miller et al., 2001). 
Citral (citral a (70) and citral b (71)), geraniol (72) and nerol (75) have molecular 
weights of 152,154 and 154 respectively. These are not phenolic compounds, but 
their molecular weights do comply with the molecular weights (140 - 250) of phenolic 
additives suggested by Miller et al. (2001) to be important for oestrogenic activity. 
The relatively low molecular weights of these monoterpenes may also reflect their 
low potencies in the oestrogen bioassays (refer to 4.7,4.8 and 4.9), as Miller et al. 
(2001) proposed that decreasing molecular weight may also reduce oestrogenic 
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potency. Eugenol (84) is a phenolic compound with a molecular weight of 164, and 
so complies with the appropriate molecular weight criteria for ER affinity, suggested 
by Miller et al. (2001), but the relatively low molecular weight may also reflect its 
relatively low affinity for ER in the bioassays (refer to 4.8 and 4.10). Interpretations 
of the possible link between molecular weight and ER affinity are not conclusive, as 
other parameters that may influence ER affinity including molecular structure and 
charge distribution, are not considered. 
The proposed antagonist molecule eugenol (84) was investigated for potential binding 
properties in the LBD of the hER and compared to the binding of the antagonist 
molecule, RAL (95). The positioning of eugenol (84) in the LBD of ERQ may 
favourably participate in hydrophobic interactions, as shown by the atomic van der 
Waals surfaces of the molecular systems, which show steric complementarity (Figure 
4.39). 
Figure 4.39. Potential interactions( of eugenol with the surrounding residues 
and potential displacement (-----4 of the surrounding residues by eugenol, in the 
ligand binding domain of the ERa. 
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The hypothetical binding mechanism of eugenol (84) may involve the interaction of 
the hydroxyl substituent with the guanidinium. substituent of ARG 394, with the 
carboxylate substituent of GLU 353, and with a water molecule (shortest bond 
lengths: 2.05A, 2.25A and 3.15A respectively) (Figure 4.39). However, for 
favourable binding to these amino acid residues of the LBD, eugenol (84) may 
displace other amino acid residues (leucine (LEU) 391 and alanine (ALA) 350), 
resulting in rotation and disruption of theses amino acid residues in the LBD. Helix 
displacement is regarded as a general feature of steroidal and non-steroidal hER 
antagonists (Brzozowski et al., 1997; Hendry et al., 1994; McDonnell, 1999; Wolf 
and Fuqua, 1995). For example, the imidazole ring of HIS 524 in the LBD rotates to 
accommodate the RAL (95) molecule, and maintain favourable hydrogen bonding 
between the hydroxyl substituent positioned at CII of the RAL (95) molecule, and the 
imidazole ring of HIS 524 (Brzozowski et al., 1997 and Figure 4.40). 
Figure 4.40. Potential interactions( ) of raloxifene (RAL) with the surrounding 
residues and potential displacement ( ------ ) of the surrounding residues by RAL, in 










Eugenol (84) is an alkyl phenolic compound. Several alkyl phenols (e. g. 
dihydroxybiphenyl (96) and naphthol-2 (97)) have been shown to displace [3 H]-17p- 
ostradiol binding to ERs (Blair et al., 2000; Dodge, 1998; Mueller and Kim, 1978; 
Routledge and Sumpter, 1997). Some of the alkyl phenols investigated were agonistic 
(Miller et al., 2001), but potential antagonistic effects of the alkyl phenols that did not 
show oestrogenic activity require further analysis. Some parabens (e. g. butylparaben 
(98)), chemically related to the alkyl phenols, have also shown affinity for ER, and 
showed weak oestrogenic activity in the recombinant yeast screen (Blair et al., 2000; 
Routledge et al., 1998). 
It is therefore not surprising that the alkyl phenol, eugenol (84) also displaced [3 H]- 
17P-ostradiol binding to ERa and ERP in the in vitro receptor binding studies and 
showed antagonistic activity in the yeast screen (refer to 4.8 and 4.10); effects which 
may be explained by the proposed ER binding mechanism (Figure 4.39). 
Ný OH 
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These studies using molecular graphics techniques appear to support the biological 
findings reported, regarding the oestrogenic and anti-oestrogenic properties of the 
monoterpene and phenylpropanoid compounds. 
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Another phenylpropanoid compound, anethole (99), has been suggested to be 
responsible for reported oestrogenic activity of fcnnel (Foeniculum vulgare) and anise 
(Pimpinella anisum L. ) oils (Albert-Puleo, 1980; Zondek and Bergmann, 1938). 




Compounds reported to possess oestrogenic and anti-oestrogenic effects may differ in 
their structure and their potential binding properties, from the typical cyclic 
molecules, such as the classical steroidal compounds. The investigation of potential 
ligands for the hER is further complicated by the presence of two ERs: ERa and ERP 
(and possibly more ER subtypes, yet to be identified). The proposed interactions of 
the monoterpenes citral a (70), citral b (71), geraniol (72) and nerol (75), and the 
phenylpropanoid eugenol (84) for the LBD of ERa, contributes to the understanding 
of the complexity of ER binding and the subsequent oestrogenic and anti-oestrogenic 
responses. 
4.12 Conclusion 
The oestrogenic activity of many plants, and compounds isolated from plants, is well 
documented (Dodge, 1998; Gehm et al., 1997; Milligan el al., 1998; Milligan et al., 
1999; Murkies et al., 1998; Stevens et al., 1998; Zava, 1998). The identification of 
oestrogenic activity in the root of Polygala tenuifolia has not previously been 
reported, but further studies are necessary to identify the compounds responsible for 
the apparent oestrogenic activity. Assessment of the oestrogenic activity of 
compounds isolated from Polygala tenui/olia in vivo is important to chamcterise 
potential ER agonists, which may be exploited for management of disorders such as 
AD. Beresford et al. (2000) emphasised the necessity of using a suite of assays to 
minimise the chances of wrongly labelling chemicals as endocrine disrupters. This 
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problem is well illustrated by the results of the present study in which oestrogenic 
activity was observed for the monoterpenes in some assays, but not others. 
The binding affinity of the monoterpenes citral (geranial (70) and neral (71)), geraniol 
(72) and nerol (75) for the isolated ERa and ERP has not previously been reported. 
The yeast bioassay provided evidence that affinity for the hER may be due to an 
oestrogenic effect. The results from the yeast screen and the receptor binding studies 
(refer to 4.7 and 4.8) support previous findings, which suggest citral may have 
oestrogenic activity (Abramovici et al., 1987; Geldof et al., 1992; Massas et al., 1991; 
Servadio et al., 1986), which raises questions concerning the physiological 
significance of exposure to these compounds. 
Monoterpenes from the essential oils of plants have been reported to have a wide 
variety of biological properties. Citral and geraniol (72) induce malformation in chick 
embryos, affecting reproduction (Abramovici, 1972). In rats, topical application of 
citral has also been reported to induce infertility due to ovarian atrophy and oocyte 
loss (Toaff et al., 1979), which may affect endocrine responses. Citral has been found 
to induce sebaceous gland hyperplasia in rats, which was proposed to have occurred 
by citral stimulating testosterone production (Sandbank et al., 1988). Citral has also 
been proposed as a retinoic acid synthesis inhibitor, perhaps by inhibiting enzymes 
responsible for retinoic acid formation (Chen et al., 1995; Connor and Smit, 1987; 
Hayden et al., 2001; Kikonyogo et al., 1999; Tanaka et al., 1996). 
However, in view of the results from the present study, which suggest that citMI may 
interact with the ER (refer to 4.7 and 4.8), the possibility is raised that citral may also 
interact with the retinoic acid receptor. The ER is a member of the steroid receptor 
family of transcription factors, which also includes receptors for vitamin D, thyroid 
hormone and retinoic acid, which share common structural features. It is interesting 
to note that geranial (70) and neral (71) are structurally similar to retinaldehyde (100). 
The effects of citmI on tissues responsive to sex hormones, such as the prostate 
(Abramovici et al., 1987), ovaries (Toaff et al., 1979) and sebaceous glands 
(Abramovici et al., 1982), suggest citral may act on a molecular level as a hormone. 
These findings support the results from this investigation, which shows citral may 
have an oestrogenic action (refer to 4.7 and 4.8). 
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The potential anti-oestrogenic effect of eugenol (84) could be exploited for the 
development of new anti-oestrogens for disorders including hormone-dependent 
carcinogenesis; eugenol (84) showed greater affinity for ERa than ERP (refer to 
4.8.2), and ERa is reported to predominate in the breast, uterus and ovary (Mason, 
2001). Eugenol (84) may not be appropriate for disorders such as AD, in which 
oestrogen agonists may be required to minimise cognitive decline. 
However, there may be potential for the monoterpenes to act as oestrogens, or to act 
as templates for the development of other oestrogenic compounds, which may be 
relevant in the management of disorders such as AD. It is important to consider the 
potential oestrogenic effects of these compounds before they are used therapeutically 
or otherwise, as there is potential for adverse effects on health. It has previously been 
reported that monoterpenes from the essential oils of plants have anticarcinogenic 
effects (Crowell, 1999), but the inclusion of potentially oestrogenic essential oil 
constituents in a vast range of products may actually contribute to the development of 
reproductive disorders and cancer. 
The essential oil constituents citral, eugenol (84), geraniol (72), and nerol (75) are 
derived from a variety of sources including fruits, vegetables and herbs. 
Consequently, such compounds are widely available for consumption. Essential oil 
constituents are also frequently included in cosmetics and household products. Their 
use in deodorants available on the European market has been analysed, and eugenol 
(84) and geraniol (72) were found to be present most frequently (57% and 76% 
respectively) in the products investigated (Rastogi el al., 1998). Use of essential oils 
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in detergent products, and raised awareness of alternative therapies such as 
aromatherapy and herbalism have also increased exposure to many essential oils. 
Commercially available insect repellents have also increased human exposure to 
monoterpenes. For example, citronella oil (obtained from Cymbopogon nardus) is 
widely used as an insect repellent. Citronella oil contains geraniol (72) as a major 
constituent, reported to compose 20% - 41% of the total oil (Lawrence, 1988). 
Citriodol, an extract of lemon eucalyptus oil, is also frequently included in insect 
repellent products (Goodyer, 2000). It is therefore of importance that the effects of 
essential oil components on the environment and to health are assessed. 
Like essential oil constituents, parabens are frequently included in a vast range of 
toiletries. Paraben preservatives have been shown to be oestrogenic agents in vitro 
and in vivo (Blair et al., 2000; Routledge et al., 1998). Emasculating effects in males 
and an increase in male reproductive disorders have been attributed to their inclusion 
in products to which humans are repeatedly exposed. Geraniol (72) has also been 
implied to cause oestrogenic activity in vivo, as gynecomastia has been reported in 
man following its use (Abramovici and Sandbank, 1988). 
Therefore, although the experimental results show that the oestrogenic, effects of 
citral, geraniol (72) and nerol (75) are far less potent than the endogenous hormone 
E2, repeated exposure may result in cumulative oestrogenic effects, or perhaps 
synergistic effects with other xenoestrogens in vivo. 
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CHAPTER5 
Investigations for Anti-Inflammatory Activity of Plant Extracts 
and Essential Oils 
Arachidonic acid (AA) is metabolised by 5-lipoxygenase (5-LOX) to yield the 
leukotriene inflammatory mediators (e. g. LT134, LTC4, LTD4, LTE4), and by cyclo- 
oxygenase (COX) to yield the prostaglandin (e. g. PGD2. PGE2. PGF2) and 
thromboxane (e. g. TXA2, TX132) inflammatory mediators (Figure 5.1). LT134 
enhances lysosomal enzyme activity and induces chemotaxis; TX132 is involved in 
platelet aggregation. 
Phospholipids 
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Figure 5.1. Sites of action of anti-inflammatory drugs (non-steroidal anti- 
inflammatory drugs (NSAIDs) and steroids) on arachidonic acid metabolism. 
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Consequently, inhibition of enzymes in the arachidonate cascade is an important 
therapeutic target to manage inflammatory disorders and, in view of current theories 
linking AD with inflammatory mechanisms (refer to Chapter 1,1.2.3), may also be 
used therapeutically in this condition. 
Crude aqueous and ethanolic plant extracts, essential oils and essential oil 
constituents, were assessed for their effects on leukocyte eicosanoid formation by 
investigating for activity against enzymes (COX and 5-LOX) of the arachidonate 
cascade. 
A radioimmunosassay (RIA) was conducted using calcium ionophore stimulated rat 
peritoneal leukocytes, as described by Moroney et aL (1988). The rat pcritoneal 
leukocytes employed for these investigations express pathways for both COX and 5- 
LOX, and inhibition of COX and 5-LOX by the test substances was assessed by 
measurement Of TXB2 and LTB4 respectively. When stimulated by calcium 
ionophore, neutrophil leukocytes also secrete the contents of the azurophil granules; 
myeloperoxidase (MPO) occurs naturally within these granules (Schultz, 1962). 
MPO is secreted during phagocytic activation and can also be released during cell 
lysis, therefore detection of MPO can be an indicator of cytotoxicity. The effect of 
the test substances on MPO secretion was also assessed to evaluate cell viability. 
5.1 Methods 
5.1.1 Materials 
LTB4 was obtained from Cascade Biochemicals Ltd., Reading, England. CH]-LTB4 
(218mCi/mmol) and [3 H]-TXB2 (140-170mCi/mmol) were obtained from Amersharn 
International, Buckinghamshire, England. Polyclonal rabbit anti-LTB4 and anti-TXB2 
antibodies were gifts from Dr R. Forder, Zeneca Pharmaceuticals, Cheshire, England. 
Dextran T-70 was obtained from Pharmacia-AB, Laboratory Separation Division, 
Uppsala, Sweden. Purified charcoal was obtained from Norit GSX. Hank's balanced 
salt solution (HBSS) was purchased from Gibco Ltd., Middlesex, England. 
Scintillation fluid (LiquiscintID) was obtained from National Diagnostics, Aylesbury, 
Buckinghamshire, England. Solvents were obtained from BDH Supplies, Poole, 
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England. All other chemicals were purchased from Sigma Chemical Company, 
Poole, Dorset, England. 
Plant material, essential oils and essential oil constituents were obtained as described 
previously (Chapter 2,2.1.1.1); Melissa offi'cinalis essential oil (organic) was obtained 
from Fragrant Earth, Taunton, England. 
5.1.2 Activity of Plant Extracts, Essential Oils and Essential Oil Constituents 
Against Leukocyte Eicosanoid Formation 
5.1.2.1 Preparation of Assgy Solutions 
Table 5.1. Composition of assay solutions used for the anti-inflammatory assay. 
Solution/Suspension Composition 
Charcoal suspension 1% charcoal, 0.5% dextran T-70 in RIA buffer 
Complete HBSS (pH 7.4) 137mM NaCl, 5.37mM KCI, 0.34mM Na2HP04 
(anhydrous), 4.17mM NaHC03.0.44mM KH2PO4. 
5.55mM glucose, 1.26mM CaC12.0.41mM MgS04, 
0.49mM MgCl2 
Caý+/Mgý+ ftee HBSS (pH 7.4) 137mM NaCl, 5.37mM KCI, 0.34mM Na2HP04 
(anhydrous), 4.17mM NaHC03.0.44mM KH2PO4, 
5.55mM glucose 
RIA buffer (pH 7.4) 0.04M NaH2PO4.2H20,0.9% NaCl, 0.1% bovine-7- 
globulin in distilled water 
Trypan blu 0.05% in sterile saline solution 
5.1.2.2 Preparation of Sus]]ensions of Rat Peritoneal Leukoc3qes 
A suspension of leukocytes containing approximately 85% polymorphonuclear 
leukocytes (PMNs) and 15% mononuclear cells was obtained as follows: 
10ml 6% oyster glycogen in saline was injected (i. p. ) into male Wistar rats (200g - 
300g) to induce peritonitis. After 16hr - 20hr, rats were asphyxiated in a C02 
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chamber and 50ml HBSS (Ca2+/Mg2+ free) (4*C) was injected into the peritoneal 
cavity. Following approximately 90s of vigorous massage, the peritoneal washing 
was removed and centrifuged at 4*C for 10min at 1500rpm. After centrifugation, the 
supernatant was discarded and the contaminating erythrocytes in the pellet were lysed 
if necessary by resuspension in I ml 0.2% NaCI for a few moments, before adding 9ml 
saline, followed by further centrifugation at 4*C for 10min at 1500rpm. The pellet 
was resuspended in 10ml HBSS, and the cell suspensions were combined. 100[d cell 
suspension was diluted with 900pl of HBSS; 100pl. of this suspension was further 
diluted with trypan blue solution (1: 1). Cells were counted using a haernocytometer 
and the average number of cells per area (4 x 4) was recorded. The required cell 
density of 2.5 x 106 cells/ml was obtained as follows: 
final volume of = average cell number x 20* x 104 ** x volume of cell suspension 
cell suspension 2.5 x 106 
dilution factor 
area in haemocytorneter 
To achieve the required cell density of 2.5 x 106 cells/ml, the cell suspension was 
made up to the final volume calculated, using complete HBSS. Cell viability based 
on trypan blue exclusion was > 95%. 
5.1.2.3 Stimulation of the Release of Eicosanoids (LTB_4_and- TXBZ) and Their 
RadioimmunoassM 
Triplicate 0.5ml aliquots of the leukocyte suspension were preincubated at 37*C for 
10min with 5ýtl of the test substance diluted in McOH. Test substances and controls 
(Table 5.2) were added prior to addition of cells, except for volatile essential oils and 
compounds and the MeOH control, which were added after addition of cells. All 
tubes containing volatile substances were stoppered to prevent loss of the volatile 
constituents during incubation. Further controls were set up to control for the effect 
of the test substance (at the highest concentration) in the RIA (C 11). 
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Table 5.2. Controls used for radioimmunoassay. 
Control Compound Volume added 
Cl cells alone (no compounds added) - 
C2 MeOH 5111 
C3 MeOH (added after cells) 5pl 
C4 DMSO 5pl 
C5 distilled H20 5[il 
C6 CH3COCH3 5[tl 
C7 20ýM indomethacin (COX 
inhibitor) 
5[il 
C8 20[LM ZM 230487 (5-LOX 
inhibitor) 
5pl 
C9 20pM ZM 211965 (5-LOX 
inhibitor) 
5pl 
CIO triton X- 100 (20%) 2[LI 
Cli Test substance added after 
incubation 
5gl 
After preincubation, I pl calcium ionophore A23187 was added in DMSO to give a 
final concentration of I pM (except to C 1) to generate eicosanoid release. Following 
further incubation at 37'C for 10min, the cells were centrifuged at 4*C for 10min at 
1500rpm, and the cell-free supernatants were decanted and frozen at -20*C. 
Supernatants were retained for analysis by RIA and for assessment of 
myeloperoxidase activity. RlAs were conducted using the supernatant as follows: 
Aliquots; (2pl for LTB4.15pl for TXB2) of the thawed superriatant samples were 
subjected to RIA by adjusting the volume to I 00pl volume with RIA bu cr. A series 
of standard solutions were also subjected to RIA; unlabelled LTB4 and TX132 standard 
solutions were assayed (3.125pg/ml - 50OOpg/ml). 200[d polyclonal rabbit anti- 
eicosanoid serum (diluted 1: 1500 for anti-TXB2 and 1: 2000 for anti-LTB4) was added 
to each sample. Tracer was diluted prior to use with RIA buffer to give 10 nCi [3 H]- 
TXB2 or 4 nCi [3 H]-LTB4 per 100[d. 100[il of tracer was then added to samples and 
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standards, and also to a zero standard, which contained no cicosanoid. The solutions 
were vortex mixed prior to incubation at 4*C for 18hr. After incubation, 200ttl 
dextran coated charcoal was added to samples to adsorb free eicosanoid. Samples 
were vortex mixed and incubated at 4*C for 15min. To separate bound eicosanoid 
from free eicosanoid, samples were centrifuged at 4*C for 30min. The supernatants 
were decanted into scintillation vials and 5ml of LiquiscintO scintillation fluid was 
added. Quantitation of CH]-TXB2 or rH]-LTB4 was conducted using a Canberra 
Packard 1900TR P-scintillation counter for 5min, followed by interpretation of the 
values using a standard curve prepared using various amounts of cicosanoid ranging 
from 3.125pg/ml to 50OOpg/ml. Sensitivity of these assays was 5pg. 
5.1.3 Data Analysis 
Results were expressed as the percentage of the controls (n=24: C2, C3, C4, C5, C6) 
with cells stimulated by A23187 (the percentage of A23187 was calculated using 
mean ng/mI of LTB4 or TXB2). Results were also expressed as eicosanoid 
concentration (ng/ml). Data are presented as the mean (n--3 for test substances and 
positive controls (C7, C8, C9) ± SEM). Data were analysed using the student t test to 
detennine the significance of the difference between the controls (C2, C3, C4, C5, 
C6) and the substance under investigation. Significance was regarded asp<0.05. 
5.1.4 Mycloperoxidase Assay Method 
5.1.4.1 Preparation of AssLay Solutions 
Table 5.3. Composition of assay solutions used for the myeloperoxiclase assay. 
Assay Solution Composition 
Phosphate buffer (pH 6) / hexadecyl- 
trimethylammonium bromide (HTAB) 
6.62mM Na2HP04 (anhydrous), 0.06M 
KH2PO4 containing 0.5% HTAB 
o-Dianisidine solution o-dianisidine in distilled water 
(0.68mg/ml) 
Hydrogen peroxide solution H202 in distilled water (0.003%) 
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5.1.4.2 Mveloneroxidase Assav Method 
Assessment of MPO activity was conducted as described by Bradley et al. (1982) and 
the Worthington Enzyme Manual (1972). The following reagents were added in the 
order stated to wells of a 96-well microtiter plate, in triplicate: 50PI leukocyte 
supernatant, 50ýd phosphate buffer (pH 6, containing HTAB to solubilise MPO) and 
50ýd o-dianisidine solution. The reaction was initiated by addition of 50[d freshly 
prepared H202 solution to each well, and the optical density at 450nm was measured 
immediately, and at Imin, 3min, 6min, 15min and at 30min after the reaction was 
started. The optical density was measured using an Anthos HT 11 plate reader. 
5.2 Results and Discussion 
5.2.1 Activity of Plant Extracts Against Leukocyte Eicosanoid Formation 
5.2.1.1 Activily of Plant Extracts Against Leukocýqe TXB-2 Fonnation 
Activation by ionophore A23187 of the peritoneal leukocytes caused a 65-fold 
increase in TXB2 generation, an effect completely inhibited by the COX inhibitor 
indomethacin at 20ýM (Figure 5.2). Aqueous and EtOH plant extracts were 
investigated at a concentration of 50pg/ml to determine their activity against 
leukocyte TXB2 formation. 
The results show that the EtOH extracts of Centella asiatica leaf, Convallaria majalis 
leaf, Rosmarinus officinalis leaf (dried) and Withania somnifera root were 
significantly active against TM32 formation (p<0.05) as were the EtOH and aqueous 
extracts of Salvia miltiorrhiza root (p<0.001); these extracts reduced TXB2 generation 






Extracts at 510pgtml 
Positivc Controls at 20pM 10 
17 18 19 
1: Cells alone (C 1) 8: Melissa officinalis 13: Salvia miltiorrhiza 
leaf root 
2: Cells + A23187 9: Polygala tenuifiblia 14: Withania somnifera 
(C2 - C6) root root 
3: Alisma orientalis root 10: Adulterated Polygonum 15: Ziziphusjujuba seed 
4: Apocynum lancifiblium multiflorum root 16: Ziziphus jujuba var 
leaf (Gentiana spp. ) spinosa seed 
5: Centella asiatica leaf 11: Rosmarinus officinalis 17: Indomethacin (C7) 
6: Codonopsis pilulosa root fresh leaf 18: ZM 230487 (C8) 
7: Convallaria majalis leaf 12: Rosmarinus officinalis 19: ZM 211965 (C9) 
dried leaf 
* p<0.05; ** p<0.01; *** p<0.001 
Figure 5.2. Effect of aqueous and ethanolic plant extracts and three reference 
compounds on TX132 generation in rat peritoneal leukocytes (n=3, except cells alone: 
n=6 and A23187 controls: n--24). 
ý Cells alone 
ý Cells+ A23187 
M EtOH varacts 
13 14 
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5.2.1.1.1 Centella asiatica 
Compounds reported to be present in Centella asiatica leaf include flavonoid 
glycosides (Prum. et aL, 1983), monoterpenoid, sesquiterpenoid and triterpenoid 
compounds (Asakawa et aL, 1982), and triterpenoid saponin compounds (GUnther and 
Wagner, 1996; Maquart et aL, 1990; Shukla et aL, 1999b; Vogel et aL, 1990) 
including asiaticoside (101) and madecassoside (26) (Inamdar et aL, 1996). Some 
terpenoid and flavonoid compounds have been reported as anti-inflammatory 
(Bruneton, 1995; Kenner and Requena, 1996) due to COX and 5-LOX inhibition, 





The monoterpenes a-pinene (53) and P-pinene (54) are reported to be present in the 
essential oil from C asiatica (Asakawa et aL, 1982), and may have been present in 
the EtOH extract. These monoterpenes are reported to be anti-inflammatory (Handa 
el aL, 1992). 
Saponins are surface-active glycosides, so can potentially alter cell membrane 
structure and thereby cause haemolysis of erythrocytes (Rosenthal and Janzen, 1979). 
Lysis of leukocyte membranes may influence eicosanoid generation. However the 
relative selectivity of C asiatica EtOH extract for the COX enzyme (Figures 5.2 and 
5.3) suggests that the surfactant effect was not responsible for the apparent activity 
(the glycosides e. g. asiaticoside (101) may also have been at a higher concentration in 
the inactive aqueous extract). Some plants containing saponins are reported to be 
anti-inflammatory, perhaps because saponins have a similar molecular structure to 
steroidal compounds (e. g. barbatosides A and B from Dianthus barbalus) (Handa et 
aL, 1992; Kenner and Requena, 1996). The triterpene saponin glycyrrhizin from 
HO CH 
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Glycyrrhiza spp. is reported to potentiate the action of hydrocortisone in rats (Handa 
et aL, 1992), so it cannot be excluded that saponins may inhibit hepatic metabolism of 
corticosteroids in vivo and enhance steroidal activity via this mechanism, and not by a 
direct steroidal action on phospholipase A2 activity. However, the topical 
administration of some saponins mimics the anti-inflammatory effects of 
corticosteroids. It has been reported that saponins are effective in the treatment of 
inflammatory skin conditions, such as atopic dermatitis and eczema (Jimdnez et aL, 
1987), perhaps due to steroidal activity. The triterpene asiatic acid (102) is reported 
to increase tensile strength of skin wounds, an effect that was attributed to steroidal 
structure of this compound (Weber, 1992). 
OH 
This biological activity of asiatic acid (102) may be evidence that steroidal 
compounds from C asiatica are pharmacologically similar to anti-inflammatory 
steroidal drugs, and may influence in vitro eicosanoid generation, this effect being 
possibly due to activity against phospholipase A2- C. asiatica is reportedly used in the 
Fiji Islands to treat inflammatory eye conditions (Brinkhaus et aL, 2000), which may 
be explained by the results of these investigations. 
5.2.1.1.2 Convallaria maialis 
Convallaria majalis leaf has not previously been reported to have potential anti- 
inflammatory effects. Compounds identified in the leaf include cardiac glycosides 
and flavonoid glycosidcs (Trease and Evans, 1996). The aglycones of the cardiac 
glycosides are steroidal compounds (e. g. convallatoxin (50) yields the aglycone 
strophanthidin (47) and (-)-rhamnose upon hydrolysis). These steroidal aglycones 
Asiatic acid (102) 
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(which would be expected to be present in the active EtOH extract, but not the 
inactive aqueous extract) may be responsible for anti-inflammatory activity, perhaps 
by influencing phospholipase A2 activity, like the anti-inflammatory corticosteroid 
drugs. However, the greater selectivity for the COX enzyme, over 5-LOX (Figures 
5.2 and 5.3), suggests COX inhibiting compounds are present in the EtOH extract. 
Many flavonoid compounds are reported to be anti-inflammatory, such as the 
flavonoid glycoside gossypin (103) from Gossypium indicum, and the flavonoid 
quercetin (104) from the Solanaceae (Harbome and Baxter, 1993). The lipophilic 
flavonol aglycone, gnaphalin (105), has been shown to inhibit LTB4 and TX132 
generation in rat peritoneal leukocytes (de la Puerta et aL, 1999). The structural 
features of flavonoid molecules required for COX inhibition have been reported to be 
the presence of a pyrocatechol group in at least one of the rings (A or B). For 
example, in flavonols hydroxylation at the 3 position is sufficient (Alcaraz and 
Feffdndiz, 1987). However, flavones without any such substituents can also inhibit 
COX (Mower et aL, 1984; Welton et aL, 1986). 
HO CH20H 

















Therefore, it is possible that flavonoid compounds present in C majalis leaf are 
responsible for COX inhibition, although activity due to other phytochemicals is 




anti-inflammatory activity (however, cournarins are yet to be isolated from C. majalis 
leao. Some cournarins are also inhibitors of both COX and 5-LOX enzymes (Hoult 
and Payd, 1996). 
5.2.1.1.3 Rosmarinus offlicinalis 
Rosmarinus officinalis leaf constituents identified include flavonoids (e. g. apigenin, 
luteolin (114)), phenolic compounds (e. g. caffeic acid (106) and chlorogenic acid 
(107)), diterpenoid (e. g. carnosol (142)) and triterpenoid compounds (e. g. oleanic 
acids and rofficerone), and a volatile oil composed mainly of monoterpenes (Bisset, 
1994; Ganeva et al., 1993; Newall et al., 1996). The herb is recommended for 
rheumatoid arthritis in the German Commission E monographs (Bisset, 1994), which 
perhaps indicates that it contains anti-inflammatory compounds. 
The EtOH extract of the fresh leaf of R. ofjzlcinalis, and the aqueous extract of the 
dried leaf of R. qfjlcinalis were not significantly active against TXB2 generation 
(Figure 5.2). This suggests that compounds responsible for activity were less polar 
than those compounds present in the aqueous extract (e. g. glycosidic compounds), and 
that the chemical composition of the herb may be affected by factors such as the 
storage conditions (e. g. light, humidity, temperature, duration of storage). 
HO 
HO OH 
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Compounds present in the EtOH extract of the dried herb may therefore be COX 
inhibitors. However, previous studies have shown that rosmarinic acid (RA) (108), a 
compound found to be present in R. officinalis leaf, enhances PGE2 formation in 
polymorphonuclear leucocytes (Kimura et aL, 1987). RA (108) and plant extracts 
containing RA (108) are scavengers of free radicals (Lamaison et al., 1991). This 
activity may explain the prevention of the inactivation of COX by oxygen radicals. 
RA (108) has also been reported to influence the complement system, a system 
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involved in the inflammatory response. RA (108) was shown to inhibit cutaneous 
anaphylaxis in rats, impaired in vivo activation of macrophages in mice and reduced 
paw oedema induced by cobra venom factor (CVF) in rats; RA (108) did not inhibit 
oedema induced by t-butyl-hydroperoxide in the rat (Englberger et aL, 1988). This 
indicates selectivity for complement dependent processes, as CVF can selectively 
activate C3 and C5. Further experiments in vitro showed that RA (108) inhibited C3- 
convcrtase in the complement pathway (Englberger et aL, 1988), but it did not inhibit 
COX activity in studies investigating TXB2 and 17-hydroxyheptadecatrienoic acid 
(HHT) formation (Rampart et aL, 1986). 
It may be concluded that compounds present in the R. officinalis EtOH extract, other 
than RA (108), inhibit COX activity (as COX inhibition would also suppress PGE2 
formation), or that other pathways in the arachidonate cascade are influenced by the 
extract. This may include effects against thromboxane synthase activity. Inhibition 
of thromboxane synthase activity by RA (108) has not been established, however RA 
(108) does not inhibit prostaglandin synthase activity (Kuhnt et aL, 1995), an enzyme 
involved in PG12 synthesis. 
H0 COOH 
H HO 
'zýý 0.1 "., CH 2 OH 
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Rosmarinic acid (108) 
5.2.1.1.4 Salvia miltiorrhiza 
Both the aqueous and EtOH extracts of Salvia miltiorrhiza root exhibited superior 
activity against TXB2 generation (p<0.001), compared to the other extracts. 
Activation by ionophore A23187 of the peritoneal leukocytes caused a 63-fold 
increase in TXB2 generation, which was reduced by 82% by the EtOH extract of S. 
milliorrhiza root, and by 75% by the aqueous extract of S. miltiorrhiza root (Figure 
5.2). S. miltiorrhiza root is used in TCM for rheumatoid arthritis and other 
inflammatory conditions (Duke and Ayensu, 1985). The scientific basis for these 
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indications may be explained to some extent by the activity against eicosanoid 
generation observed in these experiments. S. miltiorrhiza root extracts were also 
assessed for inhibitory activity against eicosanoid generation over the concentration 
range 25gg/ml - 200gg/ml (refer to 5.2.1.3). 
5.2.1.1.5 Withania somniýLera 
Wilhania somnifera root has been used in the Unani tradition for asthma (a pulmonary 
disease involving inflammation), bronchitis, arthritis and other inflammatory 
disorders (Asthana and Raina, 1988; Upton, 2000). W. somnifera root extracts have 
previously demonstrated immunomodulatory effects in vivo, including effects on 
immune inflammatory systems such as inhibition of ovalbumin induced paw oedema 
(Agarwal et aL, 1999). A traditional Ayurvedic prescription containing W. somnifera 
root, Bosivellia serrala stem, Curcuma longa rhizomes and a zinc complex (Articulin- 
F) produced significant pain relief and decreased disability score in a randomised, 
double-blind, placebo-controlled, cross-over study, in patients with osteoarthritis 
(Kulkami et aL, 1991). All herbal components of Articulin-F are reported to be either 
analgesic or anti-inflammatory. These herbs may act synergistically, or one herb (or 
compounds) may contribute more significantly to activity. To explain the 
observations in osteoarthritis patients, assessment of the herbs individually for 
potential activities relevant to disease management would be required. 
The leaves of W. somnifera suppress granulation tissue formation induced by cotton- 
pellet implantation in rats; this effect was attributed to steroidal compounds present in 
the plant, of which, withaferin A (109) is a major component (Al-Hindawi el aL, 
1992). A compound, 3p-hydroxy-2,3-dihydro-withanolide F, has been isolated from 
the fruits of another Withania spp. (W. coagulans); the anti-inflammatory activity 
(assessed in rats with formalin induced arthritis) of this compound was comparable to 
hydrocortisone and phenylbutazone (Budhimja el aL, 1984). Related compounds, 
withanolides A-F are reported to occur in W. somnifera root (Upton, 2000) and may 
therefore have similar biological activities against inflammation. 
These steroidal compounds (withanolides) may possess similar activity to 
corticosteroids, which are often prescribed for inflammatory conditions. This may be 
explained by the steroidal skeleton of the withanolides resembling the chemical 
structure of anti-inflammatory steroidal compounds, such as prednisolone (110). 
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Corticosteroids suppress eicosanoid generation by induction of the phospholipase A2 









Withaferin A (109) Prednisolone (110) 
An alcohol extract from W. somnifera leaves showed comparable anti-inflammatory 
effects to phenylbutazone (a NSAID) and hydrocortisone against formalin-induced 
oedema and granulation tissue formation in rats (Sudhir et aL, 1986). Further 
investigations have shown W. somnifera root to be anti-inflammatory. The root was 
effective against arthritis in rats where a reduction in rat paw oedema and the 
prevention of bony degeneration was observed (Begum and Sadique, 1988). a2- 
Macroglobulin serum levels (an indicator of arthritis and inflammatory conditions) 
were reduced following treatment with W. somnifera root (Anbalagan and Sadique, 
198 1 a; Anbalagan and Sadique, 198 1 b; Anbalagan and Sadique, 1985). The effect of 
the herb on acute phase reactants (APRs) (serum proteins which are elevated in 
inflammatory conditions), such as a2-macroglobulin, indicates that W. somnifera may 
also affect disease progression, and not just provide symptomatic relief, unlike the 
NSAIDs. The potential for the suppression of inflammatory processes could be of 
particular importance in delaying AD progression. 
The observed effect of the EtOH extract of W. somnifera root against TXB2 formation 
provides further evidence for the anti-inflammatory effects reported. Previous studies 
suggest the steroidal compounds present in the root and leaves of TV somnifera are 
responsible for anti-inflammatory activity. Treatment with NSAIDs is reported to 
have little or no effect on APRs, unlike the steroidal drugs (Anbalagan and Sadique, 
1981a); this occurrence is further evidence for a steroidal anti-inflammatory activity 
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of W. somnifera. It could also be possible that compounds present can act similarly to 
the lipocortins and influence phospholipase A2 activity directly. However, as the 
EtOH extract of W. somnifera root was more active against TXB2 generation than 
LTB4 generation (Figures 5.2 and 5.3), it is apparently more selective for COX (as 
opposed to 5-LOX). This suggests COX inhibitors are also present in the root (e. g. 
the anti-inflammatory flavonoid quercetin (104), which has been reported to be 
present in many plant families including the Solanaceae (Harborne and Baxter, 
1993)). 
Numerous alkaloids have been identified in W. somnifera root (e. g. anaferine (60), 
ashwagandhine, cuscohygrine (61), soniniferinine, withaninine and withasomine 
(Harborne and Baxter, 1993; Mills and Bone, 2000; Schwarting et al., 1963; Upton, 
2000)). Several alkaloids from various plant sources are reported to be anti- 
inflammatory, such as tomatine, a steroidal alkaloid glucoside from Solanum 
lycopersicum, which is also a member of the Solanaceae (Bing8l and $ener, 1995; 
Handa et aL, 1992). It is not only the steroidal alkaloids that have anti-inflammatory 
activity, which suggests that alkaloids may have other modes of action, besides effects 
on phospholipase A2 activity. Jatrorrhizine (111) from Plagiorhegma dubium, 
dauricine (112) from Menispermum dauricum and tetrandrine from Slephania 
tetrandra are isoquinolone alkaloids, reported to be anti-inflammatory. Cryogenine 
(113) isolated from Heimia salicifolia is an inhibitor of prostaglandin synthetase 
(Bing6l and ýener, 1995; Handa et aL, 1992; Harbome and Baxter, 1993). The 
effects of W. somnifera against eicosanoid generation may have in part, been due to 
the alkaloids present. It is therefore possible that this herb may have more than one 
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5.2.1.2 Activily of Plant Extracts Against Leukoe3le LTB4 Formation 
The aqueous and EtOH plant extracts were also investigated at a concentration of 
50pg/ml to detennine their activity against leukocyte LT134 fortnation (Figure 5.3). 
Activation by ionophore A23187 of the peritoneal leukocytes caused a 21-fold 
increase in LTB4 generation, which was significantly reduced by 87%, 94%, 92% and 
91% by the EtOH extracts of Rosmarinus offi'cinalis leaf (fresh), Rosmarinus 
officinalis leaf (dried), Salvia miltiorrhiza root and the aqueous extract of Salvia 
miltiorrhiza root respectively (p<0.05) (Figure 5.3). 
5.2.1.2.1 Alisma orientalis 
Both the aqueous and EtOH extracts of 41isma orientalis root showed no significant 
activity against LTB4 or TXB2 generation (Figures 5.2 and 5.3), suggesting absence of 
compounds that inhibit the COX and 5-LOX pathways. A. orientalis root has 
previously been reported to suppress xylene-induced mouse ear oedema (Yue et aL, 
1991), which was attributed to an anti-inflammatory effect. Activity in vivo may have 
been observed following metabolism of inactive compounds in the extract to 
compounds that are active against enzymes of the amchidonate pathways, or may 
have occurred independently from effects on TX132 or LTB4 generation. These effects 
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1234789 10 11 12 13 14 15 16 1718 19 
Extracts at 50pg/nd 
Positiw Controls at 20pM 
Kev 
1: Cells alone (C 1) 8: Melissa officinalis 13: Salvia miltiorrhiza 
leaf root 
2: Cells + A23187 9: Polygala tenuifiblia 14: Withania somnifera 
(C2 - C6) root root 
3:, 41isma orientalis root 10: Adulterated Polygonum 15: Ziziphusjujuba seed 
4: Apocynum lancifiblium multiflorum root 16: Ziziphus jujuba var 
leaf (Gentiana spp. ) spinosa seed 
5: Centella asiatica leaf 11: Rosmarinus officinalis 17: Indomethacin (C7) 
6: Codonopsis pilulosa root fresh leaf 18: ZM 230487 (C8) 
7: Convallaria majalis leaf 12: Rosmarinus officinalis 19: ZM 211965 (C9) 
dried leaf 
* p<0.05; ** p<0.0 1; *** p<0.00 I 
Figure 5.3. Effect of aqueous and ethanolic plant extracts and three reference 
compounds on LT134 generation in rat peritoneal leukocytes (n=3, except cells alone: 
n=6, and A23187 controls: n=24). 
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5.2.1.2.2 Apocvnum lanciLolium 
Apocynum lancifolium leaf extracts were not significantly active against TXB IF 2 and 
LT134 formation (Figures 5.2 and 5.3). The leaf of this plant has previously been 
reported to suppress inflammatory and also allergic reactions (Jianming, 1988). 
Further investigations to assess potential anti-inflammatory activity would be 
warranted to confirm inactivity of this plant, against the reputed anti-inflammatory 
disorders for which the leaf was used in TCM. 
5.2.1.2.3 Gentiana spp. (Adulterated Polvaonum multiAorum) 
Neither the aqueous nor the EtOH extracts of Gentiana spp. root were significantly 
active against TXB2 or LTB4 formation in vitro, but the EtOH extract was more active 
against eicosanoid formation than the aqueous extract (Figures 5.2 and 5.3). These 
results indicate that less polar compounds in the root may be more active against 
eicosanoid generation than the more polar compounds. 
Constituents isolated from Gentiana spp. include flavonoids (e. g. isovitexin, quercetin 
(104)) (Lin et al., 1997), secoiridoids (e. g. arnarogentin, gentiopicroside, 
swertiamarine) (Chuch et al., 2001; Tan et al., 1997; Verotta, 1985) and xanthones 
(e. g. belliffolin, neolancerin, swerchirin) (Schaufelberger and Hostettmann, 1988). 
Some flavonoid compounds are reported to have anti-inflammatory activity (de la 
Puerta et al., 1999; Mower et al., 1984; Welton et al., 1986), but the identification and 
pharmacological activities of any flavonoids, or other compounds, present in the 
Gentiana spp. used in the present study remain to be further investigated. 
5.2.1.2.4 Polv-aala tenuifolia 
Polygala tenuifolia extracts were not significantly active in these assays. P. tenitifolia 
has not been reported to date to have anti-inflammatory activity. However, a species 
related to P. tenuifolia, Polygala cyparissias, antagonised the contractions induced by 
chemical inflammatory mediators in the guinea-pig trachea in vitro, and this effect 
was also observed with the isolated compound 1,7-dihydroxy-2,3-dimethoxy 
xanthone (ElSayah et aL, 1999). It would be of interest to assess Polygala cyparissias 
for activity against eicosanoid generation to gain further information regarding its 
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mode of action. P. tenuffolia has also been reported to contain xanthone compounds 
(Fujita et aL, 1992; Ikeya et aL, 1991a; Ikeya et aL, 1994) and could therefore be 
assessed and compared for the activity observed with Polygala cyparissids. The 
apparent differences in activity observed between these two related species of 
Polygala emphasises the need to assess extracts and isolated compounds in various 
assays to identify modes of action, potency and potential toxicity. 
5.2.1.2.5 Rosmarinus oEicinalis 
The phenolic compounds RA (108) and caffeic acid (106) have been identified in 
Rosmarinus officinalis leaf RA (108) and caffeic acid (106) are reported to inhibit 
the formation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) and LT134 in 
human polymorphonuclear leucocytes (Kimura et aL, 1987). RA (108) and caffeic 
acid (106) may have been responsible for the observed activity to reduce LTB4 
formation. However, the occurrence of other active compounds in the extract cannot 
be excluded. It is therefore possible that RA (108), and perhaps other compounds 
(e. g. other monocaffeoyl derivatives), present in the EtOH extract of R. officinalis 
leaf, are 5-LOX inhibitors. The phenylpropanoid compounds RA (108) and caffeic 
acid (106) are relatively hydrophobic in nature, so their presence in the active EtOH 
extract rather than the less active aqueous extract may be expected. The 
phenylpropanoid anethole (99), present in anise oil, also blocks inflammation, an 
effect attributed to inhibition of NF-KB activation (Chainy et aL, 2000). 
The flavonoid components of R. officinalis leaf may also be responsible for S-LOX 
(and also COX) inhibition. It has been shown that flavones and flavanones with 3,7, 
4-hydroxyl substituents are potent inhibitors of 5-LOX, and the presence of hydroxyl 
at the 5 position is reported to increase the activity (Welton et A, 1986). The 
hydroxyl substituents on the flavone luteolin (114), which is present in R. ojficinalis 
leaf, are at the 5,7,3 and 4 positions, which would favour 5-LOX inhibition. These 
structural features required for 5-LOX selectivity were also confirmed by analysis of a 
flavonoid glycoside and related aglycones (Moroney et aL, 1988). It has also been 
suggested that flavonoid glycosides are weaker inhibitors of 5-LOX than the 
corresponding aglycones (Moroney et al., 1988); this may explain why the EtOH 
extract of R. officinalis (more likely to contain flavonoid aglycones) was more active 
against 5-LOX activity than the aqueous extract (more likely to contain flavonoid 
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glycosides). Flavonoids isolated from other Labiates, Slachys chr santha and Stachys ,y 
candida, inhibit LTC4 release from mouse peritoneal platelets and TXB2 release from 
human platelets (Skaltsa et aL, 2000). Flavonoids may also influence phospholipase, 
A2 activity (Welton el aL, 1986), which may also explain activity of the EtOH extract 





5.2.1.3 Activi! y of Salvia miltiorrhiza Root Extmcts Against LeukocVe Eicosanoid 
Formation 
The EtOH extract of S. miltiorrhiza root was highly active against both TXB2 and 
LTB4 generation over the dose range 25pg/ml - 200[tg/ml (Figures 5.4 and 5.5). This 
effect may be due to the presence of both COX and 5-LOX inhibitors in the extract, or 
due to the presence of constituents inhibiting phospholipase A2 in the inflammatory 
pathway. 
Several other Salvia spp. and their constituents are reputed to have anti-inflammatory 
effects, such as S. chinensis, S. lavandulaefolia, S. officinalis and S. transsylvancia 
(Bartram, 1995; Bisset, 1994; Duke, 1985; Duke and Ayensu, 1985; Maklad et al., 
1999). S. plebeia is used in Taiwan to treat inflammatory disorders; activity being 
attributed to naphthoquinone derivatives which have a similar pharmacological profile 
to NSAIDs (Hemandez-Perez el al., 1995). Anti-inflammatory constituents isolated 
from Salvia spp. include flavonoids (e. g. cirsiliol), monoterpenoids (e. g. carvacrol 
(147), 1,8-cineole (56), thymol) and phenylpropanoids (e. g. caffeic acid (106), 
eugenol (84), RA (108)) (Kuhnt et al., 1995; Marder et al., 1996; Santos and Rao, 
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Figure 5.4. Effect of Salvia miltiorrhiza root extracts and two reference compounds 
on TXB2 generation in rat peritoneal leukocytes (n=3, except cells alone: n=6, and 
A23187 controls: n=24). 
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Figure 5.5. Effect of Salvia miltiorrhiza root extracts and two reference 
compounds on LT134generation in rat peritoneal leukocytes (n=3, except cells alone: 
n=6, and A23187 controls: n=24). 
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Compounds isolated from S. miltiorrhiza root include several diterpenoid compounds 
such as tanshinones 1 (115) and Ila (116), cryptotanshinone (117), tanshindiols A 
(119) and B (120), isotanshinones 1 (121) and 11 (122) and neocryptotanshinone II 
(118) (Lin and Chang, 2000; Tang and Eisenbrand, 1992). Several water-soluble 
compounds have been isolated from the aqueous extract of S. miltiorrhiza root, 
including danshensu (45) (Chen and Liu, 1980), the salvianolic acids A (123) (Li et 
aL, 1984), B (124) and C (125) (Ai and Li, 1988) and RA (Huang et al., 1992). 
Tanshinones are reported to be anti-inflammatory in rats with infective arthritis (Duke 
and Ayensu, 1985) and in mice with croton oil induced inflammation of the car (Tang 
and Eisenbrand, 1992), but the mechanism of action was not established. 
Dihydrotanshinone and cryptotanshinone (117) are significant inhibitors of 0- 
hexosaminidase release from mast cells in vitro (Ryu et A, 1999), which indicates 
they may have anti-allergic activity. Tanshinones 1 (115) and Ila (116), 
cryptotanshinone (117) and dihydrotanshinone have also been identified as platelet 
aggregation inhibitors, suggesting a potential anti-inflammatory action (Onitsuka, A 
et aL, 1983). 
Many diterpenoid compounds have demonstrated anti-inflammatory activity from 
both plant and marine sources. These include the solenolide diterpenes from marine 
Solenopodium spp.; solenolide A (126) is an inhibitor of 5-LOX and solenolide E 
(127) is an inhibitor of COX (Harborne and Tomas-Barberan, 1991). Diterpenes 
isolated from the genus Sideritis (also a Labiate) are anti-inflarnmatory in several 
animal models, such as the diterpene bodatriol (Alcaraz and Villar, 1987; Villar et al., 
1983; Villar et al., 1984); the two diterpenes (ent-13-epi-12a-acetoxymanoyl oxide 
and ent-8a-hydroxy-labda-13(16), 14-diene) isolated from Sideritis javalambrensis 
inhibited PGE2 generation in cultured mouse peritoneal macroPhages (de las Hems 
and Hoult, 1994). 
C H2 
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It is therefore likely that the diterpenes present in S. miltiorrhiza root are responsible 
for the activity against eicosanoid generation, although other compounds present may 
also contribute to activity, perhaps synergistically. Recent investigations support the 
findings of these studies. Tanshinone 1 (115), dihydrotanshinone, tanshinone Ila 
(116) and cryptotanshinone (117) isolated from the lipophilic, extracts of S. 
miltiorrhiza root demonstrated activity against 5-LOX in porcine leukocytes, but were 
not as active as the crude extracts (Paulus and Bauer, 2000). This confirms that less 
polar extracts (which include diterpene components) are more active than the more 
polar, aqueous extract, and although diterpenes may contribute to activity, other 
compounds or synergism may explain the higher potency observed with the crude 
EtOH extract. Therefore, isolation of compounds responsible for COX inhibition, and 
continued assessment of 5-LOX inhibitors, is required. 
5.2.2 Activity of Essential Oils and Essential Oil Constituents Against Leukocyte 
Eicosanoid Fonnation 
5.2.2.1 ActiviLy of Essential Oils and Essential Oil Constituents Against Lcukoc3ýe 
TXB2 Formation 
The essential oils from Rosmarinus officinalis and Melissa officinalis and the essential 
oil constituents trans-caryophyllene (82), citral, geraniol (72) and nerol (75), the 
ma or constituents present in M. officinalis essential oil (refer to Chapter 2,2.2.7.1), 
were investigated at a concentration of 50[Lg/ml to determine their activity against 
leukocyte TXB2 formation. The results show that M. ofji'cinalis essential oil, citral 
and nerol (75) were significantly active against TXB2 formation (p<0.001) (Figure 
5.6). 
Activation by ionophore A23187 of the peritoneal leukocytes caused a 63-fold 
increase in TXB2 generation, which was reduced by 81%. 84% and 82% by M. 
officinalis essential oil, citral and nerol (75) respectively (p<0.001). Geraniol (72) 
and trans-caryophyllene (82) were also significantly active against TXB2 formation 
(p<0.01 and p<0.005 respectively) (Figure 5.6). The terpenes citral, geraniol (72), 
nerol (75) and trans-caryophyllene (82) comprise 42% of the M. officinalis essential 




Essential Oils and Pure Compounds at 50lig/m I 
Positive Controls at 20pM 
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1: Cells alone (C 1) 
2: Cells+A23187 (C2-C6) 
3: M officinalis essential oil 





9: Indomethacin (C7) 
10: ZM 230487 (C8) 
11: ZM 211965 (C9) 
Figure 5.6. Effect of essential oils, essential oil constituents and three reference 
compounds on TXB2 generation in rat peritoneal leukocytes (n--3, except cells alone: 
n=6 and A23187 controls: n=24). 
*p<0.05; **p<0.01; ***p<0.001 
1 10 
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R. offi'cinalis essential oil is not reported to contain significant quantities of these 
compounds, but is reported to contain 1,8-cineole (56) (15-30%), camphor (57) (15- 
25%), a-pinene (53) (up to 25%) and other monoterpenes (e. g. bomcol (58), bornyl 
acetate (51)) as the major constituents (Bisset, 1994; Trease and Evans, 1996). 
It may be concluded that the terpene components of M officinalis essential oil (citral, 
geraniol (72), nerol (75) and trans-caryophyllene (82)) are most likely to be 
responsible for the activity of this oil (although activity of other compounds present 
remains to be determined), and that their low concentration (or absence) in R. 
officinalis essential oil explains the inactivity of R. officinalis essential oil against 
T'XB2 generation. 1,8-cineole (56), reported to be present in R. officinalis essential 
oil (Bisset, 1994; Trease and Evans, 1996), inhibits carrageenan-induced oedema in 
paws of mice, and is reported to inhibit LTB4,, TXB2 and PGE2 in human blood 
monocytes (Juergans et aL, 1998; Santos and Rao, 2000). A low concentration of 
1,8-cineole (56) in the R. 6fficinalis essential oil may explain the low activity against 
T'XB2 generation in the rat peritoneal leukocytes. 
5.2.2.2 Activi! y of Essential Oils and Essential Oil Constituents Against Leukogýje 
LTB4 Formation 
The essential oils from Rosmarinus officinalis and Melissa officinalis, and the 
essential oil constituents trans-caryophyllene (82), citral, geraniol (72) and nerol (75) 
were also investigated at a concentration of 50gg/ml to deten-nine their activity 
against leukocyte LT134 formation. The results show that R. officinalis, M officinalis 
and citral were active against LTB4 fannation (p<0.05) (Figure 5.7). These results 
indicate the presence of 5-LOX inhibitors in both essential oils. Different compounds 
in each essential oil may be responsible for activity, as the oil compositions differ. 
The presence of citral in M. qjfIcinalis essential oil may have contributed to activity, 
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3: M. officinalis essential oil 
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11: ZM 211965 (C9) 
Figure 5.7. Effect of essential oils, essential oil constituents and three reference 
compounds on LT134 generation in rat peritoneal leukocytes (n=3, except cells alone: 
n=6 and A23187 controls: n=24). 
* p<0.05; ** p<0.0 1; *** p<0.00 I 
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5.2.3 Activity of Melissa offIcinalis Extracts, Essential Oil and Essential Oil 
Constituents Against Leukocyte Eicosanoid Formation 
Initial investigations demonstrated that the essential oil from Melissa officinalis and 
the major constituents, trans-caryophyllene (82), citral, geraniol (72) and nerol (75), 
identified to be present in M. officinalis essential oil (refer to Chapter 2,2.2.7.1) were 
active against leukocyte eicosanoid formation (refer to 5.2.2). Therefore, further 
experiments were conducted to assess the effect of the essential oil and constituents 
over the concentration range 12.5pg/ml - 200Vg/ml. The aqueous and EtOH extracts 
of M. offi'cinalis herb were also further assessed over the concentration range 50pg/ml 
- 200gg/ml. The effect of each test substance (at the highest concentration: 
200[ig/ml) in the RIA was also assessed (C 11) (refer to method, 5.1.2.3). 
5.2.3.1 Activily of Melissa officinalis Extracts, Essential Oil and Essential Oil 
Constituents Against Leukoe3le TXB-) Formation 
The EtOH extract of Melissa officinalis herb demonstrated concentration dependent 
activity against leukocyte TXB2 formation; this activity could not be attributed to 
interference in the RIA (Figure 5.8). This suggests that compound(s) in the EtOH 
extract of M. o inalis herb may cause COX inhibition. In contrast, the aqueous 01 C 
extract of M. officinalis herb was not significantly active against TXB2 formation over 
the concentration range tested (Figure 5.8). This suggests that COX inhibitors are 
absent in this extract. However, COX inhibitors may be present at concentrations too 
low to cause enzyme inhibition, or both inducers and inhibitors of the COX enzyme 
may be present, which may also explain inactivity. 
M. officinalis herb constituents include RA (108), chlorogenic (107) and caffeic (106) 
acids, triterpenes and flavonoids (e. g. quercetin (104), rhamnocitrin and the 
glycosides of apigenin and luteolin (114)) (Bisset, 1994; Bruneton, 1995; Mulkens 
and Kapetanidis, 1987). The flavone aglycones apigenin and luteolin (114) are 
reportedly anti-inflammatory (Harborne, 1993), which may explain the activity of the 
less polar EtOH extract. Other flavonoid compounds may also be responsible for the 
inhibitory effects against TXB2 generation observed, but isolation of compounds is 
necessary to investigate effects of such compounds against TXB2 formation. 
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Cells alone 
Cells + A23187 
Melissa officinalis, ROH extract 
Melissa officinalis water extract 
Melissa officinalis essential oil 
1 
Extracts (pig/ml) 
Positive Controls at 20pM 
(# added alker incubation) 
Figure 5.8. Effect of Melissa officinalis leaf extracts, essential oil and two reference 
compounds on TX132 generation in rat peritoneal leukocytes (n=3, except cells alone: 
n=6 and A23187 controls: n=24). 
* p<0.05; ** p<0.0 1; *** p<0.00 1 
M. officinalis essential oil and the pure compounds citral. and geraniol (72) showed 
dose dependent activity against TXB2 formation, and were significantly active over 
the concentration range 50pg/ml - 200pg/ml (p<0.001) (Figures 5.8,5.9 and 5.10). 
Trans-caryophyllene (82) was inactive against TXB2 formation over the concentration 
range, which suggests this compound is not a potent COX inhibitor (Figure 5.9). It 
may therefore be concluded that the presence of trans-caryophyllene (82) in M. 
q cinalis essential oil does not contribute significantly to the activity of the essential Of, 
oil against TY. 132 formation. 
The cis-isomer of geraniol (72) is nerol (75) and it showed significant dose dependent 
activity against TX132 formation over the concentration range 12.5ýLg/ml - 200pg/ml 
(p<0.001) (Figure 5.10). Neither the essential oil, nor the pure compounds appeared 
to influence TX132 formation as a result of interference in the RIA. Therefore, it is 






Extracts (pg/m I) 
Positive Controls at 20pM 
(N added after incubation) 
Figure 5.9. Effect of the pure compounds irans-caryophyllene and citral, and two 
reference compounds on TXB2 generation in rat peritoneal leukocytes (n=3, except 
cells alone: n=6 and A23187 controls: n=24). 
Cells alone 
Cells + A23187 
M Geraniol 
Nerol 
Extracts (pg/m 1) 
Positive Controls at 20p&M 
(# added ater incubation) 
Figure 5.10. Effect of the pure compounds geraniol and nerol, and two reference 
compounds on TX132 generation in rat peritoneal leukocytes (n=3, except cells alone: 
n=6 and A23187 controls: n=24). 
* p<0.05; ** p<0.01; *** p<0.001 
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The proposed anti-inflammatory activity of M. officinalis essential oil may be 
attributed to the presence of citral, geraniol (72) and nerol (75); however, other oil 
constituents present may also contribute to activity. M officinalis essential oil is 
composed of monoterpenes (e. g. citronellal (68), geraniol (72), limonene (73), 
linalool (74), nerol (75)), sesquiterpenes (e. g. 6-cadinene, trans-caryophyllene (82), 
cubebene (80), a-humulene (81)) and other unidentified components (determined by 
GC-MS analysis: refer to Chapter 2,2.2.7.1). Neither this essential oil, nor the 
monoterpenes tested, have previously been shown to be potential anti-inflarnmatory 
agents by inhibition of COX. 
Iff relation toi anti-inflammatory essential oils, the essential oil from Buplellrum 
fructicosum is reported to be anti-inflammatory in carrageenin-induced rat Paw 
oedema (carrageenin-induced rat paw oedema can be potentiated by PGEI and PGE2), 
and a-pinene (53) and P-pinene (54) were found to be the active constituents (Bing6l 
and $ener, 1995; Handa et aL, 1992). (-)-Car-3-ene ftom Bupleurum falcatum 
essential oil is reported to be more potent than a- (53) or P-pinene (54) (Bing6l and 
ýener, 1995; Handa et aL, 1992). However, the mechanism of anti-inflammatory 
action for these monoterpenes is unknown. Although a-pinene (53) may contribute to 
the anti-inflammatory activity of M officinalis essential oil, only 0.3% of the total oil 
was composed of a-pinene (53) (refer to Chapter 2,2.2.7.1) so it is probable that a 
synergistic action with other essential oil components (e. g. geraniol (72)) occurred. 
The structural features required to favour COX inhibition suggested by Alcara and 
Fen-dndiz (1987), are the presence of a pyrocatechol groups in at least one of the rings 
(A or B) in flavonoid molecules. The active acyclic monoterpenes are quite different 
in structure to flavonoids and some other COX inhibiting compounds (e. g. 
diterpenes). Their hydrophobicity may favour interaction with the active site of the 
COX enzyme, but the effect of the functional group on COX inhibition requires 
further investigation to identify any structure-activity relationships. 
5.2.3.2 Activily of Melissa offlcinalky Extracts, Essential Oil and Essential Oil 
Constituents Against Leukoc3je LTB4 Formation 
The EtOH extract of Melissa officinalis herb demonstrated significant activity against 
LTB4 formation at concentrations 100gg/ml - 200tig/ml (Figure 5.11). The aqueous 
extract of M. officinalis herb was not active against LTB4 formation over the 
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concentration range tested (Figure 5.11), and at both I 00[Lg/ml and 200pg/ml, this 
extract appeared to actually promote LTB4 fon-nation. This suggests that 5-LOX 
inducers may be present in this extract, and that inhibitors of 5-LOX are either absent 
or present in concentrations too low to inhibit enzyme activity. 
E 
ctfis A2318? % IOD 200 2000 50 100 200 200# 
Extracts (jLg/nml) 
Positive Controls at 20pM 
(# added after incubation) 
Figure 5.11. Effect of Melissa officinalis leaf extracts, essential oil and two reference 
compounds on LTB4 generation in rat peritoneal leukocytes (n=3, except cells alone: 
n=6 and A23187 controls: n--24). 
* p<0.05; ** p<0.0 1; *** p<0.00 I 
The constituent profile of M. officinalis leaf is similar to that of Rosmarinus officinalis 
leaf This may explain the activities observed against cicosanoid generation with the 
EtOH extracts of both these plants (refer to 5.2.1, Figures 5.2 and 5.3, and 5.2.3, 
Figures 5.8 and 5.11). However, different percentage compositions of each 
constituent, and synergistic effects, may influence potency. For example, the known 
5-LOX inhibitor RA (108) is present in both herbs, but may be present at a higher 
concentration in R. officinalis; this may explain the higher activity against LT134 
formation, when assayed at 50ýig/ml (Figure 5.3). The concentration dependent 
activity observed with the EtOH extract of M officinalis herb may be due to the 
presence of RA (108) or other monocaffeoyl derivatives, or due to the flavonoid 
components of the extract and/or other unidentified phytochemicals. 
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The essential oil from M officinalis was significantly active against LTB4 formation 
over the concentration range 50ýLg/ml - 200gg/ml (p<0.01) (Figure 5.11). The 
inhibition of LTB4 generation caused by the EtOH extract and the essential oil did not 
appear to be due to interference in the RIA, as a reduction in LTB4 formation was not 
observed when these test substances were added after incubation prior to analysis by 
RIA. However, an increase in LT134 formation was observed when these test 
substances were added prior to RIA, suggesting that interference in the RIA may have 
occurred, but did not contribute to the inhibitory activity observed with the test 
compounds. 
Of the pure compounds assessed, trans-caryophyllene (82) appeared to show weak 
activity against LTB4 forination over the concentration range 50gg/ml - 200[Lg/ml 
(Figure 5.12). 
Cells alone 
MCells + A23187 
M trans-Caryophyllene 
Milill Citral 
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Positive Controls at 20pM 
(#added after incubation) 
Figure 5.12. Effect of the pure compounds trans-caryophyllene and citral, and two 
reference compounds on LT134 generation in rat peritoneal leukocytes (n=3, except 
cells alone: n=6 and A23187 controls: n=24). 
* p<0.05; ** p<0.0 1; *** p<0.00 I 
The absence of activity against TX132 formation (refer to 5.2.3.1, Figure 5.9) suggests 
trans-caryophyllene (82) is not an inhibitor of COX, but may be an inhibitor of 5- 
LOX. This terpenoid has also been detected in Centella asiatica (Asakawa et aL, 
1982), and may have influenced eicosanoid generation in the assays investigating this 
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plant (refer to 5.2.1, Figures 5.2 and 5.3). Trans-caryophyllene (82) has not 
previously been shown to demonstrate activity against eicosanoid generation. 
However, the oleoresin from Copaifera spp. (composed of sesquiterpenes including 
caryophyllene (82), a-copaene, P-elemcne and humulene (81)) is reported to inhibit 
carageenan-induced oedema in rats in a dose dependent manner (Handa et aL, 1992). 
These sesquiterpenes were also found to be present in the active M. officinalis 
essential oil (refer to Chapter 2,2.2.7.1), and so may have contributed to the effects 
against eicosanoid generation observed here. 
Other sesquiterpenoid compounds are reported to be anti-inflammatory, including (+ 
a-bisabolol, y-cadinene, caryophyllene oxide (78), chamazulene, cuparene and 
guaizulene (Bing6l and $ener, 1995; Handa et aL, 1992; Harborne and Baxter, 1993). 
The sesquiterpene lactone hydroxyachillin isolated from Tanacelum microphyllum is 
anti-inflammatory in vivo and in vitro, and inhibits 5-LOX (Abad et aL, 1994). 
Sesquiterpene lactones have more than one mode of action against inflammation; 
effects observed include inhibition of human polymorphonuclear neutrophil 
chernotaxis and inhibition of prostaglandin synthetase (Hall et aL, 1980). 
Citral demonstrated significant activity against LTB4 formation over the concentration 
range 25pg/ml - 200pg/ml (p<0.001) (Figure 5.12). Citral appeared to be more active 
against LTB4 formation than TXB2 formation (Figures 5.9 and 5.12). This indicates 
that citral may be more selective for 5-LOX than COX. 
Geraniol (72) and nerol (75) showed concentration dependent activity against LTB4 
formation; geraniol (72) showed significant activity at concentrations 50pg/ml - 
200[tg/ml (p<0.01) and nerol (75) at concentrations 100Pg/ml - 200pg/ml (P<0.01) 
(Figure 5.13). 
Both geraniol (72) and nerol (75) demonstrated greater activity against TXB2 
formation than against LTB4 formation (Figures 5.10 and 5.13). This suggests that 
geraniol (72) and nerol (75) are more selective for COX than 5-LOX. Hydroxylation 
of flavonoid compounds has been suggested as an important feature for 5-LOX 
inhibition (Welton et aL, 1986). However, of the monoterpenes tested for activity 
against 5-LOX, it is the aldehyde citral (geranial (70) and neral (71)) which was a 
more potent inhibitor than the alcohols, geraniol (72) and nerol (75). This suggests an 
aldehyde functional group favours 5-LOX inhibition, however further investigations 
using other monoterpenes with alcohol and aldehyde (and perhaps other) functional 
groups may yield more information regarding structure-activity relationships. 
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ý Cells alone 
M Cells + A23187 
E 
Extracts (pgIm 1) 
Positive Controls at 20pM 
(# added ater i acubstion) 
Figure 5.13. Effect of the pure compounds geraniol and nerol, and two reference 
compounds on LT134 generation in rat peritoneal. leukocytes (n=3, except cells alone: 
n=6 and A23187 controls: n=24). 
* p<0.05; ** p<0.0 1; *** p<0.00 I 
Those test substances that exhibit activity against both TXB2 and LTB4 formation 
may not exert their effects by inhibition of the COX and 5-LOX enzymes only. It 
may be possible that these test substances can also influence other steps in the 
arachidonate cascade, such as inhibition of phospholipase A2 activity. It has been 
previously reported that some eugenol (84), thymol and carvacrol (147) containing 
essential oils are inhibitors of prostaglandin synthesis, as are the pure compounds 
eugenyl acetate, capsaicin, curcumin, carvacrol (147) and urushiol (Wagner el aL, 
1986). The phenylpropanoid eugenol (84) has also been shown to inhibit LT134 and 
HETE formation in human polymorphonuclear leukocytes and reduced carrageenin- 
induced foot inflammation in rats (Bennett et aL, 1988). Other phenylpropanoid 
compounds are reported to be anti-inflammatory by inhibition of prostaglandin 
synthesis, including myristicin (128) from Myristica ftagrans (Bing6l and $ener, 
1995). A chloroform extract from Myristica ftagrans, which may contain the 
phenylpropanoid constituents, is also reported to have anti-inflammatory activity in 







The anti-inflammatory effects observed by M officinalis essential oil and oil 
constituents, and R. officinalis essential oil (against 5-LOX activity) have not 
previously been reported. These observations may explain the pharmacological basis 
of the traditional use of these herbs against inflanunatory disorders. 
5.2.4 Effect of Plant Extracts, Essential Oils and Essential Oil Constituents on 
Myelopcroxidase Activity in Rat Pcritoneal Leukocytes 
5.2.4.1 Myeloperoxidase Activily in Rat Peritoneal Leukocytes 
An initial investigation was conducted to determine MPO catalytic activity in rat 
peritoneal leukocytes over time, as a function of cell number. Results show that as 
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Figure 5.14. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes, as a function of cell number. 
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This reflects the increase in MPO concentration as cell number is increased. 'Mis 
occurrence can be explained by MPO activating HOCI production; HOCI reacts with 
the dye o-dianisidine to yield a coloured product, consequently increasing the optical 
density. 
5.2.4.2 Effect of Plant Exftwts and Rosmarinus officinalis Essential Oil on 
Myeloperoxidase Activijy in Rat Peritoneal Leukoc3qes 
Plant extracts, which produced inhibitory activity against leukocyte eicosanoid 
generation in previous investigations (refer to 5.2.1 ), were assessed for their effect on 
MPO activity, to investigate if the apparent effects against eicosanoid generation were 
actually due inhibition of enzymes in the arachidonate cascade, or due to cytotoxicity. 
The essential oil from Rosmarinus officinalis was also investigated. Results indicate 
that some of the extracts were cytotoxic (Figure 5.15) as MPO activity was greater in 
the presence of these extracts than the MPO activity in the control (A23187 alone: C2, 
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Figure 5.15. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of some 
plant extracts and Rosmarinus officinalis essential oil. 
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Of those extracts tested, the EtOH extract of Withania somnifera was most cytotoxic; 
(Figure 5.15). The EtOH extract of Convallaria majalis and the R. offi'cinalis 
essential oil also demonstrated cytotoxicity (Figure 5.15). Therefore the possibility 
that eicosanoid generation was influenced by the cytotoxicity of these test substances 
cannot be excluded. However, the EtOH extracts of C majalis and W. somnifera 
were more active against TXB2 than LTB4 formation (refer to 5.2.1), which suggests 
compound(s) in these extracts may be more selective for COX than 5-LOX. 
Similarly, R. officinalis essential oil appeared more selective for 5-LOX, as the oil 
was significantly more active against LTB4 formation than TXB2 formation (refer to 
5.2.2). Therefore ftirther investigations may be wan-anted to establish the anti- 
inflammatory potential of these substances. 
The EtOH extracts of both the fresh and dried leaf of R. offi'cinalis showed similar 
effects on MPO activity to the A23187 control (Figure 5.15). Therefore, these 
extracts may have influenced eicosanoid generation by activity against enzymes in the 
arachidonate cascade, and not by a cytotoxic, action. The fresh R. offi'cinalis leaf 
EtOH extract was significantly more active against LTB4 formation than TXB2 
formation (refer to 5.2.1), suggesting 5-LOX selectivity (and not cytotoxicity). 
The aqueous extract of R. officinalis leaf showed a low optical density reading as 
compared to the control (A23187), indicating low MPO activity (Figure 5.15). This 
occurrence suggests that this extract may have anti-oxidant activity because the 
compounds in the extract may have reacted with H202, so decreasing the 
concentration of H202 available to MPO. It may also be possible that the HOCI 
produced by MPO may be scavenged by anti-oxidant(s) present in the extract, 
subsequently decreasing the concentration of HOCI available to react with o- 
dianisidine. Thus, optical density will be lower than in the absence of a free radical 
scavenger. 
R. officinalis leaf is widely used as a preservative and anti-oxidant. An aqueous 
extract of R. officinalis is reported to be anti-oxidant by free radical scavenging 
activity (Joyeux et al., 1995) and anti-oxidant flavonoid glycosides, including 
hesperidin, have been isolated from an aqueous MeOH extract of R. officinalis leaf 
(Cuvelier et aL, 1996; Okamura et aL, 1994). The anti-oxidant activity of flavonoids 
is well documented (Takaharna, 1985; Torel et aL, 1986). It is therefore possible that 
flavonoid compounds in the aqueous extract of R. officinalis leaf were responsible for 
the low optical density readings observed. Some other phenolic compounds such as 
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coumarins and tannins are also known free radical scavengers (Bouchet et A, 1998; 
Hoult and PayA, 1996; Montesinos et aL, 1991), and their presence may also 
contribute to an anti-oxidant effect. 
The presence of free radical scavengers may have influenced eicosanoid generation. 
Both COX and 5-LOX are reported to catalyse free radical peroxidation of AA (Hanel 
and Lands, 1982; Riendeau et aL, 1989). It has been proposed that inhibition of 5- 
LOX is due to the reaction of the inhibitor with free radicals generated at the 
enzyme's active site (Takaharna, 1985; Torel et aL, 1986); therefore in the presence of 
free radical scavengers, inhibition of the enzyme by this mechanism would be 
decreased, thus increasing eicosanoid generation. This occurrence may explain the 
apparent inactivity of the aqueous extract of R. ojjlcinalis leaf against eicosanoid 
generation (refer to 5.2.1, Figures 5.2 and 5.3). However, the potency of the 
inhibition of COX and 5-LOX by flavonoid compounds was not found to significantly 
correlate with anti-oxidant activity, suggesting that scavenging effects on free radicals 
(generated at the active site of the enzyme) do not explain enzyme inhibition 
(Laughton el aL, 1991). It is apparent that the relationship between the anti-oxidant 
and eicosanoid inhibiting effects of compounds requires ftirther investigation. It has 
also been found that a combination of iron-chelating and iron ion-reducing effects 
may be necessary for selective 5-LOX inhibition by phenolic compounds (Laughton 
el aL, 1991); it may be useftil to assess the effects of R. officinalis aqueous extract on 
iron chelation and reduction to further understand the apparent inactivity of this 
extract against eicosanoid generation. Free-radical scavenging effects of other 
extracts (e. g. M ojjlcinafis leaf extracts; refer to 5.2.4.4) may also explain the 
observed inactivity against eicosanoid generation, and this also warrants further 
investigation. 
5.2.4.3 Effect of Salvia miltiorrhiza Root Extracts on Myeloperoxidase Activity in 
Rat Peritoncal Leukoc3les 
Both the aqueous and EtOH extracts of S. miltiorrhiza root produced a dose 
dependent decrease in optical density, as the concentration of extract was increased 
(Figures 5.16 and 5.17). 
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Figure 5.16. Myeloperoxidase activity in supernatants prepared from rat peritonea] 
leukocytes under control and A23187 stimulated conditions, in the presence of Salvia 
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Time (min) 
Control: 200*ml Salvia milliorrhca root EtOll extract added after 
** MeOH added after cells 
Figure 5.17. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of Salvia 
milliorrhiza root ethanolic extract. 
05 10 15 20 25 30 35 
rime (min) 
Control: 200pg/ml Salvia milliorrhiza root water eyaract added after 
* MeOH added after cells 
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Neither extract produced a similar profile for effects on MPO activity, as compared to 
the A23187 control. These observations also suggest that compounds present in both 
extracts may be free radical scavengers. The optical density recorded for the EtOH 
extract was lower than the corresponding concentration for the aqueous extract. This 
indicates that the EtOH extract may contain more potent free radical scavenging 
compounds. Anti-oxidant constituents that have been isolated from S. miltiorrhiza 
root include salvianolic acids A (123) and B (124) and RA (108), which have strong 
anti-lipoperoxidant activity in vitro, partly through scavenging of free radicals 
(Guanhua and Juntian, 1997; Huang and Zhang, 1992; Liu, et al., 1992. 
Quinones isolated from less polar fractions of S. miltiorrhiza root, including 
rosmariquinone, dihydrotanshinone and cryptotanshinone (117), also demonstrated 
anti-oxidant activity; fractions of a MeOH extract of S. miltiorrhiza root and the 
isolated compounds dimethyl lithspermate and 3-(3,4-dihydroxyphenyl) lactamidc 
(140) were identified as free radical scavengers (Kang et aL, 1997; Weng and Gordon, 
1992; Zhao et aL, 1996; also refer to Chapter 6,6.1.2.2.6). 
It appears that the presence of these free radical scavenging compounds in the S. 
miltiorrhiza extracts, may be responsible for the possible anti-oxidant effects 
observed in the MPO assay. 
5.2.4.4 Effect of Melissa officinalis Extracts and the Essential Oil on 
Myeloperoxidase Activi! y in Rat Peritoneal LeukocZes 
The optical density observed with the supernatants treated with the aqueous extract of 
Melissa offlicinalis leaf was low, compared to the A23187 control, which indicates the 
extract may have had potent free radical scavenging activity at all concentrations 
tested (Figure 5.18). 
The EtOH extract of the leaf also demonstrated anti-oxidant activity, which was dose 













Figure 5.18. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of 
Melissa officinalis leaf aqueous extract. 
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Figure 5.19. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of 
Melissa o inalis leaf ethanolic extract. offic 
05 10 15 20 25 30 35 
Time (min) 
Control: 200pg/ml Melissa officinaliv herb water extract added after 
* MeOH added after cells 
05 10 15 20 25 30 35 
Time (min) 
Cortrol: 20OWrnI Mehssa officinalis herb ROH extract added after 
MeOH added after cells 
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The flavonoid content of M qfjlcinalis leaf may have contributed to the free-radical 
scavenging activity observed; the major flavonoid identified in M officinalis leaf is 
luteolin Y-glucuronide (129) (Heitz et aL, 2000). Other compounds isolated from the 
leaf are known free radical scavengers. These include caffeic acid (106), RA (108) 
and 2-(3,4-dihydroxyphenyl)-I, 3-benzodioxole-5-aldehyde (130) isolated from a 
ficinalis leaf (Tagashira and Ohtake, 1998). The apparent free MeOH fraction of M of 
radical scavenging effects of these extracts may help to explain the relatively low 










2-(3,4-Dihydroxyphenyl)- 1,3 - 
benzodioxole-5-aldehyde (130) 
The M. officinalis essential oil did not appear to be cytotoxic, as MPO activity at all 
concentrations tested (including the control C 11: test substance added after incubation 
prior to RIA) was lower than the A23187 control (Figure 5.20). This suggests that the 
activity against eicosanoid generation was unlikely to be due to cytotoxic; effects, and 
supports previous results, which indicated that activity against enzymes in the 
arachidonate cascade occurred (refer to 5.2.2 and 5.2.3). Optical density was 
decreased as concentration of the essential oil increased, which may indicate free 
radical scavenging action. Essential oils derived from other herbs (e. g. Myrislica 
fragrans, Thymus vulgaris) have been identified as being anti-oxidant (Dorman et aL, 
1995). The monoterpenes carvacrol (147) and thymol (although not identified in the 
M. officinalis essential oil) are also anti-oxidant, and are effective scavengers of 
Luteolin Y-glucuronide (129) 
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peroxyl radicals (Aesbach et aL, 1994). It is therefore feasible that the apparent free 
radical scavenging activity of M officinalis essential oil may be due to the 
monoterpene content, perhaps citral (refer to 5.2.4.5). 
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Control: 200pg/H Melissa officinalis essential o0 added after 
Figure 5.20. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of 
Melissa officinalis essential oil. 
5.2.4.5 Effect of the Pure Compgunds Trans-CpI3ýophyllene, Citral, Geraniol and 
Nerol on MyeloNroxidase Activity in Rat Peritoneal Leukocytes 
Trans-caryophyllene (82) did not demonstrate cytotoxicity or fi-ee radical scavenging 
activity; each concentration tested (and the control, C 11) showed MPO activity 
similar to the A23187 control, but did not exceed that of the control (Figure 5.21). It 
is therefore possible that the activity against LT134 generation (refer to 5.2.3.2) was 
due to 5-LOX inhibition and not due to cytotoxicity (the lack of activity against TXB2 
generation (refer to 5.2.3.1 ) is ftuther evidence for this). 
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Figure 5.21. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
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Figure 5.22. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of citral. 
05 10 15 20 25 30 35 
rime (min) 
Control: 200pg/ml trans-caryophylienc added after 
05 10 15 20 25 30 35 
Time (min) 
Control: 200*ml citral added after 
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Citral also appeared to be non-toxic at the concentrations tested (Figure 5.22); 
therefore the possibility of a cytotoxic effect influencing eicosanoid generation may 
be excluded. A dose dependent decrease in optical density was observed with 
increasing citral concentration. This suggests citral may have free radical scavenging 
activity. 
The isomeric compounds geraniol (72) and nerol (75) showed a similar profile for 
MPO activity to the A23187 control, at all concentrations tested (including the 
control, CII) (Figures 5.23 and 5.24). The similar results obtained with both 
compounds for MPO activity may be a reflection of their structural similarity, as 
geraniol (72) is the trans-isomer of nerol (75). Neither of these compounds showed 
evidence of cytotoxicity, nor did they demonstrate free-radical scavenging activity 
(Figures 5.23 and 5.24). Their effects on eicosanoid generation may therefore have 
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Figure 5.23. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of 
geraniol. 
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Figure 5.24. Myeloperoxidase activity in supernatants prepared from rat peritoneal 
leukocytes under control and A23187 stimulated conditions, in the presence of nerol. 
5.3 Conclusion 
Those extracts which are inactive in vitro cannot be regarded as inactive as anti- 
inflammatory agents, until ftu-ther investigations, including in vivo studies (to account 
for the effects of metabolism), are conducted. Similarly, those extracts demonstrating 
potential anti-inflammatory activity in vitro may not necessarily be active in vivo, 
perhaps as a result of metabolic conversion to inactive compounds or inability to be 
absorbed across cell membranes. 
The extracts and compounds that inhibit COX may be clinically relevant in AD 
progression. However, COX inhibition is further complicated by the existence of two 
subtypes of enzyme: COX-1 and COX-2 (and perhaps other unidentified subtypes). 
Inhibitors selective for COX-2 include meloxicam, and are associated with a reduced 
incidence of adverse effects (Furst, 1997); inhibitors selective for COX-1 include 
indomethacin, and equipotent inhibitors of both COX-1 and COX-2 include 
diclofenac. The neuroprotective potency of NSAIDs is not related to their selectivity 
for COX-1 or COX-2 (Klegeris el aL, 1999). This is of therapeutic importance as 
inhibitors selective for COX-2, or other unidentified COX subtypes would minimise 
5 10 15 20 25 30 35 
Time (min) 
Control: 200*ml nerol added after 
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adverse effects while maintaining the beneficial properties. However, it is 
undetermined if there is a significant difference between use of COX-1 and COX-2 
selective inhibitors in clinical practice. If COX-2 selective inhibitors were identified 
as advantageous over COX-1 inhibitors in their protection against AD, it would be 
necessary to isolate active compounds from the relevant Plant extracts and assess 
them (and the active essential oil constituents) for COX selectivity. 
It is interesting to note that the most potent neuroprotective agent of the NSAID's 
investigated was an inhibitor of LOX, nordihydroguaiaretic acid (NDGA) (Klegeris et 
al., 1999). NDGA is also an anti-oxidant (Robinson et al., 1990), which may have 
contributed to the potent neuroprotective effect. The effect of LOX inhibitors on 
development of AD remains to be elucidated; however in view of the reported 
neuroprotective effects, their potential in AD management should not be ignored. 
An established causal link between corticosteroid use and reduced risk of AD has not 
been established, however some studies report that corticosteroids effectively 
suppress complement activation in AD (Aisen, 1996). Adverse effects that include 
psychogenic effects, which would be contra-indicated in Alzheimer's patients, also 
limit the use of corticosteroids for the management of inflammatory disorders. 
Corticosteroids (dexamethasone and prednisone) did not protect against neurotoxicity 
induced by human monocytic THM cells (cells which show similar toxicity to 
human microglia), unlike the neuroProtective NSAIDs (Klegeris et al., 1999). Those 
plant extracts that may possess a steroid-like anti-inflammatory action are also of 
therapeutic potential. Steroidal compounds, such as those present in Centella asiatica 
and Withania somnifera, may demonstrate a protective action against the 
inflammatory processes that occur in AD, but lack the potentially serious adverse 
effects. Such compounds which also show activity against COX and 5-LOX may 
enhance efficacy. 
Finally, it is essential to consider that activity in vitro may not always reflect activity 
in vivo. The pharmacokinetics (including the absorption, metabolism, transfer across 
the BBB and rate of elimination) in vivo may influence the clinical effects. For 
example, citral and geraniol (72) are reported to be metabolised to hildebrandt acid 
and dihydrohildebrandt acid by the liver of mammals (Asano and Yamakawa, 1950; 
Chadha and Madyastha, 1984; Ishida et aL, 1989). Therefore the phannacology and 
pharmacokinetics of any metabolites also require investigation. Toxicity in vivo is 
also an important consideration. For example, some essential oil constituents may be 
341 
toxic (Tisserand and Balacs, 1996) at therapeutic doses. Essential oils may be 
administered via inhalation, as therapeutic effects have been observed, and essential 
oil constituents have been detected in plasma, following this route of administration, 
(J, qger et aL, 1992; Kovar et aL, 1987). 
Anti-inflammatory compounds isolated from these plants may not only be new drugs 
themselves, but may also act as templates for the development of other more effective 
drugs. For example, aspirin (acetyl salicylic acid) (131) is derived from the phenolic 







Salicylic acid (132) 
Other phenolic compounds with related chemical structures, such as caffeic acid (106) 
and RA (108), may act as templates for drug synthesis. 
From the analysis of the results from these investigations and the vast array of 
phytochemicals reported to be anti-inflammatory, there is potential for those plant 
extracts that were effective against eicosanoid generation to yield new therapeutic 
agents for the management of inflammatory disorders such as AD. 
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CHAPTER6 
Effect of Plant Extracts and Essential Oils in Othcr 
Bioassav Investigations 
6.1 Assessment of Anti-Oxidant Activitv of Plant Extracts and Essential Oils 
Using a Phospholipid Peroxidation Assav 
Most lipid peroxidation in vivo is metal-ion dependent (Halliwell and Gutteridge, 
1995). Lipid peroxide arising from lipid peroxidation in cells is cytotoxic, causing 
disruption of cell membranes (Ando et aL, 1990); this mechanism has been found to 
be one of the major biochemical markers of aging. Therefore to identify any anti- 
oxidant activity of plant extracts, their ability to inhibit iron-stimulated lipid 
peroxidation was assessed. To assess inhibition of lipid peroxidation a thiobarbituric 
acid (TBA) (133) test was employed that was a modification of the method described 
by Uchiyama and Mihara (1978). The basis of this assay is that peroxidation is 
initiated in bovine brain liposomes by the presence of Fe 3+ and ascorbic acid and 
small quantities of malonaldehyde (MDA) (134) are formed. MDA (134) reacts in the 
TBA (133) -test to generate the coloured (TBA)2-MDA adduct, perhaps by the 
following reaction, that absorbs light at 532nm in acidic solution, and is readily 
extractable into organic solvents. 




TBA (133) MDA (134) 
syN OH HO W, Y, SH 







Ascorbic acid, butylated hydroxytoluene (BHT), bovine brain extract (Type VII), n- 
butanol, FeC13, glass balls (2mm diameter), propyl gallate (PpG), phosphate buffered 
saline (PBS) tablets (pH 7.4) and thiobarbituric acid (TBA) were purchased from 
Sigma, Fancy Road, Poole, Dorset, England. Plant extracts and essential oils were 
obtained as described previously; Melissa officinalis essential oil was obtained from 
Fragrant Earth, Taunton, England (refer to Chapter 2,2.1.1.1). 
6.1.1.2 Preparation of AssM Solutions 
Preparation ofLiposomes 
50mg bovine brain extract and 10ml PBS (I OmM) was sonicated in the presence of 7 
glass balls. Sonication was conducted in an ice water bath (to minimize peroxidation 
of liposomes) until a homogenous suspension was obtained. 
Preparation of Other Assay Solutions 
Assay solutions were prepared as follows: 
Chemical Dissolution Material Concentration 
Ascorbic acid Distilled water Imm 
BHT EtOH 2% 
FeC13 Distilled water Imm 
HCI Distilled water 25% 
TBA 50mM NaOH 1% 
6.1.1.3 AssU Method 
O. Iml test substance (dissolved in EtOH), 0.2ml phospholipid liposomes (5mg/ml), 
O. Iml Fed3 (100[tM) and 0.1ml ascorbic acid (100gM) were made up to a total 
volume (per tube) of I. Oml with PBS. Controls were also made up to I. Oml with PBS 
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(Tables 6.1 and 6.2). After vortex mixing, all tubes were incubated at 371C for I hr. 
During incubation, the reaction of iron complexes with lipid peroxides generates a 
range of products, including MDA (2). 

















O. Iml - O. Iml - O. Iml O. Iml 
EtOH O. Iml O. Iml 
FeC13 O. Iml O. Iml O. Iml O. Iml 
Liposomes 0.2ml 0.2ml 0.2ml 0.2ml 
PBS 0.7ml 0.9ml 0.5ml 0.7ml 0.5ml 0.5ml 
Test 
substance 
0.1ml O. ImI O. ImI* O. Iml 
(PpG)** 
Added immediately before TBA test. 
PpG (I OýM) added instead of test substance 
Table 6.2. Purpose of controls for phospholipid peroxidation assay. 
Control Purpose 
C1 Control for the test substance interacting/complexing with the reagents, in 
the absence of liposomes 
C2 Control to identify the effect of the test substance on the reagents (by 
comparing with Cl), in the absence of liposomes 
C3 Control for the test substance interfering with the TBA test 
C4 Control for any previous peroxidation of liposomes, in the absence of any 
peroxidation inducers/inhibitors 
C5 Control for the presence of EtOH 
C6 Positive control: PpG 
After incubation, 0.1ml BHT (148) solution (2%) was added (to prevent the 
occurrence of lipid peroxidation during the TBA (133) test, as BHT (148) is a chain 
breaking anti-oxidant), followed by 0.5ml TBA (133) (1%) and 0.5ml HCI (25%). 
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After vortex mixing tubes were incubated at 90'C for 20min, to enable the reaction of 
MDA (134) with TBA (133) to form the (TBA)2-MDA adduct. After cooling, the 
(TBA)2-MDA chromogen was extracted into n-butanol by addition of 2.5ml n-butanol 
per tube (as the lipid suspension is turbid and unsuitable for spectroscopic analysis). 
After vortex mixing and centrifuging at 3500rpm for 20min at 26'C, the upper 
organic layer containing the chromogen was decanted into a cuvette, and the 
absorbance measured at 532nm using a spectrophotometer. 
6.1.1.4 Data Analysis 
The percentage inhibition of lipid peroxidation by the plant extracts was calculated 
relative to the percentage inhibition of lipid peroxidation by lOVM PpG (regarded as 
100% inhibition), as follows: 
100 -[ extractA532 X10 
(C5A532 - PPGA532) 
'I 
Data (n=3, from triplicate readings) were analysed using one-way ANOVA to 
determine the significance of the difference between lipid peroxidation in the absence 
(C5) and presence of peroxidation inducers or inhibitors (plant extracts/essential oils). 
Data are presented as the mean (n=3 ± SD). Significance was regarded asp<0.01. 
6.1.2 Results and Discussion 
6.1.2.1 Effect of Propyl Gallate on Inhibition of Phospholivid Peroxidation 
An initial investigation was conducted to assess the effect of the antioxidant PpG 
(135) on the inhibition of lipid peroxidation. PpG (135) is a synthetic anti-oxidant 
often added to foodstuffs and is a good inhibitor of lipid peroxidation (Halliwell and 
Gutteridge, 1995). Concentration dependent inhibition of lipid peroxidation was 
observed with PpG (135) (Figure 6.1). 
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Figure 6.1. Effect of propyl gallate concentration on the percentage inhibition of 
lipid peroxidation of liposomes (n=3, p<0.05). 
6.1.2.2 Effect of Plant Extracts and Essential Oils on Inhibition of Phospholinid 
Peroxidation 
Preliminary experiments showed that some of the plant extracts inhibited lipid 
peroxidation. in vitro (Figure 6.2). 
The cold EtOH extracts of Alisnia orientalis, Polygala tentlifolia, Salvia miltiorrhiza 
and Withania somnifiera, the hot EtOH extracts of Centella asiatica and Salvia 
miltiorrhiza, and the hot aqueous extracts of Polygala tentlifolia, Salvia nliltiorrhiza 
and Ziziphusjujuba (seed) significantly inhibited lipid peroxidation at Ig. L-1 (Figure 
6.2). These extracts inhibited lipid peroxidation. by 63.7%, 111.3%, 132.8%, 103.5%, 
0123456769 10 
Prop)i Gallate Concentration (101) 
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132.6%, 166.4%, 45.2%, 233.2% and 143.1% respectively, compared to the control 
PpG (135) (10ýtM). 
LýV- = PpG 
ý Cold EtOH extracts 
ý Hot EtOH extracts 
Ml Hot water extracts 




n i 0. 
23456789 to 
Concentration 
Extracts and Essential Oils at I g. U1 
PpG at I OILM 
Key for Figure 6.2. 
Number Plant 
I Alisma orientalis root 
2 Centella asiatica leaf 
13 Codonopsis pilulosa root 
4 Polygala tenuifolia root 
15 Adulterated Polygonum multiflorum root (Gentiana spp. ) 
6 Salvia miltiorrhiza root 
17 
Withania somnifera root 
8 Ziziphusjujuba fruit 
9 Ziziphusjujuha seed 
10 Melissa officinalis essential oil 
I Rosmarinus officinalis essential oil 
Figure 6.2. Effect of plant extracts and essential oils on the percentage inhibition of 
lipid peroxidation of liposomes (triplicate readings; n=3). 
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Of the extracts tested, none showed interference in the TBA (133) test, indicating that 
the effects observed were due to apparent anti-oxidant (or pro-oxidant) effects. 
Further investigations are required to identify the compounds in each of the active 
extracts responsible for the apparent anti-oxidant effects, however the chemistry of 
each plant may give some indication of the types of compound which may have 
contributed to the apparent anti-oxidant activities. 
6.1.2.2.1 Alisma orientalis 
Alisma orientalis root has not previously been investigated for anti-oxidant activity. 
The cold EtOH extract was more active against lipid peroxidation than the hot 
aqueous extract at Ig. L-1 (Figure 6.2). This suggests that the more lipophilic 
compounds present in the EtOH extract are more potent anti-oxidants than the more 
polar compounds present in the aqueous extract, or the high extraction temperature 
may have denatured compounds present in the aqueous extract. However, it cannot 
be excluded that a minor component present in the aqueous extract is a potent anti- 
oxidant. Relatively few investigations have been conducted on the chemistry of A. 
orientalis root, and isolation of compounds that may be potential anti-oxidants is 
required to understand the activity of this plant. 
OH 
OH 
OH x OH 
-- t zl%ý 
HO II CH3 ý-CH3 HO 'CH3 )--CH3 HC CH3 
H3C H3C H3C 
Orientalol A (136) Orientalol B (137) Orientalol C (138) 
Sesquiterpenes (orientalols A (136), B (137) and C (138)) and triterpenes (including 
alisols A (28) and B (30)) have been isolated from A. orientalis root (Chang and But, 
1987; Huang, 1993; Kamiya et aL, 1970; Tang and Eisenbrand, 1992; Yoshikawa et 
aL, 1992). The disesquiterpene gossypol (59) is a phenolic compound, which is a 






















The sesquiterpenes isolated to date from A. orientalis root are not phenolic. Some 
triterpenes are reported to be anti-oxidant, such as celastrol (139) from Triplerygium 
wilfordii, which is fifteen times more potent than a-tocopherol at inhibiting lipid 
peroxidation and ganoderic acids A, B, C and D from Ganoderma hicidum are 
effective inhibitors of lipid peroxidation in vitro (Sassa et aL, 1990; Zhu et aL, 1999). 
Alisols A (28) and B (30) are structurally similar to some steroidal compounds. Some 
steroidal compounds are reported to have anti-oxidant activity (Mooradian, 1993; 
Wiseman, 1994; Wiseman et aL, 1990). Several endogenous (e. g. 170-oestradiol (132) 
H3 C CH 3 




(14)) and synthetic oestrogens (e. g. 17a-ethynyloestradiol) are reported to inhibit iron 
ion-dependent lipid peroxidation, and E2 (14) protects neurons against oxidative 
stress-induced cell death in vitro (Behl et aL, 1995; Ruiz-Larrea et aL, 1994; 
Wiseman and Halliwell, 1993). The structural similarity between anti-oxidant steroid 
compounds and the alisols may explain the anti-oxidant effects observed with A. 
orientalis; however, the alisols lack a phenolic component, a feature of E2 (14) and 
many plant anti-oxidants (Kimura et aL, 1985b; Laughton et aL, 1989; Okuda et aL, 
1983). It remains to be established whether phenolic sesquiterpenes, triterpenes, or 
other phytochernicals are responsible for the anti-oxidant activity observed. 
6.1.2.2.2 Centella asiatica 
Centella asiatica leaf (hot EtOH extract) was significantly active against lipid 
peroxidation lg. L-1, and was more potent than the reference anti-oxidant, PpG (135) 
at lOpM (Figure 6.2). Tannins, flavonoids (e. g. quercetin (104)), sesquiterpenoid 
compounds, triterpenoid saponin compounds (e. g. asiaticoside (101)) and an essential 
oil, composed of sesquiterpenes and monoterpenes, are reported to occur in C 
asiatica leaf (Asakawa et aL, 1982; Brinkhaus et aL, 2000; GUnther and Wagner, 
1996; Kapoor, 1990; Maquart et aL, 1990; Shukla et aL, 1999b; Sudheesh et aL, 
1999; Vogel et aL, 1990). 
The anti-oxidant effects of some tannins, flavonoids, saponins and essential oils is 
well documented, for example, the flavonoid quercetin (104) is reported to be a potent 
inhibitor of lipid peroxidation in rat liver microsomes (Don-nan et aL, 1995; Foti et 
aL, 1996; Kelm et aL, 2000; Kimura et aL, 1985b; Laughton et al., 1989; Okuda et 
al., 1983; Torel et al., 1986). The presence of these compounds may explain the anti- 
oxidant activity observed. Isolation and identification of flavonoids from C asiatica 
may aid the understanding of the anti-oxidant effects of this plant; flavonoids with 
hydroxyl substituents on the flavonoid nucleus (e. g. quercetin (104)), particularly on 
the A and B rings, are more potent anti-oxidants than flavonoids substituted with 
methoxy substituents (Arora et al., 1998; Cimanga et aL, 1999). Glycosylation of 
flavonoids has also been associated with a reduction of anti-oxidant activity, 
compared with the corresponding aglycone (Rice-Evans et aL, 1996). 
Application of asiaticoside (101) from C asiatica to wounds, resulted in an increase 
in anti-oxidant enzymes (e. g. superoxide dismutase (SOD), glutathione peroxidase) 
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and a decrease in lipid peroxide levels in newly formed tissue (Shukla et aL, 1999a). 
These results suggest that asiaticoside (101) may be anti-oxidant in vivo, and the 
observed effects on lipid peroxide levels may be due to both the increase in levels of 
intrinsic anti-oxidants and perhaps due to an anti-oxidant effect of asiaticoside (101) 
itself. 
6.1.2.2.3 Codonopsis, 2ilulosa 
The hot EtOH extract of C pilulosa root showed apparent pro-oxidant effects in this 
assay at Ig. L-1 (Figure 6.2). Some anti-oxidants, such as vitamin E, may have pro- 
oxidant actions under certain circumstances (Halliwell, 1990; Yamamoto and Niki, 
1988) and this may occur if the substance can bind Fe (111) ions and reduce them to 
Fe 2+ . Ascorbic acid may stimulate lipid peroxidation and the formation of reactive 
oxygen species, such as hydroxyl radicals (OH) (Halliwell, 1990). C pilidosa root 
may contain compounds which bind and reduce Fe (111) ions, or may contain ascorbic 
acid or other substances, capable of promoting formation of reactive oxygen species 
that increase lipid peroxidation. The potential pro-oxidant effects of this plant require 
further assessment in other systems to establish the mechanism of action on oxidation. 
6.1.2.2.4 Gentiany spp. (Adulterated Polygonum multiflorum) 
The hot and cold EtOH extracts of Gentiana spp. root (which was substituted for 
Polygonum multiflorum root; refer to Chapter 2,2.2.1.1) showed only weak- activity 
against lipid peroxidation. at I g. L-1 (Figure 6.2). 
Some species of Gentiana have been reported to have anti-oxidant activity. G. 
decumbens showed *OH and superoxide (02*-) scavenging activity in vitro (Myagmar 
and Aniya, 2000). G. barbata and G. olivieri showed hepatoprotective activity ill vivo 
and prevented MDA (134) formation, suggesting that inhibition of lipid peroxidation 
occurred (Aktay et al., 2000; Nikolaev, 1983). The compounds responsible for these 
effects have not been confirmed, but isoorientin-6'-O-glucoside from G. arisallellsis 
showed free radical scavenging activity and inhibited lipid peroxidation in vitro (Ko 
et al., 1998). Isoorientin-6'-O-glucoside and perhaps related compounds may have 
also contributed to the reported anti-oxidant effects of other species of Gentiana. The 
identification of the Gentiana spp. used in the present study and its chemical 
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constituents requires ftirther investigation. The apparently weak- anti-oxidant activity 
of the Gentiana spp. EtOH and aqueous extracts also requires confirmation in other 
experimental studies. 
6.1.2.2.5 Pol ygala tenuiLolia 
The cold EtOH extract of Polygala tenuifolia root was more active against lipid 
peroxidation than the hot aqueous extract at lg. L-1 (Figure 6.2). This suggests that the 
more lipophilic compounds may be more effective anti-oxidants than the more polar 
compounds present in the aqueous extract. It is also possible that some anti-oxidant 
compounds present in the aqueous extract may have been denatured by the high 
extraction temperature, rendering them inactive. 
The traditional Chinese prescription, DX-9386, which consists of four herbs including 
P. tenuifiblia, improved learning behaviour in senescence accelerated mice (SAM) and 
inhibited the increase in lipid peroxide in the liver and serum in SAM (Nishiyama et 
aL, 1994a). P. tenuifolia root alone has not previously been reported to contain 
potential anti-oxidants. Constituents isolated from the root of this herb include 
saponins (including onjisaponins A-G and tenuifolin (67)), phenolic glycosides 
(tenuifolisides A- F), fixed oil and resin (Chang and But, 1986; Huang, 1993; Ikeya 
et aL, 1991b; Sakuma and Shoji, 1981a; Sakuma and Shoji, 1981b; Tang and 
Eisenbrand, 1992; Trease and Evans, 1996). 
Saponins are reported to reduce the hepatotoxicity of carbon tetrahydrochloride, 
which may be due to the deactivation of oxygen free radicals (Abe el aL, 1981); the 
saponin Rbl, a saponin from Panar ginseng, is an inhibitor of lipid peroxidation 
(Deng et aL, 1990). Saponins are also structurally related to anti-oxidant steroidal 
compounds (e. g. E2 (14)), which may also explain the anti-oxidant effects observed. 
The phytochemicals responsible for the apparent anti-oxidant effects may be either 
saponins, the phenolic compounds or other unidentified compounds. 
6.1.2.2.6 Salvia miltiorrhiza 
All three extracts from Salvia miltiorrhiza root demonstrated significant activity 
against lipid peroxidation at Ig. L-1 (Figure 6.2). Of these extracts the hot aqueous 
extract was the most potent, which suggests that the most active compounds from the 
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root are polar. The hot EtOH extract was more active than the cold EtOH extract; this 
may be due to the hot extraction process yielding more active compounds from the 
root. It cannot be excluded that the EtOH extracts may contain more potent anti- 
oxidants than the aqueous extract, but at a lower concentration. Therefore, isolation 
and comparison of anti-oxidant activity of compounds from both EtOH and aqueous 
extracts is required. 
Previous reports support these findings. S. miltiorrhiza root protects against 
peroxidative damage to biomembranes (Liu et al., 1992). This effect was attributed to 
several phenolic compounds, including the water-soluble salvianolic acids A (123) 
and B (124); these compounds also inhibited lipid peroxidation in rat brain, liver and 
kidney microsomes in vitro (Huang and Zhang, 1992; Liu et aL, 1992). Salvianolic 
acid A (123) also reduced MDA (134) levels in the cortex, hippocampus and corpus 
striaturn following cerebral ischaemia-reperfusion in rats, in vivo (Guanhua and 
Juntian, 1997). The potency of these polar compounds against lipid peroxidation 
supports the results from these in vitro experiments, which assessed lipid peroxidation 
in bovine brain liposomes. 
Several other investigations in various assay systems have been conducted on the anti- 
oxidant effects of S. miltiorrhiza. Dimethyl lithospermate and 3-(3,4- 
dihydroxyphenyl) lactamide (140) (phenolic compounds) from a McOH extract of S. 
miltiorrhiza are more potent scavengers of the 1,1-diphenyl-2-picrylhydrazyl (DPPH) 
radical than ascorbic acid; 2,10,11 -trihydroxy-8-methoxy- 1,6,7,8-tetrahydro-2H- 
benzo[e]azecine-3,5-dione (141) (a cyclic phenyl lactamide) from S. nziltiorrhiza is 
also a scavenger of the DPPH radical; the water soluble compound danshensu (45) 
(also a phenolic compound) from S. miltiorrhiza is a scavenger Of 02*- radicals, and 
the less polar tanshinone 1 (115) scavenges free radicals generated from lipid 
peroxidation of rabbit myocardial mitochondrial membranes; the root extract is active 
against human low density lipoprotein (LDL) oxidation; in rats with ischaemic brain 
injury, treatment with S. nziltiorrhiza, increased cerebral SOD (an endogenous 
scavenger of 02- radicals) activity and decreased cerebral MDA (134) levels; (Choi et 
aL, 2001; Kang et aL, 1997; Peigen et aL, 1996; Xiaoshu et aL, 1994; Zhao et aL, 
1996). 
Quinones, including dehydrorosmariquinone, rosmariquinone, miltirone I, tanshinone 
1 (115), cryptotanshinone (117), dihydrotanshinone and methylenetanshinquinone, 
isolated from S. miltiorrhiza root were anti-oxidant in heated lard, but tanshinone Ila 
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lactamide (140) tetrahydro-2H-benzo[e]azecine-3,5-dione (141) 
Other species of the genus Salvia are also reported to have anti-oxidant effects 
(Cuvelier et aL, 1996; Deans and Simpson, 2000; Hohmann et aL, 1999; Malen6id et 
aL, 2000; Yildirini et aL, 2000). Compounds from S. officinalis leaves which are anti- 
oxidant include diterpenes (e. g. carnosol (142), carnosic acid (143), methyl camosate 
(144), rosmanol. (145)), glycosidic compounds (e. g. 1-0-(2,3,4-trihydroxy-3- 
methly)butyl-6-Oferuloyl-o-D-glucopyranoside), phenylpropanoids (e. g. rosmarinic 
acid (RA) (108)) and flavonoids (e. g. genkwanin, cirsimaritin) (Al-Sereiti et aL, 1999; 
Cuvelier et aL, 1994; Cuvelier et A, 1996; Parnham. and Kesselring, 1985; Pearson et 
aL, 1997; Schwarz and Temes, 1992; Wang et aL, 2000). 
The diterpenes camosol (142), camosic acid (143) and rosmanol (145), also from 
Rosmarinus officinalis leaves, are inhibitors of mitochondrial and microsomal lipid 
peroxidation, and inhibitors Of 02*- radical production (Haraguchi et aL, 1995). 
Carnosic acid (143) and RA (108) have also been shown to act synergistically with 
lycopene against LDL oxidation (Fuhrman et aL, 2000). 
Compounds present in the S. miltiorrhiza extracts may also have acted synergistically 
against lipid peroxidation. Other compounds (e. g. flavonoid and phenolic glycosides) 
identified in S. officinalis may also have potential as anti-oxidants (Lu and Yeap Foo, 
2000). S. triloba and S. reflexa extracts are also anti-oxidant (Malen6id et aL, 2000; 
Yildirim et aL, 2000). It is therefore apparent that the genus Salvia is a valuable 
source of various anti-oxidant compounds, which may have potential therapeutic 
relevance in disorders such as AD. 
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6.1.2.2.7 Withania somnifera 
The cold EtOH extract of Withania somnifera root was also significantly active 
against lipid peroxidation at I g. L-1 (Figure 6.2). The compounds responsible for these 
effects may be the withanolides, which are reported to have anti-oxidant activity 
(Bhattacharya et aL, 2001; Mills and Bone, 2000; Mishra et aL, 2000; Scartezzini and 
Speroni, 2000; Upton, 2000), although other unidentified compounds may also 
contribute to the activity observed. 
The crude extract is reported to inhibit lipid peroxidation in mice liver homogenates; 
an aqueous extract was active against lipid peroxidation in both mice and rabbits 
(Dhuley el aL, 1998; Panda et aL, 1997; Panda and Kar, 1998). The 
glycowithanolides decreased the rise in lipid peroxidation and enhanced catalase and 
glutathione peroxidase activities in rat frontal cortex and striatum, induced by 
fbotshock stress (Bhattacharya et aL, 2001); the sitoindosides (VII - X) increased 
catalase, glutathione peroxidase and SOD levels in the frontal cortex and striaturn of 
rat brain (Bhattacharya et aL, 1997; Bhattacharya et aL, 2001), indicating protective 
effects against free-radical damage to neurons. The root extract and the 
glycowithanolides (consisting of equimolar concentrations of sitoindosides VII -X 
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and withaferin A (109)) are hepatoprotective in rats and mice, an effect attributed to 
the anti-oxidant activity against hepatic lipid peroxidation (13hattacharya et aL, 2000; 
Chaurasia et aL, 2000c). 
The leaves of JV somnifera contain several flavonol glycosides and phenolic 
compounds (Kandil et aL, 1994); the presence of these compounds suggests the leaves 
from this plant may also have anti-oxidant activity, however this is yet to be 
investigated. 
6.1.2.2.8 Ziziphus iuiub 
The cold EtOH extract of Ziziphus jt#uba fruit demonstrated only weak activity 
against lipid peroxidation at Ig. L-1, however the aqueous seed extract was 
significantly more active at Ig. L-1 (Figure 6.2). This herb has not previously been 
reported to have anti-oxidant effects. The seeds are reported to contain flavone C- 
glycosides (e. g. swertisin (150), spinosin (149)), saponins (e. g. jujubosides A and B), 
triterpenoids (e. g. betulin, betulic acid) and fixed oil, and the fruit is reported to 
contain alkaloids (e. g. zizyphusine), triterpenes (e. g. alphitolic, oleanonoic and 
maslinic acids), and vitamins (e. g. ascorbic acid) (Chang and But, 1987; Tang and 
Eisenbrand, 1992). 
The flavonoid, saponin and triterpene content of the seeds may explain the high 
activity against lipid peroxidation, although these compounds and perhaps other 
unidentified constituents remain to be investigated for anti-oxidant activity in their 
isolated form. The relative inactivity of the fruit may be due to the presence of 
inactive or poorly active compounds, or may be explained by the presence of ascorbic 
acid. It is well documented that ascorbic acid may stimulate lipid peroxidation and 
the formation of reactive oxygen species in the presence of iron salts, and may act as a 
pro-oxidant (Halliwell, 1983; Halliwell, 1990). Components present may have 
accelerated lipid peroxidation, and perhaps counteracted any effects of anti-oxidant 
compounds. 
6.1.2.2.9. Melissa officinalis and Rosmarinus officinalis Essential Oils 
Both Melissa qjficinalis and Rosmarinus qjficinalis essential oils were weakly active 
against lipid peroxidation (Figure 6.2). Essential oils from various genera have been 
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investigated for their anti-oxidant effects; Artemisia afra Jacq., Crithmum maritilnum, 
Foeniculum vulgare, Leptospernum scoparium, Monarda citriodora, Myrislica 
ftagrans, Syzigium aromaticum and Thymus vulgaris essential oils have shown anti- 
oxidant activity (Deans et aL, 1995; Dorman et aL, 1995; Graven el aL, 1992; Lis- 
Balchin et aL, 2000; Ruberto et al., 2000). Limonene (73), y-terpinene (55) and 
thymol methyl ether were the major constituents of C maritimum essential oil, so 
may have contributed to the anti-oxidant activity (Ruberto et aL, 2000). y-Terpinene 
(55) and thymol methyl ether were not detected in the Melissa officinalis essential oil 
used in the present study, and limonene (73) comprised <0.5% of this oil (refer to 
Chapter 2,2.2.7.1). 
The major components of the anti-oxidant essential oil from A afra Jacq. were a- 
(146) and 0-thujone, 1,8-cineole (56), camphor (57) and a-pinene (53), which 
comprised 82% of the total oil composition (Graven et aL, 1992). Of these terpenes, 
only a-pinene (53) was identified in the Melissa qJfIcinalis essential oil used in the 
present study and comprised <0.5% of the total oil composition. (refer to Chapter 2, 
2.2.7.1). The monoterpenes carvacrol (147), 6-gingerol and thymol are effective 
scavengers of peroxyl radicals and inhibit lipid peroxidation (Aesbach et al., 1994). 
These compounds were also not detected in the Melissa officinalis essential oil used 
in the present study (refer to Chapter 2,2.2.7.1), nor are they reported to occur in R. 
officinalis essential oil (Bisset, 1994; Newall et al., 1996; Trease and Evans, 1996). 
The absence or low concentration of terpenes known to be anti-oxidant in the Melissa 
officinalis and R. officinalis essential oils may partly explain their apparent inactivity 
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Citrus oils and their components including geraniol (72) are effective scavengers of 
the DPPH radical (Choi et al., 2000). Geraniol (72) comprised <1% of the Melissa 
officinalis essential oil (refer to Chapter 2,2.2.7.1) and is not reported to be a major 
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constituent of R. offi'cinalis essential oil, so it may be concluded that any contribution 
to the anti-oxidant activity of these essential oils was minimal and that geraniol (72) 
may not be a potent inhibitor of lipid peroxidation. 
More than 90 essential oil constituents have been evaluated for their anti-oxidant 
activity by assessing their inhibitory activity against lipid peroxidation (Ruberto and 
Baratta, 2000). The monoterpene hydrocarbons terpinolene, a- and y-terpinene (55) 
and phenols including thymol and carvacrol (147) were significantly active against 
lipid peroxidation, which is consistent with previous findings (Aesbach et al., 1994; 
Ruberto and Baratta, 2000; Yanishlieva et al., 1999). The alcohols including geraniol 
(72) and nerol (75) were also protective against lipid peroxidation, however linalool 
(74) demonstrated pro-oxidant activity (Ruberto and Baratta, 2000). Caryophyllene 
oxide (78), citral, citronellal (68), citronellol (69), a-humulene (81), limonene (73), 
ocimene (76), a-pinene (53) and trans-caryophyllene (82) were weakly active or 
inactive against lipid peroxidation (Ruberto and Baratta, 2000). These compounds 
comprised 47.1% of the Melissa offi'cinalis essential oil, and the active compounds 
geraniol (72) and nerol (75) only comprised 2.1 % of this essential oil (refer to Chapter 
2,2.2.7.1), which may also explain the apparent inactivity of the Melissa oJficinalis 
essential oil against lipid peroxidation in bovine brain liposomes. The sesquiterpenes 
(e. g. a-cedrene, a-humulene (81), trans-caryophyllene (82)) were weakly active or 
inactive against lipid peroxidation (Ruberto and Baratta, 2000), although further 
analysis of these compounds in other anti-oxidant systems would be necessary to 
determine any potential anti-oxidant effects. 
Phenylpropanoids, also constituents of some essential oils, have been assessed for 
anti-oxidant activity. Eugenol (84) has shown good anti-oxidant activity against lipid 
peroxidation in vitro and synthetic eugenol related compounds are scavengers Of 02'_ 
and also inhibit lipid peroxidation (Kelm et al., 2000; Lee and Shibamoto, 2000; 
Ogata et al., 2000; Okada et al., 2000; Ruberto and Baratta, 2000). The 
phenylpropanoid glycosides arenarioside, ballotetroside, forsythoside B and 
verbascoside (which do not chelate Cu2) are strong inhibitors of CU2+_induced LDL 
oxidation (Seidel et al., 2000). Phenylpropanoids are not reported to be major 
constituents of Melissa officinalis and R. oJficinalis essential oils, which may also 
explain the relatively poor anti-oxidant effects observed with these oils. 
The apparently weak anti-oxidant effects against lipid peroxidation may also be 
explained by the loss of the volatile components during the assay, such as during 
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incubation. This occurrence would have decreased the assay concentration. 
Assessment of each essential oil and the major components of each essential oil 
against lipid peroxidation in stoppered test tubes may minimise loss of volatile 
components and give a more accurate indication of the anti-oxidant activity. 
It cannot be concluded that Melissa qjjzicinalis and R. qfjlcinalis essential oils are 
weak inhibitors of lipid peroxidation, as essential oil samples may vary considerably 
in composition, as highlighted by Jain et al. (1991), Svoboda and Deans (1992) and 
Vokou and Margaris (1986), due to several factors (e. g. the environmental conditions 
for cultivation, the age of the plant or adulteration), and samples may therefore differ 
in their pharmacological effects. R. ofji'cinalis essential oil has previously been 
reported to be anti-oxidant but Melissa offi'cinalis essential oil was not reported to be 
anti-oxidant (Deans et al., 1993). Further investigation in various systems for 
evaluating anti-oxidant activity of the isolated monoterpene, phenylpropanoid and 
sesquiterpene components of these essential oils to identify any potentially potent 
minor constituents is therefore warranted. 
6.1.3 Conclusion 
The CNS is rich in polyunsaturated side-chains which may be susceptible to 
peroxidative damage; catalase, glutathione peroxidase and SOD activity is low which 
suggests free-radical scavenging activity is not highly efficient; some areas of brain 
(e. g. substantia nigra) are rich in iron and ascorbic acid; neuronal injury may release 
iron, which in conjunction with ascorbic acid, promotes lipid peroxidation and 'OH 
radical formation (Halliwell and Gutteridge, 1995). Consequently, measurement of 
lipid peroxidation of bovine brain liposomes was considered the most appropriate 
method for the analysis of anti-oxidant activity of the plant extracts and essential oils, 
with regard to CNS disorders such as AD. 
Assessment of inhibition of lipid peroxidation does not yield sufficient information 
concerning the mechanism of action of proposed anti-oxidants. In this assay, which is 
a metal-ion dependent system, an anti-oxidant may inhibit lipid peroxidation not only 
by scavenging peroxyl radicals, but may bind iron ions and stop them from 
accelerating peroxidation. The formation of MDA (134) as a result of fragmentation 
of cyclic- and endo-peroxides has been proposed to be inhibited by metal-ion 
chelators (Halliwell and Gutteridge, 1995). Either effect or both may explain the anti- 
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oxidant effects observed with the plant extracts. The mechanism of action may be 
determined by HPLC analysis, as an anti-oxidant binding to iron will not be 
consumed so can be detected; an anti-oxidant which scavenges peroxyl radicals will 
be consumed during the reaction. 
Those extracts that contain flavonoids may have inhibited lipid peroxidation by metal 
ion chelation, as some flavonoids have demonstrated anti-oxidant activity via this 
mechanism (Arora et al., 1998; Morel et al., 1993). The presence of ascorbic acid in 
the assay mixture may influence the results by reducing the anti-oxidant derived 
radicals back to the original anti-oxidant molecule, facilitating the anti-oxidant 
effects. This mechanism is reported to occur if the anti-oxidant derived radicals are 
lipid-soluble and are accessible for reduction at the membrane surface (Halliwell, 
1990). Anti-oxidant activity may therefore be greater in systems containing ascorbic 
acid, as has been shown with some plant phenolic compounds (Laughton, 1989). 
Although measurement of lipid peroxidation was considered as the most suitable 
assay for evaluation of anti-oxidant effects with regard to the CNS, the results cannot 
be regarded as conclusive. Indeed, there are limitations to the TBA (133) assay. 
Compounds other than MDA (134) may react in the TBA (133) test to form products 
other than the (TBA)2-MDA adduct, which also absorb at 532nm, and may not reflect 
the inhibition of lipid peroxidation by the plant extracts. This problem may be 
overcome by HPLC analysis to quantify the (TBA)2-MDA adduct. Only the 
assessment of the anti-oxidant effects of each extract in several different systems can 
conclusively identify potential therapeutic anti-oxidant activity. An anti-oxidant 
acting by inhibition of lipid peroxidation may be pro-oxidant in other systems; some 
plant phenolic compounds (e. g. myricetin and quercetin (104)) that are potent 
inhibitors of lipid peroxidation, may accelerate oxidative damage to DNA by reducing 
Fe (III) ions to Fe2+ or by oxidation to yield 02*- (Laughton et al., 1989). 
Activity in vivo is also required to determine physiologically relevant anti-oxidant 
effects. An anti-oxidant in vitro may not be anti-oxidant in vivo under conditions 
where pharmacokinetics may influence activity; similarly an inactive or pro-oxidant 
compound in vitro may be anti-oxidant in vivo, perhaps due to metabolic conversion 
to an active compound, or due to promotion of endogenous anti-oxidant substances. 
Other considerations with regard to AD include access across the BBB. Extracts that 
are more lipophilic may contain anti-oxidant constituents able to cross the BBB (e. g. 
the EtOH extracts of Centella asiatica leaf and Salvia miltiorrhiza root). These 
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extracts and their lipophilic constituents may be more active in vivo than the more 
polar aqueous extracts (e. g. the aqueous extracts of Salvia miltiorrhiza root and 
Ziziphus jujuba seed), as although they may contain equipotent anti-oxidants, they 
may not readily cross the BBB. 
Potential for production of damaging anti-oxidant derived radicals, and potential 
toxicity of the anti-oxidant must also be assessed. Some steroidal anti-oxidants are 
reported to be carcinogenic (e. g. diethylstilboestrol (15), hexoestrol and 17a- 
cthynyloestradiol) (Wiseman and Halliwell, 1993). Carcinogenic potential should 
therefore be considered when evaluating therapeutic use of plant-derived anti- 
oxidants with steroidal structures. Therefore although some compounds may protect 
against lipid peroxidation they may be pro-oxidant in vivo, perhaps by causing 
damage to DNA. Although the isolation and identification of a pure compound may 
yield the development of potent anti-oxidants, this may also have disadvantages. The 
synergistic action of a crude plant extract may be more potent than the isolated 
compounds, and may provide protection against toxic effects of some constituents. 
In conclusion, the apparent anti-oxidant effects of these plant extracts indicates that 
they may be a source of potent new anti-oxidants, and may explain their reputed 
effects in CNS disorders. In addition, there is an interest in the use of plant derived 
anti-oxidants in food and cosmetic formulations, in view of concerns raised regarding 
the safety of synthetic anti-oxidants such as BHT (148) and PpG (135); BHT (148) 
has been associated with hepatotoxicity and is a potential carcinogen (Ito et aL, 1985; 




Butylated hydroxytoluene (148) 
Herbal extracts of sage and rosemary have been investigated for their anti-oxidant 
effects in several consurnables (Karpinska et aL, 2000; Shahidi, 2000; Wada and 
Fang, 1992; Wong et aL, 1995). Consequently the plant extracts Nvarrant further 
investigation for their anti-oxidant effects, for both therapeutic and commercial 
purposes. 
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6.2 GABA Receptor Binding Assav 
Radioligand receptor binding studies are a sensitive and rapid method employed to 
measure the interaction of ligands, including neurotransmitters and hormones, with 
receptors. Plant extracts, essential oils and the monoterpenes citral, geraniol (72) and 
nerol (75) were assessed for their effects on the inhibition of [3 H]-GABA binding to 
both GABAA and GABAB receptors in vitro, based on the method described by 
Bowery et aL (1983). Such investigations do have limitations, since although ligands 
for GABA receptors may be identified, it cannot be determined if receptor affinity is 
due to agonist or antagonist effects. However, receptor binding studies can be 
employed to aid the explanation of results from bioassays, and are useful in providing 
information regarding compounds which may have potential phan-nacological effects 
in vivo, and which may be clinically relevant for disease management. 
6.2.1 Method 
6.2.1.1 Materials 
Plant extracts, essential oils and monoterpenes were obtained as described previously; 
Melissa officinalis essential oil was obtained from Fragrant Earth, Taunton, England 
(refer to Chapter 2,2.1.1.1). 
6.2.1.2 Preparation of Membranes 
The assays were conducted by Professor Norman G. Bowery, Pharmacology 
Department, The University of Birmingham, Edgbaston, Birmingham, as described by 
Bowery et aL (1983). In brief, the crude synaptic membranes were prepared from 
freshly dissected whole rat brain (from male Wistar rat) by homogenisation in 0.32M 
cold sucrose solution (25mlibrain), followed by successive centrifugations. The 
resulting crude synaptic membranes were resuspended in buffer (25ml Tris-HCI 
buffer (50mM) containing 2.5mM CaCIA After further centrifugation the 
supernatant was discarded, and the pellet reconstituted in fresh ice-cold buffer, and 
incubated for 15min on ice. The suspension was recentrifuged and the washing 
procedure was repeated twice, with 15min incubation periods between each spin. All 
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centrifugation was performed at 4'C. After removal of endogenous GABA (16) and 
other possible inhibitory substances by the washing process, the final pellet was 
resuspended in 35ml buffer prior to use in the binding assays. 
6.2.1.3 Procedures for GABAA and GABAB Binding AssUs 
GABAA Assay 
Baclofen (20) (62.5pl, lOOpM final concentration) was added to 800PI rat synaptic 
membranes to block GABAB receptors. CH]-GABA (100pl, lOnM final 
concentration) and test substances were then added. All test substances were diluted 
in EtOH or DMSO prior to addition to the incubation solution and were assayed at 
I pg/ml and I 00[tg/ml, in triplicate. Non-specific binding was deten-nined by addition 
of isoguavicine, hydrochloride (100pl, I OOpM final concentration). 
GABA, y Assay 
Isoguavicine hydrochloride (62.5VI, 40[tM final concentration) was added to 800PI mt 
synaptic membranes to block GABAA receptors. CaC12 (62.5pl, 2.5mM final 
concentration), [3 H]-GABA (100pl, IOnM final concentration) and test substances 
were then added. All test substances were diluted in EtOH or DMSO prior to addition 
to the incubation solution and were assayed at Igg/ml and 100pg/ml, in triplicate. 
Non-specific binding was determined by adding baclofen (20) (100ýil, IOOPM final 
concentration). 
For both GABAA and GABAB binding assays the final mixtures were incubated for 
15min at room temperature to allow binding to occur. The assay was terminated by 
washing with cold 50mM Tris buffer and filtered on GF/B filters; samples were then 
punched into vials and soaked in scintillation fluid, prior to quantitation of the 
radioactivity by recording CPM (10min for each measurement) using a P-scintillation 
counter (LS-6000 TA, Beckman Ltd. ). 
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6.2.1.4 Data Analysis 
Non-specific binding (Bnsb) was regarded as the binding of [3 H]-GABA in the 
presence of a receptor specific non-radioactive compound (isoguavicine 
hydrochloride for the GABAA assay, baclofen (20) for the GABAB assay). This value 
was subtracted from the total amount of radioactivity bound in the presence of the test 
substance (Bt,, tal) to determine the amount of test substance bound. This was 
expressed as a percentage of the maximum radioactivity bound in the absence of the 
test substance (B,,, a, ), and the percentage inhibition of [3 H]-GABA bound was 
calculated: 
Percentage inhibition= 100 - 





6.2.2 Results and Discussion 
Plant extracts that tested positive for the presence of GABA (refer to Chapter 2,2.2.6) 
were excluded from the receptor binding studies, as their presence in the assay 
systems may have produced false positive results. Therefore, those extracts tested for 
GABA binding effects were M. officinalis leaf aqueous extract, M. officinalis leaf 
EtOH extract, Rosmarinus officinalis dried leaf EtOH extract, R. officinalis fresh leaf 
EtOH extract, Ziziphusjujuba var. spinosa aqueous extract and Z jzýuba var. spinosa 
EtOH extract. M. officinalis and R. officinalis essential oils and citral, geraniol (72) 
and nerol (75), monoterpenes identified to be present in M officinalis essential oil 
(refer to Chapter 2,2.2.7.1 ), were also investigated. 
6.2.2.1 GABAB Receptor Binding Activily of Plant Extracts, Essential Oils and 
Essential Oil Constituents 
Test substances (at 100[tg/ml) that inhibited [3 H]-GABA binding to GABAB receptors 
by : S20% were Melissa officinalis leaf EtOH extract, Rosmarinus ojJ11cinalis dried leaf 
EtOH extract, Rosmarinus officinalis fresh leaf EtOH extract, Ziziphus jzýuha var. 
spinosa aqueous extract and Rosmarinus officinalis essential oil (data not shown). 
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6.2.2.1.1 GABAB Receptor Binding Activijy of Melissa offlcinalis Leaf Extracts 
The aqueous extract of Melissa officinalis leaf displaced [3 HI-GABA binding to 




Key for Figure 6.3 
Number Test Substance Test Substance Type 
I Citral Monoterpene, 
2 Geraniol Monoterpene 
3 Nerol Monoterpene 
4 Melissa officinalis Essential oil 
5 Melissa officinalis leaf H20 extract 
6 Ziziphusjujuba var. spinosa seed EtOH extract 
Figure 6.3. Inhibition of [3 H]-GABA binding to GABAB receptors in vitro, by plant 
extracts, Melissa officinalis essential oil and monoterpenes. 4+, inhibition of 81% - 
100%; 3+, inhibition of 61% - 80%; 2+, inhibition of 41% - 60%; +, inhibition of 21% 




These results suggest that polar compounds present in M. officinalis leaf displaced 
[3 H]-GABA binding to the GABAB receptor and that less polar compounds (present in 
the EtOH extract) have lower affinity for this receptor, but it cannot be excluded that a 
minor component of the EtOH extract has high affinity for the GABAB receptor. 
In traditional medicine M officinalis was used to treat neuroses and hysteria, and in 
Arabic medicine was used to treat depression (Bisset, 1994; Kenner and Requena, 
1996). This suggests that the plant may have anxiolytic and anti-depressant effects. 
M. officinalis leaf was reported to alleviate mild anxiety and nervousness in a double- 
blind study, and in combination with Valariana officinalis root, was reported to be as 
effective as the benzodiazepine triazolam, but did not cause drowsiness or impair 
concentration the next day (Yamell, 1998). A hydroalcoholic (30% EtOH) extract of 
M. offilcinalis leaf was sedative in mice and potentiated barbiturate induced sleep, but 
, 
ficinalis essential oil did not demonstrate these sedative effects (Soulimani et the M. of 
aL, 1991). The compounds and the mechanism of action responsible for these effects 
remain to be investigated. 
The GABAB receptor agonist baclofen (20) induces drowsiness (British National 
Formulary, 2001). Therefore the apparent affinity of the compounds present in the M. 
offilcinalis aqueous extract for the GABAB receptor may be due to agonistic effects, 
which may be associated with the sedative effects of this plant. If compounds were 
identified as GABA13 agonists, this may not be appropriate for AD treatment, as such 
compounds are reported to impair cognitive function (Carletti et aL, 1993; Castellano 
et aL, 1989; McNamara and Skelton, 1996; Tang and Hasselmo, 1996). Agonistic 
activity may be more relevant in other disorders, such as spasticity. It cannot be 
excluded that GABAB antagonistic compounds also occur in the extract, so may also 
explain the apparent receptor binding. Their presence may be relevant in memory 
disorders such as AD, as GABA13 antagonists are reported to enhance cognitive 
function (Carletti et aL, 1993; Froestl et aL, 1995; Getova and Bowery, 1998). 
Isolation of compounds from the aqueous extract is required to establish which 
compounds interact with the GABAB receptor, and their assessment in vivo may 
establish potential therapeutic effects. 
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6.2.2.1.2 GABAB Receptor Binding Activily of Melissa officinalls Essential Oil and 
Oil Constituents 
Melissa offlýinalis essential oil displaced [3 H]-GABA binding to GABAB receptors by 
32% at I OOpg/ml (Figure 6.3). The monoterpenes, citral, geraniol (72) and nerol (75), 
present in M. officinalis essential oil (refer to Chapter 2,2.2.7.1) displaced [3 H]- 
GABA binding to GABAB receptors by 78%, 85% and 81 % respectively at I 00Pg/ml, 
and by 44%, 55% and 60% respectively at I gg/ml (Figure 6.3). 
It is apparent that the isomeric compounds geraniol (72) and nerol (75) demonstrated 
greater affinity for the GABAB receptor than citral, which may reflect the similar 
chemical structures of geraniol (72) and nerol (75). These results suggest that citral, 
geraniol (72) and nerol (75), which comprise 22.7% of the essential oil (refer to 
Chapter 2,2.2.7.1), contributed to the apparent binding effects of M officinalis 
essential oil. Other essential oil components require investigation for their GABA 
receptor binding effects. Citral, geraniol (72) and nerol (75) are not reported to be the 
major constituents of Rosmarinus offi'cinalis essential oil. R. officinalis essential oil is 
reported to contain 1,8-cineole (56) (15-30%), camphor (57) (15-25%), a-pinene (53) 
(up to 25%) and other monoterpenes (e. g. bomeol (58), bornyl acetate (51)) as the 
major constituents (Bisset, 1994; Trease and Evans, 1996). This may explain why R. 
officinalis essential oil did not displace [3 H]-GABA binding as effectively as M 
officinalis essential oil. 
Several essential oils (and constituents) including lavender and neroli are reported to 
be sedative (Guillemain et al., 1989; Jfiger et al., 1992), although the mode of action 
requires further investigation. Following inhalation, neroli (Citrus aurantizini) 
essential oil and the constituents citronellal (68) and phenylethyl acetate were 
detected in mouse serum after one hour of exposure and were reported to be sedative 
in mice (Aiger et al., 1992). It may be that essential oil constituents present in neroli 
essential oil bind to GA13AB receptors agonistically to induce sedation, or may 
influence other neurotransmitter systems in the CNS. The apparent binding effects of 
M officinalis essential oil and three monoterpenes to the GABAB receptor, indicates 
that essential oil constituents may induce sedation by this effect, however in vivo 
other mechanisms may also occur; oil constituents may influence benzodiazepine or 
barbiturate modulatory receptor sites, which may enhance the actions of GABA (16). 
Citronellal (68) only comprised 1.6% of the total M officinalis essential oil 
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investigated in this study (refer to Chapter 2,2.2.7.1). This compound requires 
investigation regarding its effect on GABA binding but its low concentration in M. 
officinalis essential oil may explain the lack of sedative effects observed by Soulimani 
et aL (199 1). 
Essential oil composition may vary due to several factors (e. g. the environmental 
conditions for herb cultivation) so although Soulimani et aL (1991) found that their 
M. ofjtlcinalis essential oil did not induce sedation in mice, it may still be possible that 
other samples of the essential oil are sedative. Indeed, the constituents caryophyllene 
(82), citral, limonene (73) and linalool (74) from a preparation of M. officinalis known 
as 'balm spirit', are reported to induce sedation in mice and the monoterpenes 
citronellol (69) and geraniol (72) were also weak inducers of sedation, via an 
unknown mode of action (Wagner and Sprinkmeyer, 1973). These compounds 
comprise 42.7% of the M. offilcinalis essential oil (refer to Chapter 2,2.2.7.1) 
employed for assessment of GABA receptor binding. It may therefore be concluded 
. 
ficinalis essential oils may vary in composition and consequently differ in that M. of 
their pharmacological effects, and that the sedative effects observed by Wagner and 
Sprinkmeyer (1973) may be due to GABA receptor modulation, as citral and geraniol 
(72) were shown to bind to GABA receptors. 
M. ojjlcinalis essential oil is reported to be used in aromatherapy to alleviate 
depression and insomnia (McVicar, 1994). GABAB receptor activation is reported to 
suppress catecholamine and 5-HT release from brain slices, therefore GABAB 
antagonists may inhibit the suppression of NA release, induced by GABA (16) acting 
on presynaptic GABAB receptors on noradrenergic terminals (Bowery el aL, 1980; 
Pratt and Bowery, 1993). This suggests that GABAB antagonists may have potential 
in management of depression, and may explain the use of M officinalis essential oil to 
alleviate depression. 
6.2.2.1.3 GABA, 3 Receptor Binding ActiviLy of the Ethanolic Extract of Dziphys 
jyj by var. spinosy seed 
The EtOH extract of Dziphusjqjuba var. spinosa seed displaced [3 H]-GABA binding 
to GABAB receptors by 90% and 30% at 1 00pg/ml and 1 pg/ml respectively (Figure 
6.3). 
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Z jujuba seeds are used in traditional Chinese medicine (TCM) for anxiety and 
insomnia (Chang and But, 1987; Pharmacopoeia of the People's Republic of China, 
1992; Tang and Eisenbrand, 1992). These effects have been substantiated 
experimentally; Z jujuba var. spinosa seeds, leaves and fruit are sedative, but the pure 
compound jujuboside A did not influence CNS activity alone, suggesting this 
compound may not be responsible for sedation (Wu et aL, 1993). The seeds were also 
reported to prolong phenobarbital sodium-induced sleep in mice, and were clinically 
effective in treating insomnia when administered to 209 humans (Chang and But, 
1987). The sedative components of Z jujuba var. spinosa seeds have been identified 
as the jujubosides and flavone C-glycosides including spinosin (149) and swertisin 
(150) (Woo et aL, 1980; Yuan et aL, 1987), however these compounds may or may 
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An EtOH extract of Z jujuba seeds was anxiolytic at low doses and sedative at high 
doses, when administered to mice (Peng et aL, 2000). The mechanism of action for 
these effects is proposed to be due to a decrease in nionoaminergic activities (Hsieh et 
A, 1986a; Hsieh et A, 1986b). Z jz#uba seed components could also decrease 
monoamine levels in mouse brain (Chang and Chen, 1995). The seed extracts had no 
significant effects on baclofen (20) or muscimol (18) induced increase in locomotor 
activity in rats; it was therefore suggested that Z jzýziba seeds have no effect on 
GABAergic activity (Hsieh et aL, 1986b). 
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However, the results from the present investigations, showing high GABAB receptor 
binding, suggest that components of Z fitiuba seeds may promote sedation and 
anxiolytic effects via interaction with GABA receptors and so may have more than 
one mode of action. The suggestion by Hsieh et aL (I 986b), that compounds present 
in Z jujuba seeds do not influenece GABAergic activity, may also be explained by 
the compounds, which bind to GABA receptors, not reaching the CNS in sufficient 
concentrations, or the chemical composition of the herb used may not have contained 
sufficient quantities of GABA receptor binding compounds. Further studies are 
necessary to identify which components of the extract bind to GABA receptors and 
their bioavailability in vivo. If the sedative effects observed with this herb are 
associated with GABAB receptor binding, this may be agonistic. 
6.2.2.2 GABAA Receptor Binding Activily of Plant Extracts, Essential Oils and 
Essential Oil Constituents 
The affinity of some of the extracts, essential oils and oil constituents for the GABAA 
receptor was also investigated, to identify potential receptor selectivity. Test 
substances (at 100pg/ml) that displaced [3 H]-GABA binding to GABAA receptors by 
: 520% were Melissa ojjIcinalis leaf EtOH extract, Rosmarinus o)Ticinalis dried leaf 
EtOH extract, Rosmarinus o cinalis fresh leaf EtOH extract, Ziziphus jiýuba var. )fill 
spinosa aqueous extract and the essential oils of Melissa ojfIcinalis and Rosmarinus 
officinalis (data not shown). 
6.2.2.2.1 GABAA Receptor Binding Activity of Melissa officinalis Leaf Aqueous 
Extract 
The aqueous extract of Melissa officinalis leaf displaced [3 H]-GABA binding to 
GABAA receptors by 78% at 100[ig/ml (Figure 6.4). Affinity of the aqueous extract 
for the GABAB receptor was greater than that for the GABAA receptor (Figures 6.3 
and 6.4) but, as displacement of [3 H]-GABA binding was >70% with both receptors, 
the aqueous extract was not highly selective for the GABAB receptor. This may be a 
disadvantage in potential AD therapy, in which (antagonist) selectivity for the 





Key for Figure 6.4 
Number Test Substance Test Substance Type 
I Citral Monoterpene 
2 Geraniol Monoterpene 
3 Nerol Monoterpene 
5 Melissa officinalis H20 extract 
6_ Ziziphusjujuba var. spinosa seed EtOH extract 
Figure 6.4. Inhibition of [3 H]-GABA binding to GABAA receptors in vitro, by plant 
extracts and monoterpenes. 4+, inhibition of 81% - 100%; 3+, inhibition of 61% - 
80%; 2+, inhibition of 41% - 60%; +, inhibition of 21% - 40%. 
6.2.2.2.2 GABAA Receptor Binding Activily of Melissa offlicinalis Essential Oil and 
Oil Constituents 
Melissa officinalis essential oil inhibited [3 H]-GABA binding to GABAA receptors by 
< 20%, but had greater affinity for GABAB receptors (Figures 6.3 and 6.4), indicating 
GABAB selectivity. The essential oil constituents also showed greater affinity for the 
GABAB receptor (Figure 6.3), as citral, geraniol (72) and nerol (75) only displaced 
[3 H]-GABA binding to GABAA receptors by 28%, 32% and 28% respectively (Figure 
6.4). M. officinalis essential oil and the constituents citral, geraniol (72) and nerol 




The apparent selectivity for the GABAB receptor may be important therapeutically by 
minimising adverse effects. Whether receptor binding of these compounds induces 
agonist or antagonist effects remains to be investigated. However, if pharmacological 
studies are also taken into consideration, results may be indicative of the nature of 
receptor binding. Essential oils and the oil constituents citral, myrcene (52) and 
limonene (73) from Lippia alba, a plant known in Brazil as falsa inelissa and used 
traditionally for insomnia and anxiety, are reported to be anti-convulsant in mice 
(Viana et aL, 2000). The oil and compounds tested showed a similar pharmacological 
profile to diazepam, with citral being the most potent anti-convulsant of the 
monoterpenes (Viana et aL, 2000). Citral and geraniol (72) are reported to be 
sedative in mice (Wagner and Sprinkmeyer, 1973). Anti-convulsant and sedative 
effects of citral may reflect GABAA agonism, modulation of benzodiazepine receptors 
or other unidentified mechanisms of action. Citral binding to GABAA receptors 
agonistically may indicate a neuroprotective action, similar to that of the GABAA 
agonist muscimol (18) (Hollrigel et aL, 1996), an effect that may be exploited 
therapeutically. However, as citral did not show high affinity for the GABAA receptor 
(Figure 6.4), this theory may not be substantiated. 
It is therefore possible that citral induced sedation by a benzodiazepine-like effect, or 
may have influenced other neurotransmitter systems. Another possibility is that 
sedation occurred following agonistic binding to GABAB receptors, which citral has 
greater selectivity for (perhaps in conjunction with weak GABAA receptor agonism). 
Agonistic activity at the GABAB receptor would indicate that citral and perhaps the 
other monoterpenes are not appropriate for AD therapy, but may provide information 
on the structure-activity relationships for the GABA receptors, and may act as 
templates for the development of new GABA agonists for management of spasticity 
and antagonists or partial agonists for cognitive disorders, such as AD. 
6.2.2.2.3 GABAA Receptor Binding Activi! y of the Ethanolic Extract of Ziziphits 
jujuba var. MLnosa seed 
The EtOH extract of Dziphusjujuba var. spinosa seed displaced CH]-GABA binding 
to GABAA receptors by 23% at lOOpg/mI (Figure 6.4). The low affinity for this 
receptor suggests that compounds present in Z fiijuba var. spinosa seed may be more 
selective for the GABAB receptor (Figures 6.3 and 6.4). However, compounds may 
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also be present which have higher or equal affinity for the GABAA receptor, which 
warrants the isolation and identification of compounds from this herb to assess 
potential interactions with GABA receptors. 
Z jujuba seed extracts are reported to be anti-convulsant in animals (Chang and But, 
1987), have anxiolytic effects in vivo and in a double blind clinical trial in humans, 
and were comparable to the anxiolytic effects of diazepam with fewer adverse effects 
(Chen et aL, 1986; Peng et aL, 2000). The mechanism for these effects has not been 
established. Interaction with the GABAA or GABAB receptors may explain the anti- 
convulsant activity and anxiolytic effects, although interaction with allosteric sites on 
receptors or effects on other neurotansmitter systems may explain physiological 
effects in vivo. 
6.2.3 Conclusion 
The results for those extracts and essential oils that exhibited binding to GABAA and 
GABAB receptors are consistent with the known pharmacological activities of those 
plants. Displacement of [3 H]-GABA binding to receptors may have occurred by 
direct interaction with the ligand binding domain (LBD) of the GABA receptor, or 
due to interaction with allosteric sites. 
Other plants have previously been investigated for their interaction with the GABAA 
and GABAB receptors (Zhu et al., 1996a; Zhu et al., 1996b), and some plants (e. g. 
Afrormosia laxiflora, Hoslundia opposita Vahl. and Salvia transsylvancia) and 
compounds derived from plants (e. g. xanthone derivatives) have been identified as 
anti-convulsant compounds (Haruna, 2000; Maklad et al., 1999; Marona, 1998; 
Marona et al., 1998; Olajide el al., 1999b), suggesting their interaction with GABA 
receptors. The plants investigated in this study have not previously been analysed for 
GABA receptor binding. 
Structure-activity relationships are difficult to establish, because of the chemical 
diversity of compounds interacting with GABA receptors, and the complexity of 
physiological responses that they may initiate. The selectivity of Melissa officinalis 
essential oil and constituents for the GABAB receptor is a novel finding, as the acyclic 
monoterpenes citral, geraniol (72) and nerol (75) differ in their chemical structures 
from known ligands for the GABA receptors, such as GABA (16), the GABAA 
agonist muscimol (18), the GABAA antagonists bicuculline (17) and bis(7)-tacrine 
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(19), the cyclic GABAB receptor agonist baclofen (20) and the cyclic GABAB 
receptor antagonists phaclofen (22), 2-hydroxy saclofen (23) and the acyclic CGP 
36742 (21). These known ligands for the GABA receptors are also all nitrogen- 
containing, unlike the three monoterpenes. 
In conclusion, Melissa officinalis and its essential oil, and Dziphus jtýuba have 
potential to yield compounds, or compounds that act as templates for the development 
of new compounds, which may be relevant in CNS disorders involving GABAergic 
function such as cognitive impairment. Further investigation is required to establish 
the active constituents present in these herbs. Further studies would also be warranted 
regarding the potential agonistic and antagonistic effects of isolated compounds. 
6.3 Effect of Plant Extracts on Neural Stem Cells in vitro 
Stem cells may differentiate to give rise to a particular cell phenotype under the 
influence of various factors. In view of the cholinergic deficit associated with AD 
(Bierer et al., 1995; Collerton, 1986; Giacobini, 1990; Perry et al., 1978; Perry, 1986; 
Plotkin and Jarvik, 1986; Read, 1987), which involves the relatively selective 
degeneration and atrophy of cholinergic neurons (particularly in the nucleus of 
Meynert in the basal forebrain (Whitehouse et al., 1982)), neural stem cells (NSCs) 
may be exploited to generate a particular neuronal phenotype for transplantation ill 
vivo, as an alternative approach to the treatment of various CNS disorders. 
The extracts of the plants investigated in the present study were therefore assessed for 
their potential effects on NSC differentiation in vitro, to determine if the extracts 
promote neuronal differentiation of a particular phenotype. 
6.3.1 Method 
6.3.1.1 Materials 
Plant extracts were obtained as described previously (refer to Chapter 2,2.1.1.1). 
Chemicals were purchased from Sigma, Fancy Road, Poole, Dorset, England, unless 
otherwise stated. 
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6.3.1.2 Isolation of Foetal Ventral Rat Forebrain Tissue and Spinal Cord Tissue, and 
Propagation of Neural Stem Cells in vitro 
Isolation of foetal ventral rat forebrain tissue and spinal cord tissue, and propagation 
of NSCs in vitro was conducted by Dr Stephen Minger, King's College London, 
London, SEI IUL. 
Rats were housed in standard laboratory cages and had free access to food and water. 
Foetal ventral forebrain tissue and spinal cord tissue was isolated from pregnant 
Fischer 344 rats on gestational day 14 (crown-rump length: 9mm -II mm). The rats 
were euthanised using a mixture of ketamine (25mg/ml), rompun (1.3mg/ml) and 
acepromazine (0.25mg/ml). Following removal of foetuses by laparotomy, tissue 
comprising the ventral forebrain with associated telencephalic ventricular zone and 
the spinal cord from approximately C6 - T4 was dissected. 
Procedures for processing of NSCs were as described previously by Minger et al. 
(1996). Tissue from approximately 25 - 30 fbetuses was collected and briefly washed 
in sterile Dulbecco's phosphate buffered saline (PBS; Life Technologies Ltd., 3 
Fountain Drive, Inchinnan Business Park, Paisley, UK). Following a 30min 
incubation period at 37'C in 0.1% trypsin (in PBS), the isolated tissue was 
sedimented at 10OOg and washed in PBS three times. Single cell suspensions were 
obtained by mechanical dissociation of tissue by trituration with fire-polished, 
narrowed Pasteur pipettes. Subsequently cell viability was evaluated using trypan 
blue exclusion and estimates of cell number were obtained using a haematocytometer. 
Single cell suspensions of isolated tissue were plated at an initial density of 2xI 04 
cells/well on 13min 2 glass coverslips in 24-well plates coated with 10ýtg/ml 
polyominthine and lOpg/ml laminin (P+L) (Biogenesis Ltd., Technology Road, 
Poole, England). Cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) 1: 1 F12 high glucose medium (0.6% glucose, 2mM glutamine) with N2 
neuronal supplement (25gg/ml insulin, 100gg/ml transferrin, 20nM progesterone, 
60ýM putrescine, 30nM selenium chloride; Life Technologies Ltd., 3 Fountain Drive, 
Inchinnan Business Park, Paisley, UK) in humidified 95% air/5% C02 atmosphere. 
The medium was supplemented with 20ng/mi fibroblast growth factor (FGF) -2 
(Chemicon International Ltd., 2 Admiral House, Cardinal Way, Harrow, England). 
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Once cells reached approximately 80% confluency, the medium was replaced with 
assay medium: DMEM/Fl2/N2 medium, containing 100ng/ml all-trails retinoic acid 
and plant extracts (refer to 6.3.1.3) but no serum, thus inducing cellular differentiation 
(Takahashi et al., 1999). 
6.3.1.3 Addition of Plant Extracts to Neural Stem Cells in vitro 
Plant extracts (5mg/ml diluted in either EtOH or H20; refer to Chapter 2,2.1.3 for 
plant extraction methods) were diluted in assay medium and added to the 24-well 
plates containing the NSCs, to give a final assay concentration of 25mg. L"' (n=4 per 
plate, assay repeated >10 times). After 3 days incubation at 37'C in a humidified 
atmosphere (95% air/5% C02) the cells were processed (refer to 6.3.1.4). 
6.3.1.4 Neural Stem Cell Analysis Using Immunoc3lochemist 
For immunocytochernical analysis, cells were washed with PBS and fixed with 4% 
paraformaldehyde for 30min at 4'C. Cells were washed with Tris-buffered saline 
(TBS; 20mM Tris, 150mM NaCl, pH 7.4); washing with TBS for 15min each time 
and repeated three further times. Cells were then incubated for 30min in TBS 
containing 0.01% Triton X-100 (TBS+). This was followed by incubation in 5% milk 
(in TBS+) for 30min, in order to prevent non-specific antibody binding. Cells were 
incubated with primary antibodies (mouse P-tubulin isotype 111), diluted in 5% milk in 
TBS+ (1: 200 dilution), at 4'C overnight. 
Following overnight exposure to primary antibody, cells were washed three times in 
TBS+ for 15min each. Cells were then treated with horseradish peroxidase- 
con ugated affinipurified, goat anti-mouse IgG secondary antibody (Jackson 
Immunoresearch Laboratories Inc., Stratech Scientific Ltd., 61 - 63 Dudley Street, 
Luton, Bedfordshire), diluted in TBS+ (1: 200), and incubated for lhr at room 
temperature. After a further three 15min washes with TBS, cells were stained with 
0.05% diaminobenzidine, 0.04% nickel chloride and 0.01% H202 (Peroxidase 
Substrate Kit, Vector Laboratories Inc., 30 Ingold Road, Burlingame, USA) for 8min 
-I Omin. Cells were washed in TBS prior to being briefly dehydrated through a series 
of graded alcohols (70%, 95% and 100% sequentially). After passage in xylene, 
coverslips were mounted on glass microscope slides using DPX. NSCs were 
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examined using a Nikon E800 microscope equipped with the image analysis software 
Lucia. 
6.3.2 Results and Discussion 
The EtOH extracts of Alisma orientalis root, Apocynuni lancifolhun leaf, Centella 
asiatica leaf, Codonopsis pilulosa root, Convallaria inajalis leaf, Gentiana spp. root 
(adulterated Pol num multiflorum root), Melissa ojricinalis leaf, Polygala tenitifolia Y90 
root, Rosmarinus officinalis leaf (fresh and dried leaf), Salvia niilliorrhiza root, 
Withania somnifera root, Ziziphzisjujuba seed, and Ziziphusjzýuba var. spinosa seed 
were assessed for their potential effects on NSC (from foetal rat forebrain) 
differentiation in vitro, at a concentration range of 12.5mg. Ul - 200mg. L-1. 
All plant extracts were cytotoxic at concentrations 50mg. L-1 - 200mg. L-1, except Z 
jujuba and Z jujuba var. spinosa seed extracts, which were only cytotoxic at 
concentrations ýJ 00mg. L-1, and Codonopsis pilzilosa and Gentiana spp. (adulterated 
Pol num multiflorum) root extracts, which were not cytotoxic (data not shown). Y90 
All extracts, except for Apocynum lancifolium leaf, Codonopsis pilulosa root, 
Gentiana spp. root (adulterated Polygonum multiflorum root), Z jzýuba seed, and Z 
jujuba var. spinosa seed extracts, demonstrated notable cytotoxicity within the 
concentration range of 12.5mg. L" - 25mg. Ul (data not shown). As the EtOH extracts 
of Apocynum lancifoliuni leaf and Z jzýuba var. spinosa seed consistently affected 
NSC differentiation in vitro, they were selected for further investigation and aqueous 
extracts were also assessed for their effects on NSC (from foetal rat forebrain) 
differentiation. Further assessment of the aqueous extracts of Apocynilln lancifolillin 
leaf and Z jujuba var. spinosa seed (which were less cytotoxic than the EtOH 
extracts) on NSCs from foetal rat spinal cord was also conducted. 
The preliminary results show that both the aqueous and EtOH extracts of Apocynian 
lancifolium leaf and Z jujuba var. spinosa seed influence NSC (from foetal rat brain 
and spinal cord) differentiation at a concentration of 25mg. L-1 in the presence of 
retinoic acid (Figures 6.6 - 6.9 and 6.11 - 6.12), compared to NSC differentiation in 
the presence of retinoic acid alone (Figures 6.5 and 6.10). 
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Figure 6.5. Neural stem cells from foetal rat forebrain treated with retinoic acid and 
stained for P-tubulin (x200). 
Figure 6.6. Neural stem cells from foetal rat forebrain treated with retinoic acid and 
Apocynum lancifolium leaf aqueous extract and stained for P-tubulin (x200). 
Figure 6.7. Neural stem cells from foetal rat forebrain treated with retinoic acid and 




Figure 6.5. Neural stem cells from foetal rat forebrain treated with retinoic acid and 
stained for 0-tubulin (x2OO). 
Figure 6.8. Neural stem cells from foetal rat forebrain treated with retinoic acid and 
Ziziphusjujuba var. spinosa seed aqueous extract and stained for P-tubulin (x200). 
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Figure 6.9. Neural stem cells from foetal rat forebrain treated with retinoic acid and 




-AL. ý Figure 6.10. Neural stem cells from foetal rat spinal cord treated "Ith retinoic acid 
and stained for P-tubulin (x200). 
Figure 6.11. Neural stem cells from foetal rat spinal cord treated with retinoic acid 
and Apocynum lancifolium leaf aqueous extract and stained for 0-tubulin (x200). 
Figure 6.12. Neural stem cells from foetal rat spinal cord treated with retinoic acid 
and Ziziphus jujuba var. spinosa seed aqueous extract and stained for P-tubulin 
(x200). 
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This is apparent as the cells treated with the plant extracts stained positive for P- 
tubulin, which is regarded as a neuron-specific marker, and showed more extensive 
neurite elongation (Figures 6.6 - 6.9 and 6.11 - 6.12) than those cells treated with 
retinoic acid alone (Figure 6.5 and 6.10). Neurites also appeared to form in bundles in 
the presence of the plant extracts (Figures 6.6 - 6.9 and 6.11 - 6.12), as opposed to the 
predominantly single neurites observed in the control cells (Figure 6.5 and 6.10). 
Extensive staining (for P-tubulin) of both axons and dendrites was observed in the 
NSCs treated with the plant extracts (Figures 6.6 - 6.9 and 6.11 - 6.12), but it is 
unknown if the extracts selectively promoted either axonal or dendritic neurite 
outgrowth; further analysis using the dendritic marker microtubule-associated protein- 
2 (MAP-2) and the axonal marker tau 1 would therefore be necessary. 
Further experiments are also required to determine if the plant extracts promote 
neuronal differentiation of a specific phenotype, by conducting immunocytochernical 
analysis to identify any specific neuronal markers. For example, other primary 
antibodies may be employed including those against choline acetyltransferase 
(ChAT), which is specific for cholinergic neurons. Preliminary experiments were 
conducted using ChAT, but assay results were unsuccessful and further assay 
refinement will be required to establish if plant extract treated cells stain positive for 
cholinergic neurons. Morphological analysis of the cells treated with plant extracts 
shows that some cells are bipolar with triangular cell bodies; this may be indicative of 
cholinergic neurons, but confirmation of this is required. 
The mechanism of action to explain neuronal differentiation in the presence of the 
plant extracts also requires further investigation. Retinoic acid is reported to 
potentiate cell responsiveness to neurotrophins (e. g. nerve growth factor (NGF)), and 
promote the development of neuronal phenotypes (Takahashi el al., 1999). It is 
possible that compounds present in the plant extracts may have neurotroPhic effects, 
but those compounds responsible require isolation and identification. 
The steroid receptor superfamily of transcription factors includes receptors for 
oestrogens, thyroid hormone and retinoic acid. Thyroid hormone and retinoids are 
reported to influence CNS development (Barres et al., 1994) and basal forebrain 
cholinergic neurons are reported to have oestrogen (estrogen) receptors (ERs) that are 
co-localised with NGF receptors (Sohrabji et al., 1994; Toran-Allerand et al., 1992). 
The active plant extracts may influence neuronal differentiation by modulating the 
function of these receptors. For example, Polygala tenitifolia was previously reported 
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to increase NGF secretion in vitro (Yabe et al., 1997); this effect may be associated 
with its oestrogenic activity (observed in yeast and mammalian cells; refer to Chapter 
4,4.5). The possibility that Polygala lenitifolia, and perhaps other plant extracts, 
contain ligands for receptors that modulate neuronal growth and differentiation also 
requires further investigation. 
Apocynum lancifolium leaf is reported to contain cardiac glycosides (e. g. cymarin 
(48)), flavones (e. g. quercetin (104)), flavonol-0-glycosides (e. g. hyperin), 
phenylpropanoid substituted flavan-3-ols (e. g. apocynins A- D), lauric acid, phenolic 
compounds, steroid saponins, cournarins (e. g. scopoletin) and triterpenes (e. g. a- 
amyrin and lupeol) (Chang and But, 1987; Duke and Ayensu, 1995; Fan et al., 1999; 
Huang, 1993; Jianming, 1988; Miaohua and Fengshan, 1991). Amino acids including 
GABA (16) were also detected in the leaf extracts (refer to Chapter 2,2.2.6). 
Z jujuba var. spinosa seeds are reported to contain saponins (e. g. jujubosides A and 
B), flavone-C-glycosides (e. g. swertisin (150) and spinosin (149)), triterpenes (e. g. 
betulic acid and betulin), and fixed oil (Chang and But, 1987; Tang and Eisenbrand, 
1992). Some amino acids, but not GABA, were also detected in the seed extracts 
(refer to Chapter 2,2.2.6). 
Apocynum lancifolium leaf and Z jujuba var. spinosa seeds, nor their known 
constituents, have previously been investigated for their effects on NSC 
differentiation. Of the phytochernicals previously investigated for effects on neuronal 
differentiation, euxanthone (151), a xanthone isolated from Polygala caudata root, 
promoted neuronal growth and differentiation, identified using a marker for MAP-2, 
in neuroblastorna (Neuro-2A) cells, which is a neuropeptide-producing cell line (Mak 




Polygala tenuffolia root (a plant also used in the present study) extract, but not Z. 
jujuba var. spinosa seed extract, significantly increased NGF secretion in astroglial 
cells in vitro (Yabe et al., 1997). Polygala tenuffolia root is also reported to contain 
xanthones (Fujita et al., 1992; Huang, 1993; Ikeya et al., 1991a; Ikeya et al., 1994; 
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Sakuma and Shoji, 1981a; Sakuma and Shoji, 1981b; Tang and Eisenbrand, 1992). 
Xanthones may therefore explain the reported effects of Polygala caudata and 
Polygala tenuffiblia, and if present in the active extracts used in the present study, may 
explain their effects on NSC differentiation. The lack of notable effects of Polygala 
tenuifolia on NSC differentiation in the present study may reflect the different cell 
types used for analysis, or variation in the chemical composition of the Polygala 
tenuffolia roots used in each study. 
A MeOH extract of W. somnifiera root dose-dependently promoted dendrite extension 
in neuroblastoma (SK-N-SH) cells in vitro (Tohda et al., 2000). The cytotoxicity 
observed with W. somnifera root EtOH extract may explain why no effects on NSC 
differentiation were observed in the present study. It cannot be excluded that a 
MeOH extract of this herb may be less cytotoxic and could possibly potentiate NSC 
differentiation, but this requires investigation. 
6.3.3 Conclusion 
Grafts of foetal basal forebrain tissue into brain in animal models of AD and lesion- 
induced memory impairment, have been reported to enhance cognitive function (Fine 
et al., 1985; Welner et al., 1988). Factors that promote the development of a specific 
neuronal population and support neuronal survival in vitro could be important in the 
success of neuronal cell transplantation. For example, NSCs treated with FGF-2 in 
vitro, promoted long-term neuronal survival following transplantation into basal 
forebrain in vivo (Minger et al., 1996). 
It is apparent that both the aqueous and EtOH extracts of Apocynitni lancifolium leaf 
and Z jujuba var. spinosa seed promote neuronal differentiation in vitro (Figures 6.6 - 
6.9 and 6.11 - 6.12). Although these results are preliminary, these plant extracts may 
be a source of compounds with particular relevance in the treatment of 
neurodegenerative diseases. The extensive effects on neurite outgrowth observed 
with these plant extracts in vitro, indicate that administration of the active compounds 
in vivo (either to influence existing neurons in vivo, or to promote neuronal 
differentiation following NSC graft transplantation) may have potential in the 
treatment of paralysis caused by spinal cord transection. If further studies confirm 
that the active plant extracts promote the development of a specific neuronal 
384 
phenotype such as cholinergic or dopaminergic neurons, this may be particularly 
relevant in the treatment of AD and Parkinson's disease respectively. 
In conclusion, further studies arc clearly warranted to identify the active compounds 
present in the plant extracts and their specific effects on neuronal differentiation. It 
may be that numerous compounds, each specific for the promotion of a particular 
neuronal phenotype, may be isolated. Isolated compounds may also act as templates 
for the development of more active or specific compounds that modify neuronal 
differentiation. The active compounds isolated from the plant extracts may also have 
advantages over other compounds that influence neuronal differentiation (e. g. NGF), 
in that they may cross the BBB to promote neurite outgrowth in the CNS. 
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CHAPTER7 
General Discussion and Conclusions 
The aim of the investigations in this study was to identify a pharmacological basis for 
plants with reputed anti-aging or memory-enhancing effects used in traditional 
Ayurvedic, Chinese and European medicine. Most of the plants showed 
pharmacological activities that may explain their use in traditional medicine, and 
subsequently they may have potential in the treatment of cognitive and 
neurodegenerative disorders such as AD. However, it must also be considered that 
other pharmacological activities that were not investigated in the present study may 
also explain the reputed activities of the plants, and further investigations would 
provide even greater understanding of their pharmacological activities. The plant 
extracts could also be investigated for other activities that may be relevant in AD 
therapy, for example muscarinic or nicotinic receptor binding, or effects on P-amyloid 
deposition. As knowledge of the pathological mechanisms that occur in AD becomes 
clearer, the approaches to treatment may differ from current therapy. The plants with 
reputed effects on cognition could also be assessed for other effects on the 
pathological mechanisms that occur in AD as they become more fully understood. 
Fractionation of the active plant extracts is necessary to identify which compounds are 
responsible for the pharmacological activities observed, or if compounds act 
synergistically to enhance activity. It must also be considered that the majority of 
investigations in the present study were in vitro bioassays, so although the results 
from these studies may show extracts and essential oils to have relevant activities in 
relation to AD, further testing in vivo is necessary to establish their therapeutic 
potential. In vivo pharmacokinetic studies would be necessary to assess the 
absorption, metabolism and elimination of extracts and compounds, whilst access of 
active compounds across the BBB and toxicity should also be evaluated. Extracts that 
showed activity in vitro may not necessarily be active in vivo, perhaps to due 
metabolic conversion to inactive compounds. Similarly, extracts that were inactive in 
vitro could show activity in vivo, perhaps because of metabolic conversion to active 
compounds. 
386 
In the present study, all of the plants investigated except two (Codonopsis pilillosa 
root and Gentiana spp. (found substituted for Polygonum multiflorian root), refer to 
Chapter 2,2.2.1.1), showed at least one pharmacological activity that may be relevant 
in AD therapy. This suggests that selection of plants with regard to their 
ethnobotanical uses is a relatively successful approach to identify pharmacological 
activities that may be relevant to a particular disorder. The main conclusions 
regarding the pharmacological activities of each plant in this study, and their 
relevance in AD therapy, are discussed below. 
7.1 PIants Investiuated in this Stud 
7.1.1 A lisma orientalis 
The cold ethanolic extract of Alisma orientalis root significantly inhibited lipid 
peroxidation in vitro (refer to Chapter 6,6.1.2.2). This extract may therefore be 
useful in disorders where oxidative processes may be contributing factors, such as 
carcinogenesis and AD. The compounds responsible for anti-oxidant activity and 
their potency require further investigation. As discussed previously (refer to 6.1.3), 
the extract (and active compounds) also requires evaluation in other anti-oxidant 
systems in vitro and in vivo before the characterisation of compounds as anti-oxidants. 
A. orientalis root extracts did not inhibit AChE activity in vitro (refer to Chapter 3, 
3.2.2), did not show significant oestrogenic activity in vitro (refer to Chapter 4,4.5.1), 
were not significantly active against eicosanoid formation in vitro (refer to Chapter 5, 
5.2.1) and the ethanolic extract was cytotoxic to neural stem cells (NSCs) in vitro, so 
did not significantly influence NSC differentiation (refer to Chapter 6,6.3.2). Any 
favourable effects of A. orientalis root on cognitive and age-related disorders 
therefore, is unlikely to be due to anti-inflammatory mechanisms, oestrogenic activity 
or inhibition of AChE, but may be due to other pharmacological activities, perhaps 
anti-oxidant activity. 
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7.1.2 Apocynum lancifolium 
Both the aqueous and ethanolic extracts of Apocynum lancifolium leaf significantly 
inhibited AChE activity in vitro, with the aqueous extract being the more active (refer 
to Chapter 3,3.2.2). Fractionation of these extracts is necessary to identify which 
compounds were responsible for this activity. As the aqueous extract was more active 
than the ethanolic extract, the most active compounds may be more polar, and are 
perhaps the cardiac glycosides. Cymarin (48), a constituent of A lancifolillin leaf, 
only weakly inhibited AChE (refer to Chapter 3,3.2.4.2) but it cannot be excluded 
that other cardiac glycosides present in the extracts were more potent inhibitors of 
AChE. 
Both the aqueous and ethanolic extracts of A. lancifolium leaf influenced NSC 
differentiation in vitro (refer to Chapter 6,6.3.2). Compounds isolated from these 
extracts may therefore have potential in the treatment of neurodegenerative disorders, 
including AD, Parkinson's disease and spinal cord injury. Further investigations are 
necessary to identify active compounds and establish their therapeutic potential in 
vivo. 
Neither the aqueous nor the ethanolie extract of A. lancifolhan leaf showed significant 
oestrogenic activity in vitro (refer to Chapter 4,4.5.1), nor were they significantly 
active against eicosanoid formation in vitro (refer to Chapter 5,5.2.1). 
The reputed effects of this plant on cognitive disorders may be explained by 
enhancement of cholinergic function via inhibition of AChE, but this requires 
confirmation in vivo. This plant may potentially yield new (and perhaps novel, if it is 
confirmed to be the cardenolide compounds that are antiChEs) AChE inhibitors that 
may be used for the symptomatic treatment of AD. 
7.1.3 Centella asiatica 
All extracts of Centella asiatica leaf inhibited AChE activity in vitro, in the order of 
potency: aqueous extract < ethanolic extract < petroleum spirit extract (refer to 
Chapter 3,3.2.2) and, the ethanolic extract of Centella asiatica leaf was significantly 
active against TXB2 formation in vitro (refer to Chapter 5,5.2.1). The hot ethanolic 
extract of C. asiatica leaf significantly inhibited lipid peroxidation in vitro (refer to 
Chapter 6,6.1.2.2). None of the C. asiatica leaf extracts showed significant 
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oestrogenic activity in vitro (refer to Chapter 4,4.5.1), and the ethanolic extract was 
cytotoxic to NSCs in vitro and so did not significantly influence NSC differentiation 
(refer to Chapter 6,6.3.2). 
The reputed effects of this plant on memory may therefore be due to a combination of 
activities, including antiChE, anti-inflammatory and anti-oxidant effects. The 
ethanolic extract showed the greatest variety of pharmacological activities, compared 
to the aqueous and petroleum spirit extracts. It remains to be investigated if the same 
compounds were responsible for all the pharmacological activities observed, or if 
different compounds were responsible for each activity. If the latter is confirmed by 
fractionation and isolation, use of the crude extract that has multiple activities may be 
more appropriate than the use of isolated compounds, which may only have one 
beneficial effect in relation to AD treatment. The results from the in vitro studies 
show that C. asiatica leaf may also be a source of new therapeutic agents that are not 
only appropriate for use in AD, but may also provide compounds or template 
compounds for other disorders, including inflammatory diseases such as rheumatoid 
arthritis. 
7.1.4 Codonopsispiltilosa 
Codonopsis pilulosa root extracts did not inhibit AChE activity in vitro (refer to 
Chapter 3,3.2.2), did not show significant oestrogenic: activity in vitro (refer to 
Chapter 4,4.5.1), were not significantly active against eicosanoid formation in vitro 
(refer to Chapter 5,5.2.1), the hot ethanolic extract did not inhibit lipid peroxidation 
in vitro (refer to Chapter 6,6.1.2.2) and although not cytotoxic, the ethanolic; extract 
did not significantly influence NSC differentiation in vitro (refer to Chapter 6,6.3.2). 
These results indicate that the reputed anti-amnesic effect of C pilillosa root in TCM 
may not be due to inhibition of AChE, inhibition of eicosanoid generation, inhibition 
of lipid peroxidation or oestrogenic activity. Further studies are necessary to identify 
any other pharmacological basis for the reputed effects of this plant. 
Although no pharmacological activities were identified with this plant in the present 
study, the root may have other pharmacological activities relevant to AD treatment. 
For example, the root extracts may have activities in vivo that do not occur in vitro, 
perhaps due to metabolic conversion to active compounds in vivo. 
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7.1.5. Convallaria majalis 
The dichloromethane and ethanolic extracts (not the aqueous or the hexane extracts) 
of Convallaria majalis leaf significantly inhibited AChE activity in vitro (refer to 
Chapter 3,3.2.4.1). Several fractions of the ethanolic extract and also the 
dichloromethane fraction of the ethanolic extract of C. majalis leaf, obtained by flash 
column chromatography (FCC) significantly inhibited AChE activity in vitro (refer to 
Chapter 3,3.2.4.2 and 3.2.4.3). The active fractions obtained by FCC were analysed 
using TLC to identify the types of compounds that may have been responsible for 
activity. Neither flavonoids nor alkaloids were detected in active fractions obtained 
(FCC (a)), but two fractions (173a and F8a) each contained a different unidentified 
cardenolide, indicating that cardenolides may have contributed to the antiChE activity 
of these active fractions (refer to Chapter 2,2.2.2.1 and 2.2.2.5, and Chapter 3, 
3.2.4.2). 
The commercially obtained cardenolides convallatoxin (50) and cymarin (48) (which 
are found in C. majalis and Apocynum lancifolium respectively) showed no, or only 
weak, activity against AChE activity respectively (refer to Chapter 3,3.4.2). 
Cardenolide compounds were not detected in other fractions obtained from FCC (a), 
which suggests that compounds other than cardenolides contributed to the antiChE 
activity of these fractions (refer to Chapter 2,2.2.2.1 ). 
Fractionation of the ethanolic extract of C majalis leaf using droplet counter-current 
chromatography (DCCQ and preparative thin-layer chromatography (TLC), also 
yielded several fractions that significantly inhibited AChE activity in vitro (refer to 
Chapter 3,3.2.4.4 and 3.2.4.5). The most active ftaction (174) obtained using DCCC 
did not contain constituents that were common to the active fractions F8a from FCC 
(a) and F3 and F4 from preparative TLC separation (refer to Chapter 2,2.2.2.4), 
confirming that different compounds were responsible for antiChE activity of the 
active fractions, and that they may have acted synergistically in the crude extract. 
The compounds present in the preparative TLC fractions were investigated using TLC 
and LC-MS, and compounds present in the active fractions F3 and F4 were shown not 
to be alkaloids, flavonoids or chlorophyll, and using TLC analysis, three zones in F3 
and F4 were common to F8a from FCC (a), indicating that the compounds in these 
zones may have been responsible for the antiChE activity observed (refer to Chapter 
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2,2.2.2.5 and 2.2.3.2, and Chapter 3,3.2.4.2 and 3.2.4.5). HPLC analysis also 
confirmed the absence of flavonoid compounds in F3 (refer to Chapter 2,2.2.3.2). 
It may be concluded that C. majalis leaf is a potential source of new AChE inhibitors, 
which are not flavonoids or alkaloids but may be other unidentified compounds, 
perhaps cardenolides. Further fractionation of the ethanolic and dichloromethanc 
extracts is required to confirm which compounds were responsible for the antiChE 
activity, and their potency in vivo. Isolation of the antiChE compounds may lead to 
the development of novel AChE inhibitors for AD therapy, particularly if confirmed 
not to be the known types of AChE inhibitor i. e. the alkaloids and monoterpenes. 
The ethanolic extract of C. majalis leaf was also significantly active against TX132 
formation in vitro (refer to Chapter 5,5.2.1). This result indicates that the leaf extract 
may have anti-inflammatory activity via inhibition of COX, but further fractionation 
and isolation is necessary to identify the compounds responsible for this activity. 
None of the C. majalis leaf extracts showed significant oestrogenic activity in vitro 
(refer to Chapter 4,4.5.1) and the ethanolic extract was cytotoxic to NSCs in vitro, so 
did not influence NSC differentiation (refer to Chapter 6,6.3.2). 
The claims in European traditional medicine that C nzajalis leaf may enhance 
memory could perhaps be explained by enhancement of cholinergic function via 
inhibition of AChE and perhaps anti-inflammatory activity. It would also be 
important to investigate whether the same compounds are responsible for both 
activities. Confirmation of this may provide an ACK inhibitor with additional anti- 
inflammatory activity, which may have advantages over existing AChE inhibitors 
used for symptomatic treatment of AD. 
7.1.6 Gentiana spp. (Adulterated Polygonuin multiflornin) 
The original aim of this study was to investigate if Polygonzini nuilliflorun) root, 
which is reputed in TCM to restore youth and treat neurosis, showed pharmacological 
activities that may be useful in AD treatment. However, authentication of the root 
used in the bioassays in the present study, showed that it was not P. nudliflorian but a 
species of Gentiana (refer to Chapter 2,2.2.1.1). Therefore the pharmacological basis 
for the reputed effects of P. multifloruin root still requires further investigation. 
Gentiana spp. root (adulterated P. multiflorum root) extracts did not inhibit AChE 
activity in vitro (refer to Chapter 3,3.2.2), nor did they show significant oestrogenic 
391 
activity in vitro (refer to Chapter 4,4.5.1) and were not significantly active against 
eicosanoid formation in vitro (refer to Chapter 5,5.2.1); neither the hot nor the cold 
ethanolic extracts significantly inhibited lipid peroxidation it? vitro (refer to Chapter 6, 
6.1.2.2). Although not cytotoxic, the ethanolic extract also showed no significant 
effect on NSC differentiation in vitro (refer to Chapter 6,6.3.2). These results show 
that a Gentiana spp., a plant that does not have a reputation for enhancing memory or 
anti-aging effects, does not appear to have pharmacological activities that may 
alleviate such cognitive disorders. 
7.1.7 Melissa officinalis 
The Melissa officinalis leaf extracts, essential oils and oil constituents showed 
numerous pharmacological effects that may be appropriate in AD therapy. Both the 
M. offi'cinalis leaf aqueous extract and the essential oil significantly inhibited AChE 
activity in vitro (refer to Chapter 3,3.2.2). This result indicates that both polar (from 
the aqueous extract) and less polar compounds (present in the essential oil) from M. 
officinalis were antiChE. The compounds responsible for the antiChE activity of the 
aqueous extract require further investigation by fractionation and isolation of the 
active compounds; the antiChE activity of the essential oil may be due to the 
monoterpenes citral, geraniol (72) and linalool (74) (these compounds were identified 
in M officinalis essential oil using GC-MS analysis; refer to Chapter 2,2.2.7.1), as 
these monoterpenes have previously been reported to inhibit AChE (Ryan and Byme, 
1988; Perry et al., 2000a). 
Neither the aqueous nor the ethanolic extracts of M officinalis leaf showed significant 
oestrogenic activity in vitro (refer to Chapter 4,4.5.1). The M. officinalis essential 
oil, phytol and crude phytol extracts, and the essential oil constituents (citral, 
citronellol (69), geraniol (72), nerol (75), nerolidol (83), irans-caryophyliene (82) and 
nonanal (86)) showed significant dose-dependent oestrogenic activity in genetically 
modified yeast cells in vitro, but neither the essential oil nor the monoterpenes citml 
and geraniol (72), showed significant oestrogenic activity in human Ishikawa cells it? 
vitro (refer to Chapter 4,4.6 and 4.7). They also showed no oestrogenic activity in 
vivo following transdermal administration to mice (refer to Chapter 4,4.9). Citral, 
eugenol (84), geraniol (72) and nerol (75) did however, dose-dependently displace 
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[3 H]-17p-oestradiol binding to ERa and ERP in vitro (refer to Chapter 4,4.8.2) and 
eugenol (84) showed weak ER antagonistic activity in vitro (refer to Chapter 4,4.10). 
Although these results, regarding the oestrogenic activity of the monoterpenes, are not 
conclusive, it is clear that there is potential for oestrogenic activity to occur it? vivo 
perhaps following longer-terrn exposure. This may be relevant in AD as oestrogenic 
compounds have been proposed to protect against AD, and ERa and ERP have been 
detected in the amygdala, hippocampus and cerebral cortex (Butler el al., 1999; 
Osterlund et al., 1998; Osterlund et al., 2000; Register et al., 1998). The 
monoterpenes are relatively low molecular-weight lipophilic molecules; criteria that 
may permit their access across the BBB (Pardridge, 1998). These monoterpenes may 
therefore interact with ERa and ERP in the CNS and influence cognitive function, or 
they may act as templates for the development of other oestrogenic compounds. The 
adverse effects of human (and other animal) exposure to potentially oestrogenic 
monoterpenes must be given careful consideration, as cumulative exposure may 
promote carcinogenesis, reproductive disorders and emasculating effects in males. 
The anti-oestrogenic activity of eugenol (84) could be exploited for the development 
of compounds for the treatment of hormone-dependent cancers. 
The ethanol extract and the essential oil of M offilcinalis leaf and the oil constituents 
citral, geraniol (72) and nerol (75) demonstrated dose-dependent activity against 
T`XB2 and LT134 formation in vitro; trans-caryophyllene (82) also showed activity 
against LT134 formation in vitro (refer to Chapter 5,5.2.3). These results indicate that 
the less polar compounds, including monoterpenes, from M. officinalis may have anti- 
inflammatory activity. Further fractionation and isolation of the active compounds in 
the ethanolic extract are required. 
The aqueous extract, but not the ethanolic extract, of M. officinalis leaf significantly 
displaced [3 H]-GABA binding to GABAB and GABAA receptors in vitro (refer to 
Chapter 6,6.2.2.1 and 6.2.2.2). This extract was not highly selective for either 
receptor, which may be inappropriate in clinical use as the potential for adverse 
effects may be greater. However, the essential oil of M. officinalis and the oil 
constituents citral, geraniol (72) and nerol (75) displaced [3 H]-GABA binding to 
GABAB receptors more selectively than displacement of binding to GABAA receptors 
in vitro (refer to Chapter 6,6.2.2.1 and 6.2.2.2). It is therefore apparent that polar 
compounds from the aqueous extract, which require identification, and less polar 
monoterpenes from the essential oil may interact with GABA receptors and perhaps 
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influence cognition. The active monoterpenes identified in the essential oil were 
more selective for GABAB receptors than GABAA receptors, which may be associated 
with fewer adverse effects. It is unknown if the active compounds would induce an 
agonistic or antagonistic response in vivo. It requires further investigation to 
determine if antagonistic binding occurs at the GABAB receptor, an effect that may 
promote favourable effects in cognitive function. Agonistic activity at the GABA13 
receptor may be more appropriate for the treatment of spasticity. 
The differences in the pharmacological activity and potency between each extract 
(aqueous and ethanolic extracts) and the essential oil, illustrate how the diverse 
mixture of compounds in a plant may result in various pharmacological effects, and 
that compounds may act synergistically. It is also apparent that the monoterpenes, 
may have numerous activities, including oestrogenic, anti-inflammatory or GABA 
receptor binding effects. This may reflect their general lipophilicity, which may 
permit favourable hydrophobic interactions with receptors and enzymes. The precise 
nature of these interactions requires further study, but the molecular graphics 
investigations in the present study give some indication of the ligand-binding of the 
monoterpenes and eugenol (84) in ERa (refer to Chapter 4,4.11). 
The M. officinalis essential oil did not significantly inhibit lipid peroxidation in vitro 
(refer to Chapter 6,6.1.2.2), and the ethanolic extract of M. officinalis leaf was 
cytotoxic to NSCs in vitro, so did not influence NSC differentiation (refer to Chapter 
6,6.3.2). Oestrogenic, anti-inflammatory and GABA receptor binding activities may 
therefore explain the reputed memory-enhancing effects of M. oj'ricinalis in traditional 
European medicine. 
7.1.8 Polygala tenuifolia 
The ethanolic; extract of Polygala tenuifolia root showed significant oestrogenic: 
activity in both genetically modified yeast cells and human Ishikawa cells in vitro 
(refer to Chapter 4,4.5.1 and 4.5.2). The compounds responsible for the apparent 
oestrogenic effects require isolation, and their activity confirmed in receptor binding 
studies and in vivo. 
The cold ethanolic, extract and the hot aqueous extract of P. tenuifolia root 
significantly inhibited lipid peroxidation in vitro (refer to Chapter 6,6.1.2.2). This 
suggests that both polar and less polar compounds present in the root were able to 
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inhibit lipid peroxidation. Oestrogens are reported to have anti-oxidant activity (Behl 
et al., 1995; Mooradian, 1993; Ruiz-Larrea et al., 1994). Thus, it is possible that the 
oestrogenic compounds in the ethanolic extract were also responsible for the anti- 
oxidant effects observed. Confirmation of the anti-oxidant and oestrogenic effects it? 
vivo is required. 
P. lenuifolia root extracts did not inhibit AChE activity in vitro (refer to Chapter 3, 
3.2.2); nor did they significantly inhibit cicosanoid formation in vitro (refer to Chapter 
5,5.2.1). The ethanolic extract was cytotoxic to NSCs in vitro and did not influence 
NSC differentiation (refer to Chapter 6,6.3.2). The proposed anti-amnesic effects of 
P. tenuifolia root are perhaps not due to antiChE or anti-inflammatory effects, but 
may be due to a combination of oestrogenic and anti-oxidant effects. 
7.1.9 Rosinarinits officinalis 
Both the aqueous and ethanolic extracts of Rosmarintis officinalis dried leaf and the 
essential oil, significantly inhibited AChE activity in vitro; the ethanolic extract of the 
fresh leaf did not significantly inhibit AChE activity in vitro (refer to Chapter 3, 
3.2.2). The antiChE compounds present in the aqueous and ethanolic extracts of the 
dried leaf are unknown until fractionation and isolation of the extracts is conducted. 
The compounds responsible for the antiChE activity of the essential oil may be 1,8- 
cineole (56), camphor (57) and limonene (73) as these known constituents of R. 
ofjilcinalis essential oil have previously been reported to inhibit AChE (Grundy and 
Still, 1985; Perry et aL, 2000a) 
The ethanolic extract of R. officinalis dried leaf was significantly active against TXB2 
and LTB4 forination in vitro; the ethanolic extract of the fresh leaf was significantly 
active against LTB4 formation in vitro (refer to Chapter 5,5.2.1). Further analysis of 
the active compounds is necessary to identify any compounds that may have potential 
in the treatment of inflammatory disorders, including AD. 
Neither the essential oil, nor the extracts of the fresh leaf or the dried leaf of R. 
officinalis showed significant oestrogenic activity in vitro (refer to Chapter 4,4.5.1 
and 4.6.1) and, the ethanolic extracts of the dried and fresh leaf and the essential oil of 
R. officinalis did not significantly displace [3 H]-GABA binding to GABAB or GABAA 
receptors in vitro (refer to Chapter 6,6.2.2.1 and 6.2.2.2). The ethanolie extract of the 
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dried leaf was cytotoxic to NSCs in vitro, and no effect on NSC differentiation was 
observed (refer to Chapter 6,6.3.2). 
It may be concluded that the antiChE and anti-inflammatory effects of R. officinalis 
leaf may explain the reputed favourable effects of this herb in traditional European 
medicine, and R. officinalis may be a source of new antiChE and anti-inflammatory 
compounds for use in future AD therapy. 
7.1.10 Salvia miltiorrhiza 
Both the aqueous and ethanolic extracts of Salvia miltiorrhiza root dose-dependently 
inhibited AChE activity in vitro, with the ethanolic extract being the most active (refer 
to Chapter 3,3.2.3). The ethanolic extract of S. miltiorrhiza root also showed 
significant activity against TXB2 and LTB4 formation but the less active aqueous 
extract showed weaker activity against TXB2 formation in vitro (refer to Chapter 5, 
5.2.1.3). The hot aqueous extract and the cold and hot ethanolic extracts of S. 
miltiorrhiza root significantly inhibited lipid peroxidation in vitro (refer to Chapter 6, 
6.1.2.2). 
The compounds present in the root that contributed to these activities also need 
further assessment. Tanshinone 1 (115), dihydrotanshinone, tanshinone Ila (116) and 
cryptotanshinone (117) isolated from the lipophilic extracts of S. miltiorrhiza root 
have previously shown activity against 5-LOX formation in porcine leukocytes 
(Paulus and Bauer, 2000). These diterpenes may have also been responsible for the 
inhibition of eicosanoid generation in the present study. Several compounds present 
in the root have also shown anti-oxidant effects. These include the water-soluble 
salvianolic acids A (123) and B (124) (Huang and Zhang, 1992; Liu et aL, 1992) and 
several quinones, including dehydrorosmariquinone, rosmariquinone, miltirone 1, 
tanshinone 1 (115), cryptotanshinone (117), dihydrotanshinone and 
methylenetanshinquinone (Weng and Gordon, 1992; Zhang et aL, 1990). The 
salvianolic acids and the quinones may have been responsible for the anti-oxidant 
effects of the aqueous and the ethanolic extracts respectively in the present study. 
Although, the activities may also have been due to other compounds, perhaps by 
acting synergistically. 
S. miltiorrhiza root is therefore also a potential source of antiChE, anti-inflammatory 
and anti-oxidant compounds. If a particular compound were to be isolated that had 
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two or more of these pharmacological activities, it might have particular usefulness in 
AD therapy to maximise efficacy and to reduce dose frequency to patients. Multiple 
drug therapy may require dosing of numerous drugs daily, which may be problematic 
in patients with cognitive dysfunction, and administration of a compound with 
multiple activities, may overcome this problem. 
The antiChE, anti-inflammatory and anti-oxidant effects of S miltiorrhiza root may 
explain its use in TCM. None of the S. nfiltiorrhiza root extracts showed significant 
oestrogenic activity in vitro (refer to Chapter 4,4.5.1) and the ethanolic extract was 
cytotoxic to NSCs in vitro, and did not influence NSC differentiation (refer to Chapter 
6,6.3.2). 
7.1.11 Withaniasomnifera 
Both the aqueous and ethanolic extracts of Withania somnifera root significantly 
inhibited AChE activity in vitro (refer to Chapter 3,3.2.2). The ethanolic extract of 
W. somnifiera root was significantly active against TXB2 fori-nation in vitro (refer to 
Chapter 5,5.2.1) and significantly inhibited lipid peroxidation. in vitro (refer to 
Chapter 6,6.1.2.2). But, none of the TV somnifera root extracts showed significant 
oestrogenic activity in vitro (refer to Chapter 4,4.5.1) and the ethanolic extract was 
cytotoxic to NSCs in vitro, showing no effect on NSC differentiation (refer to Chapter 
6,6.3.2). 
Phytochemical analysis of the compounds responsible for these activities is still 
required. However, as the ethanolic extract showed apparent antiChE, anti- 
inflammatory (perhaps via inhibition of COX) and anti-oxidant activities, the 
compounds responsible are likely to be those that are less polar. This plant also has 
potential for the identification of new therapeutic compounds that may be relevant in 
AD therapy. Compounds from the root have previously been shown to influence 
cognitive function. For example, the sitoindosides IX (65) and X (66) augmented 
learning acquisition and memory in both young and old rats (Ghosal et aL, 1989) and 
an extract containing the sitoindosides VII -X and withaferin A (109) also reversed 
the ibotenic acid-induced cognitive deficit and reversed the reduction in cholinergic 
markers (e. g. ACh (1), ChAT) in rats (Bhattacharya et aL, 1995). The 
pharmacological activities in the present study may explain these previous 
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observations, or may provide additional therapeutic activities to those observed 
previously. 
Therefore W. somnifera root may have multiple pharmacological activities relevant to 
the treatment of AD. The use of the crude extract may be advantageous by providing 
numerous beneficial effects perhaps by compounds acting synergistically, unless 
compounds were to be isolated that exhibited more than one pharmacological activity. 
7.1.12 Dziphusjujitba 
The hot aqueous extract of Ziziphits jujuba seed significantly inhibited lipid 
peroxidation in vitro (refer to Chapter 6,6.1.2.2). The seeds are reported to contain 
flavone C-glycosides (e. g. swertisin (150), spinosin (149)), saponins (e. g. jujubosides 
A and B) and triterpenoids (e. g. betulin, betulic acid), which may have been 
responsible for the observed anti-oxidant activity, but their isolation is required to 
assess their individual potency. 
The ethanolic extract of Z jujuba var. spinosa seed, showed greater displacement of 
CH]-GABA binding to GABAB receptors, than GABAA receptors in vitro; the 
aqueous extract did not significantly displace [3 H]-GABA binding to GABAA and 
GABAB receptors in vitro (refer to Chapter 6,6.2.2.1 and 6.2.2.2). Selectivity for the 
GABAB receptor may be important to minimise adverse effects and to enhance 
efficacy. Isolation of the active compounds and their potential as GABAB receptor 
antagonists in vivo is necessary to identify any potential for the use in cognitive 
disorders, such as AD. 
Neither ethanolic extracts of Z jujuba seed or Z jujuba var. spinosa seed, nor the 
aqueous extract of Z jqjuba var. spinosa seed, were cytotoxic to NSCs in vitro, and 
the aqueous and ethanolic extracts of Z jujuba var. spinosa seed consistently showed 
effects on NSC differentiation (refer to Chapter 6,6.3.2). These extracts may 
therefore yield compounds that may support neuronal growth and encourage 
development of a particular neuronal phenotype (e. g. cholinergic neurons), either by 
acting directly in the CNS or prior to transplantation of neuronal grafts into brain, for 
the treatment of neurodegenerative disorders. Investigations in the present study are 
preliminary, but the promising results warrant the isolation and further investigation 
of active compounds. 
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Neither the aqueous nor the ethanolic, nor the petroleum spirit extracts of Z jujuba 
seed or fruit (or Z jujuba var. spinosa seed) inhibited AChE activity in vitro (refer to 
Chapter 3,3.2.2) and none of the Z jujuba, or Z jujuba var. spinosa, seed or fruit 
extracts showed significant oestrogenic activity in vitro (refer to Chapter 4,4.5.1). 
Neither the ethanolic nor the aqueous extracts of Z fiýuba, or Z jujuba var. spinosa, 
seed were significantly active against eicosanoid formation in vitro (refer to Chapter 
5,5.2.1). 
The reputed anti-amnesic effects of Z jujuba seeds may be due to anti-oxidant and 
GABA receptor binding effects, or perhaps effects on neuronal populations, and are 
perhaps not due to antiChE, oestrogenic or anti-inflammatory effects. 
7.2 Conclusion 
It is apparent that adulteration of plant material, including substitution of one plant 
species for another (in the present study a Gentiana spp. was substituted for 
Polygonum multiflorum, refer to Chapter 2,2.2.1.1) may pose numerous problems. 
Unless the correct species is confirmed, a plant may be reported to have activities (or 
a lack of activities) that do not reflect the activities of the correct species. Adulterated 
plant material used clinically may reduce efficacy and perhaps induce toxicity. It is 
therefore essential that plant material is authenticated prior to use experimentally and 
clinically. 
This study has shown that numerous plant species may be potential sources for 
compounds that may be relevant in the treatment of various disorders, including 
cancer (the anti-oxidants and anti-oestrogens), inflammatory disorders such as 
rheumatoid arthritis (anti-inflammatory compounds) and cognitive disorders such as 
AD (the anti-oxidants, oestrogenic compounds, anti-inflammatory compounds, 
antiChE compounds and perhaps GABA receptor ligands and compounds that 
influence NSC differentiation). The plant extracts that were identified to have the 
various pharmacological activities in the present study may yield new therapeutic 
compounds, therefore further work involving the isolation of these active compounds 
is warranted. 
Finally, it must be noted that the majority (>90%) of plants in this study, which were 
selected on the basis of their reputed cognitive enhancing effects (excluding the 
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adulterated Polygonum multiflorum root), showed at least one pharmacological 
activity, and many (>70%) showed at least two pharmacological activities, that may 
be relevant in cognitive disorders. Therefore the pharmacological activities of plants 
generally appears to reflect their uses in traditional medicine. The ethnobotanical 
approach for selecting plants to investigate for the treatment of a particular disease, 
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